

EAST Search History

Ref #	Hits	Search Query	DBs	Default Operator	Plurals	Time Stamp
L1	827	(548/235).CCLS.	US-PGPU B; USPAT; USOCR; EPO; JPO; DERWEN T; IBM_TDB	OR	OFF	2006/11/26 18:52
L2	1719	(514/374).CCLS.	US-PGPU B; USPAT; USOCR; EPO; JPO; DERWEN T; IBM_TDB	OR	OFF	2006/11/26 18:52
L3	305	I2 and I1	US-PGPU B; USPAT; USOCR; EPO; JPO; DERWEN T; IBM_TDB	OR	ON	2006/11/26 18:53
L4	115	I3 and diabetes	US-PGPU B; USPAT; USOCR; EPO; JPO; DERWEN T; IBM_TDB	OR	ON	2006/11/26 18:54

10788996 11/26/06

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:SSSPTA1626KAS

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * Welcome to STN International * * * * *

NEWS	1		Web Page URLs for STN Seminar Schedule - N. America
NEWS	2		"Ask CAS" for self-help around the clock
NEWS	3	AUG 09	INSPEC enhanced with 1898-1968 archive
NEWS	4	AUG 28	ADISCTI Reloaded and Enhanced
NEWS	5	AUG 30	CA(SM)/CAPLUS(SM) Austrian patent law changes
NEWS	6	SEP 11	CA/CAPLUS enhanced with more pre-1907 records
NEWS	7	SEP 21	CA/CAPLUS fields enhanced with simultaneous left and right truncation
NEWS	8	SEP 25	CA(SM)/CAPLUS(SM) display of CA Lexicon enhanced
NEWS	9	SEP 25	CAS REGISTRY(SM) no longer includes Concord 3D coordinates
NEWS	10	SEP 25	CAS REGISTRY(SM) updated with amino acid codes for pyrrolysine
NEWS	11	SEP 28	CEABA-VTB classification code fields reloaded with new classification scheme
NEWS	12	OCT 19	LOGOFF HOLD duration extended to 120 minutes
NEWS	13	OCT 19	E-mail format enhanced
NEWS	14	OCT 23	Option to turn off MARPAT highlighting enhancements available
NEWS	15	OCT 23	CAS Registry Number crossover limit increased to 300,000 in multiple databases
NEWS	16	OCT 23	The Derwent World Patents Index suite of databases on STN has been enhanced and reloaded
NEWS	17	OCT 30	CHEMLIST enhanced with new search and display field
NEWS	18	NOV 03	JAPIO enhanced with IPC 8 features and functionality
NEWS	19	NOV 10	CA/CAPLUS F-Term thesaurus enhanced
NEWS	20	NOV 10	STN Express with Discover! free maintenance release Version 8.01c now available
NEWS	21	NOV 13	CA/CAPLUS pre-1967 chemical substance index entries enhanced with preparation role
NEWS	22	NOV 20	CAS Registry Number crossover limit increased to 300,000 in additional databases
NEWS	23	NOV 20	CA/CAPLUS to MARPAT accession number crossover limit increased to 50,000
NEWS	24	NOV 20	CA/CAPLUS patent kind codes will be updated
NEWS EXPRESS			NOVEMBER 10 CURRENT WINDOWS VERSION IS V8.01c, CURRENT MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP), AND CURRENT DISCOVER FILE IS DATED 25 SEPTEMBER 2006.
NEWS HOURS			STN Operating Hours Plus Help Desk Availability
NEWS LOGIN			Welcome Banner and News Items
NEWS IPC8			For general information regarding STN implementation of IPC 8
NEWS X25			X.25 communication option no longer available

Enter NEWS followed by the item number or name to see news on that specific topic.

10788996 11/26/06

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

* * * * * STN Columbus * * * * *

FILE 'HOME' ENTERED AT 17:31:52 ON 26 NOV 2006

=> file reg

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

0.42

0.42

FILE 'REGISTRY' ENTERED AT 17:32:44 ON 26 NOV 2006

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2006 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 24 NOV 2006 HIGHEST RN 913944-64-6

DICTIONARY FILE UPDATES: 24 NOV 2006 HIGHEST RN 913944-64-6

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH June 30, 2006



Please note that search-term pricing does apply when conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

<http://www.cas.org/ONLINE/UG/regprops.html>

=>

Uploading C:\Program Files\Stnexp\Queries\10788996.str




chain nodes :
 12 13 14 15
 ring nodes :
 1 2 3 4 5 6 7 8 9 10 11
 chain bonds :
 4-7 10-12 12-13 13-14 14-15
 ring bonds :
 1-2 1-6 2-3 3-4 4-5 5-6 7-8 7-11 8-9 9-10 10-11
 exact/norm bonds :
 7-8 7-11 8-9 9-10 10-11 12-13 13-14
 exact bonds :
 4-7 10-12 14-15
 normalized bonds :
 1-2 1-6 2-3 3-4 4-5 5-6
 isolated ring systems :
 containing 1 : 7 :

Match level :
 1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:Atom
 11:Atom 12:CLASS 13:CLASS 14:CLASS 15:Atom

L1 STRUCTURE UPLOADED

=> d
 L1 HAS NO ANSWERS
 L1 STR

10788996 11/26/06



Structure attributes must be viewed using STN Express query preparation.

=> s l1

SAMPLE SEARCH INITIATED 17:33:08 FILE 'REGISTRY'

SAMPLE SCREEN SEARCH COMPLETED - 1167 TO ITERATE

100.0% PROCESSED 1167 ITERATIONS

50 ANSWERS

INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)

SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**

BATCH **COMPLETE**



PROJECTED ITERATIONS: 21291 TO 25389

PROJECTED ANSWERS: 6671 TO 9049

L2 50 SEA SSS SAM L1

=>

Uploading C:\Program Files\Stnexp\Queries\107889961.str



chain nodes :
 12 13 14 15 21 22 24 25 26
 ring nodes :
 1 2 3 4 5 6 7 8 9 10 11
 chain bonds :
 4-7 10-12 12-13 13-14 14-15 15-21 21-22 22-24 24-25 25-26
 ring bonds :
 1-2 1-6 2-3 3-4 4-5 5-6 7-8 7-11 8-9 9-10 10-11
 exact/norm bonds :
 7-8 7-11 8-9 9-10 10-11 12-13 13-14 21-22 22-24 25-26
 exact bonds :
 4-7 10-12 14-15 15-21 24-25
 normalized bonds :.
 1-2 1-6 2-3 3-4 4-5 5-6
 isolated ring systems :
 containing 1 : 7 :

G1:O,S,N

Match level :
 1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:Atom
 11:Atom 12:CLASS 13:CLASS 14:CLASS 15:Atom 21:CLASS 22:CLASS 24:CLASS
 25:CLASS 26:CLASS


10788996 11/26/06

L3 STRUCTURE UPLOADED

=> d

L3 HAS NO ANSWERS

L3 STR



G1 O, S, N

Structure attributes must be viewed using STN Express query preparation.

=> s l3

SAMPLE SEARCH INITIATED 17:37:16 FILE 'REGISTRY'

SAMPLE SCREEN SEARCH COMPLETED - 2382 TO ITERATE

84.0% PROCESSED 2000 ITERATIONS
INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)
SEARCH TIME: 00.00.01

48 ANSWERS

FULL FILE PROJECTIONS: ONLINE **COMPLETE**
BATCH **COMPLETE**

PROJECTED ITERATIONS: 44713 TO 50567

PROJECTED ANSWERS: 690 TO 1596

L4 48 SEA SSS SAM L3

=> s l3 full

FULL SEARCH INITIATED 17:37:30 FILE 'REGISTRY'

FULL SCREEN SEARCH COMPLETED - 47421 TO ITERATE

100.0% PROCESSED 47421 ITERATIONS

1216 ANSWERS

10788996 11/26/06

SEARCH TIME: 00.00.01

L5 1216 SEA SSS FUL L3

=> file caplus

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

170.02

170.44

FILE 'CAPLUS' ENTERED AT 17:37:42 ON 26 NOV 2006

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2006 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 26 Nov 2006 VOL 145 ISS 23

FILE LAST UPDATED: 24 Nov 2006 (20061124/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply. They are available for your review at:

<http://www.cas.org/infopolicy.html>

=> s l5

L6 115 L5

=> s l6 and diabetes

117935 DIABETES

L7 83 L6 AND DIABETES

=> d ibib abs hitstr tot

10788996


11/26/06

L7 ANSWER 1 OF 83 CAPLUS COPYRIGHT 2006 ACS on STN
 ACCESSION NUMBER: 2006:1147258 CAPLUS
 TITLE: Preparation of multicyclic peptide derivatives as dipeptidyl peptidase-IV inhibitors
 INVENTOR(S): Kroth, Heiko; Feuerstein, Tim; Richter, Frank; Boer, Jurgen; Essers, Michael; Nolte, Bert; Schneider, Matthias; Hochguertel, Matthias; Prickel, Fritz-Frieder; Taveras, Arthur
 PATENT ASSIGNEE(S): Alantox Pharmaceuticals, Inc., USA
 SOURCE: PCT Int. Appl., 542pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2006116157	A2	20061102	WO 2006-US15200	20060421
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CP, CO, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				


PRIORITY APPLN. INFO.: US 2005-674151P P 20050422

GI



AB The invention relates generally to pyrrolidine and thiazolidine DPP-IV inhibitory compds. A-B-CO-D (A is a bicyclic or tricyclic ring system attached to B at carbon or nitrogen; B is a linking group such as an amino acid residue or fragment; D is a pyrrolidine or thiazolidine residue or derivative), including isomers and pharmaceutically-acceptable salts, for

L7 ANSWER 1 OF 83 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
 treatment of DPP-IV mediated diseases, in particular, type-2 diabetes. Thus, pyrrolidinecarboxamide deriv. I was prepd. by reaction of 5-[(8)-2-aminopropyl]-10,11-dihydro-5H-dibenzo[a,d]cycloheptene-5-carboxamide with N-glyoxyloxy-L-prolinecarboxamide (prepns. given) and showed Ki < 6 nM for inhibition of DPP-IV.
 IT INDEXING IN PROGRESS
 IT 331741-94-7, Muraglitazar
 RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses) (preparation of multicyclic peptide derivs. as dipeptidyl peptidase-IV inhibitors)
 RN 331741-94-7 CAPLUS
 CN Glycine, N-[(4-methoxyphenoxy)carbonyl]-N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- (9C1) (CA INDEX NAME)



L7 ANSWER 2 OF 83 CAPLUS COPYRIGHT 2006 ACS on STN
 ACCESSION NUMBER: 2006:945760 CAPLUS
 DOCUMENT NUMBER: 145:328394
 TITLE: Roflumilast for the treatment of diabetes mellitus
 INVENTOR(S): Kley, Hans-Peter; Hansauer, Guido; Hauser, Daniela; Schmidt, Beate; Bredenbroeker, Dirk; Wurst, Wilhelm; Remkowski, Joerg
 PATENT ASSIGNEE(S): Altana Pharma AG, Germany
 SOURCE: PCT Int. Appl., 67pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2006094942	A1	20060914	WO 2006-EP60445	20060303
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CP, CO, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				

PRIORITY APPLN. INFO.: EP 2005-101780 A 20050308

AB The invention discloses the use of Roflumilast and/or Roflumilast-N-Oxide for the treatment of diabetes mellitus and accompanying disorders thereof. The invention addnl. discloses combinations of Roflumilast and/or Roflumilast-N-Oxide with other active agents for the treatment of diabetes mellitus.

IT 331741-94-7, Muraglitazar
 RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (Roflumilast for treatment of diabetes mellitus and accompanying disorders, and combinations with other agents)

RN 331741-94-7 CAPLUS
 CN Glycine, N-[(4-methoxyphenoxy)carbonyl]-N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- (9C1) (CA INDEX NAME)



REFERENCE COUNT: 14 THERE ARE 14 CITED REFERENCES AVAILABLE FOR THIS

10788996

11/26/06

L7 ANSWER 3 OF 83 CAPLUS COPYRIGHT 2006 ACS ON STN
 ACCESSION NUMBER: 2006:944442 CAPLUS
 DOCUMENT NUMBER: 145:238392
 TITLE: Roflumilast for the treatment of diabetes mellitus and accompanying disorders, and combinations with other agents
 INVENTOR(S): Kley, Hans-Peter; Hansauer, Guido; Hauser, Daniela; Schmidt, Beate; Bredenbroeker, Dirk; Wurst, Wilhelm; Kemkowski, Joerg
 PATENT ASSIGNEE(S): Altana Pharma AG, Germany
 SOURCE: PCT Int. Appl., 7ipp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2006094933	A1	20060914	WO 2006-EP0418	20060303
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RM:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CP, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
PRIORITY APPLN. INFO.:			EP 2005-101772	A 20050308


AB The invention relates to the use of Roflumilast and/or Roflumilast-N-Oxide for the treatment of diabetes mellitus and accompanying disorders thereof. The invention addnl. relates to combinations of Roflumilast and/or Roflumilast-N-Oxide with other active agents for the treatment of diabetes mellitus.
 IT 331741-94-7, Muraglitazur
 RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (Roflumilast for treatment of diabetes mellitus and accompanying disorders, and combinations with other agents)
 RN 331741-94-7 CAPLUS
 CN Glycine, N-[(4-methoxyphenoxy)carbonyl]-N-[[4-[2-[5-methyl-2-phenyl-4-oxazolyl]ethoxy]phenyl]methyl]- (9CI) (CA INDEX NAME)

L7 ANSWER 4 OF 83 CAPLUS COPYRIGHT 2006 ACS ON STN
 ACCESSION NUMBER: 2006:679307 CAPLUS
 DOCUMENT NUMBER: 145:124344
 TITLE: Preparation of bicyclooctanecarboxamides as modulators of the glucocorticoid receptor, AP-1, and/or NF-κB activity and use thereof
 INVENTOR(S): Yang, Bingwei V.; Doweyko, Lidia M.; Doweyko, Arthur M.
 PATENT ASSIGNEE(S): USA
 SOURCE: U.S. Pat. Appl. Publ., 28 pp.
 CODEN: USXXCO
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2006154975	A1	20060713	US 2006-330748	20060112
WO 2006076633	A1	20060720	WO 2006-US1329	20060113
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RM:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CP, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
PRIORITY APPLN. INFO.:			US 2005-643462P	P 20050113
			US 2006-330748	A 20060112


GI

L7 ANSWER 3 OF 83 CAPLUS COPYRIGHT 2006 ACS ON STN (Continued)



REFERENCE COUNT: 13 THERE ARE 13 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE
 FORMAT


L7 ANSWER 4 OF 83 CAPLUS COPYRIGHT 2006 ACS ON STN (Continued)



AB Title compds. I [X = S, O, or NH; Z = TCOR6 or TCOR6; T = bond or (un)substituted alkylene; R1 and R2 independently = H, halo, OH, alkyl, etc.; R3 and R4 independently = H, alkyl, alkenyl, etc.; R5 = H, alkyl, alkenyl, aryl, etc.; R6 = alkyl, alkenyl, alkoxy, aryl, etc.; ring A and ring B independently represent (un)saturated 6-membered carbocycle or heterocyclic rings], and their pharmaceutical salts, are prepared and disclosed as a class of novel nonsteroidal compds. which are useful in treating diseases associated with modulation of the glucocorticoid receptor, AP-1, and/or NF-κB activity including obesity, diabetes, inflammatory and immune diseases. Thus, e.g., II was prepared by coupling of the corresponding acid (preparation given) with Pr 2-aminothiazole-4-carboxylate. Methods for assaying glucocorticoid receptor inhibition (>25% at 10 M, preferably >95% at 10 M) and/or AP-1 inhibition activity (EC < 15 M) are described. Also provided are pharmaceutical compns. and methods of treating obesity, diabetes and inflammatory or immune-associated diseases comprising said compds.
 IT 258345-41-4
 RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (preparation of bicyclooctanecarboxamides as modulators of glucocorticoid receptor, AP-1, and/or NF-κB activity)
 RN 258345-41-4 CAPLUS
 CN L-Tyrosine, N-[(12)-1-methyl-3-oxo-3-phenyl-1-propenyl]-O-[2-(5-methyl-2-phenyl-4-oxazolyl)ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
 Double bond geometry as shown.

L7 ANSWER 4 OF 83 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



L7 ANSWER 5 OF 83 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2006:679180 CAPLUS

DOCUMENT NUMBER: 145:145429

TITLE: Preparation of bicyclooctanecarboxamides as modulators

of glucocorticoid receptor, AP-1 and NF- κ B activity and use thereof
 INVENTOR(S): Shepeck, James; Dhar, T. g. Murali; Doweyko, Lidia; Gilmore, John; Weinstein, David; Xiao, Hai-Yun; Yang, Bingwei V.; Doweyko, Arthur M.

PATENT ASSIGNEE(S): USA

SOURCE: U.S. Pat. Appl. Publ., 71 pp.

CODEN: USXXCO

DOCUMENT TYPE: Patent

LANGUAGE: English



FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2006154973	A1	20060713	US 2006-330553	20060112
WO 2006076632	A1	20060720	WO 2006-US1328	20060113
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GR, GU, HK, HN, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, ME, MG, MK, MN, MW, MX, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SN, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
PRIORITY APPLN. INFO.:			US 2005-643509P	P 20050113
			US 2006-330553	A 20060112

GI

L7 ANSWER 5 OF 83 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



AB Title compds. I [X = N, NH, O, and S; Y = N, NH, or CR2; R1 = H, CN, OH, alkyl, etc.; R2 = H, halo, OH, alkenyl, etc.; R3 and R6 independently =

H, halo, alkoxy, aryl, etc.; R4 and R5 independently = H, alkyl, aryl, cycloalkyl, etc.; R7 and R8 independently = H, alkoxy, heteroaryl, etc.; R9 = H or alkyl; R10 and R11 independently = H, halo, alkynyl, etc.; Z = cycloalkyl, cycloalkenyl, heterocycloalkyl, aryl, or heteroaryl; m = 0-2; n = 0-2], and their pharmaceutically acceptable salts, are prepared and disclosed as useful in treating diseases associated with modulation of

the glucocorticoid receptor, AP-1, and/or NF- κ B activity including obesity, diabetes, inflammatory, and immune-associated diseases. Thus, e.g., I was prepared by alkylation of corresponding alc. (preparation given)

with 4-iodobutane. Methods for assaying glucocorticoid receptor inhibition (>25% at 10 M, preferably >95% at 10 M) and/or AP-1 inhibition activity (EC < 15 M) are described. Also provided are pharmaceutical compns. and methods of treating obesity, diabetes and inflammatory or immune-associated diseases comprising said compds.

IT 258345-41-4

RI: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(preparation of bicyclooctanecarboxamides as modulators of glucocorticoid


receptor, AP-1 and NF- κ B activity)

RN 258345-41-4 CAPLUS

CN L-Tyrosine, N-[(1Z)-1-methyl-3-oxo-3-phenyl-1-propenyl]-O-[2-(5-methyl-2-phenyl-4-oxazolyl)ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
 Double bond geometry as shown.

L7 ANSWER 5 OF 83 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



L7 ANSWER 6 OF 83 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2006:678383 CAPLUS

DOCUMENT NUMBER: 145:124343

TITLE: Preparation of
dibenzobicyclo[2.2.2]octadienylcarboxam
ides as modulators of the glucocorticoid receptor,
ap-1, and/or NF-kb activity and use thereof
Yang, Bingwei V.

INVENTOR(S): USA

PATENT ASSIGNEE(S): USA

SOURCE: U.S. Pat. Appl. Publ., 33 pp.

CODEN: USXXCO

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1



PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2006154962	A1	20060713	US 2006-330511	20060112
WO 2006076509	A1	20060720	WO 2006-US1117	20060113
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GR, GU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, ME, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GO, GM, ML, MR, NE, SN, TD, TG, BH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				

PRIORITY APPLN. INFO.: US 2005-643760P P 20050113

GI

L7 ANSWER 6 OF 83 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



AB Title compds. I (R1 = H, OH, alkyl, etc.; R3 and R6 independently = H, halo, OH, alkyl, alkenyl, etc.; R7 and R8 independently = H, alkynyl, aryl, etc.; R4 and R5 independently = OH, alkoxy, aryloxy, etc.; Z = S(O)tNR1R2, CONR1R2 or CH2NR1R2 wherein R1 and R2 independently = H, alkyl, alkenyl, alkynyl, heteroaryl, etc.; m and n independently = 0-4 provided m+n ≥ 1; t = 1-2), and their pharmaceutically acceptable salts, are prepared and disclosed as novel non-steroidal compds. which


are useful in treating diseases associated with modulation of the glucocorticoid receptor, AP-1, and/or NF-κB activity including obesity, diabetes, inflammatory and immune diseases. Thus, e.g., II was prepared by coupling of the corresponding acid (preparation given) with 4-(4-methylnaphthalen-1-yl)thiazol-2-ylamine. Methods for assaying glucocorticoid receptor inhibition (>25% at 10 μM, preferably >95% at 10 μM) and/or AP-1 inhibition activity (EC50 < 15 μM) are described. Also provided are pharmaceutical compds. and methods of treating obesity, diabetes and inflammatory or immune associated diseases comprising said compds.

IT 258345-41-4
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(preparation of dibenzobicyclo[2.2.2]octadienylcarboxamide deriva. as modulators of glucocorticoid receptor, AP-1 and/or NF-κB activity)

RN 258345-41-4 CAPLUS
CN L-Tyrosine, N-[(1Z)-1-methyl-3-oxo-3-phenyl-1-propenyl]-O-[2-(5-methyl-2-phenyl-4-oxazolyl)ethyl]- (9CI) (CA INDEX NAME)

L7 ANSWER 6 OF 83 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)

Absolute stereochemistry.
Double bond geometry as shown.



L7 ANSWER 7 OF 83 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2006:598865 CAPLUS

DOCUMENT NUMBER: 145:240929

TITLE: 2D QSAR of PPARγ agonist binding and
transactivation

AUTHOR(S): Ruecker, Christoph; Scarsì, Marco; Meringer, Markus
CORPORATE SOURCE: Biocenter, University of Basel, Basel, CH-4056,
Switz.

SOURCE: Bioorganic & Medicinal Chemistry (2006), 14(15),
5178-5195
CODEN: BMECEP; ISSN: 0968-0896

PUBLISHER: Elsevier B.V.

DOCUMENT TYPE: Journal

LANGUAGE: English

AB Multilinear QSAR models are developed for the largest and most diverse
set

of PPARγ agonists treated hitherto. Binding of these small mols. to the human nuclear receptor PPARγ is described by models that are built on simple 2D mol. descriptors and nevertheless are of good quality and predictive power (e.g., 144 compds., 10 descriptors, r2 = 0.79, r2cv =


0.76). The models presented are thoroughly validated by cross-validation, randomization expts., bootstrapping, and training set/test set partitioning. They may therefore be helpful in the design of new antidiabetic drug candidates. For gene transactivation, the functional activity of the agonists, a corresponding model for a similarly diverse compound set is of somewhat lower statistical quality.

IT 258345-41-4
RL: PAC (Pharmacological activity); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(2D QSAR of PPARγ agonist binding and transactivation)

RN 258345-41-4 CAPLUS

CN L-Tyrosine, N-[(1Z)-1-methyl-3-oxo-3-phenyl-1-propenyl]-O-[2-(5-methyl-2-phenyl-4-oxazolyl)ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



REFERENCE COUNT: 59 THERE ARE 59 CITED REFERENCES AVAILABLE FOR
THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE
FORMAT

10788996

11/26/06

L7 ANSWER 8 OF 83 CAPLUS COPYRIGHT 2006 ACS ON STN
 ACCESSION NUMBER: 2006:558822 CAPLUS
 145:40277
 DOCUMENT NUMBER:
 TITLE: Treatment of dyslipidemia and other conditions with
 w-3 fatty acids and a PPAR agonist and/or
 antagonist, and a combination product thereof
 Bobotas, George; Rongen, Roelof M. L.; Shalwitz,
 Robert A.
 INVENTOR(S):
 PATENT ASSIGNEE(S): Reliant Pharmaceuticals, Inc., USA
 SOURCE: PCT Int. Appl., 29 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 3
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2006062932	A2	20060615	WO 2005-US44035	20051205
WO 2006062932	A3	20060928		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GR, GU, HK, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
US 2006211749	A1	20060921	US 2005-293513	20051205
PRIORITY APPLN. INFO.:			US 2004-633125P	P 20041206

AB The invention discloses a method and composition for blood lipid therapy that comprises administering to the subject an effective amount of a PPAR agonist and/or antagonist and an w-3 fatty acid. The methods and compns. include combination products or concomitant therapy for the treatment of subjects with hypertriglyceridemia, hypercholesterolemia, mixed dyslipidemia, vascular disease, atherosclerotic disease, and related conditions, obesity, the prevention or reduction of cardiovascular and vascular events, the reduction of insulin resistance, fasting glucose levels and postprandial glucose levels, and/or the reduction of incidence and/or the delay of onset of diabetes.

IT 331741-94-7D, Muraglitazar, mixts. with polyunsatd. omega-3 fatty acids
 RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (w-3 fatty acids and PPAR modulators for treatment of dyslipidemia and other conditions)

RN 331741-94-7 CAPLUS


L7 ANSWER 9 OF 83 CAPLUS COPYRIGHT 2006 ACS ON STN
 ACCESSION NUMBER: 2006:507352 CAPLUS
 145:431560
 DOCUMENT NUMBER:
 TITLE: Muraglitazar: beneficial or detrimental in the treatment of Type 2 diabetes?
 Doggrell, Sheila A.
 AUTHOR(S):
 CORPORATE SOURCE: School of Science, Charles Darwin University, Casuarina, 0811, Australia
 SOURCE: Expert Opinion on Pharmacotherapy (2006), 7(9), 1229-1233
 CODEN: EOPHF7; ISSN: 1465-6566
 PUBLISHER: Informa Healthcare
 DOCUMENT TYPE: Journal; General Review
 LANGUAGE: English

AB A review. Hyperglycemia in Type 2 diabetes has a major role in the development of microvascular complications, whereas the dyslipidemia is the major cause of macrovascular complications. In patients with Type 2 diabetes, activation of PPAR- α and PPAR- γ with the fibrates and glitazones improves dyslipidemia and increases insulin sensitivity, resp. Muraglitazar is an agonist at both of these receptors and has been shown to increase high-d. lipoprotein cholesterol, decrease triglycerides and improve insulin sensitivity. However, there is also some evidence that muraglitazar has detrimental effects on the cardiovascular system. Before muraglitazar is widely used in the treatment of Type 2 diabetes, more safety testing needs to be undertaken.

IT 331741-94-7, Muraglitazar
 RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (PPAR- α and PPAR- γ agonist muraglitazar increased high-d. lipoprotein cholesterol, decreased triglyceride and improved insulin sensitivity but had detrimental effect on cardiovascular system in patient with type 2 diabetes)

RN 331741-94-7 CAPLUS


CN Glycine, N-[(4-methoxyphenoxy)carbonyl]-N-[(4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl)methyl]- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 10 THERE ARE 10 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RECORD.

FORMAT

L7 ANSWER 8 OF 83 CAPLUS COPYRIGHT 2006 ACS ON STN (Continued)
 CN Glycine, N-[(4-methoxyphenoxy)carbonyl]-N-[(4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl)methyl]- (9CI) (CA INDEX NAME)




L7 ANSWER 10 OF 83 CAPLUS COPYRIGHT 2006 ACS ON STN
 ACCESSION NUMBER: 2006:464090 CAPLUS
 145:75955
 DOCUMENT NUMBER:
 TITLE: A 96-well single-pot liquid-liquid extraction, hydrophilic interaction liquid chromatography-mass spectrometry method for the determination of Muraglitazar in human plasma
 Xue, Y.-J.; Liu, Jane; Unger, Steve
 AUTHOR(S):
 CORPORATE SOURCE: Preclinical Candidate Optimization, Pharmaceutical Research Institute, Bristol-Myers Squibb, New Brunswick, NJ, 08903, USA
 SOURCE: Journal of Pharmaceutical and Biomedical Analysis (2006), 41(3), 979-988
 CODEN: JPBADA; ISSN: 0731-7085
 PUBLISHER: Elsevier B.V.
 DOCUMENT TYPE: Journal
 LANGUAGE: English

AB A single-pot liquid-liquid extraction (LLE) with hydrophilic interaction liquid chromatography (HILIC/MS/MS) method was developed and validated for the determination of Muraglitazar, a hydrophobic diabetes drug, in human plasma. To 0.050 mL of each plasma sample in a 96-well plate, the internal standard solution in acetonitrile and toluene were added to extract the compound of interest. The plate was vortexed, followed by centrifugation. The organic layer was then directly injected into an LC/MS/MS system. Chromatog. separation was achieved isocratically on a ThermoHypersil-Keystone, Hypersil silica column (3 mm \times 50 mm, 3 μ m). The mobile phase contained 85% of Me t-Bu ether and 15% of 90/10 (volume/volume) acetonitrile/water with 0.3% trifluoroacetic acid. Post-column mobile phase of 50/50 (volume/volume) acetonitrile/water containing 0.1% formic acid was added. Detection was by pos. ion electrospray tandem mass spectrometry on a Sciex API 4000. The standard curve, ranged from 1 to 1000 ng/mL, was fitted to a 1/x weighted quadratic regression model. This single-pot LLE approach effectively eliminated time-consuming organic layer transfer, dry-down, and sample reconstitution steps, which are essential for a conventional liquid-liquid extraction procedure. The modified mobile phase was more compatible with the direct injection of the commonly used extraction solvents in LLE. Furthermore, the modified mobile phase improved the retention of Muraglitazar, a hydrophobic compound, on the normal phase silica column. The validation results demonstrated that this method was rugged and suitable for analyzing Muraglitazar in human plasma. In comparison with a revised-phase LC/MS/MS method, this single-pot LLE, HILIC/MS/MS method improved the detection sensitivity by >4 -fold based upon the LLOQ signal to noise ratio. This approach may be applied to other hydrophobic compds. with proper modification of the mobile phase compns.


IT 331741-94-7, Muraglitazar
 RL: ANT (Analyte); ANST (Analytical study)
 (96-well single-pot liquid-liquid extraction and hydrophilic interaction liquid chromatog.-mass spectrometry method for determination of Muraglitazar in human

L7 ANSWER 10 OF 83 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
 plasmale
 RN 331741-94-7 CAPLUS
 CN Glycine, N-[[4-(methoxyphenoxy)carbonyl]-N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 33 THERE ARE 33 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE
 FORMAT


L7 ANSWER 11 OF 83 CAPLUS COPYRIGHT 2006 ACS on STN
 ACCESSION NUMBER: 2006:460741 CAPLUS
 DOCUMENT NUMBER: 145:116664
 TITLE: Biotransformation of carbon-14-labeled muraglitazar in male mice: interspecies difference in metabolic pathways leading to unique metabolites
 AUTHOR(S): Li, Wenying; Zhang, Donglu; Wang, Lifei; Zhang, Hao; Cheng, Peter T.; Zhang, Duxi; Everett, Donald W.; Humphreys, W. Griffith
 CORPORATE SOURCE: Pharmaceutical Candidate Optimization, Pharmaceutical Research Institute, Princeton, NJ, USA
 SOURCE: Drug Metabolism and Disposition (2006), 34(5), 807-820
 PUBLISHER: American Society for Pharmacology and Experimental Therapeutics
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 GI




AB Muraglitazar (Pargluva; Bristol-Myers Squibb), a dual α/γ peroxisome proliferator-activated receptor activator, is under development for treatment of type 2 diabetes. This study describes the biotransformation profile of carbon-14-labeled muraglitazar in plasma, urine, feces, and bile samples from male CD-1 mice (intact and bile duct cannulation (BDC)) after single oral doses of 1 and 40 mg/kg. The major drug-related component circulating in mouse plasma was the parent compound for up to 4 h postdose. Similar to excretion profiles of muraglitazar in humans, monkeys, and rats, urinary excretion was the minor and fecal excretion via the biliary route was the major elimination pathway for muraglitazar in mice. The parent compound was a minor component in urine, bile, and feces, indicating that muraglitazar was extensively metabolized in mice. Major biotransformation pathways of muraglitazar in mice included taurine conjugate formation, acyl glucuronidation, hydroxylation,

L7 ANSWER 11 OF 83 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
 and O-dealkylation. In addn. to those metabolites previously identified in humans, monkeys, and rats (M1-M21), several unique metabolites identified in mice included taurine conjugates (M24, M25, M26a,b,c, and M31), oxazole-ring-opened metabolites (M27 and M28), glutathione conjugates (M29a,b and M30), a dihydroxylated metabolite (M32), hydroxylated metabolites (M33 and M35), and a dehydrogenated metabolite (M34). The taurine conjugate of muraglitazar (I), was a major metabolite in mice, accounting for 12 to 15% of the total dose in BDC mice or 7 to 13% of the total dose in intact mice. None of these taurine and glutathione conjugates were found in the bile samples of humans, monkeys, or rats.
 IT 331741-94-7D, Muraglitazar, metabolites 331742-23-5
 875430-17-4 875430-18-5 875430-19-6
 875430-20-9 875430-21-0 875430-23-2
 875430-24-3 875430-25-4 875430-27-6
 875541-39-2 875541-41-6 886984-57-2
 886984-58-3 896131-26-3 896131-27-4
 896131-28-5

RL: BSU (Biological study, unclassified); BIOL (Biological study) (biotransformation of carbon-14-labeled muraglitazar in male mice and interspecies difference in metabolic pathways leading to unique metabolites)
 RN 331741-94-7 CAPLUS
 CN Glycine, N-[[4-(methoxyphenoxy)carbonyl]-N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- (9CI) (CA INDEX NAME)




RN 331742-23-5 CAPLUS
 CN Glycine, N-[[4-(4-hydroxyphenoxy)carbonyl]-N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- (9CI) (CA INDEX NAME)




RN 875430-17-4 CAPLUS
 CN Glycine, N-[[4-[2-hydroxy-2-[5-(hydroxymethyl)-2-phenyl-4-oxazolyl]ethoxy]phenyl]methyl]-N-[[4-(methoxyphenoxy)carbonyl]- (9CI) (CA INDEX NAME)


L7 ANSWER 11 OF 83 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 875430-18-5 CAPLUS
 CN Glycine, N-[[4-[2-[5-(hydroxymethyl)-2-phenyl-4-oxazolyl]ethoxy]phenyl]methyl]-N-[[4-(4-hydroxyphenoxy)carbonyl]- (9CI) (CA INDEX NAME)



RN 875430-19-6 CAPLUS
 CN Glycine, N-[[4-(4-hydroxyphenoxy)carbonyl]-N-[[4-[2-[2-(4-hydroxyphenyl)-5-methyl-4-oxazolyl]ethoxy]phenyl]methyl]- (9CI) (CA INDEX NAME)




RN 875430-20-9 CAPLUS
 CN Glycine, N-[[4-[2-hydroxy-2-[5-(hydroxymethyl)-2-phenyl-4-oxazolyl]ethoxy]phenyl]methyl]-N-[[4-(4-hydroxyphenoxy)carbonyl]- (9CI) (CA INDEX NAME)




RN 875430-21-0 CAPLUS


L7 ANSWER 11 OF 83 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
 CN Glycine, N-[[4-[2-[5-(hydroxymethyl)-2-(4-hydroxyphenyl)-4-oxazolyl]ethoxy]phenyl]methyl]-N-[(4-methoxyphenoxy)carbonyl]- (9CI) (CA INDEX NAME)



RN 875430-23-2 CAPLUS
 CN Glycine, N-[[4-[2-[5-(hydroxymethyl)-2-phenyl-4-oxazolyl]ethoxy]phenyl]methyl]-N-[(4-methoxyphenoxy)carbonyl]- (9CI) (CA INDEX NAME)




RN 875430-24-3 CAPLUS
 CN Glycine, N-[[4-[2-[2-(4-hydroxyphenyl)-5-methyl-4-oxazolyl]ethoxy]phenyl]methyl]-N-[(4-methoxyphenoxy)carbonyl]- (9CI) (CA INDEX NAME)



RN 875430-25-4 CAPLUS
 CN 5-Oxazolecarboxylic acid, 4-[2-[4-[[[(carboxymethyl)[(4-methoxyphenoxy)carbonyl]amino]methyl]phenoxy]ethyl]-2-phenyl- (9CI) (CA INDEX NAME)


L7 ANSWER 11 OF 83 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



D1-OH


RN 886984-57-2 CAPLUS
 CN β-D-Glucopyranosiduronic acid, 4-[4-[2-[4-[[[(carboxymethyl)[(4-hydroxyphenoxy)carbonyl]amino]methyl]phenoxy]ethyl]-5-methyl-2-oxazolyl]phenyl (9CI) (CA INDEX NAME)

Absolute stereochemistry.




PAGE 1-A


PAGE 1-B




L7 ANSWER 11 OF 83 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 875430-27-6 CAPLUS
 CN Glycine, N-[[4-[2-[5-(hydroxy-2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-N-[(4-methoxyphenoxy)carbonyl]- (9CI) (CA INDEX NAME)



RN 875541-39-2 CAPLUS
 CN Glycine, N-[[4-[2-[5-(hydroxymethyl)-2-phenyl-4-oxazolyl]ethoxy]phenyl]methyl]-N-[(4-methoxyphenoxy)carbonyl]-, monohydroxy deriv. (9CI) (CA INDEX NAME)



D1-OH


RN 875541-41-6 CAPLUS
 CN Glycine, N-[[4-[2-[5-(hydroxymethyl)-2-phenyl-4-oxazolyl]ethoxy]phenyl]methyl]-N-[(4-methoxyphenoxy)carbonyl]-, monohydroxy deriv. (9CI) (CA INDEX NAME)

L7 ANSWER 11 OF 83 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)


RN 886984-58-3 CAPLUS
 CN β-D-Glucopyranosiduronic acid, 4-[4-[2-[4-[[[(carboxymethyl)[(4-methoxyphenoxy)carbonyl]amino]methyl]phenoxy]ethyl]-5-methyl-2-oxazolyl]phenyl (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B




RN 896131-26-3 CAPLUS
 CN Ethanesulfonic Acid, 2-[[[[(4-methoxyphenoxy)carbonyl][4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]amino]acetyl]amino]- (9CI) (CA INDEX NAME)


10788996

11/26/06


L7 ANSWER 11 OF 83 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 896131-27-4 CAPLUS
 CN Ethanesulfonic acid, 2-[[[4-(4-hydroxyphenoxy)carbonyl] [4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]amino]acetyl]amino]- (9CI) (CA INDEX NAME)



RN 896131-28-5 CAPLUS
 CN Glycine, N-[[4-(4-methoxyphenoxy)carbonyl]-N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- (9CI) (CA INDEX NAME)



IT 331741-94-7, Mureglitazar
 RL: PKT (Pharmacokinetics); BIOL (Biological study)
 (biotransformation of carbon-14-labeled mureglitazar in male mice and interspecies difference in metabolic pathways leading to unique metabolites)

RN 331741-94-7 CAPLUS
 CN Glycine, N-[[4-(4-methoxyphenoxy)carbonyl]-N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- (9CI) (CA INDEX NAME)

L7 ANSWER 12 OF 83 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2006:383580 CAPLUS
 DOCUMENT NUMBER: 144:404429
 TITLE: A method using farnesoid X receptor (FXR) agonists with PPAR agonists for reducing drug-induced adverse side effects in a patient
 INVENTOR(S): Fiorucci, Stefano; Pellicciari, Roberto; Pruzanski, Mark
 PATENT ASSIGNEE(S): Intercept Pharmaceuticals Inc., USA
 SOURCE: PCT Int. Appl., 35 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2006044391	A1	20060427	WO 2005-US16536	20051014
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
US 2006252670	A1	20061109	US 2005-250298	20051013
PRIORITY APPLN. INFO.:			US 2004-619381P	P 20041014


AB The invention relates to the discovery that farnesoid X receptor (FXR) agonists can be used in combination with peroxisome proliferation activated receptor γ (PPAR γ) agonists to reduce drug-induced adverse side effects in patients suffering from conditions such as insulin resistance, Type II diabetes, metabolic syndrome, non-alc. fatty liver disease (NAFLD), non-alc. steatohepatitis (NASH), and heart disease.

Particularly, the invention encompasses methods for treating patients suffering from drug-induced adverse side effects with selective PPAR γ , dual PPAR α/γ and pan PPAR $\alpha/\gamma/\delta$ agonists in combination with FXR agonists.

IT 331741-94-7, Mureglitazar
 RL: ADV (Adverse effect, including toxicity); PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (FXR agonist combination with PPAR agonist for reduction of drug-induced adverse effects)

RN 331741-94-7 CAPLUS
 CN Glycine, N-[[4-(4-methoxyphenoxy)carbonyl]-N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- (9CI) (CA INDEX NAME)


L7 ANSWER 11 OF 83 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



REFERENCE COUNT: 12 THERE ARE 12 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE

FORMAT

L7 ANSWER 12 OF 83 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



REFERENCE COUNT: 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE

FORMAT

10788996

11/26/06

L7 ANSWER 13 OF 83 CAPLUS COPYRIGHT 2006 ACS ON STN

ACCESSION NUMBER: 2006:328189 CAPLUS

DOCUMENT NUMBER: 145:302

TITLE: Structure-Based Drug Design of a Novel Family of PPAR γ Partial Agonists: Virtual Screening, X-ray Crystallography, and in Vitro/in Vivo Biological Activities

AUTHOR(S): Lu, I-Lin; Huang, Chien-Fu; Peng, Yi-Hui; Lin, Ying-Ting; Heieh, Heing-Pang; Chen, Chiung-Tong; Lien,

Tzu-Wen; Lee, Hwei-Jen; Mahindroo, Neeraj; Prakash, Ekambaranilore; Yuch, Andrew; Chen, Hsin-Yi; Goparaju, Chandra M. V.; Chen, Xin; Liao, Chun-Chen; Chao, Yu-Sheng; Hsu, John T.-A.; Wu, Su-Ying

CORPORATE SOURCE: Division of Biotechnology and Pharmaceutical Research, National Health Research Institutes, Taipei, Taiwan

SOURCE: Journal of Medicinal Chemistry (2006), 49(9), 2703-2712

CODEN: JMCMAJ; ISSN: 0022-2623

PUBLISHER: American Chemical Society

DOCUMENT TYPE: Journal

LANGUAGE: English

AB Peroxisome proliferator-activated receptor γ (PPAR γ) is well-known as the receptor of thiazolidinedione antidiabetic drugs. In this paper, we present a successful example of employing structure-based virtual screening, a method that combines shape-based database searchwith a docking study and analog search, to discover a novel family of PPAR γ agonists based upon pyrazol-5-ylbenzenesulfonamide. Two analogs in the family show high affinity for, and specificity to, PPAR γ and act as partial agonists. They also demonstrate glucose-lowering efficacy in vivo. A structural biol. study reveals that they both adopt a distinct binding mode and have no H-bonding interactionswith PPAR γ . The absence of H-bonding interaction with the protein provides an explanation why both function as partial agonists since most full agonists form conserved H-bonds with the activation function helix (AF-2 helix) which, in turn, enhances the recruitment of coactivators. Moreover, the structural biol. and computer docking studies reveal the specificity of the compds. for PPAR γ could be due to the restricted access to the binding pocket of other PPAR subtypes, i.e., PPAR α and PPAR δ , and steric hindrance upon the ligand binding.

IT 888487-50-1


RL: PRP (Properties) (pharmacophore; structure-based drug design of PPAR γ partial agonists; virtual screening, X-ray crystallog., and biol. action)

RN 888487-50-1 CAPLUS

CN D-Tyrosine, N-(1-methyl-3-oxo-3-phenylpropyl)-O-[2-(5-methyl-2-phenyl-4-oxazolyl)ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L7 ANSWER 13 OF 83 CAPLUS COPYRIGHT 2006 ACS ON STN (Continued)



REFERENCE COUNT: 32 THERE ARE 32 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE

FORMAT

L7 ANSWER 14 OF 83 CAPLUS COPYRIGHT 2006 ACS ON STN

ACCESSION NUMBER: 2006:328189 CAPLUS

DOCUMENT NUMBER: 144:305154

TITLE: C-aryl glucoside SGLT2 inhibitors and method for the treatment of diabetes and related diseases

INVENTOR(S): Washburn, William; Meng, Wei

PATENT ASSIGNEE(S): USA

SOURCE: U.S. Pat. Appl. Publ., 19 pp.

CODEN: USXXCO

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2006063722	A1	20060323	US 2005-233617	20050923
WO 2006034489	A2	20060330	WO 2005-US34359	20050923
WO 2006034489	A3	20060706		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GR, GU, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW

RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

PRIORITY APPLN. INFO.: US 2004-612599P P 20040923

GI



AB The invention discloses a compound I, (preparation described) as well as a method

for treating diabetes and related diseases employing I alone or in combination with another therapeutic agent

IT 331741-94-7, Muraglitazone 331744-64-0, Peliglitazone

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)


(aryl glucoside SGLT2 inhibitors for treatment of diabetes and related diseases, and use with other agents)

RN 331741-94-7 CAPLUS

CN Glycine, N-[(4-methoxyphenoxy)carbonyl]-N-[(4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl)methyl]- (9CI) (CA INDEX NAME)

Page 16 SAEED

L7 ANSWER 14 OF 83 CAPLUS COPYRIGHT 2006 ACS ON STN (Continued)




RN 331744-64-0 CAPLUS

CN Glycine,

N-[(4-methoxyphenoxy)carbonyl]-N-[(1S)-1-[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L7 ANSWER 15 OF 83 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2006:181010 CAPLUS

DOCUMENT NUMBER: 145:137069

TITLE: Muraglitazar: an agent for the treatment of type 2 diabetes and associated dyslipidemia

AUTHOR(S): Cox, Sandra L.

CORPORATE SOURCE: Medical Information Department, Prous Science, Barcelona, Spain

SOURCE: Drugs of Today (2005), 41(9), 579-587

CODEN: MDACAP; ISSN: 0025-7656

PUBLISHER: Prous Science

DOCUMENT TYPE: Journal; General Review

LANGUAGE: English

AB A review. Many studies indicate that postprandial metabolic abnormalities, such as hyperglycemia and dyslipidemia, which are exaggerated and prolonged in type 2 diabetes, are important risk factors for cardiovascular disease. Different pharmacotherapies have been

developed to specifically target these risk factors associated with type

2 diabetes. The peroxisome proliferator-activated receptor (PPAR) agonists, which are potent insulin sensitizers, have been the focus of much research during the past decade. Since their development, PPAR agonists have emerged as an important target for the treatment of insulin resistance and dyslipidemia. The more recent development of agonists

that selectively target both the α and γ PPARs has provided a potential treatment of global risk in patients with the metabolic syndromeor type 2 diabetes. Muraglitazar is a non-thiazolidinedione, oxybenzylglycine dual PPAR α/γ agonist that is in advanced clin. development for the treatment of type 2 diabetes and its associated dyslipidemia. This article summarizes the available clin.

data on the efficacy and safety of muraglitazar in patients with type 2 diabetes.

IT 331741-94-7, Muraglitazar


RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(non-thiazolidinedione, oxybenzylglycine dual PPAR α/γ agonist muraglitazar, potent insulin sensitizer improved insulin resistance with favorable safety and tolerability in patient with type 2 diabetes and associated dyslipidemia)

RN 331741-94-7 CAPLUS

CN Glycine, N-[[4-(methoxyphenoxy)carbonyl]-N-[[4-[(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- (9CI) (CA INDEX NAME)

L7 ANSWER 15 OF 83 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



REFERENCE COUNT: 29 THERE ARE 29 CITED REFERENCES AVAILABLE FOR THIS

FORMAT RECORD. ALL CITATIONS AVAILABLE IN THE RE

L7 ANSWER 16 OF 83 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2006:167981 CAPLUS

DOCUMENT NUMBER: 144:233064

TITLE: Preparation of 2-phenyloxazoles as peroxisome proliferator agonist

INVENTOR(S): Glombik, Heiner; Stepper, Christian; Falk, Eugen; Keil, Stefanie; Schaefer, Hans-Ludwig; Wendler, Wolfgang; Knieps, Stephanie

PATENT ASSIGNEE(S): Sanofi-Aventis Deutschland G.m.b.H., Germany

SOURCE: PCT Int. Appl., 74 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: German

FAMILY ACC. NUM. COUNT: 1


PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2006018118	A1	20060223	WO 2005-EP8284	20050730
WO 2006018118	C1	20060518		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RN: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GO, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
DE 102004039533	A1	20060302	DE 2004-102004039533	20040814
DE 102004039533	B4	20060928		
PRIORITY APPLN. INFO.: DE 2004-102004039533A 20040814				

OTHER SOURCE(S): MARPAT 144:233064

GI

L7 ANSWER 16 OF 83 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)

AB Title compe. I [R = H, CF₃; R₁ = H, CF₃, alkyl, etc.; R₂ = H, alkyl, alkoxy, etc.; R₃ = alkyl; R₄ = alkyl, benzyl; R₅ = H, alkyl] and their pharmaceutically acceptable salts were prepared. For example, TPA mediateddeprotection of t-Bu ester II (R₅ = t-Bu) afforded carboxylic acid II (R₅ = H). In PPAR γ receptor binding assays, compe. I exhibited EC₅₀values ranging from 0.0016-0.3813 μ M.

IT 876586-74-2P 876586-75-3P 876586-76-4P

876586-77-5P 876586-78-6P 876586-79-7P

876586-80-0P 876586-81-1P 876586-82-2P

876586-83-3P 876586-85-5P 876586-86-6P

876586-88-8P 876586-89-9P 876586-90-2P

876586-91-3P 876586-93-5P 876586-94-6P


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of 2-phenyloxazoles as peroxisome proliferator agonist)

RN 876586-74-2 CAPLUS

CN Propanoic acid, 2-[[[(1S,3R)-3-[[[5-ethyl-2-[4-(trifluoromethyl)phenyl]-4-oxazolyl]methoxy]methyl]cyclohexyl]methoxy]-2-methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 876586-75-3 CAPLUS

CN Propanoic acid, 2-[[[(1S,3R)-3-[[[5-ethyl-2-[4-(trifluoromethyl)phenyl]-4-


L7 ANSWER 16 OF 83 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
oxazolyl)methoxy)methyl)cyclohexyl)methoxy]-2-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 876586-76-4 CAPLUS
CN Propanoic acid, 2-[[[(1S,3R)-3-[[[5-ethyl-2-(2-(trifluoromethyl)phenyl]-4-oxazolyl)methoxy)methyl]cyclohexyl)methoxy]-2-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 876586-77-5 CAPLUS
CN Propanoic acid, 2-[[[(1S,3R)-3-[[[2-(3,4-dimethylphenyl)-5-ethyl-4-oxazolyl)methoxy)methyl]cyclohexyl)methoxy]-2-methyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 876586-78-6 CAPLUS
CN Propanoic acid, 2-[[[(1S,3R)-3-[[[2-(4-(1,1-dimethylethyl)phenyl)-5-ethyl-4-oxazolyl)methoxy)methyl]cyclohexyl)methoxy]-2-methyl- (9CI) (CA INDEX NAME)


L7 ANSWER 16 OF 83 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
NAME)

Absolute stereochemistry.




RN 876586-82-2 CAPLUS
CN Propanoic acid, 2-[[[(1S,3R)-3-[[[2-(4-(1,1-dimethylethyl)phenyl)-5-(1-methylethyl)-4-oxazolyl)methoxy)methyl]cyclohexyl)methoxy]-2-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 876586-83-3 CAPLUS
CN Propanoic acid, 2-[[[(1S,3R)-3-[[[2-(3-methoxyphenyl)-5-(1-methylethyl)-4-oxazolyl)methoxy)methyl]cyclohexyl)methoxy]-2-methyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 876586-85-5 CAPLUS
CN Propanoic acid, 2-[[[(1R,3S)-3-[[[2-(3,4-dimethylphenyl)-5-(1-methylethyl)-4-oxazolyl)methoxy)methyl]cyclohexyl)methoxy]-2-methyl- (9CI) (CA INDEX NAME)


L7 ANSWER 16 OF 83 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
oxazolyl)methoxy)methyl)cyclohexyl)methoxy]-2-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 876586-79-7 CAPLUS
CN Propanoic acid, 2-methyl-2-[[[(1S,3R)-3-[[[5-(1-methylethyl)-2-(4-(trifluoromethyl)phenyl)-4-oxazolyl)methoxy)methyl]cyclohexyl)methoxy]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 876586-80-0 CAPLUS
CN Propanoic acid, 2-methyl-2-[[[(1S,3R)-3-[[[5-(1-methylethyl)-2-(3-(trifluoromethyl)phenyl)-4-oxazolyl)methoxy)methyl]cyclohexyl)methoxy]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 876586-81-1 CAPLUS
CN Propanoic acid, 2-[[[(1S,3R)-3-[[[2-(3,4-dimethylphenyl)-5-(1-methylethyl)-4-oxazolyl)methoxy)methyl]cyclohexyl)methoxy]-2-methyl- (9CI) (CA INDEX NAME)

L7 ANSWER 16 OF 83 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
Absolute stereochemistry.




RN 876586-86-6 CAPLUS
CN Propanoic acid, 2-[[[(1R,3S)-3-[[[2-(1,1'-biphenyl)-4-yl-5-methyl-4-oxazolyl)methoxy)methyl]cyclohexyl)methoxy]-2-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 876586-88-8 CAPLUS
CN Propanoic acid, 2-[[[(1R,3S)-3-[[[5-ethyl-2-(3-methoxyphenyl)-4-oxazolyl)methoxy)methyl]cyclohexyl)methoxy]-2-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 876586-89-9 CAPLUS
CN Propanoic acid, 2-methyl-2-[[[(1R,3S)-3-[[[5-(1-methylethyl)-2-(3-(trifluoromethyl)phenyl)-4-oxazolyl)methoxy)methyl]cyclohexyl)methoxy]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


10788996 11/26/06

L7 ANSWER 16 OF 83 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 876586-90-2 CAPLUS
CN Propanoic acid, 2-[[[(1R,3S)-3-[[[2-(2,2-dimethylpropyl)phenyl]-5-(1-methylethyl)-4-oxazolyl]methoxy]methyl]cyclohexyl]methoxy]-2-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 876586-91-3 CAPLUS
CN Propanoic acid, 2-[[[(1R,3S)-3-[[[2-(1,1-dimethylethyl)phenyl]-5-(1-methylethyl)-4-oxazolyl]methoxy]methyl]cyclohexyl]methoxy]-2-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 876586-93-5 CAPLUS
CN Propanoic acid, 2-methyl-2-[[[(1R,3S)-3-[[[5-methyl-2-(4-phenoxyphenyl)-4-oxazolyl]methoxy]methyl]cyclohexyl]methoxy]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


L7 ANSWER 16 OF 83 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
FORMAT RECORD. ALL CITATIONS AVAILABLE IN THE RE

L7 ANSWER 16 OF 83 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 876586-94-6 CAPLUS
CN Propanoic acid, 2-[[[(1R,3S)-3-[[[2-(3,4-dimethylphenyl)-5-ethyl-4-oxazolyl]methoxy]methyl]cyclohexyl]methoxy]-2-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




IT 876587-02-9P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation of 2-phenyloxazoles as peroxisome proliferator agonist)

RN 876587-02-9 CAPLUS
CN Propanoic acid, 2-[[[(1S,3R)-3-[[[5-ethyl-2-(4-(trifluoromethyl)phenyl)-4-oxazolyl]methoxy]methyl]cyclohexyl]methoxy]-2-methyl-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS

L7 ANSWER 17 OF 83 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2006:166904 CAPLUS
DOCUMENT NUMBER: 144:233062
TITLE: Preparation of 2-phenyloxazoles as peroxisome proliferator agonist
INVENTOR(S): Glombik, Heiner; Stapper, Christian; Falk, Eugen; Keil, Stefanie; Schaefer, Hans-Ludwig; Wendler, Wolfgang; Knieps, Stephanie
PATENT ASSIGNEE(S): Sanofi-Aventis Deutschland G.m.b.H., Germany
SOURCE: PCT Int. Appl., 73 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: German
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2006018115	A1	20060223	WO 2005-EP8281	20050730
M: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MY, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CP, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
DE 102004039532	A1	20060302	DE 2004-102004039532	20040814
DE 102004039532	B4	20060921		
PRIORITY APPLN. INFO.:			DE 2004-102004039532A	20040814
OTHER SOURCE(S):			MARPAT 144:233062	
GI				

L7 ANSWER 17 OF 83 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



AB Title compds. I [R1 = H, alkyl; R2 = H, alkoxy, CF3; R3 = alkyl; R4 = alkyl, benzyl; R5 = H, alkyl] and their pharmaceutically acceptable salts were prepared. For example, TPA mediated deprotection of ester II (R5 = t-Bu) afforded acid II (R5 = H). In PPARY receptor binding assays, compds. I exhibited EC50 values ranging from 0.00016-0.32μM.

IT 876588-46-4P 876588-47-5P 876588-48-6P
876588-50-0P 876588-52-2P 876588-53-3P
876588-54-4P 876588-55-5P 876588-56-6P
876588-59-9P 876588-60-2P 876588-61-3P


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of 2-phenyloxazoles as peroxisome proliferator agonist)

RN 876588-46-4 CAPLUS

CN Propanoic acid, 2-[[[(1R,3S)-3-[[5-ethyl-2-(3-methoxyphenyl)-4-oxazolyl]methoxy]cyclohexyl]methoxy]-2-methyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 876588-47-5 CAPLUS

CN Propanoic acid, 2-[[[(1R,3S)-3-[[5-ethyl-2-(4-methylphenyl)-4-


L7 ANSWER 17 OF 83 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 876588-53-3 CAPLUS

CN Propanoic acid, 2-[[[(1R,3S)-3-[[2-(3-methoxyphenyl)-5-(1-methylethyl)-4-oxazolyl]methoxy]cyclohexyl]methoxy]-2-methyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 876588-54-4 CAPLUS

CN Pentanoic acid, 2-[[[(1R,3S)-3-[[5-ethyl-2-(3-methoxyphenyl)-4-oxazolyl]methoxy]cyclohexyl]methoxy]-2-methyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 876588-55-5 CAPLUS

CN Pentanoic acid, 2-[[[(1R,3S)-3-[[5-ethyl-2-(4-methylphenyl)-4-oxazolyl]methoxy]cyclohexyl]methoxy]-2-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 876588-56-6 CAPLUS

L7 ANSWER 17 OF 83 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)

oxazolyl]methoxy]cyclohexyl]methoxy]-2-methyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 876588-48-6 CAPLUS

CN Propanoic acid, 2-[[[(1R,3S)-3-[[2-(4-(2,2-dimethylpropyl)phenyl)-5-ethyl-4-oxazolyl]methoxy]cyclohexyl]methoxy]-2-methyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 876588-50-0 CAPLUS

CN Propanoic acid, 2-[[[(1R,3S)-3-[[5-ethyl-2-(3-(trifluoromethyl)phenyl)-4-oxazolyl]methoxy]cyclohexyl]methoxy]-2-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 876588-52-2 CAPLUS

CN Propanoic acid, 2-[[[(1R,3S)-3-[[2-(3-methoxyphenyl)-5-(1-methylethyl)-4-oxazolyl]methoxy]cyclohexyl]methoxy]-2-methyl- (9CI) (CA INDEX NAME)

L7 ANSWER 17 OF 83 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)

CN Pentanoic acid, 2-[[[(1R,3S)-3-[[2-(4-(2,2-dimethylpropyl)phenyl)-5-ethyl-4-oxazolyl]methoxy]cyclohexyl]methoxy]-2-methyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 876588-59-9 CAPLUS

CN Benzenepropanoic acid, α-[[[(1R,3S)-3-[[5-ethyl-2-(3-methoxyphenyl)-4-oxazolyl]methoxy]cyclohexyl]methoxy]-α-methyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 876588-60-2 CAPLUS

CN Benzenepropanoic acid, α-[[[(1R,3S)-3-[[5-ethyl-2-(4-methylphenyl)-4-oxazolyl]methoxy]cyclohexyl]methoxy]-α-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 876588-61-3 CAPLUS

CN Benzenepropanoic acid, α-[[[(1R,3S)-3-[[2-(4-(2,2-dimethylpropyl)phenyl)-5-ethyl-4-oxazolyl]methoxy]cyclohexyl]methoxy]-α-methyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L7 ANSWER 17 OF 83 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




IT 876588-68-OP 876588-74-8P 876588-77-1P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (preparation of 2-phenyloxazoles as peroxisome proliferator agonist)
 RN 876588-68-0 CAPLUS
 CN Propanoic acid, 2-[[[(1R,3S)-3-[[[5-ethyl-2-(3-methoxyphenyl)-4-oxazolyl]methoxy]cyclohexyl]methoxy]-2-methyl-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 876588-74-8 CAPLUS
 CN Pentanoic acid, 2-[[[(1R,3S)-3-[[[5-ethyl-2-(3-methoxyphenyl)-4-oxazolyl]methoxy]cyclohexyl]methoxy]-2-methyl-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 876588-77-1 CAPLUS
 CN Benzenepropanoic acid, α-[[[(1R,3S)-3-[[[5-ethyl-2-(3-methoxyphenyl)-4-oxazolyl]methoxy]cyclohexyl]methoxy]-α-methyl-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L7 ANSWER 18 OF 83 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2006:119838 CAPLUS

DOCUMENT NUMBER: 144:213022

TITLE:

Preparation of human glucagon-like-peptide-1 modulators and their use in the treatment of diabetes and related conditions

INVENTOR(S): Ewing, William R.; Mapelli, Claudio; Sulsky, Richard B.; Haque, Tasir S.; Lee, Ying G.; Riexinger, Douglas James; Martinez, Rogelio L.; Zhu, Yeheng

PATENT ASSIGNEE(S): Bristol-Myers Squibb Company, USA

SOURCE: PCT Int. Appl., 236 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2006014287	A1	20060209	WO 2005-US23076	20050630
WO 2006014287	C1	20060526		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MY, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW


RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

PRIORITY APPLN. INFO.: US 2004-585358P P 20040702
 US 2005-684805P P 20050526

AB The invention provides novel human glucagon-like peptide-1 (GLP-1)-receptor modulators Xaa1-Xaa2-Xaa3-Xaa4-Xaa5-Xaa6-Xaa7-Xaa8-Xaa9-Xaa10-Xaa11 [Xaa1-Xaa3, Xaa5-Xaa11 are (certain) naturally or non-naturally occurring amino acid residues; Xaa4 is glycine] that have biol. activity similar or superior to native GLP-1 peptide and thus are useful for the treatment or prevention of diseases or disorders associated with GLP activity. The novel, chemical modified peptides not only stimulate insulin secretion in type II diabetics, but also produce other beneficial insulinotropic responses. These synthetic peptide GLP-1 receptor modulators exhibit increased stability to proteolytic cleavage making them ideal therapeutic candidates for oral or parenteral administration. Peptides of the invention show desirable pharmacokinetic properties and desirable potency in efficacy models of diabetes. Thus, claimed peptide H-N-Aib-EGT-L-α-MePhe(2'-fluoro)-TSD-Bip(2'-Et-4'-OMe)-4-(2'-methylphenyl)-3-pyridylalanine-NH2 (H, E, G, T, S and D are one-letter amino acid symbols, Aib = α-aminoisobutyric acid residue, Bip = biphenylalanine residue) was prepared by the solid-phase method and shown to produce a time-dependent statistically significant decrease in postprandial plasma glucose following s.c. administration in ob/ob mice.

Page 21 SAEED

L7 ANSWER 17 OF 83 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE

FORMAT

L7 ANSWER 18 OF 83 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)

IT 258345-41-4, GW 409544 331741-94-7, Muraglitazar

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)


(preparation of human glucagon-like-peptide-1 modulators and their use in treatment of diabetes and related conditions)

RN 258345-41-4 CAPLUS

CN L-Tyrosine, N-[[[(12)-1-methyl-3-oxo-3-phenyl-1-propenyl]-O-[2-(5-methyl-2-phenyl-4-oxazolyl)ethyl]]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

Double bond geometry as shown.



RN 331741-94-7 CAPLUS

CN Glycine, N-[[[(4-methoxyphenoxy)carbonyl]-N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- (9CI) (CA INDEX NAME)




REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE


FORMAT

L7 ANSWER 19 OF 83 CAPLUS COPYRIGHT 2006 ACS on STN
 ACCESSION NUMBER: 2006:104477 CAPLUS
 DOCUMENT NUMBER: 144:205122
 TITLE: Structural elucidation of human oxidative metabolites of mureglitazur: use of microbial bioreactors in the biosynthesis of metabolite standards
 AUTHOR(S): Zhang, Donglu; Zhang, Haiying; Aranibar, Nelly; Hanson, Ronald; Huang, Yande; Cheng, Peter T.; Wu, Shung; Bonacorsi, Samuel; Zhu, Mingshe; Swaminathan, Arun; Humphreys, W. Griffith
 CORPORATE SOURCE: Pharmaceutical Candidate Optimization, Pharmaceutical Research Institute, Princeton, NJ, USA
 SOURCE: Drug Metabolism and Disposition (2006), 34(2), 267-280
 PUBLISHER: American Society for Pharmacology and Experimental Therapeutics
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 AB Mureglitazur (Pargluva), a dual α/γ peroxisome proliferator-activated receptor activator, is currently in clin. development for treatment of type 2 diabetes. This study describes the structural elucidation of the human oxidative metabolites of mureglitazur through the use of a combination of microbial bioreactors, NMR and accurate mass analyses, and organic synthesis. Plasma, urine, and feces were collected from six healthy subjects following oral administration of ^{14}C -labeled mureglitazur (10 mg, 100 μCi) and pooled samples were analyzed. Approx. 96% of the recovered radioactive dose was found in the feces and 3.5% in the urine. The parent compound represented >85% of the radioactivity in plasma. The fecal radioactivity was distributed among 16 metabolites (M1-M12, M14-M16, and M8a) and the parent drug, of which hydroxylation and O-demethylation metabolites (M5, M10, M11, M14, and M15) represented the prominent human metabolites. The urinary radioactivity was distributed into several peaks including mureglitazur glucuronide (M13) and the parent drug. Low concns. of metabolites in human samples prevented direct identification of metabolites beyond liquid chromatog. (LC)-mass spectrometric anal. Microbial strains *Cunninghamella elegans* and *Saccharopolyspora hireuta* produced mureglitazur metabolites that had the same high performance liquid chromatog. retention times and the same tandem mass spectrometric (MS/MS) properties as the corresponding human metabolites. The microbial metabolites M5, M10, M11, M14, M15, and M16 were isolated and analyzed by NMR. Based on these LC-MS/MS and NMR analyses, and organic synthesis, the structures of 16 human oxidative metabolites were identified. The oxidative metabolism of mureglitazur was characterized by hydroxylation, O-demethylation, oxazole ring opening, and O-demethylation/hydroxylation, as well as O-dealkylation and carboxylic acid formation. This study demonstrated the utility of microbial bioreactors for the identification of metabolites.
 IT 331742-23-5 875430-17-4 875430-19-6


L7 ANSWER 19 OF 83 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
 oxazolyl]ethoxy]phenyl]methyl]-N-[(4-hydroxyphenoxy)carbonyl]- (9CI) (CA INDEX NAME)



RN 875430-21-0 CAPLUS
 CN Glycine, N-[(4-{2-[5-(hydroxymethyl)-2-(4-hydroxyphenyl)-4-oxazolyl]ethoxy]phenyl]methyl]-N-[(4-methoxyphenoxy)carbonyl]- (9CI) (CA INDEX NAME)



RN 875430-23-2 CAPLUS
 CN Glycine, N-[(4-{2-[5-(hydroxymethyl)-2-phenyl-4-oxazolyl]ethoxy]phenyl]methyl]-N-[(4-methoxyphenoxy)carbonyl]- (9CI) (CA INDEX NAME)




RN 875430-24-3 CAPLUS
 CN Glycine, N-[(4-{2-[5-(hydroxymethyl)-2-phenyl-4-oxazolyl]ethoxy]phenyl]methyl]-N-[(4-methoxyphenoxy)carbonyl]- (9CI) (CA INDEX NAME)

L7 ANSWER 19 OF 83 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)


875430-20-9 875430-21-0 875430-23-2
 875430-24-3 875430-26-5 875430-27-6
 875541-38-1 875541-39-2 875541-40-5
 875541-41-6

RL: BSU (Biological study, unclassified); BIOL (Biological study) (structures of human oxidative metabolites of mureglitazur and use of microbial bioreactors in biosynthesis of metabolite stds.)


RN 331742-23-5 CAPLUS
 CN Glycine, N-[(4-hydroxyphenoxy)carbonyl]-N-[(4-{2-[5-methyl-2-phenyl-4-oxazolyl]ethoxy]phenyl]methyl]- (9CI) (CA INDEX NAME)



RN 875430-17-4 CAPLUS
 CN Glycine, N-[(4-{2-hydroxy-2-[5-(hydroxymethyl)-2-phenyl-4-oxazolyl]ethoxy]phenyl]methyl]-N-[(4-methoxyphenoxy)carbonyl]- (9CI) (CA INDEX NAME)




RN 875430-19-6 CAPLUS
 CN Glycine, N-[(4-hydroxyphenoxy)carbonyl]-N-[(4-{2-[2-(4-hydroxyphenyl)-5-methyl-4-oxazolyl]ethoxy]phenyl]methyl]- (9CI) (CA INDEX NAME)




RN 875430-20-9 CAPLUS
 CN Glycine, N-[(4-{2-hydroxy-2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-N-[(4-methoxyphenoxy)carbonyl]- (9CI) (CA INDEX NAME)

L7 ANSWER 19 OF 83 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 875430-26-5 CAPLUS
 CN β -D-Glucopyranuronic acid, 1-ester with N-[(4-methoxyphenoxy)carbonyl]-N-[(4-{2-[5-methyl-2-phenyl-4-oxazolyl]ethoxy]phenyl]methyl]glycine (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 875430-27-6 CAPLUS
 CN Glycine, N-[(4-{2-hydroxy-2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-N-[(4-methoxyphenoxy)carbonyl]- (9CI) (CA INDEX NAME)



RN 875541-38-1 CAPLUS
 CN Glycine, N-[(4-hydroxyphenoxy)carbonyl]-N-[(4-{2-[5-methyl-2-phenyl-4-oxazolyl]ethoxy]phenyl]methyl]-, monohydroxy deriv. (9CI) (CA INDEX NAME)


L7 ANSWER 19 OF 83 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



D1-OH

RN 875541-39-2 CAPLUS

CN Glycine, N-[[4-[2-[5-(hydroxymethyl)-2-phenyl-4-oxazolyl]ethoxy]phenyl]methyl]-N-[(4-methoxyphenoxy)carbonyl]-, monohydroxy deriv. (9CI) (CA INDEX NAME)




D1-OH

RN 875541-40-5 CAPLUS


CN β-D-Glucopyranuronic acid, glycoside with N-[[4-[2-[5-methyl-2-phenyl-4-oxazolyl]ethoxy]phenyl]methyl]glycine monohydroxy deriv. (9CI) (CA INDEX NAME)

L7 ANSWER 19 OF 83 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 875430-25-4 CAPLUS

CN 5-Oxazolecarboxylic acid, 4-[2-[4-[[[carboxymethyl]([4-methoxyphenoxy)carbonyl]amino]methyl]phenoxy]ethyl]-2-phenyl- (9CI) (CA INDEX NAME)




IT 331741-94-7, Muraglitazar

RL: PKT (Pharmacokinetics); BIOL (Biological study)
(structures of human oxidative metabolites of muraglitazar and use of microbial bioreactors in biosynthesis of metabolite stds.)

RN 331741-94-7 CAPLUS

CN Glycine, N-[[4-[2-[5-(hydroxymethyl)-2-phenyl-4-oxazolyl]ethoxy]phenyl]methyl]-N-[(4-methoxyphenoxy)carbonyl]- (9CI) (CA INDEX NAME)





IT 875430-13-0P 875430-15-2P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(structures of human oxidative metabolites of muraglitazar and use of microbial bioreactors in biosynthesis of metabolite stds.)

RN 875430-13-0 CAPLUS


CN Glycine, N-[[4-[2-[5-(hydroxymethyl)-2-phenyl-4-oxazolyl]ethoxy]phenyl]methyl]-N-[[4-(phenylmethoxy)phenoxy]carbonyl]-, methyl ester (9CI) (CA INDEX NAME)

L7 ANSWER 19 OF 83 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 875541-41-6 CAPLUS

CN Glycine, N-[(4-methoxyphenoxy)carbonyl]-N-[[4-[2-[5-methyl-2-phenyl-4-oxazolyl]ethoxy]phenyl]methyl]-, monohydroxy deriv. (9CI) (CA INDEX NAME)



D1-OH


IT 875430-18-5P 875430-25-4P

RL: BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
(structures of human oxidative metabolites of muraglitazar and use of microbial bioreactors in biosynthesis of metabolite stds.)

RN 875430-18-5 CAPLUS


CN Glycine, N-[[4-[2-[5-(hydroxymethyl)-2-phenyl-4-oxazolyl]ethoxy]phenyl]methyl]-N-[(4-hydroxyphenoxy)carbonyl]- (9CI) (CA INDEX NAME)

L7 ANSWER 19 OF 83 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 875430-15-2 CAPLUS

CN Glycine, N-[[4-[2-[5-formyl-2-phenyl-4-oxazolyl]ethoxy]phenyl]methyl]-N-[(4-methoxyphenoxy)carbonyl]- (9CI) (CA INDEX NAME)

REFERENCE COUNT:
THIS


23 THERE ARE 23 CITED REFERENCES AVAILABLE FOR

FORMAT

RECORD. ALL CITATIONS AVAILABLE IN THE RE

L7 ANSWER 20 OF 83 CAPLUS COPYRIGHT 2006 ACS ON STN
 ACCESSION NUMBER: 2006:16040 CAPLUS
 DOCUMENT NUMBER: 144:285495
 TITLE: A 96-well single-pot protein precipitation, liquid chromatography/tandem mass spectrometry (LC/MS/MS) method for the determination of muraglitazar, a novel diabetes drug, in human plasma
 AUTHOR(S): Xue, Y.-J.; Liu, Jane; Pursley, Janice; Unger, Steve
 CORPORATE SOURCE: Pharmaceutical Candidate Optimization, Pharmaceutical Research Institute, Bristol-Myers Squibb, New Brunswick, NJ, 08903, USA
 SOURCE: Journal of Chromatography, B: Analytical Technologies in the Biomedical and Life Sciences (2006), 831(1-2), 213-222
 CODEN: JCBAAI; ISSN: 1570-0232
 PUBLISHER: Elsevier B.V.
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 AB A 96-well single-pot protein precipitation, liquid chromatog./tandem mass spectrometry (LC/MS/MS) method has been developed and validated for the determination of muraglitazar, a PPAR α/γ dual agonist, in human plasma. The internal standard, a chemical analog, was dissolved in acetonitrile containing 0.1% formic acid. The solvent system was also served as a protein precipitation reagent. Human plasma samples (0.1 mL) and the internal standard solution (0.3 mL) were added to a 96-well plate. The plate was vortexed for 1 min and centrifuged for 5 min. Then the supernatant layers were directly injected into the LC/MS/MS system. The chromatog. separation was achieved isocratically on a Phenomenex C18(2) Luna column (2 mm + 50 mm, 5 μ m). The mobile phase contained 20/80 (volume/volume) of water and acetonitrile containing 0.1% formic acid. Detection was by pos. ion electrospray tandem mass spectrometry on a Sciex API 3000. The standard curve, which ranged from 1 to 1000 ng/mL, was fitted to a 1/x weighted quadratic regression model. This single pot approach effectively eliminated three time consuming sample preparation steps: sample transfer, dry-down, and reconstitution before the injection, while it preserved all the benefits of the traditional protein precipitation. By properly adjusting the autosampler needle offset level, only the supernatant was injected, without disturbing the precipitated proteins in the bottom. As a result, the quality of chromatog. and column life were not compromised. After more than 600 injections, there was only slightly increase of column backpressure. The validation results demonstrated that this method was rugged and provide satisfactory precision and accuracy. The method has been successfully applied to analyze human plasma samples in support of a first-in-man study. This method has also been validated in monkey and mouse plasma for the determination of muraglitazar.
 IT 331741-94-7, Muraglitazar
 RL: AMT (Analyte); AMST (Analytical study)
 (high-throughput single pot protein precipitation of LC/MS/MS determination of


L7 ANSWER 20 OF 83 CAPLUS COPYRIGHT 2006 ACS ON STN (Continued)
 muraglitazar in human plasma)
 RN 331741-94-7 CAPLUS
 CN Glycine, N-[(4-methoxyphenoxy)carbonyl]-N-[[4-(2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy)phenyl]methyl]- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 27 THERE ARE 27 CITED REFERENCES AVAILABLE FOR THIS
 RECORD. ALL CITATIONS AVAILABLE IN THE RE
 FORMAT

L7 ANSWER 21 OF 83 CAPLUS COPYRIGHT 2006 ACS ON STN
 ACCESSION NUMBER: 2006:58079 CAPLUS
 DOCUMENT NUMBER: 144:80977
 TITLE: Muraglitazar, a novel dual (α/γ) peroxisome proliferator-activated receptor activator, improves diabetes and other metabolic abnormalities and preserves β -cell function in db/db mice
 AUTHOR(S): Harrity, Thomas; Farrelly, Dennis; Tieman, Aaron; Chu, Cuixia; Kunselman, Lori; Gu, Ligu; Ponticciello, Randolph; Cep, Michael; Qu, Fucheng; Shao, Chunning; Wang, Wei; Zhang, Hao; Fenderson, William; Chen, Devasthale, Pratik; Jeon, Yoon; Seethala, Ramakrishna; Yang, Wen-Pin; Ren, Jimmy; Zhou, Min; Rycno, Denis; Biller, Scott; Mookhtiar, Kasim A.; Wetterau, John; Gregg, Richard; Cheng, Peter T.; Hariharan, Narayanan
 CORPORATE SOURCE: Department of Metabolic Diseases Biology, Bristol-Myers Squibb Pharmaceutical Research Institute, Princeton, NJ, USA
 SOURCE: Diabetes (2006), 55(1), 240-248
 CODEN: DIAEAS; ISSN: 0012-1797
 PUBLISHER: American Diabetes Association
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 AB Muraglitazar, a novel dual (α/γ) peroxisome proliferator-activated receptor (PPAR) activator, was investigated for its antidiabetic properties and its effects on metabolic abnormalities in genetically obese diabetic db/db mice. In db/db mice and normal mice, muraglitazar treatment modulates the expression of PPAR target genes in white adipose tissue and liver. In young hyperglycemic db/db mice, muraglitazar treatment (0.03-50 mg \cdot kg $^{-1}$ \cdot day $^{-1}$ for 2 wk) results in dose-dependent redns. of glucose, insulin, triglycerides, free fatty acids, and cholesterol. In older hyperglycemic db/db mice, longer-term muraglitazar treatment (30 mg \cdot kg $^{-1}$ \cdot day $^{-1}$ for 4 wk) prevents time-dependent deterioration of glycemic control and development of insulin deficiency. In severely hyperglycemic db/db mice, muraglitazar treatment (10 mg \cdot kg $^{-1}$ \cdot day $^{-1}$ for 2 wk) improves oral glucose tolerance and reduces plasma glucose and insulin levels. In addition, treatment increases insulin content in the pancreas. Finally, muraglitazar treatment increases abnormally low plasma adiponectin levels, increases high-mol. weight adiponectin complex levels, reduces elevated plasma corticosterone levels, and lowers elevated liver lipid content in db/db mice. The overall conclusions are that in db/db mice, the novel dual (α/γ) PPAR activator muraglitazar (1) exerts potent and efficacious antidiabetic effects, (2) preserves pancreatic insulin content, and (3) improves metabolic abnormalities such as hyperlipidemia, fatty liver, low adiponectin levels, and elevated corticosterone levels.
 IT 331741-94-7, Muraglitazar
 RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (muraglitazar, a novel dual (α/γ) peroxisome proliferator-activated receptor activator, improves diabetes and other metabolic abnormalities and preserves β -cell function in

L7 ANSWER 21 OF 83 CAPLUS COPYRIGHT 2006 ACS ON STN (Continued)
 db/db mice)
 RN 331741-94-7 CAPLUS
 CN Glycine, N-[(4-methoxyphenoxy)carbonyl]-N-[[4-(2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy)phenyl]methyl]- (9CI) (CA INDEX NAME)




REFERENCE COUNT: 47 THERE ARE 47 CITED REFERENCES AVAILABLE FOR THIS
 RECORD. ALL CITATIONS AVAILABLE IN THE RE
 FORMAT

L7 ANSWER 22 OF 83 CAPLUS COPYRIGHT 2006 ACS ON STN
 ACCESSION NUMBER: 2006:54690 CAPLUS
 DOCUMENT NUMBER: 144:128961
 TITLE: Preparation of oxazole-containing sulfamides as PPAR α agonists and their pharmaceutical compositions useful for upregulation of lipid metabolism
 INVENTOR(S): Cho, Joong Myung; Lee, Tae Gyu; Ro, Seonggu; Kim, Jin Hwan; Jeon, Young Ho; Shin, Dong Kyu; Hyun, Young-Lan;
 Yon, Gyu Hwan; Yoon, Young-Gwi; Choi, Eun Bok; Lee, Hyeon Kyu; Pak, Chwang Siek
 PATENT ASSIGNEE(S): Crystalgenomics, Inc., S. Korea; Korea Research Institute of Chemical Technology
 SOURCE: PCT Int. Appl., 210 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2006006832	A1	20060119	WO 2005-KR2266	20050714
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MY, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TN, TM, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CP, CG, CI, CM, GA, GN, GO, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
KR 2006005838	A	20060118	KR 2004-54818	20040714
KR 2004-54818	A	20040714		
PRIORITY APPLN. INFO.:				
OTHER SOURCE(S):	MARPAT 144:128961			
GI				

L7 ANSWER 22 OF 83 CAPLUS COPYRIGHT 2006 ACS ON STN (Continued)




AB Title compds. I [R1-R3, R6 = independently H, alkyl; R4, R5 = independently H, alk(en/yn)yl, (un)substituted Ph, etc.; R7 = thiophenyl, (un)substituted Ph; X = N when Y = O; X = O when Y = N; W = (CH2)m; Z = (CH2)n; m = 0-1; n = 1-2; and their pharmaceutically acceptable salts, hydrates and solvates] were prepared as PPAR α agonists for upregulation of lipid metabolism. For example, II was prepared in 6 steps by (1) reductive amination of 4-benzoyloxybenzaldehyde with glycine Et ester hydrochloride; (2) reaction with chlorosulfonylisocyanic acid; (3) debenzoylation; (4) O-alkylation with 2-(5-methyl-2-phenyloxazol-4-yl)ethanol; (5) deprotection; and (6) saponification. I are modulators of glucose, HDL-cholesterol, LDL-cholesterol, triglyceride and free fatty acid levels in blood. In an antidiabetic test, selected I have a positive effect on reducing feed intake in mice. Thus, I and their pharmaceutical compns. are useful for treating obesity, hyperlipidemia, and non-insulin dependent diabetes mellitus, etc.

IT RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses) (PPAR α agonist; preparation of oxazole-containing sulfamides as PPAR α agonists and their pharmaceutical compns. useful for upregulation of lipid metabolism)

RN 873534-40-8 CAPLUS
 CN Glycine,
 N-[(2,3-dihydro-1H-indol-1-yl)sulfonyl]-N-[(4-[(5-methyl-2-phenyl-4-oxazolyl)methoxy]phenyl)methyl]- (9CI) (CA INDEX NAME)

L7 ANSWER 22 OF 83 CAPLUS COPYRIGHT 2006 ACS ON STN (Continued)



IT 873533-03-0P, [N-(Aminosulfonyl)-N-[(4-[(2-phenyl-5-methyloxazol-4-yl)ethoxy]benzyl]amino]acetic acid 873533-08-5P, (S)-3-Methyl-2-(N-(sulfamoyl)-N-[3-[(5-methyl-2-(p-tolyl)oxazol-4-yl)methoxy]benzyl]amino]butanoic acid 873533-11-0P, (N-[(N,N-Dimethylamino)sulfonyl]-N-[3-[(2-phenyl-5-methyloxazol-4-yl)methoxy]benzyl]amino]acetic acid 873533-16-5P,

[N-[(N,N-Dimethylamino)sulfonyl]-N-[3-[(2-(4-methylphenyl)-5-methyloxazol-4-yl)methoxy]benzyl]amino]acetic acid 873533-18-7P,
 [N-[(N,N-Dimethylamino)sulfonyl]-N-[3-[(2-(4-trifluoromethylphenyl)-5-methyloxazol-4-yl)methoxy]benzyl]amino]acetic acid 873533-20-1P,
 [N-[(N-cert-Butylamino)sulfonyl]-N-[3-[(2-(4-trifluoromethylphenyl)-5-methyloxazol-4-yl)methoxy]benzyl]amino]acetic acid 873533-23-4P,
 [N-[(N,N-Diethylamino)sulfonyl]-N-[3-[(2-(4-trifluoromethylphenyl)-5-methyloxazol-4-yl)methoxy]benzyl]amino]acetic acid 873533-25-6P,
 [N-[(N-Isopropyl)-N-methylamino)sulfonyl]-N-[3-[(2-(4-trifluoromethylphenyl)-5-methyloxazol-4-yl)methoxy]benzyl]amino]acetic acid 873533-27-8P, [N-[(N-Allyl)-N-methylamino)sulfonyl]-N-[3-[(2-(4-trifluoromethylphenyl)-5-methyloxazol-4-yl)methoxy]benzyl]amino]acetic acid 873533-29-0P, [N-[(N-Methyl-N-propargylamino)sulfonyl]-N-[3-[(2-(4-trifluoromethylphenyl)-5-methyloxazol-4-yl)methoxy]benzyl]amino]acetic acid 873533-31-4P,
 [N-[(Piperidin-1-yl)sulfonyl]-N-[3-[(2-(4-trifluoromethylphenyl)-5-methyloxazol-4-yl)methoxy]benzyl]amino]acetic acid 873533-37-0P,
 [N-[(N-Methyl-N-phenylamino)sulfonyl]-N-[3-[(2-phenyl-5-methyloxazol-4-yl)methoxy]benzyl]amino]acetic acid 873533-41-6P,
 [N-[(N-Methyl-N-phenylamino)sulfonyl]-N-[3-[(2-(4-methylphenyl)-5-methyloxazol-4-yl)methoxy]benzyl]amino]acetic acid 873533-43-8P,

[N-[(N-Methyl-N-phenylamino)sulfonyl]-N-[3-[(2-(4-trifluoromethylphenyl)-5-methyloxazol-4-yl)methoxy]benzyl]amino]acetic acid 873533-47-2P,
 [N-[(N-Methyl-N-(4-chlorophenyl)amino)sulfonyl]-N-[3-[(2-phenyl-5-methyloxazol-4-yl)methoxy]benzyl]amino]acetic acid 873533-50-7P,

[N-[(N-Methyl-N-(4-chlorophenyl)amino)sulfonyl]-N-[3-[(2-(4-methylphenyl)-5-methyloxazol-4-yl)methoxy]benzyl]amino]acetic acid 873533-52-9P,
 [N-[(N-Methyl-N-(4-chlorophenyl)amino)sulfonyl]-N-[3-[(2-(4-trifluoromethylphenyl)-5-methyloxazol-4-yl)methoxy]benzyl]amino]acetic acid 873533-54-1P, [N-[(N-Ethyl-N-(m-tolyl)amino)sulfonyl]-N-[3-[(2-(4-trifluoromethylphenyl)-5-methyloxazol-4-yl)methoxy]benzyl]amino]acetic acid 873533-57-4P,
 [N-[(N-(4-Methoxyphenyl)-N-methylamino)sulfonyl]-N-[3-[(2-(4-trifluoromethylphenyl)-5-methyloxazol-4-yl)methoxy]benzyl]amino]acetic acid 873533-60-9P, [N-[(N-(3-Fluorophenyl)-N-methylamino)sulfonyl]-N-[3-[(2-(4-trifluoromethylphenyl)-5-methyloxazol-4-yl)methoxy]benzyl]amino]acetic acid 873533-64-3P,
 [N-[(Pyrrolidin-1-yl)sulfonyl]-N-[3-[(2-(4-trifluoromethylphenyl)-5-methyloxazol-4-yl)methoxy]benzyl]amino]acetic acid 873533-70-1P,

[N-[(N,N-Dimethylamino)sulfonyl]-N-[3-[(2-(4-trifluoromethylphenyl)-5-methyloxazol-4-yl)methoxy]benzyl]amino]acetic acid 873533-73-4P,
 [N-[(Morpholino)sulfonyl]-N-[3-[(2-(4-methylphenyl)-5-methyloxazol-4-yl)methoxy]benzyl]amino]acetic acid 873533-79-0P,
 [N-[(Indolin-1-yl)sulfonyl]-N-[3-[(2-phenyl-5-methyloxazol-4-yl)methoxy]benzyl]amino]acetic acid 873533-83-6P,
 [N-[(Indolin-1-yl)sulfonyl]-N-[3-[(2-(4-methylphenyl)-5-methyloxazol-4-yl)methoxy]benzyl]amino]acetic acid 873533-85-8P,
 [N-[(Indolin-1-yl)sulfonyl]-N-[3-[(2-(4-trifluoromethylphenyl)-5-methyloxazol-4-yl)methoxy]benzyl]amino]acetic acid 873533-90-5P,
 [N-[(1,2,3,4-Tetrahydroquinolin-1-yl)sulfonyl]-N-[3-[(2-phenyl-5-methyloxazol-4-yl)methoxy]benzyl]amino]acetic acid 873533-93-8P,

[N-[(1,2,3,4-Tetrahydroquinolin-1-yl)sulfonyl]-N-[3-[(2-(4-methylphenyl)-5-methyloxazol-4-yl)methoxy]benzyl]amino]acetic acid 873533-95-0P,
 [N-[(N,N-Dimethylamino)sulfonyl]-N-[4-[(2-phenyl-5-methyloxazol-4-yl)methoxy]benzyl]amino]acetic acid 873534-03-3P,

[N-[(N,N-Dimethylamino)sulfonyl]-N-[4-[(2-(4-methylphenyl)-5-methyloxazol-4-yl)methoxy]benzyl]amino]acetic acid 873534-05-5P,
 [N-[(N,N-Dimethylamino)sulfonyl]-N-[4-[(2-(4-trifluoromethylphenyl)-5-methyloxazol-4-yl)methoxy]benzyl]amino]acetic acid 873534-09-9P,

[N-[(Pyrrolidin-1-yl)sulfonyl]-N-[4-[(2-(4-methylphenyl)-5-methyloxazol-4-yl)methoxy]benzyl]amino]acetic acid 873534-13-5P,
 [N-[(4-Methyl-1-piperazinyl)sulfonyl]-N-[4-[(2-(4-methylphenyl)-5-methyloxazol-4-yl)methoxy]benzyl]amino]acetic acid 873534-17-9P,
 [N-[(Morpholin-4-yl)sulfonyl]-N-[4-[(2-(4-methylphenyl)-5-methyloxazol-4-yl)methoxy]benzyl]amino]acetic acid 873534-21-5P,
 [N-[(N-Methyl-N-phenylamino)sulfonyl]-N-[4-[(2-phenyl-5-methyloxazol-4-yl)methoxy]benzyl]amino]acetic acid 873534-25-9P,
 [N-[(N-Methyl-N-phenylamino)sulfonyl]-N-[4-[(2-(4-methylphenyl)-5-methyloxazol-4-yl)methoxy]benzyl]amino]acetic acid 873534-27-1P,

[N-[(N-Methyl-N-phenylamino)sulfonyl]-N-[4-[(2-(4-trifluoromethylphenyl)-5-methyloxazol-4-yl)methoxy]benzyl]amino]acetic acid 873534-31-7P,
 [N-[(N-Methyl-N-(4-chlorophenyl)amino)sulfonyl]-N-[4-[(2-phenyl-5-methyloxazol-4-yl)methoxy]benzyl]amino]acetic acid 873534-34-0P,

[N-[(N-Methyl-N-(4-chlorophenyl)amino)sulfonyl]-N-[4-[(2-(4-methylphenyl)-5-methyloxazol-4-yl)methoxy]benzyl]amino]acetic acid 873534-36-2P,
 [N-[(N-Methyl-N-(4-chlorophenyl)amino)sulfonyl]-N-[4-[(2-(4-trifluoromethylphenyl)-5-methyloxazol-4-yl)methoxy]benzyl]amino]acetic acid 873534-44-2P, [N-[(Indolino)sulfonyl]-N-[4-[(2-(4-methylphenyl)-5-methyloxazol-4-yl)methoxy]benzyl]amino]acetic acid 873534-46-4P, [N-[(Indolino)sulfonyl]-N-[4-[(2-(4-trifluoromethylphenyl)-5-methyloxazol-4-yl)methoxy]benzyl]amino]acetic acid 873534-50-0P, [N-[(1,2,3,4-Tetrahydroquinolin-1-yl)sulfonyl]-N-[4-[(2-phenyl-5-methyloxazol-4-yl)methoxy]benzyl]amino]acetic acid 873534-53-3P,
 [N-[(N,N-Dimethylamino)sulfonyl]-N-[4-[(2-(4-methylphenyl)-5-methyloxazol-4-yl)methoxy]benzyl]amino]acetic acid 873534-59-9P,
 [N-[(N,N-Dimethylamino)sulfonyl]-N-[3-[(2-(2-phenyl-5-methyloxazol-4-yl)ethoxy]benzyl]amino]acetic acid 873534-61-3P,
 [N-[(N,N-Dimethylamino)sulfonyl]-N-[3-[(2-(2-(4-methylphenyl)-5-methyloxazol-4-yl)ethoxy]benzyl]amino]acetic acid 873534-63-5P,

[N-[(N,N-Diethylamino)sulfonyl]-N-[3-[(2-(2-(4-methylphenyl)-5-methyloxazol-4-yl)ethoxy]benzyl]amino]acetic acid 873534-66-8P,

L7 ANSWER 22 OF 83 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
 [N-[(N-Isopropyl-N-methylamino)sulfonyl]-N-[3-[2-[2-(4-methylphenyl)-5-methyloxazol-4-yl]ethoxy]benzyl]amino]acetic acid 873534-68-0P,
 [N-[(N,N-Dimethylamino)sulfonyl]-N-[3-[2-[2-(4-trifluoromethylphenyl)-5-methyloxazol-4-yl]ethoxy]benzyl]amino]acetic acid 873534-70-4P,
 [N-[(N-tert-Butylamino)sulfonyl]-N-[3-[2-[2-(4-trifluoromethylphenyl)-5-methyloxazol-4-yl]ethoxy]benzyl]amino]acetic acid 873534-73-7P,
 [N-[(N,N-Diethylamino)sulfonyl]-N-[3-[2-[2-(4-trifluoromethylphenyl)-5-methyloxazol-4-yl]ethoxy]benzyl]amino]acetic acid 873534-75-9P,
 [N-[(N-Isopropyl-N-methylamino)sulfonyl]-N-[3-[2-[2-(4-trifluoromethylphenyl)-5-methyloxazol-4-yl]ethoxy]benzyl]amino]acetic acid
 acid 873534-77-1P, [N-[(N-Allyl-N-methylamino)sulfonyl]-N-[3-[2-[2-(4-trifluoromethylphenyl)-5-methyloxazol-4-yl]ethoxy]benzyl]amino]acetic acid
 acid 873534-79-3P, [N-[(N-Methyl-N-propargylamino)sulfonyl]-N-[3-[2-[2-(4-trifluoromethylphenyl)-5-methyloxazol-4-yl]ethoxy]benzyl]amino]acetic acid 873534-81-7P, [N-[(Piperidino)sulfonyl]-N-[3-[2-[2-(4-trifluoromethylphenyl)-5-methyloxazol-4-yl]ethoxy]benzyl]amino]acetic acid
 acid 873534-85-1P, [N-[(N-Methyl-N-phenylamino)sulfonyl]-N-[3-[2-[2-(2-phenyl-5-methyloxazol-4-yl)ethoxy]benzyl]amino]acetic acid
 873534-87-3P, [N-[(N-Methyl-N-phenylamino)sulfonyl]-N-[3-[2-[2-(4-methylphenyl)-5-methyloxazol-4-yl]ethoxy]benzyl]amino]acetic acid
 873534-89-5P, [N-[(N-Methyl-N-phenylamino)sulfonyl]-N-[3-[2-[2-(4-trifluoromethylphenyl)-5-methyloxazol-4-yl]ethoxy]benzyl]amino]acetic acid
 acid 873534-93-1P, [N-[(N-Methyl-N-(4-chlorophenyl)amino)sulfonyl]-N-[3-[2-[2-(2-phenyl-5-methyloxazol-4-yl)ethoxy]benzyl]amino]acetic acid
 873534-95-3P, [N-[(N-Methyl-N-(4-chlorophenyl)amino)sulfonyl]-N-[3-[2-[2-(4-methylphenyl)-5-methyloxazol-4-yl]ethoxy]benzyl]amino]acetic acid
 acid 873534-97-5P, [N-[(N-Methyl-N-(4-chlorophenyl)amino)sulfonyl]-N-[3-[2-[2-(4-trifluoromethylphenyl)-5-methyloxazol-4-yl]ethoxy]benzyl]amino]acetic acid
 acid 873535-01-4P, [N-[(N-(4-Methoxyphenyl)-N-methylamino)sulfonyl]-N-[3-[2-[2-(4-trifluoromethylphenyl)-5-methyloxazol-4-yl]ethoxy]benzyl]amino]acetic acid 873535-03-6P,
 [N-[(N-(3-Fluorophenyl)-N-methylamino)sulfonyl]-N-[3-[2-[2-(4-trifluoromethylphenyl)-5-methyloxazol-4-yl]ethoxy]benzyl]amino]acetic acid
 acid 873535-07-0P, [N-[(Pyrrolidino)sulfonyl]-N-[3-[2-[2-(4-methylphenyl)-5-methyloxazol-4-yl]ethoxy]benzyl]amino]acetic acid
 873535-10-5P, [N-[(Pyrrolidino)sulfonyl]-N-[3-[2-[2-(4-trifluoromethylphenyl)-5-methyloxazol-4-yl]ethoxy]benzyl]amino]acetic acid
 acid 873535-12-7P, [N-[(Morpholino)sulfonyl]-N-[3-[2-[2-(4-methylphenyl)-5-methyloxazol-4-yl]ethoxy]benzyl]amino]acetic acid
 873535-15-0P, [N-[(Morpholino)sulfonyl]-N-[3-[2-[2-(4-trifluoromethylphenyl)-5-methyloxazol-4-yl]ethoxy]benzyl]amino]acetic acid
 acid 873535-17-2P, [N-[(4-Methyl-1-piperazinyl)sulfonyl]-N-[3-[2-[2-(4-methylphenyl)-5-methyloxazol-4-yl]ethoxy]benzyl]amino]acetic acid


L7 ANSWER 22 OF 83 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
 methyloxazol-4-yl]ethoxy]benzyl]amino]acetic acid 873535-84-3P,
 [N-[(1,2,3,4-Tetrahydroquinolin-1-yl)sulfonyl]-N-[4-[2-[2-(4-methylphenyl)-5-methyloxazol-4-yl]ethoxy]benzyl]amino]acetic acid 873535-86-5P,
 [N-[(1,2,3,4-Tetrahydroquinolin-1-yl)sulfonyl]-N-[4-[2-[2-(4-trifluoromethylphenyl)-5-methyloxazol-4-yl]ethoxy]benzyl]amino]acetic acid
 acid 873535-90-1P, (S)-2-[N-[(N,N-Dimethylamino)sulfonyl]-N-[3-[[(5-methyl-2-(p-tolyl)oxazol-4-yl)methoxy]benzyl]amino]propionic acid
 873535-93-4P, (S)-3-Methyl-2-[N-[(N,N-Dimethylamino)sulfonyl]-N-[3-[[(5-methyl-2-(p-tolyl)oxazol-4-yl)methoxy]benzyl]amino]butanoic acid
 873535-95-6P, [N-[(N,N-Dimethylamino)sulfonyl]-N-[1-[3-[[(5-methyl-2-(p-tolyl)oxazol-4-yl)methoxy]phenyl]ethyl]amino]acetic acid
 873535-98-9P, [N-[(Pyrrolidino)sulfonyl]-N-[1-[3-[[(5-methyl-2-(p-tolyl)oxazol-4-yl)methoxy]phenyl]ethyl]amino]acetic acid
 873536-00-6P, [N-[(N,N-Dimethylamino)sulfonyl]-N-[1-[3-[[(5-methyl-2-(p-tolyl)oxazol-4-yl)methoxy]phenyl]ethyl]amino]acetic acid
 873536-02-8P, [N-[(N-Isopropyl-N-methylamino)sulfonyl]-N-[1-[3-[[(5-methyl-2-(p-tolyl)oxazol-4-yl)methoxy]phenyl]ethyl]amino]acetic acid
 873536-04-0P, 3-[N-[(N,N-Dimethylamino)sulfonyl]-N-[3-[[(5-methyl-2-(p-tolyl)oxazol-4-yl)methoxy]benzyl]amino]propionic acid
 873536-07-3P, [N-[(N,N-Dimethylamino)sulfonyl]-N-[3-[2-(2-phenyloxazol-4-yl)ethoxy]benzyl]amino]acetic acid 873536-10-8P,
 [N-[(N,N-Dimethylamino)sulfonyl]-N-[4-[2-[2-(2-phenyloxazol-4-yl)ethoxy]benzyl]amino]acetic acid 873536-13-1P,

[N-[(N-(4-Chlorophenyl)-N-methylamino)sulfonyl]-N-[4-[2-[2-(2-phenyloxazol-4-yl)ethoxy]benzyl]amino]acetic acid 873536-15-3P,
 [N-[(N,N-Dimethylamino)sulfonyl]-N-[4-[2-(2-phenyl-5-isopropoxyoxazol-4-yl)methoxy]benzyl]amino]acetic acid
 RN: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(PPARα agonist; prepn. of oxazole-contg. sulfamides as PPARα agonists and their pharmaceutical compns. useful for upregulation of lipid metab.)

RN 873533-03-0 CAPLUS

CN Glycine, N-(amino)sulfonyl]-N-[4-[2-[5-methyl-2-(4-methylphenyl)-4-oxazolyl]ethoxy]phenyl]methyl]- (9CI) (CA INDEX NAME)



RN 873533-08-5 CAPLUS

CN L-Valine, N-(amino)sulfonyl]-N-[3-[[(5-methyl-2-(4-methylphenyl)-4-oxazolyl)methoxy]phenyl]methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L7 ANSWER 22 OF 83 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
 873535-20-7P, [N-[(4-Methyl-1-piperazinyl)sulfonyl]-N-[3-[2-[2-(4-trifluoromethylphenyl)-5-methyloxazol-4-yl]ethoxy]benzyl]amino]acetic acid
 acid 873535-22-9P, [N-[(Indolino)sulfonyl]-N-[3-[2-(2-phenyl-5-methyloxazol-4-yl)ethoxy]benzyl]amino]acetic acid 873535-24-1P,
 [N-[(Indolino)sulfonyl]-N-[3-[2-[2-(4-methylphenyl)-5-methyloxazol-4-yl]ethoxy]benzyl]amino]acetic acid 873535-26-3P,
 [N-[(Indolino)sulfonyl]-N-[3-[2-[2-(4-trifluoromethylphenyl)-5-methyloxazol-4-yl]ethoxy]benzyl]amino]acetic acid 873535-30-9P,
 [N-[(1,2,3,4-Tetrahydroquinolin-1-yl)sulfonyl]-N-[3-[2-(2-phenyl-5-methyloxazol-4-yl)ethoxy]benzyl]amino]acetic acid 873535-32-1P
 873535-34-3P, [N-[(1,2,3,4-Tetrahydroquinolin-1-yl)sulfonyl]-N-[3-[2-[2-(4-trifluoromethylphenyl)-5-methyloxazol-4-yl]ethoxy]benzyl]amino]acetic acid 873535-38-7P,
 [N-[(N,N-Dimethylamino)sulfonyl]-N-[4-[2-(2-phenyl-5-methyloxazol-4-yl)ethoxy]benzyl]amino]acetic acid 873535-40-1P,
 [N-[(N,N-Dimethylamino)sulfonyl]-N-[4-[2-[2-(4-methylphenyl)-5-methyloxazol-4-yl]ethoxy]benzyl]amino]acetic acid 873535-42-3P,
 [N-[(N-tert-Butylamino)sulfonyl]-N-[4-[2-[2-(4-methylphenyl)-5-methyloxazol-4-yl]ethoxy]benzyl]amino]acetic acid 873535-45-6P,

[N-[(N,N-Diethylamino)sulfonyl]-N-[4-[2-[2-(4-methylphenyl)-5-methyloxazol-4-yl]ethoxy]benzyl]amino]acetic acid 873535-47-8P,
 [N-[(N-Isopropyl-N-methylamino)sulfonyl]-N-[4-[2-[2-(4-methylphenyl)-5-methyloxazol-4-yl]ethoxy]benzyl]amino]acetic acid 873535-49-0P,
 [N-[(N,N-Dimethylamino)sulfonyl]-N-[4-[2-[2-(4-trifluoromethylphenyl)-5-methyloxazol-4-yl]ethoxy]benzyl]amino]acetic acid 873535-53-6P,
 [N-[(N-Methyl-N-phenylamino)sulfonyl]-N-[4-[2-(2-phenyl-5-methyloxazol-4-yl)ethoxy]benzyl]amino]acetic acid 873535-55-8P,
 [N-[(N-Methyl-N-phenylamino)sulfonyl]-N-[4-[2-[2-(4-methylphenyl)-5-methyloxazol-4-yl]ethoxy]benzyl]amino]acetic acid 873535-57-0P,


[N-[(N-Methyl-N-phenylamino)sulfonyl]-N-[4-[2-[2-(4-trifluoromethylphenyl)-5-methyloxazol-4-yl]ethoxy]benzyl]amino]acetic acid 873535-61-6P,
 [N-[(N-Methyl-N-(4-chlorophenyl)amino)sulfonyl]-N-[4-[2-(2-phenyl-5-methyloxazol-4-yl)ethoxy]benzyl]amino]acetic acid 873535-62-7P,
 [N-[(N-Methyl-N-(4-chlorophenyl)amino)sulfonyl]-N-[4-[2-[2-(4-methylphenyl)-5-methyloxazol-4-yl]ethoxy]benzyl]amino]acetic acid 873535-64-9P,
 [N-[(N-Ethyl-N-(m-tolyl)amino)sulfonyl]-N-[4-[2-[2-(4-methylphenyl)-5-methyloxazol-4-yl]ethoxy]benzyl]amino]acetic acid 873535-66-1P,
 [N-[(N-(4-Methoxyphenyl)-N-methylamino)sulfonyl]-N-[4-[2-[2-(4-methylphenyl)-5-methyloxazol-4-yl]ethoxy]benzyl]amino]acetic acid 873535-68-3P,
 [N-[(N-(3-Fluorophenyl)-N-methylamino)sulfonyl]-N-[4-[2-[2-(4-methylphenyl)-5-methyloxazol-4-yl]ethoxy]benzyl]amino]acetic acid 873535-70-7P,
 [N-[(N-Methyl-N-(4-chlorophenyl)amino)sulfonyl]-N-[4-[2-[2-(4-trifluoromethylphenyl)-5-methyloxazol-4-yl]ethoxy]benzyl]amino]acetic acid
 acid 873535-74-1P, [N-[(Indolino)sulfonyl]-N-[4-[2-(2-phenyl-5-methyloxazol-4-yl)ethoxy]benzyl]amino]acetic acid 873535-76-3P,
 [N-[(Indolino)sulfonyl]-N-[4-[2-[2-(4-methylphenyl)-5-methyloxazol-4-yl]ethoxy]benzyl]amino]acetic acid 873535-78-5P,
 [N-[(Indolino)sulfonyl]-N-[4-[2-[2-(4-trifluoromethylphenyl)-5-methyloxazol-4-yl]ethoxy]benzyl]amino]acetic acid 873535-82-1P,
 [N-[(1,2,3,4-Tetrahydroquinolin-1-yl)sulfonyl]-N-[4-[2-(2-phenyl-5-

L7 ANSWER 22 OF 83 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 873533-11-0 CAPLUS

CN Glycine, N-[(dimethylamino)sulfonyl]-N-[3-[[(5-methyl-2-(4-methylphenyl)-4-oxazolyl)methoxy]phenyl]methyl]- (9CI) (CA INDEX NAME)




RN 873533-16-5 CAPLUS

CN Glycine, N-[(dimethylamino)sulfonyl]-N-[3-[[(5-methyl-2-(4-methylphenyl)-4-oxazolyl)methoxy]phenyl]methyl]- (9CI) (CA INDEX NAME)



RN 873533-18-7 CAPLUS


CN Glycine, N-[(dimethylamino)sulfonyl]-N-[3-[[(5-methyl-2-(4-trifluoromethylphenyl)-4-oxazolyl)methoxy]phenyl]methyl]- (9CI) (CA INDEX NAME)




RN 873533-20-1 CAPLUS

CN Glycine, N-[(1,1-dimethylethylamino)sulfonyl]-N-[3-[[(5-methyl-2-(4-trifluoromethylphenyl)-4-oxazolyl)methoxy]phenyl]methyl]- (9CI) (CA INDEX NAME)


L7 ANSWER 22 OF 83 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 873533-23-4 CAPLUS
CN Glycine, N-[(diethylamino)sulfonyl]-N-[[3-[[5-methyl-2-(4-(trifluoromethyl)phenyl)-4-oxazolyl]methoxy]phenyl]methyl]- (9CI) (CA INDEX NAME)




RN 873533-25-6 CAPLUS
CN Glycine, N-[(methyl(1-methylethylamino)sulfonyl)-N-[[3-[[5-methyl-2-(4-(trifluoromethyl)phenyl)-4-oxazolyl]methoxy]phenyl]methyl]- (9CI) (CA INDEX NAME)




RN 873533-27-8 CAPLUS
CN Glycine, N-[(methyl-2-propenylamino)sulfonyl]-N-[[3-[[5-methyl-2-(4-(trifluoromethyl)phenyl)-4-oxazolyl]methoxy]phenyl]methyl]- (9CI) (CA INDEX NAME)




L7 ANSWER 22 OF 83 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 873533-43-8 CAPLUS
CN Glycine, N-[(methylphenylamino)sulfonyl]-N-[[3-[[5-methyl-2-(4-(trifluoromethyl)phenyl)-4-oxazolyl]methoxy]phenyl]methyl]- (9CI) (CA INDEX NAME)



RN 873533-47-2 CAPLUS
CN Glycine, N-[[4-(4-chlorophenyl)methylamino)sulfonyl]-N-[[3-[[5-methyl-2-(4-phenyl)-4-oxazolyl]methoxy]phenyl]methyl]- (9CI) (CA INDEX NAME)




RN 873533-50-7 CAPLUS
CN Glycine, N-[[4-(4-chlorophenyl)methylamino)sulfonyl]-N-[[3-[[5-methyl-2-(4-methylphenyl)-4-oxazolyl]methoxy]phenyl]methyl]- (9CI) (CA INDEX NAME)




RN 873533-52-9 CAPLUS
CN Glycine, N-[[4-(4-chlorophenyl)methylamino)sulfonyl]-N-[[3-[[5-methyl-2-(4-(trifluoromethyl)phenyl)-4-oxazolyl]methoxy]phenyl]methyl]- (9CI) (CA INDEX NAME)

L7 ANSWER 22 OF 83 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)


RN 873533-29-0 CAPLUS
CN Glycine, N-[(methyl-2-propynylamino)sulfonyl]-N-[[3-[[5-methyl-2-(4-(trifluoromethyl)phenyl)-4-oxazolyl]methoxy]phenyl]methyl]- (9CI) (CA INDEX NAME)



RN 873533-31-4 CAPLUS
CN Glycine, N-[[3-[[5-methyl-2-(4-(trifluoromethyl)phenyl)-4-oxazolyl]methoxy]phenyl]methyl]-N-(1-piperidyl)sulfonyl]- (9CI) (CA INDEX NAME)




RN 873533-37-0 CAPLUS
CN Glycine, N-[(methylphenylamino)sulfonyl]-N-[[3-[[5-methyl-2-phenyl-4-oxazolyl]methoxy]phenyl]methyl]- (9CI) (CA INDEX NAME)




RN 873533-41-6 CAPLUS
CN Glycine, N-[[3-[[5-methyl-2-(4-methylphenyl)-4-oxazolyl]methoxy]phenyl]methyl]-N-[(methylphenylamino)sulfonyl]- (9CI) (CA INDEX NAME)


L7 ANSWER 22 OF 83 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 873533-54-1 CAPLUS
CN Glycine, N-[[ethyl(3-methylphenylamino)sulfonyl]-N-[[3-[[5-methyl-2-(4-(trifluoromethyl)phenyl)-4-oxazolyl]methoxy]phenyl]methyl]- (9CI) (CA INDEX NAME)




RN 873533-57-4 CAPLUS
CN Glycine, N-[[4-(4-methoxyphenyl)methylamino)sulfonyl]-N-[[3-[[5-methyl-2-(4-(trifluoromethyl)phenyl)-4-oxazolyl]methoxy]phenyl]methyl]- (9CI) (CA INDEX NAME)




RN 873533-60-9 CAPLUS
CN Glycine, N-[[3-(4-fluorophenyl)methylamino)sulfonyl]-N-[[3-[[5-methyl-2-(4-(trifluoromethyl)phenyl)-4-oxazolyl]methoxy]phenyl]methyl]- (9CI) (CA INDEX NAME)


L7 ANSWER 22 OF 83 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 873533-64-3 CAPLUS
CN Glycine, N-([3-([5-methyl-2-(4-(trifluoromethyl)phenyl)-4-oxazolyl]methoxy]phenyl)methyl]-N-(1-pyrrolidinylsulfonyl)- (9CI) (CA INDEX NAME)




RN 873533-70-1 CAPLUS
CN Glycine, N-([4-methyl-1-piperazinyl]sulfonyl)-N-([3-([5-methyl-2-(4-(trifluoromethyl)phenyl)-4-oxazolyl]methoxy]phenyl)methyl]- (9CI) (CA INDEX NAME)




RN 873533-73-4 CAPLUS
CN Glycine, N-([3-([5-methyl-2-(4-methylphenyl)-4-oxazolyl]methoxy]phenyl)methyl]-N-(4-morpholinylsulfonyl)- (9CI) (CA INDEX NAME)



L7 ANSWER 22 OF 83 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 873533-93-8 CAPLUS
CN Glycine, N-([3,4-dihydro-1(2H)-quinolinyl]sulfonyl)-N-([3-([5-methyl-2-(4-methylphenyl)-4-oxazolyl]methoxy]phenyl)methyl]- (9CI) (CA INDEX NAME)




RN 873533-95-0 CAPLUS
CN Glycine, N-([3,4-dihydro-1(2H)-quinolinyl]sulfonyl)-N-([3-([5-methyl-2-(4-(trifluoromethyl)phenyl)-4-oxazolyl]methoxy]phenyl)methyl]- (9CI) (CA INDEX NAME)

L7 ANSWER 22 OF 83 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)


RN 873533-79-0 CAPLUS
CN Glycine, N-([2,3-dihydro-1H-indol-1-yl]sulfonyl)-N-([3-([5-methyl-2-phenyl-4-oxazolyl]methoxy]phenyl)methyl]- (9CI) (CA INDEX NAME)



RN 873533-83-6 CAPLUS
CN Glycine, N-([2,3-dihydro-1H-indol-1-yl]sulfonyl)-N-([3-([5-methyl-2-(4-methylphenyl)-4-oxazolyl]methoxy]phenyl)methyl]- (9CI) (CA INDEX NAME)




RN 873533-85-8 CAPLUS
CN Glycine, N-([2,3-dihydro-1H-indol-1-yl]sulfonyl)-N-([3-([5-methyl-2-(4-(trifluoromethyl)phenyl)-4-oxazolyl]methoxy]phenyl)methyl]- (9CI) (CA INDEX NAME)




RN 873533-90-5 CAPLUS
CN Glycine, N-([3,4-dihydro-1(2H)-quinolinyl]sulfonyl)-N-([3-([5-methyl-2-phenyl-4-oxazolyl]methoxy]phenyl)methyl]- (9CI) (CA INDEX NAME)


L7 ANSWER 22 OF 83 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 873533-99-4 CAPLUS
CN Glycine, N-([dimethylamino]sulfonyl)-N-([4-([5-methyl-2-phenyl-4-oxazolyl]methoxy]phenyl)methyl]- (9CI) (CA INDEX NAME)




RN 873534-03-3 CAPLUS
CN Glycine, N-([dimethylamino]sulfonyl)-N-([4-([5-methyl-2-(4-methylphenyl)-4-oxazolyl]methoxy]phenyl)methyl]- (9CI) (CA INDEX NAME)




RN 873534-05-5 CAPLUS
CN Glycine, N-([dimethylamino]sulfonyl)-N-([4-([5-methyl-2-(4-(trifluoromethyl)phenyl)-4-oxazolyl]methoxy]phenyl)methyl]- (9CI) (CA INDEX NAME)


L7 ANSWER 22 OF 83 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 873534-09-9 CAPLUS
 CN Glycine, N-[[4-[[[5-methyl-2-(4-methylphenyl)-4-oxazolyl]methoxy]phenyl]methyl]-N-(1-pyrrolidinylsulfonyl)- (9CI) (CA INDEX NAME)




RN 873534-13-5 CAPLUS
 CN Glycine, N-[[4-[[[5-methyl-2-(4-methylphenyl)-4-oxazolyl]methoxy]phenyl]methyl]-N-[(4-methyl-1-piperazinyl)sulfonyl]- (9CI) (CA INDEX NAME)




RN 873534-17-9 CAPLUS
 CN Glycine, N-[[4-[[[5-methyl-2-(4-methylphenyl)-4-oxazolyl]methoxy]phenyl]methyl]-N-(4-morpholinylsulfonyl)- (9CI) (CA INDEX NAME)


L7 ANSWER 22 OF 83 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 873534-31-7 CAPLUS
 CN Glycine, N-[[4-[(4-chlorophenyl)methylamino]sulfonyl]-N-[[4-[[5-methyl-2-phenyl-4-oxazolyl]methoxy]phenyl]methyl]- (9CI) (CA INDEX NAME)




RN 873534-34-0 CAPLUS
 CN Glycine, N-[[4-[(4-chlorophenyl)methylamino]sulfonyl]-N-[[4-[[5-methyl-2-(4-methylphenyl)-4-oxazolyl]methoxy]phenyl]methyl]- (9CI) (CA INDEX NAME)




RN 873534-36-2 CAPLUS
 CN Glycine, N-[[4-[(4-chlorophenyl)methylamino]sulfonyl]-N-[[4-[[5-methyl-2-(4-(trifluoromethyl)phenyl)-4-oxazolyl]methoxy]phenyl]methyl]- (9CI) (CA INDEX NAME)


L7 ANSWER 22 OF 83 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 873534-21-5 CAPLUS
 CN Glycine, N-[(methylphenylamino)sulfonyl]-N-[[4-[[5-methyl-2-phenyl-4-oxazolyl]methoxy]phenyl]methyl]- (9CI) (CA INDEX NAME)




RN 873534-25-9 CAPLUS
 CN Glycine, N-[[4-[[[5-methyl-2-(4-methylphenyl)-4-oxazolyl]methoxy]phenyl]methyl]-N-[(methylphenylamino)sulfonyl]- (9CI) (CA INDEX NAME)




RN 873534-27-1 CAPLUS
 CN Glycine, N-[(methylphenylamino)sulfonyl]-N-[[4-[[5-methyl-2-(4-(trifluoromethyl)phenyl)-4-oxazolyl]methoxy]phenyl]methyl]- (9CI) (CA INDEX NAME)


L7 ANSWER 22 OF 83 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 873534-44-2 CAPLUS
 CN Glycine, N-[(2,3-dihydro-1H-indol-1-yl)sulfonyl]-N-[[4-[[5-methyl-2-(4-methylphenyl)-4-oxazolyl]methoxy]phenyl]methyl]- (9CI) (CA INDEX NAME)




RN 873534-46-4 CAPLUS
 CN Glycine, N-[(2,3-dihydro-1H-indol-1-yl)sulfonyl]-N-[[4-[[5-methyl-2-(4-(trifluoromethyl)phenyl)-4-oxazolyl]methoxy]phenyl]methyl]- (9CI) (CA INDEX NAME)



RN 873534-50-0 CAPLUS
 CN Glycine, N-[(3,4-dihydro-1(2H)-quinolinyl)sulfonyl]-N-[[4-[[5-methyl-2-phenyl-4-oxazolyl]methoxy]phenyl]methyl]- (9CI) (CA INDEX NAME)

L7 ANSWER 22 OF 83 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)

PAGE 1-A




PAGE 2-A




RN 873534-53-3 CAPLUS
 CN Glycine,
 N-((3,4-dihydro-1(2H)-quinolinyl)sulfonyl)-N-([4-([5-methyl-2-(4-methylphenyl)-4-oxazolyl)methoxy]phenyl)methyl)- (9CI) (CA INDEX NAME)

L7 ANSWER 22 OF 83 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)


PAGE 1-A



PAGE 2-A



RN 873534-59-9 CAPLUS
 CN Glycine, N-((dimethylamino)sulfonyl)-N-([3-([2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl)methyl]- (9CI) (CA INDEX NAME)




RN 873534-61-3 CAPLUS
 CN Glycine,
 N-((1,1-dimethylethyl)amino)sulfonyl)-N-([3-([2-(5-methyl-2-(4-methylphenyl)-


Page 30 SAEED

L7 ANSWER 22 OF 83 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)

PAGE 1-A




PAGE 2-A




RN 873534-55-5 CAPLUS
 CN Glycine,
 N-((3,4-dihydro-1(2H)-quinolinyl)sulfonyl)-N-([4-([5-methyl-2-(4-(trifluoromethyl)phenyl)-4-oxazolyl)methoxy]phenyl)methyl)- (9CI) (CA INDEX NAME)

L7 ANSWER 22 OF 83 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)


4-oxazolyl]ethoxy]phenyl)methyl]- (9CI) (CA INDEX NAME)




RN 873534-63-5 CAPLUS
 CN Glycine,
 N-((diethylamino)sulfonyl)-N-([3-([2-(5-methyl-2-(4-methylphenyl)-4-oxazolyl)ethoxy]phenyl)methyl]- (9CI) (CA INDEX NAME)



RN 873534-66-8 CAPLUS
 CN Glycine,
 N-([methyl(1-methylethyl)amino]sulfonyl)-N-([3-([2-(5-methyl-2-(4-methylphenyl)-4-oxazolyl)ethoxy]phenyl)methyl]- (9CI) (CA INDEX NAME)




RN 873534-68-0 CAPLUS
 CN Glycine, N-((dimethylamino)sulfonyl)-N-([3-([2-(5-methyl-2-(4-(trifluoromethyl)phenyl)-4-oxazolyl)ethoxy]phenyl)methyl]- (9CI) (CA INDEX NAME)




RN 873534-70-4 CAPLUS
 CN Glycine, N-((1,1-dimethylethyl)amino)sulfonyl)-N-([3-([2-(5-methyl-2-(4-


L7 ANSWER 22 OF 83 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
(trifluoromethyl)phenyl]-4-oxazolyl]ethoxy]phenyl]methyl]- (9CI) (CA INDEX NAME)



RN 873534-73-7 CAPLUS
CN Glycine, N-[(diethylamino)sulfonyl]-N-[[3-[2-[5-methyl-2-[4-(trifluoromethyl)phenyl]-4-oxazolyl]ethoxy]phenyl]methyl]- (9CI) (CA INDEX NAME)




RN 873534-75-9 CAPLUS
CN Glycine, N-[(methyl(1-methylethyl)amino)sulfonyl]-N-[[3-[2-[5-methyl-2-[4-(trifluoromethyl)phenyl]-4-oxazolyl]ethoxy]phenyl]methyl]- (9CI) (CA INDEX NAME)




RN 873534-77-1 CAPLUS
CN Glycine, N-[(methyl-2-propenylamino)sulfonyl]-N-[[3-[2-[5-methyl-2-[4-(trifluoromethyl)phenyl]-4-oxazolyl]ethoxy]phenyl]methyl]- (9CI) (CA INDEX NAME)


L7 ANSWER 22 OF 83 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
Glycine, N-[[3-[2-[5-methyl-2-[4-(4-methylphenyl)-4-oxazolyl]ethoxy]phenyl]methyl]-N-[(methylphenylamino)sulfonyl]- (9CI) (CA INDEX NAME)



RN 873534-89-5 CAPLUS
CN Glycine, N-[(methylphenylamino)sulfonyl]-N-[[3-[2-[5-methyl-2-[4-(trifluoromethyl)phenyl]-4-oxazolyl]ethoxy]phenyl]methyl]- (9CI) (CA INDEX NAME)




RN 873534-93-1 CAPLUS
CN Glycine, N-[[4-(4-chlorophenyl)methylamino]sulfonyl]-N-[[3-[2-[5-methyl-2-[4-phenyl-4-oxazolyl]ethoxy]phenyl]methyl]- (9CI) (CA INDEX NAME)




RN 873534-95-3 CAPLUS
CN Glycine, N-[[4-(4-chlorophenyl)methylamino]sulfonyl]-N-[[3-[2-[5-methyl-2-[4-methylphenyl]-4-oxazolyl]ethoxy]phenyl]methyl]- (9CI) (CA INDEX NAME)


L7 ANSWER 22 OF 83 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 873534-79-3 CAPLUS
CN Glycine, N-[(methyl-2-propenylamino)sulfonyl]-N-[[3-[2-[5-methyl-2-[4-(trifluoromethyl)phenyl]-4-oxazolyl]ethoxy]phenyl]methyl]- (9CI) (CA INDEX NAME)



RN 873534-81-7 CAPLUS
CN Glycine, N-[[3-[2-[5-methyl-2-[4-(trifluoromethyl)phenyl]-4-oxazolyl]ethoxy]phenyl]methyl]-N-(1-piperidinyl)sulfonyl]- (9CI) (CA INDEX NAME)




RN 873534-85-1 CAPLUS
CN Glycine, N-[(methylphenylamino)sulfonyl]-N-[[3-[2-[5-methyl-2-phenyl-4-oxazolyl]ethoxy]phenyl]methyl]- (9CI) (CA INDEX NAME)




RN 873534-87-3 CAPLUS


L7 ANSWER 22 OF 83 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 873534-97-5 CAPLUS
CN Glycine, N-[[4-(4-chlorophenyl)methylamino]sulfonyl]-N-[[3-[2-[5-methyl-2-[4-(trifluoromethyl)phenyl]-4-oxazolyl]ethoxy]phenyl]methyl]- (9CI) (CA INDEX NAME)




RN 873534-99-7 CAPLUS
CN Glycine, N-[[ethyl(3-methylphenyl)amino]sulfonyl]-N-[[3-[2-[5-methyl-2-[4-(trifluoromethyl)phenyl]-4-oxazolyl]ethoxy]phenyl]methyl]- (9CI) (CA INDEX NAME)




RN 873535-01-4 CAPLUS
CN Glycine, N-[[4-(4-methoxyphenyl)methylamino]sulfonyl]-N-[[3-[2-[5-methyl-2-[4-(trifluoromethyl)phenyl]-4-oxazolyl]ethoxy]phenyl]methyl]- (9CI) (CA INDEX NAME)


L7 ANSWER 22 OF 83 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 873535-03-6 CAPLUS
CN Glycine, N-[(3-fluorophenyl)methylamino)sulfonyl]-N-[(3-[2-[5-methyl-2-[4-(trifluoromethyl)phenyl]-4-oxazolyl]ethoxy]phenyl)methyl]- (9CI) (CA INDEX NAME)




RN 873535-07-0 CAPLUS
CN Glycine, N-[(3-[2-[5-methyl-2-(4-methylphenyl)-4-oxazolyl]ethoxy]phenyl)methyl]-N-(1-pyrrolidinylsulfonyl)- (9CI) (CA INDEX NAME)




RN 873535-10-5 CAPLUS
CN Glycine, N-[(3-[2-[5-methyl-2-[4-(trifluoromethyl)phenyl]-4-oxazolyl]ethoxy]phenyl)methyl]-N-(1-pyrrolidinylsulfonyl)- (9CI) (CA INDEX NAME)


L7 ANSWER 22 OF 83 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 873535-20-7 CAPLUS
CN Glycine, N-[(4-methyl-1-piperazinyl)sulfonyl]-N-[(3-[2-[5-methyl-2-[4-(trifluoromethyl)phenyl]-4-oxazolyl]ethoxy]phenyl)methyl]- (9CI) (CA INDEX NAME)



RN 873535-22-9 CAPLUS
CN Glycine, N-[(2,3-dihydro-1H-indol-1-yl)sulfonyl]-N-[(3-[2-[5-methyl-2-phenyl-4-oxazolyl]ethoxy]phenyl)methyl]- (9CI) (CA INDEX NAME)




RN 873535-24-1 CAPLUS
CN Glycine, N-[(2,3-dihydro-1H-indol-1-yl)sulfonyl]-N-[(3-[2-[5-methyl-2-(4-methylphenyl)-4-oxazolyl]ethoxy]phenyl)methyl]- (9CI) (CA INDEX NAME)




RN 873535-26-3 CAPLUS
CN Glycine, N-[(2,3-dihydro-1H-indol-1-yl)sulfonyl]-N-[(3-[2-[5-methyl-2-(4-(trifluoromethyl)phenyl)-4-oxazolyl]ethoxy]phenyl)methyl]- (9CI) (CA INDEX NAME)


L7 ANSWER 22 OF 83 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 873535-12-7 CAPLUS
CN Glycine, N-[(3-[2-[5-methyl-2-(4-methylphenyl)-4-oxazolyl]ethoxy]phenyl)methyl]-N-(4-morpholinylsulfonyl)- (9CI) (CA INDEX NAME)




RN 873535-15-0 CAPLUS
CN Glycine, N-[(3-[2-[5-methyl-2-[4-(trifluoromethyl)phenyl]-4-oxazolyl]ethoxy]phenyl)methyl]-N-(4-morpholinylsulfonyl)- (9CI) (CA INDEX NAME)




RN 873535-17-2 CAPLUS
CN Glycine, N-[(3-[2-[5-methyl-2-(4-methylphenyl)-4-oxazolyl]ethoxy]phenyl)methyl]-N-[(4-methyl-1-piperazinyl)sulfonyl]- (9CI) (CA INDEX NAME)


L7 ANSWER 22 OF 83 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 873535-30-9 CAPLUS
CN Glycine, N-[(3,4-dihydro-1(2H)-quinolinyl)sulfonyl]-N-[(3-[2-[5-methyl-2-phenyl-4-oxazolyl]ethoxy]phenyl)methyl]- (9CI) (CA INDEX NAME)




RN 873535-32-1 CAPLUS
CN Glycine, N-[(3,4-dihydro-1(2H)-quinolinyl)sulfonyl]-N-[(3-[2-[5-methyl-2-(4-methylphenyl)-4-oxazolyl]ethoxy]phenyl)methyl]- (9CI) (CA INDEX NAME)




RN 873535-34-3 CAPLUS
CN Glycine, N-[(3,4-dihydro-1(2H)-quinolinyl)sulfonyl]-N-[(3-[2-[5-methyl-2-(4-(trifluoromethyl)phenyl)-4-oxazolyl]ethoxy]phenyl)methyl]- (9CI) (CA INDEX NAME)


L7 ANSWER 22 OF 83 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 873535-38-7 CAPLUS
CN Glycine, N-[(dimethylamino)sulfonyl]-N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- (9CI) (CA INDEX NAME)




RN 873535-40-1 CAPLUS
CN Glycine, N-[(dimethylamino)sulfonyl]-N-[[4-[2-(5-methyl-2-(4-methylphenyl)-4-oxazolyl)ethoxy]phenyl]methyl]- (9CI) (CA INDEX NAME)




L7 ANSWER 22 OF 83 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
CN Glycine, N-[(dimethylamino)sulfonyl]-N-[[4-[2-(5-methyl-2-(4-(trifluoromethyl)phenyl)-4-oxazolyl)ethoxy]phenyl]methyl]- (9CI) (CA INDEX NAME)



RN 873535-53-6 CAPLUS
CN Glycine, N-[(methylphenylamino)sulfonyl]-N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- (9CI) (CA INDEX NAME)




RN 873535-55-8 CAPLUS
CN Glycine, N-[[4-[2-(5-methyl-2-(4-methylphenyl)-4-oxazolyl)ethoxy]phenyl]methyl]-N-[(methylphenylamino)sulfonyl]- (9CI) (CA INDEX NAME)




RN 873535-57-0 CAPLUS
CN Glycine, N-[(methylphenylamino)sulfonyl]-N-[[4-[2-(5-methyl-2-(4-(trifluoromethyl)phenyl)-4-oxazolyl)ethoxy]phenyl]methyl]- (9CI) (CA INDEX NAME)

L7 ANSWER 22 OF 83 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)


RN 873535-42-3 CAPLUS
CN Glycine, N-[[1,1-dimethylethylamino)sulfonyl]-N-[[4-[2-(5-methyl-2-(4-methylphenyl)-4-oxazolyl)ethoxy]phenyl]methyl]- (9CI) (CA INDEX NAME)



RN 873535-45-6 CAPLUS
CN Glycine, N-[(diethylamino)sulfonyl]-N-[[4-[2-(5-methyl-2-(4-methylphenyl)-4-oxazolyl)ethoxy]phenyl]methyl]- (9CI) (CA INDEX NAME)




RN 873535-47-8 CAPLUS
CN Glycine, N-[(methyl(1-methylethylamino)sulfonyl)-N-[[4-[2-(5-methyl-2-(4-methylphenyl)-4-oxazolyl)ethoxy]phenyl]methyl]- (9CI) (CA INDEX NAME)




RN 873535-49-0 CAPLUS

L7 ANSWER 22 OF 83 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)


RN 873535-61-6 CAPLUS
CN Glycine, N-[[4-(4-chlorophenyl)methylamino)sulfonyl]-N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- (9CI) (CA INDEX NAME)



RN 873535-62-7 CAPLUS
CN Glycine, N-[[4-(4-chlorophenyl)methylamino)sulfonyl]-N-[[4-[2-(5-methyl-2-(4-methylphenyl)-4-oxazolyl)ethoxy]phenyl]methyl]- (9CI) (CA INDEX NAME)




RN 873535-64-9 CAPLUS
CN Glycine, N-[[ethyl(3-methylphenylamino)sulfonyl]-N-[[4-[2-(5-methyl-2-(4-methylphenyl)-4-oxazolyl)ethoxy]phenyl]methyl]- (9CI) (CA INDEX NAME)




RN 873535-57-0 CAPLUS
CN Glycine, N-[(methylphenylamino)sulfonyl]-N-[[4-[2-(5-methyl-2-(4-(trifluoromethyl)phenyl)-4-oxazolyl)ethoxy]phenyl]methyl]- (9CI) (CA INDEX NAME)


L7 ANSWER 22 OF 83 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 873535-66-1 CAPLUS
 CN Glycine, N-[(4-methoxyphenyl)methylamino]sulfonyl-N-[(4-[2-[5-methyl-2-(4-methylphenyl)-4-oxazolyl]ethoxy]phenyl)methyl]- (9CI) (CA INDEX NAME)




RN 873535-68-3 CAPLUS
 CN Glycine,
 N-[(3-fluorophenyl)methylamino]sulfonyl-N-[(4-[2-[5-methyl-2-(4-methylphenyl)-4-oxazolyl]ethoxy]phenyl)methyl]- (9CI) (CA INDEX NAME)



RN 873535-70-7 CAPLUS
 CN Glycine,
 N-[(4-chlorophenyl)methylamino]sulfonyl-N-[(4-[2-[5-methyl-2-(4-(trifluoromethyl)phenyl)-4-oxazolyl]ethoxy]phenyl)methyl]- (9CI) (CA INDEX NAME)

L7 ANSWER 22 OF 83 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
 CN Glycine, N-[(3,4-dihydro-1(2H)-quinolinyl)sulfonyl]-N-[(4-[2-[5-methyl-2-phenyl-4-oxazolyl]ethoxy]phenyl)methyl]- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 873535-84-3 CAPLUS
 CN Glycine, N-[(3,4-dihydro-1(2H)-quinolinyl)sulfonyl]-N-[(4-[2-[5-methyl-2-(4-methylphenyl)-4-oxazolyl]ethoxy]phenyl)methyl]- (9CI) (CA INDEX NAME)


L7 ANSWER 22 OF 83 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 873535-74-1 CAPLUS
 CN Glycine, N-[(2,3-dihydro-1H-indol-1-yl)sulfonyl]-N-[(4-[2-[5-methyl-2-phenyl-4-oxazolyl]ethoxy]phenyl)methyl]- (9CI) (CA INDEX NAME)



RN 873535-76-3 CAPLUS
 CN Glycine, N-[(2,3-dihydro-1H-indol-1-yl)sulfonyl]-N-[(4-[2-[5-methyl-2-(4-methylphenyl)-4-oxazolyl]ethoxy]phenyl)methyl]- (9CI) (CA INDEX NAME)




RN 873535-78-5 CAPLUS
 CN Glycine, N-[(2,3-dihydro-1H-indol-1-yl)sulfonyl]-N-[(4-[2-[5-methyl-2-(4-(trifluoromethyl)phenyl)-4-oxazolyl]ethoxy]phenyl)methyl]- (9CI) (CA INDEX NAME)




RN 873535-82-1 CAPLUS

L7 ANSWER 22 OF 83 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)

PAGE 1-A




PAGE 2-A




RN 873535-86-5 CAPLUS
 CN Glycine, N-[(3,4-dihydro-1(2H)-quinolinyl)sulfonyl]-N-[(4-[2-[5-methyl-2-(4-(trifluoromethyl)phenyl)-4-oxazolyl]ethoxy]phenyl)methyl]- (9CI) (CA INDEX NAME)

L7 ANSWER 22 OF 83 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)

PAGE 1-A




PAGE 2-A




RN 873535-90-1 CAPLUS
CN L-Alanine,
N-[(dimethylamino)sulfonyl]-N-[1-[3-[[5-methyl-2-(4-methylphenyl)-4-oxazolyl]methoxy]phenyl]ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


L7 ANSWER 22 OF 83 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 873536-00-6 CAPLUS
CN Glycine,
N-[(dimethylamino)sulfonyl]-N-[1-[3-[[5-methyl-2-(4-methylphenyl)-4-oxazolyl]methoxy]phenyl]ethyl]- (9CI) (CA INDEX NAME)




RN 873536-02-8 CAPLUS
CN Glycine,
N-[[methyl(1-methylethyl)amino]sulfonyl]-N-[1-[3-[[5-methyl-2-(4-methylphenyl)-4-oxazolyl]methoxy]phenyl]ethyl]- (9CI) (CA INDEX NAME)




RN 873536-04-0 CAPLUS
CN β-Alanine, N-[(dimethylamino)sulfonyl]-N-[1-[3-[[5-methyl-2-(4-methylphenyl)-4-oxazolyl]methoxy]phenyl]ethyl]- (9CI) (CA INDEX NAME)

L7 ANSWER 22 OF 83 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 873535-93-4 CAPLUS
CN L-Valine,
N-[(dimethylamino)sulfonyl]-N-[1-[3-[[5-methyl-2-(4-methylphenyl)-4-oxazolyl]methoxy]phenyl]ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 873535-95-6 CAPLUS
CN Glycine,
N-[(dimethylamino)sulfonyl]-N-[1-[3-[[5-methyl-2-(4-methylphenyl)-4-oxazolyl]methoxy]phenyl]ethyl]- (9CI) (CA INDEX NAME)




RN 873535-98-9 CAPLUS
CN Glycine, N-[1-[3-[[5-methyl-2-(4-methylphenyl)-4-oxazolyl]methoxy]phenyl]ethyl]-N-(1-pyrrolidinylsulfonyl)- (9CI) (CA INDEX NAME)


L7 ANSWER 22 OF 83 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 873536-07-3 CAPLUS
CN Glycine, N-[(dimethylamino)sulfonyl]-N-[1-[2-(2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- (9CI) (CA INDEX NAME)




RN 873536-10-8 CAPLUS
CN Glycine, N-[(dimethylamino)sulfonyl]-N-[1-[2-(2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- (9CI) (CA INDEX NAME)



RN 873536-13-1 CAPLUS
CN Glycine, N-[[4-(4-chlorophenyl)methylamino]sulfonyl]-N-[1-[2-(2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- (9CI) (CA INDEX NAME)



RN 873536-15-3 CAPLUS
CN Glycine,
N-[(dimethylamino)sulfonyl]-N-[1-[4-[[5-(1-methylethyl)-2-phenyl-4-oxazolyl]methoxy]phenyl]methyl]- (9CI) (CA INDEX NAME)



IT 866623-01-2P, -N-[(-[Methyl-N-(4-chlorophenyl)amino]sulfonyl)-N-[4-
 (2-(phenyl-5-methyloxazol-4-yl)ethyl)benzyl]aminolacetic acid ethyl
 ester 866623-02-3P, -N-[(-[Methyl-N-(4-
 chlorophenyl)amino]sulfonyl)-N-[4-((2-phenyl-5-methyloxazol-4-
 yl)methoxy)benzyl]aminolacetic acid ethyl ester 866623-03-4P,
 -N-[(-[Methyl-N-(4-chlorophenyl)amino]sulfonyl)-N-[4-((2-phenyl-5-
 methyloxazol-4-yl)methoxy)benzyl]aminolacetic acid ethyl ester
 866623-04-7P, -N-[(-[1,2,3,4-Tetrahydroquinolin-1-yl)sulfonyl]-N-[4-
 ((2-phenyl-5-methyloxazol-4-yl)methoxy)benzyl]aminolacetic acid ethyl
 ester 866623-05-8P, -N-[(-[1,2,3,4-Tetrahydroquinolin-1-
 yl)sulfonyl]-N-[4-((2-phenyl-5-methyloxazol-4-yl)methoxy)benzyl]
 aminolacetic acid ethyl ester 873533-06-3P,

[N-[(tert-Butoxycarbonylamino)sulfonyl]-N-[4-[2-(2-phenyl-5-methyloxazol-4-yl)ethoxy]benzyl]amino]acetic acid ethyl ester 873533-07-4P,
[N-(Aminosulfonyl)-N-[4-[2-(2-phenyl-5-methyloxazol-4-yl)ethoxy]benzyl]amino]acetic acid ethyl ester 873533-09-6P,
Verbul

(S)-3-methyl-2-[N-(sulfamoyl)-N-{3-[[5-methyl-2-(p-tolyl)oxazol-4-yl]methoxy]phenyl}methyl]amino]butanoate 875533-15-4P,
[N-[[N,N-Dimethylamino]sulfonyl]-N-3-[[2-phenyl-5-methyloxazol-4-yl]methoxy]benzyl]amino]acetic acid ethyl ester 875533-17-6P,

[N-([N,N-Dimethylamino)sulfonyl]-N-[3-{[2-(4-methylphenyl)-5-methyloxazol-4-yl]methoxy}benzyl)amino]acetic acid ethyl ester 87533-19-8P,
[N-([N,N-Dimethylamino)sulfonyl]-N-[3-{[2-(4-trifluoromethylphenyl)-5-methyloxazol-4-yl]methoxy}benzyl)amino]acetic acid ethyl ester
87533-21-2P, [N-(tert-butylamino)sulfonyl]-N-[3-{[2-(4-trifluoromethylphenyl)-5-methyloxazol-4-yl]methoxy}benzyl)amino]acetic acid ethyl ester 87533-23-5P, N-([N,N-Diethylamino)sulfonyl]-N-[3-{[2-(4-trifluoromethylphenyl)-5-methyloxazol-4-yl]methoxy}benzyl)amino]acetic acid ethyl ester 87533-26-7P,
[N-(Isopropyl)-N-methylsulfonyl]-N-[3-{[2-(4-trifluoromethylphenyl)-5-methyloxazol-4-yl]methoxy}benzyl)amino]acetic acid ethyl ester 87533-28-3P, OR-[N-Allyl]-N-

methylamino)sulfonyl]-N-[3-[(2-(4-(trifluoromethyl)phenyl)-5-methyloxazol-4-yl)methoxy]benzyl]amino]acetic acid ethyl ester 875333-30-3P, [N-[4-(N-methoxyethoxy)phenyl]amino]sulfonyl]-N-[3-[(2-(4-(trifluoromethyl)phenyl)-5-methyloxazol-4-yl)methoxy]benzyl]amino]acetic acid ethyl ester 875333-32-5P, [N-[(Piperidin-1-yl)sulfonyl]-N-[3-[(2-(4-(trifluoromethyl)phenyl)-5-methyloxazol-4-

L7 ANSWER 22 OF 8 CASIUS COPYRIGHT 2006 ACS ON STM (Continued)
 73534-33-3P, [N-[(N-Methyl-1-(4-chlorophenyl)amino)sulfonyl]-N-[(4-
 [2-(trifluoromethyl)phenyl]-5-methoxyoxazol-4-yl)methoxycarbonyl]benzylamino]acetic acid ethyl ester 873534-43-1P,
 [N-[(Indolin-1-yl)sulfonyl]-N-[(4-(2-phenyl-5-methyloxazol-4-
 yl)methoxy)benzylamino]acetic acid ethyl ester 873534-45-3P,
 [N-[(Indolinol)sulfonyl]-N-[(4-(2-4-methylphenyl)-5-methyloxazol-4-
 yl)methoxy)benzylamino]acetic acid ethyl ester 873534-47-5P.

[N-[[[Indolino]sulfonyl]-N-[4-[[2-(4-trifluoromethylphenyl)-5-methyloxazol-
-yl]methoxy]benzyl]amino]acetic acid ethyl ester 873534-54-4P,
873534-56-6P, [N-[[1,2,3,4-Tetrahydroquinolin-1-yl]sulfonyl]-N-[4-
[[2-(4-trifluoromethylphenyl)-5-methyloxazol-4-
-yl]methoxy]benzyl]amino]acetic acid ethyl ester 873534-60-3P,
[N-((N,N-Dimethylamino)sulfonyl)-N-[3-[[2-(4-methylphenyl)-5-
methyloxazol-4-yl]ethoxy]benzyl]amino]acetic acid ethyl ester 873534-62-4P,
[N-((N,N-Dimethylamino)sulfonyl)-N-[3-[[2-(4-methylphenyl)-5-
methyloxazol-4-yl]ethoxy]benzyl]amino]acetic acid ethyl ester
873534-64-6P, [N-((N-Diethylamino)sulfonyl)-N-[3-[[2-(4-
methylphenyl)-5-methyloxazol-4-yl]ethoxy]benzyl]amino]acetic acid ethyl
ester 873534-67-9P, [N-((N-Isopropyl-N-methylamino)sulfonyl)-N-

[3-[2-(2-(4-methylphenyl))-5-methyloxaol-4-yl]ethoxy]benzylaminoacetic acid ethyl ester 873534-69-1P, [N-[(N-Dimethylamino)sulfonyl]-N-[3-[2-(2-(4-trifluoromethyl)phenyl)-5-methyloxaol-4-yl]ethoxy]benzylamino]acetic acid ethyl ester 873534-71-5P, [N-[(N-tert-Butylamino)sulfonyl]-N-[3-[2-(2-(4-trifluoromethyl)phenyl)-5-methyloxaol-4-yl]ethoxy]benzylamino]acetic acid ethyl ester 873534-74-8P, [N-[(N,N-Diethylamino)sulfonyl]-N-[3-[2-(2-(4-trifluoromethyl)phenyl)-5-methyloxaol-4-yl]ethoxy]benzylamino]acetic

acid
ethyl ester 873534-76-0P, [N-(N-Isopropyl-N-methylamino)sulfonyl]-N-[3-[2-[2-(4-trifluoromethylphenyl)-5-methyloxazol-4-yl]ethoxy]benzyl]aminolacetic acid ethyl ester 873534-78-2P.

[N-([N-Allyl-N-methylamino)sulfonyl]-N-[3-(2-[2-(4-trifluoromethylphenyl)-5-methyloxazol-4-yl]ethoxy)benzyl]amino)acetic acid ethyl ester 873534-80-6P, [N-([N-Methyl-N-propargylamino)sulfonyl]-N-[3-(2-[2-(4-trifluoromethylphenyl)-5-methyloxazol-4-yl]ethoxy)benzyl]amino)acetic acid ethyl ester 873534-82-6P, N-((Piperidin-1-yl)sulfonyl)-N-[3-(2-[2-(4-trifluoromethylphenyl)-5-methyloxazol-4-yl]ethoxy)benzyl]amino)acetic acid ethyl ester 873534-86-3P, N-([N-Methyl-N-phenylamino)sulfonyl]-N-[3-(2-[2-(4-methylphenyl)-5-methyloxazol-4-yl]ethoxy)benzyl]amino)acetic acid ethyl ester 873534-88-4P, [N-([N-Methyl-N-phenylamino)sulfonyl]-N-[3-(2-[2-(4-methylphenyl)-5-methyloxazol-4-yl]ethoxy)benzyl]amino)acetic acid ethyl ester 873534-90-6P, N-([N-Methyl-N-phenylamino)sulfonyl]-N-[3-(2-[2-(4-trifluoromethylphenyl)-5-methyloxazol-4-yl]ethoxy)benzyl]amino)acetic acid

ethyl ester 873534-94-3P, [N-[[N-Methyl-N-(4-chlorophenyl)amino]sulfonyl]-N-[3-[2-(2-phenyl-5-methyloxazol-4-yl)ethoxy]benzyl]amino]acetic acid ethyl ester 873534-96-4P, [N-[[N-Methyl-N-(4-chlorophenyl)amino]sulfonyl]-N-[3-[2-(4-methylphenyl)-5-methyloxazol-4-yl)ethoxy]benzyl]amino]acetic acid ethyl ester 873534-98-6P, [N-[[N-Methyl-N-(4-chlorophenyl)amino]sulfonyl]-N-[3-[2-[2-(4-trifluoromethylphenyl)-5-methyloxazol-4-yl)ethoxy]benzyl]amino]acetic acid ethyl ester 873535-00-3P, [N-[[N-Ethyl-N-(m-tolyl)amino]sulfonyl]-N-[3-[2-(4-trifluoromethylphenyl)-5-methyloxazol-4-yl)ethoxy]benzyl]amino]acetic acid ethyl ester 873535-02-5P, [N-[[N-(4-Methoxyphenyl)-N-

[illegible]

tolyl)amino)sulfonyl]-N-[3-[(2-(4-trifluoromethylphenyl)-5-methyloxazol-4-yl)methoxy]benzyl]amino]acetic acid ethyl ester 875353-56-7P,
N-[(N-(4-Methoxyphenyl)-N-methylamino)sulfonyl]-N-[3-[(2-(4-trifluoromethylphenyl)-5-methyloxazol-4-yl)methoxy]benzyl]amino]acetic acid ethyl ester 875353-67-6P, N-[(Pyrrolidin-1-yl)sulfonyl]-N-[3-[(2-(4-trifluoromethylphenyl)-5-methyloxazol-4-yl)methoxy]benzyl]amino]acetic acid ethyl ester 875353-76-7P, N-[(Morpholin)sulfonyl]-N-[3-[(2-(4-methylphenyl)-5-methyloxazol-4-yl)methoxy]benzyl]amino]acetic acid ethyl ester 875353-82-5P, N-[(Indolin-1-yl)sulfonyl]-N-[3-[(2-(4-methylphenyl)-5-methyloxazol-4-yl)methoxy]benzyl]amino]acetic acid ethyl ester 875353-84-7P, N-[(Indolin-1-yl)sulfonyl]-N-[3-[(2-(4-methylphenyl)-5-methyloxazol-4-yl)methoxy]benzyl]amino]acetic acid ethyl ester 875353-87-0P, N-[(Indolin-1-yl)sulfonyl]-N-[3-[(2-(4-trifluoromethylphenyl)-5-methyloxazol-4-yl)methoxy]benzyl]amino]acetic acid ethyl ester 875353-94-9P, N-[(1,2,3,4-Tetrahydroquinolin-1-yl)sulfonyl]-N-[3-[(2-(4-methylphenyl)-5-methyloxazol-4-yl)methoxy]benzyl]amino]acetic acid ethyl ester 875353-96-1P 875354-02-2P, N-[(N,N-Dimethylamino)sulfonyl]-N-(4-[(2-phenyl-5-methyloxazol-4-yl)methoxy]benzyl]amino]acetic acid ethyl ester 875354-04-4P.

[N-([N-(N,N-Dimethylamino)sulfonyl]-N-4-[(2-(4-methylphenyl)-5-methyloxazol-4-yl)methoxy]benzyl)amino]acetic acid ethyl ester 873534-06-6P,
[N-([N-(N-Dimethylamino)sulfonyl]-N-4-[(2-(4-trifluoromethylphenyl)-5-methyloxazol-4-yl)methoxy]benzyl)amino]acetic acid ethyl ester
873534-12-4P, Methyl [N-((pyrrolidin-1-yl)sulfonyl)-N-([4-[(2-(4-methylphenyl)-5-methyloxazol-4-yl)methoxy]phenyl)methyl]amino)acetate
873534-16-8P, Methyl [N-([4-methyl-1-piperazinyl)sulfonyl]-N-([4-

[12-[4-methylphenyl]-5-methyloxazol-4-yl)methoxy]phenyl)methyl]amino]acetate 875354-20-AP, Methyl [N-[(morpholino)sulfonyl]-N-[4-[[2-[4-methylphenyl]-5-methyloxazol-4-yl)methoxy]phenyl)methyl]amino]acetate 875354-24-8P, [N-[(N-Methyl-N-phenylamino)sulfonyl]-N-[4-[[2-phenyl-5-methyloxazol-4-yl)methoxy]benzyl]amino]acetic acid ethyl ester 875354-26-OP 875354-28-2P, [N-[(N-Methyl-N-

phenylamino)sulfonyl]-N-[4-[[2-(4-trifluoromethylphenyl)-5-methyloxazol-4-yl)methoxy]benzyl]aminolacetic acid ethyl ester 873534-35-1P,

[N-[[N-Methyl-N-(4-chlorophenyl)amino)sulfonyl]-N-[4-[[2-(4-methylphenyl)-5-methyloxazol-4-yl]methoxy]benzyl]aminolacetic acid ethyl ester

L7 ANSWER 22 OF 83 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)

methylammonium]sulfonfyl]-N-[3-[2-[2-(4-trifluoromethylphenyl)phenyl]-5-methyloxazol-4-yl]ethoxy]benzyl]amino]acetic acid ethyl ester 873535-08-17, [N-[[N-(3-Fluorophenyl)-N-methylammonium]sulfonfyl]-N-[3-[2-[2-(4-trifluoromethylphenyl)phenyl]-5-methyloxazol-4-yl]ethoxy]benzyl]amino]acetic acid ethyl ester 873535-08-19. Methyl [N-[(pyrrolidinomethylammonium]sulfonfyl]-N-

[{3-[2-[2-(4-methylphenyl)-5-methyloxazol-4-yl]ethoxy]phenyl]methyl]amino} acetate 873535-11-6P, [N-[[Pyrrolidino)sulfonyl]-N-[3-[2-[2-(4-trifluoromethylphenyl)-5-methyloxazol-4-yl]ethoxy]benzyl]amino]acetic acid

ethyl ester 873535-13-8P, [N-[(Morpholino)sulfonyl]-N-[3-[2-[2-(4-methylphenyl)-5-methyloxazol-4-yl]ethoxy]benzyl]amino]acetic acid
ethyl
ester 873535-16-1P, [N-[(Morpholino)sulfonyl]-N-[3-[2-[2-(4-

acid ethyl ester 873535-18-3P, Methyl [N-[(4-methylpiperazin-1-yl)sulfonyl]-N-[[3-[2-[2-(4-methylphenyl)-5-methyloxazol-4-yl]ethoxy]phenyl]methyl]amino]acetate 873535-21-8P,

[N-[[4-Methyl-1-pi-prazinyl)sulfonyl]-N-[3-[2-[2-(4-trifluoromethylphenyl)-5-methyloxazol-4-yl]ethoxy]benzyl]amino]acetic acid ethyl ester
873535-23-OP, [N-[[Indolino)sulfonyl]-N-[3-[2-(phenyl)-5-methyloxazol-4-yl]ethoxy]benzyl]amino]acetic acid ethyl ester
873535-25-2P, [N-[[Indolino)sulfonyl]-N-[3-[2-[2-(4-methylphenyl)-5-methyloxazol-4-yl]ethoxy]benzyl]amino]acetic acid ethyl ester

acid 873535-27-4P, N-[[[Indolino]sulfonyl]-N-[3-[2-[2-(4-trifluoromethylphenyl)-5-methyloxazol-4-yl]ethoxy]benzyl]amino]acetic ethyl ester 873535-31-0P, [N-[[1,2,3,4-Tetrahydroquinolin-1-yl]sulfonyl]-N-[3-[2-(2-methyl-5-methyloxazol-4-

yl)ethoxy]benzylamino]acetic acid ethyl ester 875355-33-2P
875355-35-4P, N-[(1,2,3,4-Tetrahydroquinolin-1-yl)sulfonyl]-N-[3-
[4-(2-trifluoromethyl-5-methoxyphenyl)-5-methylphenyl]-5-
yl)ethoxy]benzylamino]acetic acid ethyl ester 875355-39-8P,
N-[(N,N-Dimethylamino)sulfonyl]-N-[4-[2-(2-phenyl-5-methyloxazol-4-
yl)ethoxy]benzylamino]acetic acid ethyl ester 875355-41-2P,
N-[(N,N-Dimethylamino)sulfonyl]-N-[4-[2-[2-(4-methylphenyl)-5-
yl)ethoxy]benzylamino]acetic acid ethyl ester 875355-43-4P,
875355-43-4P, Methyl N-[(N-tert-butylamino)sulfonyl]-N-[(4-[2-(2-
-4-methylphenyl)-5-methyloxazol-4-yl)ethoxy]methylamino]acetate
875355-46-7P, Methyl N-[(N,N-diethylamino)sulfonyl]-N-[(4-[2-(2-
-4-methylphenyl)-5-methyloxazol-4-yl)ethoxy]methylamino]acetate
875355-49-8P, Methyl N-[(N-isopropylamino)sulfonyl]-N-[(4-[2-(2-
-4-methylphenyl)-5-methyloxazol-4-yl)ethoxy]methylamino]acetate

[[[4-[2-(4-(4-methylphenyl)-5-methyloxoazol-4-yl)ethoxy]benzyl]methyl]amino] acetate 873555-50-3P. [N-[(N,N-Dimethylethanoyl)amino]sulfonyl]-N-4-[2-(2-(4-trifluoromethylphenyl)-5-methyloxoazol-4-yl)ethoxy]benzyl]amino]acetic acid ethyl ester 873555-54-7P. [N-[(N-Methyl-N-phenylamino)sulfonyl]-N-4-[2-(2-phenyl-5-methyloxoazol-4-yl)ethoxy]benzyl]amino]acetic acid ethyl ester 873555-56-9P. [N-[(N-Methyl-N-phenylamino)sulfonyl]-N-4-[2-(2-(4-methylphenyl)-5-methyloxoazol-4-yl)ethoxy]benzyl]amino]acetic acid ethyl ester 873555-58-1P. [N-[(N-Methyl-N-phenylamino)sulfonyl]-N-4-[2-(2-(4-phenoxyphenyl)-5-methyloxoazol-4-yl)ethoxy]benzyl]amino]acetic acid ethyl ester 873555-60-5P.

ethyl ester 873535-63-8P, [N-[[N-Methyl-N-(4-

L7 ANSWER 22 OF 83 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)

chlorophenylamino)sulfonyl]-N-[4-[2-[2-(4-methylphenyl)-5-methyloxazol-4-yl]ethoxy]benzylamino]acetic acid ethyl ester 873535-65-0P, Methyl [N-[(N-ethyl-N-(m-tolyl)amino)sulfonyl]-N-[4-[2-[2-(4-methylphenyl)-5-methyloxazol-4-yl]ethoxy]phenyl]methylamino]acetate 873535-67-2P, Methyl [N-[(N-(4-methoxyphenyl)-N-methylamino)sulfonyl]-N-[4-[2-[2-(4-methylphenyl)-5-methyloxazol-4-yl]ethoxy]phenyl]methylamino]acetate 873535-71-8P, 873535-75-2P, [N-[(Indolino)sulfonyl]-N-[4-[2-[2-phenyl-5-methyloxazol-4-yl]ethoxy]benzylamino]acetic acid ethyl ester 873535-77-4P, [N-[(Indolino)sulfonyl]-N-[4-[2-[2-(4-methylphenyl)-5-methyloxazol-4-yl]ethoxy]benzylamino]acetic acid ethyl ester 873535-79-6P, [N-[(Indolino)sulfonyl]-N-[4-[2-[2-(4-trifluoromethylphenyl)-5-methyloxazol-4-yl]ethoxy]benzylamino]acetic acid ethyl ester 873535-83-2P, [N-[(1,2,3,4-Tetrahydroquinolin-1-yl)sulfonyl]-N-[4-[2-[2-phenyl-5-methyloxazol-4-yl]ethoxy]benzylamino]acetic acid ethyl ester 873535-85-4P,

[N-[(1,2,3,4-Tetrahydroquinolin-1-yl)sulfonyl]-N-[4-[2-[2-(4-methylphenyl)-5-methyloxazol-4-yl]ethoxy]benzylamino]acetic acid ethyl ester 873535-87-6P, [N-[(1,2,3,4-Tetrahydroquinolin-1-yl)sulfonyl]-N-[4-[2-[2-(4-trifluoromethylphenyl)-5-methyloxazol-4-yl]ethoxy]benzylamino]acetic acid ethyl ester 873535-91-2P, Ethyl [S]-2-[N-[(N,N-dimethylamino)sulfonyl]-N-[3-[5-methyl-2-(p-tolyl)oxazol-4-yl]methoxy]phenyl]methylamino]propionate 873535-94-5P, Methyl [S]-2-methyl-2-[N-[(N,N-dimethylamino)sulfonyl]-N-[3-[5-methyl-2-(p-tolyl)oxazol-4-yl]methoxy]phenyl]methylamino]butanoate 873535-96-7P, Methyl [N-[(N,N-dimethylamino)sulfonyl]-N-[1-[3-[5-methyl-2-(p-tolyl)oxazol-4-yl]methoxy]phenyl]ethylamino]acetate 873535-99-0P, Methyl [N-[(pyrrolidino)sulfonyl]-N-[1-[3-[5-methyl-2-(p-tolyl)oxazol-4-yl]methoxy]phenyl]ethylamino]acetate 873536-01-7P, Methyl [N-[(N,N-diethylamino)sulfonyl]-1-[3-[5-methyl-2-(p-tolyl)oxazol-4-yl]methoxy]phenyl]ethylamino]acetate 873536-03-9P, Methyl [N-[(N-isopropyl-N-methylamino)sulfonyl]-N-[1-[3-[5-methyl-2-(p-tolyl)oxazol-4-yl]methoxy]phenyl]ethylamino]acetate 873536-05-1P, Ethyl 3-[N-[(N,N-dimethylamino)sulfonyl]-N-[3-[5-methyl-2-(p-tolyl)oxazol-4-yl]methoxy]phenyl]methylamino]propionate 873536-08-4P, Ethyl [N-[(N,N-dimethylamino)sulfonyl]-N-[3-[2-(2-phenyloxazol-4-yl)ethoxy]phenyl]methylamino]acetate 873536-11-9P, [N-[(N,N-Dimethylamino)sulfonyl]-N-[4-[2-(2-phenyloxazol-4-yl)ethoxy]benzylamino]acetic acid ethyl ester 873536-14-2P, Ethyl [N-[(N-(4-chlorophenyl)-N-methylamino)sulfonyl]-N-[4-[2-(2-phenyloxazol-4-yl)ethoxy]phenyl]methylamino]acetate 873536-16-4P, [N-[(N,N-Dimethylamino)sulfonyl]-N-[4-[2-phenyl-5-isopropoxyoxazol-4-yl]methoxy]benzylamino]acetic acid ethyl ester


RU: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(intermediate; prepn. of oxazole-contg. sulfamides as PPAR α agonists and their pharmaceutical compns. useful for upregulation of lipid metab.)

RN 868623-01-2 CAPLUS

L7 ANSWER 22 OF 83 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)

RN 868623-06-7 CAPLUS
CN Glycine, N-[(3,4-dihydro-1(2H)-quinolinyl)sulfonyl]-N-[4-[5-methyl-2-phenyl-4-oxazolyl]methoxy]phenyl]methyl-, ethyl ester (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A



RN 868623-07-8 CAPLUS
CN Glycine, N-[(3,4-dihydro-1(2H)-quinolinyl)sulfonyl]-N-[3-[5-methyl-2-phenyl-4-oxazolyl]methoxy]phenyl]methyl-, ethyl ester (9CI) (CA INDEX NAME)


L7 ANSWER 22 OF 83 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)

CN Glycine, N-[(4-chlorophenyl)methylamino)sulfonyl]-N-[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl-, ethyl ester (9CI) (CA INDEX NAME)




RN 868623-02-3 CAPLUS

CN Glycine, N-[(4-chlorophenyl)methylamino)sulfonyl]-N-[4-[5-methyl-2-phenyl-4-oxazolyl]methoxy]phenyl]methyl-, ethyl ester (9CI) (CA INDEX NAME)




RN 868623-03-4 CAPLUS

CN Glycine, N-[(4-chlorophenyl)methylamino)sulfonyl]-N-[3-[5-methyl-2-phenyl-4-oxazolyl]methoxy]phenyl]methyl-, ethyl ester (9CI) (CA INDEX NAME)




L7 ANSWER 22 OF 83 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)

RN 873533-06-3 CAPLUS
CN 7-Oxa-3-thia-2,4-diazanonanoic acid, 4-[(4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl)methyl]-6-oxo-, 1,1-dimethylethyl ester, 3,3-dioxide (9CI) (CA INDEX NAME)



RN 873533-07-4 CAPLUS

CN Glycine, N-(aminosulfonyl)-N-[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl-, ethyl ester (9CI) (CA INDEX NAME)




RN 873533-09-6 CAPLUS


CN L-Valine, N-(aminosulfonyl)-N-[3-[5-methyl-2-(4-methylphenyl)-4-oxazolyl]methoxy]phenyl]methyl-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.


L7 ANSWER 22 OF 83 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 873533-15-4 CAPLUS
CN Glycine, N-[(dimethylamino)sulfonyl]-N-[[3-[(5-methyl-2-phenyl-4-oxazolyl)methoxy]phenyl]methyl]-, ethyl ester (9CI) (CA INDEX NAME)



RN 873533-17-6 CAPLUS
CN Glycine, N-[(dimethylamino)sulfonyl]-N-[[3-[(5-methyl-2-(4-methylphenyl)-4-oxazolyl)methoxy]phenyl]methyl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 873533-19-8 CAPLUS
CN Glycine, N-[(dimethylamino)sulfonyl]-N-[[3-[(5-methyl-2-(4-(trifluoromethyl)phenyl)-4-oxazolyl)methoxy]phenyl]methyl]-, ethyl ester (9CI) (CA INDEX NAME)




L7 ANSWER 22 OF 83 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)


RN 873533-21-2 CAPLUS
CN Glycine, N-[[1,1-dimethylethylamino)sulfonyl]-N-[[3-[(5-methyl-2-(4-(trifluoromethyl)phenyl)-4-oxazolyl)methoxy]phenyl]methyl]-, ethyl ester (9CI) (CA INDEX NAME)



RN 873533-24-5 CAPLUS
CN Glycine, N-[(diethylamino)sulfonyl]-N-[[3-[(5-methyl-2-(4-(trifluoromethyl)phenyl)-4-oxazolyl)methoxy]phenyl]methyl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 873533-26-7 CAPLUS
CN Glycine, N-[(methyl(1-methylethyl)amino)sulfonyl]-N-[[3-[(5-methyl-2-(4-(trifluoromethyl)phenyl)-4-oxazolyl)methoxy]phenyl]methyl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 873533-28-9 CAPLUS
CN Glycine, N-[(methyl(2-propenyl)amino)sulfonyl]-N-[[3-[(5-methyl-2-(4-(trifluoromethyl)phenyl)-4-oxazolyl)methoxy]phenyl]methyl]-, ethyl ester (9CI) (CA INDEX NAME)


L7 ANSWER 22 OF 83 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 873533-30-3 CAPLUS
CN Glycine, N-[(methyl(2-propynyl)amino)sulfonyl]-N-[[3-[(5-methyl-2-(4-(trifluoromethyl)phenyl)-4-oxazolyl)methoxy]phenyl]methyl]-, ethyl ester (9CI) (CA INDEX NAME)



RN 873533-32-5 CAPLUS
CN Glycine, N-[[3-[(5-methyl-2-(4-(trifluoromethyl)phenyl)-4-oxazolyl)methoxy]phenyl]methyl]-N-(1-piperidyl)sulfonyl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 873533-40-5 CAPLUS
CN Glycine, N-[(methylphenylamino)sulfonyl]-N-[[3-[(5-methyl-2-phenyl-4-oxazolyl)methoxy]phenyl]methyl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 873533-42-7 CAPLUS
CN Glycine, N-[[3-[(5-methyl-2-(4-methylphenyl)-4-oxazolyl)methoxy]phenyl]methyl]-N-[(methylphenylamino)sulfonyl]-, ethyl ester (9CI) (CA INDEX NAME)


L7 ANSWER 22 OF 83 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 873533-44-9 CAPLUS
CN Glycine, N-[(methylphenylamino)sulfonyl]-N-[[3-[(5-methyl-2-(4-(trifluoromethyl)phenyl)-4-oxazolyl)methoxy]phenyl]methyl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 873533-51-8 CAPLUS
CN Glycine, N-[[4-(4-chlorophenyl)methylamino)sulfonyl]-N-[[3-[(5-methyl-2-(4-methylphenyl)-4-oxazolyl)methoxy]phenyl]methyl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 873533-53-0 CAPLUS
CN Glycine, N-[[4-(4-chlorophenyl)methylamino)sulfonyl]-N-[[3-[(5-methyl-2-(4-(trifluoromethyl)phenyl)-4-oxazolyl)methoxy]phenyl]methyl]-, ethyl ester (9CI) (CA INDEX NAME)


L7 ANSWER 22 OF 83 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 873533-55-2 CAPLUS
CN Glycine, N-[[[ethyl (3-methylphenyl)amino]sulfonyl]-N-[[[3-[[[5-methyl-2-(4-(trifluoromethyl)phenyl]-4-oxazolyl)methoxy]phenyl]methyl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 873533-58-5 CAPLUS
CN Glycine, N-[[[4-methoxyphenyl)methylamino]sulfonyl]-N-[[[3-[[[5-methyl-2-(4-(trifluoromethyl)phenyl]-4-oxazolyl)methoxy]phenyl]methyl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 873533-67-6 CAPLUS
CN Glycine, N-[[[3-[[[5-methyl-2-(4-(trifluoromethyl)phenyl]-4-oxazolyl)methoxy]phenyl]methyl]-N-(1-pyrrolidinyl)sulfonyl]-, ethyl ester (9CI) (CA INDEX NAME)


L7 ANSWER 22 OF 83 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 873533-87-0 CAPLUS
CN Glycine, N-[(2,3-dihydro-1H-indol-1-yl)sulfonyl]-N-[[[3-[[[5-methyl-2-(4-(trifluoromethyl)phenyl]-4-oxazolyl)methoxy]phenyl]methyl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 873533-94-9 CAPLUS
CN Glycine, N-[(3,4-dihydro-1(2H)-quinolinyl)sulfonyl]-N-[[[3-[[[5-methyl-2-(4-methylphenyl)-4-oxazolyl)methoxy]phenyl]methyl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 873533-96-1 CAPLUS
CN Glycine, N-[(3,4-dihydro-1(2H)-quinolinyl)sulfonyl]-N-[[[3-[[[5-methyl-2-(4-(trifluoromethyl)phenyl]-4-oxazolyl)methoxy]phenyl]methyl]-, ethyl ester (9CI) (CA INDEX NAME)


L7 ANSWER 22 OF 83 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 873533-76-7 CAPLUS
CN Glycine, N-[[[3-[[[5-methyl-2-(4-methylphenyl)-4-oxazolyl)methoxy]phenyl]methyl]-N-(4-morpholinyl)sulfonyl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 873533-82-5 CAPLUS
CN Glycine, N-[(2,3-dihydro-1H-indol-1-yl)sulfonyl]-N-[[[3-[[[5-methyl-2-phenyl-4-oxazolyl)methoxy]phenyl]methyl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 873533-84-7 CAPLUS
CN Glycine, N-[(2,3-dihydro-1H-indol-1-yl)sulfonyl]-N-[[[3-[[[5-methyl-2-(4-methylphenyl)-4-oxazolyl)methoxy]phenyl]methyl]-, ethyl ester (9CI) (CA INDEX NAME)


L7 ANSWER 22 OF 83 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 873534-02-2 CAPLUS
CN Glycine, N-[(dimethylamino)sulfonyl]-N-[[[4-[[[5-methyl-2-phenyl-4-oxazolyl)methoxy]phenyl]methyl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 873534-04-4 CAPLUS
CN Glycine, N-[(dimethylamino)sulfonyl]-N-[[[4-[[[5-methyl-2-(4-methylphenyl)-4-oxazolyl)methoxy]phenyl]methyl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 873534-06-6 CAPLUS
CN Glycine, N-[(dimethylamino)sulfonyl]-N-[[[4-[[[5-methyl-2-(4-(trifluoromethyl)phenyl]-4-oxazolyl)methoxy]phenyl]methyl]-, ethyl ester (9CI) (CA INDEX NAME)


L7 ANSWER 22 OF 83 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 873534-12-4 CAPLUS
CN Glycine, N-[[4-[[[5-methyl-2-(4-methylphenyl)-4-oxazolyl]methoxy]phenyl]methyl]-N-[(1-pyrrolidinyl)sulfonyl]-, methyl ester (9CI) (CA INDEX NAME)




RN 873534-16-8 CAPLUS
CN Glycine, N-[[4-[[[5-methyl-2-(4-methylphenyl)-4-oxazolyl]methoxy]phenyl]methyl]-N-[(4-methyl-1-piperazinyl)sulfonyl]-, methyl ester (9CI) (CA INDEX NAME)




RN 873534-20-4 CAPLUS
CN Glycine, N-[[4-[[[5-methyl-2-(4-methylphenyl)-4-oxazolyl]methoxy]phenyl]methyl]-N-[(4-morpholinyl)sulfonyl]-, methyl ester (9CI) (CA INDEX NAME)


L7 ANSWER 22 OF 83 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 873534-35-1 CAPLUS
CN Glycine, N-[[4-[(4-chlorophenyl)methylamino]sulfonyl]-N-[[4-[[[5-methyl-2-(4-methylphenyl)-4-oxazolyl]methoxy]phenyl]methyl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 873534-37-3 CAPLUS
CN Glycine, N-[[4-[(4-chlorophenyl)methylamino]sulfonyl]-N-[[4-[[[5-methyl-2-(4-(trifluoromethyl)phenyl]-4-oxazolyl]methoxy]phenyl]methyl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 873534-43-1 CAPLUS
CN Glycine, N-[(2,3-dihydro-1H-indol-1-yl)sulfonyl]-N-[[4-[[[5-methyl-2-(4-oxazolyl)methoxy]phenyl]methyl]-, ethyl ester (9CI) (CA INDEX NAME)


L7 ANSWER 22 OF 83 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 873534-24-8 CAPLUS
CN Glycine, N-[(methylphenylamino)sulfonyl]-N-[[4-[[[5-methyl-2-phenyl-4-oxazolyl]methoxy]phenyl]methyl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 873534-26-0 CAPLUS
CN Glycine, N-[[4-[[[5-methyl-2-(4-methylphenyl)-4-oxazolyl]methoxy]phenyl]methyl]-N-[(methylphenylamino)sulfonyl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 873534-28-2 CAPLUS
CN Glycine, N-[(methylphenylamino)sulfonyl]-N-[[4-[[[5-methyl-2-(4-(trifluoromethyl)phenyl]-4-oxazolyl]methoxy]phenyl]methyl]-, ethyl ester (9CI) (CA INDEX NAME)


L7 ANSWER 22 OF 83 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 873534-45-3 CAPLUS
CN Glycine, N-[(2,3-dihydro-1H-indol-1-yl)sulfonyl]-N-[[4-[[[5-methyl-2-(4-methylphenyl)-4-oxazolyl]methoxy]phenyl]methyl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 873534-47-5 CAPLUS
CN Glycine, N-[(2,3-dihydro-1H-indol-1-yl)sulfonyl]-N-[[4-[[[5-methyl-2-(4-(trifluoromethyl)phenyl)-4-oxazolyl]methoxy]phenyl]methyl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 873534-54-4 CAPLUS
CN Glycine, N-[(3,4-dihydro-1(2H)-quinolinyl)sulfonyl]-N-[[4-[[[5-methyl-2-(4-methylphenyl)-4-oxazolyl]methoxy]phenyl]methyl]-, ethyl ester (9CI) (CA INDEX NAME)


PAGE 1-A




PAGE 2-A




RN 873534-56-6 CAPLUS
CN Glycine,
N-((dimethylamino)sulfonyl)-N-([3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl)-, ethyl ester (9CI) (CA INDEX NAME)




RN 873534-62-4 CAPLUS
CN Glycine,
N-((diethylamino)sulfonyl)-N-([3-[2-(5-methyl-2-(4-methylphenyl)-4-oxazolyl)ethoxy]phenyl]methyl)-, ethyl ester (9CI) (CA INDEX NAME)



RN 873534-64-6 CAPLUS
CN Glycine,
N-((diethylamino)sulfonyl)-N-([3-[2-(5-methyl-2-(4-methylphenyl)-4-oxazolyl)ethoxy]phenyl]methyl)-, ethyl ester (9CI) (CA INDEX NAME)




RN 873534-67-9 CAPLUS
CN Glycine,
N-([methyl(1-methylethyl)amino]sulfonyl)-N-([3-[2-(5-methyl-2-(4-methylphenyl)-4-oxazolyl)ethoxy]phenyl]methyl)-, ethyl ester (9CI) (CA INDEX NAME)




RN 873534-69-1 CAPLUS
CN Glycine, N-((dimethylamino)sulfonyl)-N-([3-[2-(5-methyl-2-(4-(trifluoromethyl)phenyl)-4-oxazolyl)ethoxy]phenyl]methyl)-, ethyl ester


PAGE 1-A




PAGE 2-A




RN 873534-60-2 CAPLUS
CN Glycine, N-((dimethylamino)sulfonyl)-N-([3-[2-(5-methyl-2-(4-(trifluoromethyl)phenyl)-4-oxazolyl)ethoxy]phenyl]methyl)-, ethyl ester (9CI) (CA INDEX NAME)




RN 873534-71-5 CAPLUS
CN Glycine, N-((1,1-dimethylethylamino)sulfonyl)-N-([3-[2-(5-methyl-2-(4-(trifluoromethyl)phenyl)-4-oxazolyl)ethoxy]phenyl]methyl)-, ethyl ester (9CI) (CA INDEX NAME)



RN 873534-74-8 CAPLUS
CN Glycine, N-((diethylamino)sulfonyl)-N-([3-[2-(5-methyl-2-(4-(trifluoromethyl)phenyl)-4-oxazolyl)ethoxy]phenyl]methyl)-, ethyl ester (9CI) (CA INDEX NAME)




RN 873534-76-0 CAPLUS
CN Glycine,
N-([methyl(1-methylethyl)amino]sulfonyl)-N-([3-[2-(5-methyl-2-(4-(trifluoromethyl)phenyl)-4-oxazolyl)ethoxy]phenyl]methyl)-, ethyl ester (9CI) (CA INDEX NAME)




RN 873534-78-2 CAPLUS


L7 ANSWER 22 OF 83 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
 CN Glycine, N-[(methyl-2-propenylamino)sulfonyl]-N-[[3-[2-[5-methyl-2-(4-(trifluoromethyl)phenyl]-4-oxazolyl)ethoxy]phenyl]methyl]-, ethyl ester (9CI) (CA INDEX NAME)



RN 873534-80-6 CAPLUS
 CN Glycine, N-[(methyl-2-propynylamino)sulfonyl]-N-[[3-[2-[5-methyl-2-(4-(trifluoromethyl)phenyl]-4-oxazolyl)ethoxy]phenyl]methyl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 873534-82-8 CAPLUS
 CN Glycine, N-[[3-[2-[5-methyl-2-(4-(trifluoromethyl)phenyl]-4-oxazolyl)ethoxy]phenyl]methyl]-N-(1-piperidinylsulfonyl)-, ethyl ester (9CI) (CA INDEX NAME)




RN 873534-86-2 CAPLUS
 CN Glycine, N-[(methylphenylamino)sulfonyl]-N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-, ethyl ester (9CI) (CA INDEX NAME)


L7 ANSWER 22 OF 83 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 873534-96-4 CAPLUS
 CN Glycine, N-[[4-(4-chlorophenyl)methylamino]sulfonyl]-N-[[3-[2-[5-methyl-2-(4-methylphenyl)-4-oxazolyl)ethoxy]phenyl]methyl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 873534-98-6 CAPLUS
 CN Glycine, N-[[4-(4-chlorophenyl)methylamino]sulfonyl]-N-[[3-[2-[5-methyl-2-(4-(trifluoromethyl)phenyl)-4-oxazolyl)ethoxy]phenyl]methyl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 873535-00-3 CAPLUS
 CN Glycine, N-[[ethyl(3-methylphenyl)amino]sulfonyl]-N-[[3-[2-[5-methyl-2-(4-(trifluoromethyl)phenyl)-4-oxazolyl)ethoxy]phenyl]methyl]-, ethyl ester (9CI) (CA INDEX NAME)


L7 ANSWER 22 OF 83 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 873534-88-4 CAPLUS
 CN Glycine, N-[[3-[2-[5-methyl-2-(4-methylphenyl)-4-oxazolyl)ethoxy]phenyl]methyl]-N-[(methylphenylamino)sulfonyl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 873534-90-8 CAPLUS
 CN Glycine, N-[(methylphenylamino)sulfonyl]-N-[[3-[2-[5-methyl-2-(4-(trifluoromethyl)phenyl)-4-oxazolyl)ethoxy]phenyl]methyl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 873534-94-2 CAPLUS
 CN Glycine, N-[[4-(4-chlorophenyl)methylamino]sulfonyl]-N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-, ethyl ester (9CI) (CA INDEX NAME)


L7 ANSWER 22 OF 83 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 873535-02-5 CAPLUS
 CN Glycine, N-[[4-(4-methoxyphenyl)methylamino]sulfonyl]-N-[[3-[2-[5-methyl-2-(4-(trifluoromethyl)phenyl)-4-oxazolyl)ethoxy]phenyl]methyl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 873535-04-7 CAPLUS
 CN Glycine, N-[[3-(3-fluorophenyl)methylamino]sulfonyl]-N-[[3-[2-[5-methyl-2-(4-(trifluoromethyl)phenyl)-4-oxazolyl)ethoxy]phenyl]methyl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 873535-08-1 CAPLUS
 CN Glycine, N-[[3-[2-[5-methyl-2-(4-methylphenyl)-4-oxazolyl)ethoxy]phenyl]methyl]-N-(1-pyrrolidinylsulfonyl)-, methyl ester (9CI) (CA INDEX NAME)


L7 ANSWER 22 OF 83 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 873535-11-6 CAPLUS
CN Glycine, N-([3-[2-[5-methyl-2-[4-(trifluoromethyl)phenyl]-4-oxazolyl]ethoxy]phenyl)methyl]-N-(1-pyrrolidinylsulfonyl)-, ethyl ester (9CI) (CA INDEX NAME)




RN 873535-13-8 CAPLUS
CN Glycine, N-([3-[2-[5-methyl-2-(4-methylphenyl)-4-oxazolyl]ethoxy]phenyl)methyl]-N-(4-morpholinylsulfonyl)-, ethyl ester (9CI) (CA INDEX NAME)




RN 873535-16-1 CAPLUS
CN Glycine, N-([3-[2-[5-methyl-2-[4-(trifluoromethyl)phenyl]-4-oxazolyl]ethoxy]phenyl)methyl]-N-(4-morpholinylsulfonyl)-, ethyl ester (9CI) (CA INDEX NAME)


L7 ANSWER 22 OF 83 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 873535-25-2 CAPLUS
CN Glycine, N-((2,3-dihydro-1H-indol-1-yl)sulfonyl)-N-([3-[2-[5-methyl-2-(4-methylphenyl)-4-oxazolyl]ethoxy]phenyl)methyl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 873535-27-4 CAPLUS
CN Glycine, N-((2,3-dihydro-1H-indol-1-yl)sulfonyl)-N-([3-[2-[5-methyl-2-(4-(trifluoromethyl)phenyl]-4-oxazolyl]ethoxy]phenyl)methyl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 873535-31-0 CAPLUS
CN Glycine, N-((3,4-dihydro-1(2H)-quinolinyl)sulfonyl)-N-([3-[2-[5-methyl-2-phenyl-4-oxazolyl]ethoxy]phenyl)methyl]-, ethyl ester (9CI) (CA INDEX NAME)


L7 ANSWER 22 OF 83 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 873535-18-3 CAPLUS
CN Glycine, N-([3-[2-[5-methyl-2-(4-methylphenyl)-4-oxazolyl]ethoxy]phenyl)methyl]-N-((4-methyl-1-piperazinyl)sulfonyl)-, methyl ester (9CI) (CA INDEX NAME)




RN 873535-21-8 CAPLUS
CN Glycine, N-((4-methyl-1-piperazinyl)sulfonyl)-N-([3-[2-[5-methyl-2-(4-(trifluoromethyl)phenyl)-4-oxazolyl]ethoxy]phenyl)methyl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 873535-23-0 CAPLUS
CN Glycine, N-((2,3-dihydro-1H-indol-1-yl)sulfonyl)-N-([3-[2-[5-methyl-2-phenyl-4-oxazolyl]ethoxy]phenyl)methyl]-, ethyl ester (9CI) (CA INDEX NAME)

L7 ANSWER 22 OF 83 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 873535-33-2 CAPLUS
CN Glycine, N-((3,4-dihydro-1(2H)-quinolinyl)sulfonyl)-N-([3-[2-[5-methyl-2-(4-methylphenyl)-4-oxazolyl]ethoxy]phenyl)methyl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 873535-35-4 CAPLUS
CN Glycine, N-((3,4-dihydro-1(2H)-quinolinyl)sulfonyl)-N-([3-[2-[5-methyl-2-(4-(trifluoromethyl)phenyl)-4-oxazolyl]ethoxy]phenyl)methyl]-, ethyl ester (9CI) (CA INDEX NAME)


L7 ANSWER 22 OF 83 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 873535-39-8 CAPLUS
 CN Glycine, N-[(dimethylamino)sulfonyl]-N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 873535-41-2 CAPLUS
 CN Glycine, N-[(dimethylamino)sulfonyl]-N-[[4-[2-(5-methyl-2-(4-methylphenyl)-4-oxazolyl)ethoxy]phenyl]methyl]-, ethyl ester (9CI) (CA INDEX NAME)




L7 ANSWER 22 OF 83 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
 RN 873535-50-3 CAPLUS
 CN Glycine, N-[(dimethylamino)sulfonyl]-N-[[4-[2-(5-methyl-2-(4-(trifluoromethyl)phenyl)-4-oxazolyl)ethoxy]phenyl]methyl]-, ethyl ester (9CI) (CA INDEX NAME)



RN 873535-54-7 CAPLUS
 CN Glycine, N-[(methylphenylamino)sulfonyl]-N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 873535-56-9 CAPLUS
 CN Glycine, N-[[4-[2-(5-methyl-2-(4-methylphenyl)-4-oxazolyl)ethoxy]phenyl]methyl]-N-[(methylphenylamino)sulfonyl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 873535-58-1 CAPLUS
 CN Glycine, N-[(methylphenylamino)sulfonyl]-N-[[4-[2-(5-methyl-2-(4-(trifluoromethyl)phenyl)-4-oxazolyl)ethoxy]phenyl]methyl]-, ethyl ester (9CI) (CA INDEX NAME)

L7 ANSWER 22 OF 83 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)


RN 873535-43-4 CAPLUS
 CN Glycine, N-[[1,1-dimethylethylamino)sulfonyl]-N-[[4-[2-(5-methyl-2-(4-methylphenyl)-4-oxazolyl)ethoxy]phenyl]methyl]-, methyl ester (9CI) (CA INDEX NAME)



RN 873535-46-7 CAPLUS
 CN Glycine, N-[(diethylamino)sulfonyl]-N-[[4-[2-(5-methyl-2-(4-methylphenyl)-4-oxazolyl)ethoxy]phenyl]methyl]-, methyl ester (9CI) (CA INDEX NAME)




RN 873535-48-9 CAPLUS
 CN Glycine, N-[[methyl(1-methylethylamino)sulfonyl]-N-[[4-[2-(5-methyl-2-(4-methylphenyl)-4-oxazolyl)ethoxy]phenyl]methyl]-, methyl ester (9CI) (CA INDEX NAME)




L7 ANSWER 22 OF 83 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)


RN 873535-63-8 CAPLUS
 CN Glycine, N-[[4-(4-chlorophenyl)methylamino)sulfonyl]-N-[[4-[2-(5-methyl-2-(4-methylphenyl)-4-oxazolyl)ethoxy]phenyl]methyl]-, ethyl ester (9CI) (CA INDEX NAME)



RN 873535-65-0 CAPLUS
 CN Glycine, N-[[ethyl(2-methylphenylamino)sulfonyl]-N-[[4-[2-(5-methyl-2-(4-methylphenyl)-4-oxazolyl)ethoxy]phenyl]methyl]-, methyl ester (9CI) (CA INDEX NAME)



RN 873535-67-2 CAPLUS
 CN Glycine, N-[[4-(4-methoxyphenyl)methylamino)sulfonyl]-N-[[4-[2-(5-methyl-2-(4-methylphenyl)-4-oxazolyl)ethoxy]phenyl]methyl]-, methyl ester (9CI) (CA INDEX NAME)




RN 873535-69-4 CAPLUS
 CN Glycine, N-[[4-(4-methoxyphenyl)methylamino)sulfonyl]-N-[[4-[2-(5-methyl-2-(4-methylphenyl)-4-oxazolyl)ethoxy]phenyl]methyl]-, methyl ester (9CI) (CA INDEX NAME)


10788996

11/26/06


L7 ANSWER 22 OF 83 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 873535-69-4 CAPLUS
 CN Glycine,
 N-[(3-fluorophenyl)methylamino)sulfonyl]-N-[(4-[2-[5-methyl-2-(4-methylphenyl)-4-oxazolyl]ethoxy]phenyl)methyl]-, methyl ester (9CI) (CA INDEX NAME)




RN 873535-71-8 CAPLUS
 CN Glycine,
 N-[(4-chlorophenyl)methylamino)sulfonyl]-N-[(4-[2-[5-methyl-2-(4-(trifluoromethyl)phenyl)-4-oxazolyl]ethoxy]phenyl)methyl]-, ethyl ester (9CI) (CA INDEX NAME)



RN 873535-75-2 CAPLUS

L7 ANSWER 22 OF 83 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)

PAGE 1-A




PAGE 2-A




RN 873535-85-4 CAPLUS
 CN Glycine, N-[(3,4-dihydro-1(2H)-quinolinyl)sulfonyl]-N-[(4-[2-[5-methyl-2-(4-methylphenyl)-4-oxazolyl]ethoxy]phenyl)methyl]-, ethyl ester (9CI)
 (CA INDEX NAME)


L7 ANSWER 22 OF 83 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
 CN Glycine, N-[(2,3-dihydro-1H-indol-1-yl)sulfonyl]-N-[(4-[2-[5-methyl-2-phenyl-4-oxazolyl]ethoxy]phenyl)methyl]-, ethyl ester (9CI) (CA INDEX NAME)



RN 873535-77-4 CAPLUS
 CN Glycine, N-[(2,3-dihydro-1H-indol-1-yl)sulfonyl]-N-[(4-[2-[5-methyl-2-(4-methylphenyl)-4-oxazolyl]ethoxy]phenyl)methyl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 873535-79-6 CAPLUS
 CN Glycine, N-[(2,3-dihydro-1H-indol-1-yl)sulfonyl]-N-[(4-[2-[5-methyl-2-(4-(trifluoromethyl)phenyl)-4-oxazolyl]ethoxy]phenyl)methyl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 873535-83-2 CAPLUS
 CN Glycine, N-[(3,4-dihydro-1(2H)-quinolinyl)sulfonyl]-N-[(4-[2-[5-methyl-2-phenyl-4-oxazolyl]ethoxy]phenyl)methyl]-, ethyl ester (9CI) (CA INDEX NAME)

L7 ANSWER 22 OF 83 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)

PAGE 1-A




PAGE 2-A



RN 873535-87-6 CAPLUS
 CN Glycine, N-[(3,4-dihydro-1(2H)-quinolinyl)sulfonyl]-N-[(4-[2-[5-methyl-2-(4-(trifluoromethyl)phenyl)-4-oxazolyl]ethoxy]phenyl)methyl]-, ethyl ester (9CI) (CA INDEX NAME)

L7 ANSWER 22 OF 83 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)


PAGE 1-A




RN 873535-91-2 CAPLUS
CN L-Alanine,
N-[(dimethylamino)sulfonyl]-N-[1-[3-[[5-methyl-2-(4-methylphenyl)-4-oxazolyl]methoxy]phenyl]methyl]-, ethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.


PAGE 2-A




L7 ANSWER 22 OF 83 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 873536-01-7 CAPLUS
CN Glycine,
N-[(diethylamino)sulfonyl]-N-[1-[3-[[5-methyl-2-(4-methylphenyl)-4-oxazolyl]methoxy]phenyl]ethyl]-, methyl ester (9CI) (CA INDEX NAME)




RN 873536-03-9 CAPLUS
CN Glycine,
N-[methyl(1-methylethylamino)sulfonyl]-N-[1-[3-[[5-methyl-2-(4-methylphenyl)-4-oxazolyl]methoxy]phenyl]ethyl]-, methyl ester (9CI) (CA INDEX NAME)




RN 873536-05-1 CAPLUS
CN β-Alanine, N-[(dimethylamino)sulfonyl]-N-[1-[3-[[5-methyl-2-(4-methylphenyl)-4-oxazolyl]methoxy]phenyl]methyl]-, ethyl ester (9CI) (CA INDEX NAME)

L7 ANSWER 22 OF 83 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 873535-94-5 CAPLUS
CN L-Valine,
N-[(dimethylamino)sulfonyl]-N-[1-[3-[[5-methyl-2-(4-methylphenyl)-4-oxazolyl]methoxy]phenyl]methyl]-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 873535-96-7 CAPLUS
CN Glycine,
N-[(dimethylamino)sulfonyl]-N-[1-[3-[[5-methyl-2-(4-methylphenyl)-4-oxazolyl]methoxy]phenyl]ethyl]-, methyl ester (9CI) (CA INDEX NAME)




RN 873535-99-0 CAPLUS
CN Glycine, N-[1-[3-[[5-methyl-2-(4-methylphenyl)-4-oxazolyl]methoxy]phenyl]ethyl]-N-(1-pyrrolidinyl)sulfonyl]-, methyl ester (9CI) (CA INDEX NAME)


L7 ANSWER 22 OF 83 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 873536-08-4 CAPLUS
CN Glycine, N-[(dimethylamino)sulfonyl]-N-[1-[2-(2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-, ethyl ester (9CI) (CA INDEX NAME)



RN 873536-11-9 CAPLUS
CN Glycine, N-[(dimethylamino)sulfonyl]-N-[1-[4-(2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 873536-14-2 CAPLUS
CN Glycine, N-[(4-chlorophenyl)methylamino)sulfonyl]-N-[1-[4-(2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 873536-16-4 CAPLUS
CN Glycine,
N-[(dimethylamino)sulfonyl]-N-[1-[4-[[5-(1-methylethyl)-2-phenyl-4-


L7 ANSWER 22 OF 83 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
 RN 873533-22-3 CAPLUS
 CN Glycine, N-([3-([5-methyl-2-(4-methylphenyl)-4-oxazolyl)methoxy]phenyl)methyl]-, ethyl ester (9CI) (CA INDEX NAME)




IT 873533-10-9, Methyl (S)-3-methyl-2-[[[3-([5-methyl-2-(p-tolyl)oxazol-4-yl)methoxy]phenyl)methyl]amino]butanoate
 873533-22-3, N-([3-([2-(4-Trifluoromethylphenyl)-5-methyloxazol-4-yl)methoxy]benzyl]amino)acetic acid ethyl ester 873534-65-7, N-([3-([2-(2-(4-Methylphenyl)-5-methyloxazol-4-yl)ethoxy]benzyl]amino)acetic acid ethyl ester 873534-72-6, Ethyl N-([3-([2-(2-(4-Trifluoromethylphenyl)-5-methyloxazol-4-yl)ethoxy]phenyl)methyl]amino)acetate 873535-44-5, Methyl N-([4-([2-(2-(4-Methylphenyl)-5-methyloxazol-4-yl)ethoxy]phenyl)methyl]amino)acetate 873535-92-3
 873535-97-8, Methyl [1-([3-([5-methyl-2-(p-tolyl)oxazol-4-yl)methoxy]phenyl)ethyl]amino]acetate 873536-06-2, Ethyl
 3-[[[3-([5-methyl-2-(p-tolyl)oxazol-4-yl)methoxy]phenyl)methyl]amino]propionate 873536-09-5, [3-([2-(2-Phenylloxazol-4-yl)ethoxy]benzyl]amino)acetic acid ethyl ester 873536-12-0, [4-([2-(2-Phenylloxazol-4-yl)ethoxy]benzyl]amino)acetic acid ethyl ester 873536-17-5, [3-([5-Isopropyl-2-phenyloxazol-4-yl)methoxy]benzyl]amino)acetic acid ethyl ester
 RL: RCT (Reactant); RACT (Reactant or reagent)
 (preparation of oxazole-containing sulfamides as PPAR α agonists and their pharmaceutical compns. useful for upregulation of lipid metabolism)
 RN 873533-10-9 CAPLUS
 CN L-Valine, N-([3-([5-methyl-2-(4-methylphenyl)-4-oxazolyl)methoxy]phenyl)methyl]-, methyl ester (9CI) (CA INDEX NAME)
 Absolute stereochemistry.




L7 ANSWER 22 OF 83 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
 RN 873535-92-3 CAPLUS
 CN L-Alanine, N-([3-([5-methyl-2-(4-methylphenyl)-4-oxazolyl)methoxy]phenyl)methyl]-, ethyl ester (9CI) (CA INDEX NAME)
 Absolute stereochemistry.




RN 873535-97-8 CAPLUS
 CN Glycine, N-([3-([5-methyl-2-(4-methylphenyl)-4-oxazolyl)methoxy]phenyl)methyl]-, methyl ester (9CI) (CA INDEX NAME)




RN 873536-06-2 CAPLUS
 CN β -Alanine, N-([3-([5-methyl-2-(4-methylphenyl)-4-oxazolyl)methoxy]phenyl)methyl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 873536-09-5 CAPLUS
 CN Glycine, N-([3-([2-(2-phenyl-4-oxazolyl)ethoxy]phenyl)methyl]-, ethyl ester (9CI) (CA INDEX NAME)




L7 ANSWER 22 OF 83 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
 RN 873533-22-3 CAPLUS
 CN Glycine, N-([3-([5-methyl-2-(4-(trifluoromethyl)phenyl)-4-oxazolyl)methoxy]phenyl)methyl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 873534-65-7 CAPLUS
 CN Glycine, N-([3-([2-(5-methyl-2-(4-methylphenyl)-4-oxazolyl)ethoxy]phenyl)methyl]-, ethyl ester (9CI) (CA INDEX NAME)



RN 873534-72-6 CAPLUS
 CN Glycine, N-([3-([2-(5-methyl-2-(4-(trifluoromethyl)phenyl)-4-oxazolyl)ethoxy]phenyl)methyl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 873535-44-5 CAPLUS
 CN Glycine, N-([4-([2-(5-methyl-2-(4-methylphenyl)-4-oxazolyl)ethoxy]phenyl)methyl]-, methyl ester (9CI) (CA INDEX NAME)




L7 ANSWER 22 OF 83 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)

RN 873536-12-0 CAPLUS
 CN Glycine, N-([4-([2-(2-phenyl-4-oxazolyl)ethoxy]phenyl)methyl]-, ethyl ester (9CI) (CA INDEX NAME)



RN 873536-17-5 CAPLUS
 CN Glycine, N-([3-([5-(1-methylethyl)-2-phenyl-4-oxazolyl)methoxy]phenyl)methyl]-, ethyl ester (9CI) (CA INDEX NAME)



REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE REFORMAT

L7 ANSWER 23 OF 83 CAPLUS COPYRIGHT 2006 ACS ON STN
 ACCESSION NUMBER: 2006:15049 CAPLUS
 DOCUMENT NUMBER: 144:444723
 TITLE: Dual and pan-peroxisome proliferator-activated
 receptors (PPAR) co-agonism: The bezafibrate lessons
 Tenenbaum, Alexander; Motro, Michael; Fisman, Enrique
 Z.
 CORPORATE SOURCE: Sheba Medical Center, Cardiac Rehabilitation
 Institute, Tel-Hashomer, 52621, Israel
 SOURCE: Cardiovascular Diabetology (2005), 4, No pp. given
 CODEN: CDIAZ, ISSN: 1475-2840
 URL: <http://www.cardiab.com/content/pdf/1475-2840-4-14.pdf>
 PUBLISHER: BioMed Central Ltd.
 DOCUMENT TYPE: Journal; General Review; (online computer file)
 LANGUAGE: English

AB A review. There are three peroxisome proliferator-activated receptors (PPARs) subtypes which are commonly designated PPAR alpha, PPAR gamma and PPAR beta/delta. PPAR alpha activation increases high d. lipoprotein (HDL) cholesterol synthesis, stimulates "reverse" cholesterol transport and reduces triglycerides. PPAR gamma activation results in insulin sensitization and antidiabetic action. Until recently, the biol. role of PPAR beta/delta remained unclear. However, treatment of obese animals by specific PPAR delta agonists results in normalization of metabolic parameters and reduction of adiposity. Combined treatments with PPAR

gamma and alpha agonists may potentially improve insulin resistance and alleviate atherogenic dyslipidemia, whereas PPAR delta properties may prevent the development of overweight which typically accompanies "pure" PPAR gamma ligands. The new generation of dual-action PPARs - the glitazars, which target PPAR-gamma and PPAR-alpha (like muraglitazar and tesaglitazar) are on deck in late-stage clin. trials and may be effective in reducing cardiovascular risk, but their long-term clin. effects are still unknown. A number of glitazars have presented problems at a late

stage of clin. trials because of serious side-effects (including re-aglitazar and farglitazar). The old and well known lipid-lowering fibric acid derivative bezafibrate is the first clin. tested pan - (alpha, beta/delta,

gamma) PPAR activator. It is the only pan-PPAR activator with more than a quarter of a century of therapeutic experience with a good safety profile.

Therefore, bezafibrate could be considered (indeed, as a "post hoc" understanding) as an "archetype" of a clin. tested pan-PPAR ligand. Bezafibrate leads to considerable raising of HDL cholesterol and reduces triglycerides, improves insulin sensitivity and reduces blood glucose level, significantly lowering the incidence of cardiovascular events and new diabetes in patients with features of metabolic syndrome. Clin. evidences obtained from bezafibrate-based studies strongly support the concept of pan-PPAR therapeutic approach to conditions which comprise the metabolic syndrome. However, from a biochem. point of view, bezafibrate is a PPAR ligand with a relatively low potency. More


powerful new compds. with pan-PPAR activity and proven long-term safety should be highly effective in a clin. setting of patients with coexisting relevant

L7 ANSWER 23 OF 83 CAPLUS COPYRIGHT 2006 ACS ON STN (Continued)
 lipid and glucose metab. disorders.

IT 331741-94-7 CAPLUS
 RI: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (dual-action peroxisome proliferator-activated receptor glitazar target

PPAR-gamma and PPAR-alpha like muraglitazar and may be effective in reducing cardiovascular risk in patient with metabolic syndrome)

RN 331741-94-7 CAPLUS
 CN Glycine, N-[(4-methoxyphenoxy)carbonyl]-N-[(4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl)methyl]- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 43 THERE ARE 43 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE

FORMAT

L7 ANSWER 24 OF 83 CAPLUS COPYRIGHT 2006 ACS ON STN
 ACCESSION NUMBER: 2006:13751 CAPLUS
 DOCUMENT NUMBER: 144:128966
 TITLE: Constrained cyano compounds as selective inhibitors of dipeptidyl peptidase IV, their preparation, pharmaceutical compositions, and use in therapy
 INVENTOR(S): Campbell, David Alan; Betancourt, Juan Manuel; Winn, David T.
 PATENT ASSIGNEE(S): USA
 SOURCE: U.S. Pat. Appl. Publ., 35 pp.
 CODEN: USXXCO
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2006009518	A1	20060112	US 2005-179797	20050712
WO 2006017292	A1	20060216	WO 2005-224695	20050712

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LU, LV, MA, MD, MG, MK, MN, MW, MX, MY, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW

RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BP, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

PRIORITY APPLN. INFO.: US 2004-587391P P 20040712

OTHER SOURCE(S): MARPAT 144:128966
 GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB The invention relates to constrained cyano compds. of formula I, which are selective inhibitors of dipeptidyl peptidase IV (DPP-IV). In compds. I, X is (un)substituted C, optionally forming a double bond with one of the carbon atoms to which it is attached, S, or O; R1 and R4 are independently

H, (un)substituted alkyl, (un)substituted alkenyl, (un)substituted alkynyl, (un)substituted cycloalkyl, (un)substituted cycloalkyl-alkyl, (un)substituted aryl, (un)substituted aralkyl, etc.; and R2, R3, R5, and R6 are independently selected from H, P, Cl, Br, I, OH, NH2, CN, alkoxy, (di)alkylamino, acyl, alkoxycarbonyl, aryloxy, etc. The invention also relates to the preparation of I, pharmaceutical compns. comprising a compound I

together with at least one pharmaceutically acceptable carrier or diluent, optionally in combination with another active ingredient, as well as to

L7 ANSWER 24 OF 83 CAPLUS COPYRIGHT 2006 ACS ON STN (Continued)
 the use of the compns. for treating, controlling, or preventing conditions

affected by dipeptidyl peptidase-IV inhibition. Esterification of (S)-phenylglycine followed by condensation with benzaldehyde, alpha-allylation, hydrolysis and N-protection gave amino acid II, which underwent ozonolysis, ester hydrolysis, and cyclization with L-cysteine

Me ester to give thiazolidine III. Intramol. cyclocondensation of III, amidation, dehydration and deprotection resulted in the formation of hexahydropyridothiazole IV. The compds. of the invention are selective for DPP-IV over other dipeptidyl peptidases with compd. IV being more

than 100-fold selective for DPP-IV over DPP-VII, DPP-VIII, and fibroblast activation protein (FAP) and between 10- and 100-fold for DPP-IV over DPP-IX.


IT 258345-41-4, GW 409544

RI: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (preparation of constrained cyano compds. as selective inhibitors of dipeptidyl peptidase IV)

RN 258345-41-4 CAPLUS

CN L-Tyrosine, N-[(12)-1-methyl-3-oxo-3-phenyl-1-propenyl]-O-[2-(5-methyl-2-phenyl-4-oxazolyl)ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
 Double bond geometry as shown.



L7 ANSWER 25 OF 83 CAPLUS COPYRIGHT 2006 ACS on STN
 ACCESSION NUMBER: 2005:1261265 CAPLUS
 DOCUMENT NUMBER: 144:80961
 TITLE: Effect of muraglitazar on death and major adverse cardiovascular events in patients with type 2 Diabetes Mellitus
 AUTHOR(S): Nissen, Steven E.; Wolski, Kathy; Topol, Eric J.
 CORPORATE SOURCE: Department of Cardiovascular Medicine, Cleveland Clinic Foundation, Cleveland, OH, 44195, USA
 SOURCE: JAMA, the Journal of the American Medical Association (2005), 294(20), 2581-2586
 CODEN: JAMAAP; ISSN: 0098-7484
 PUBLISHER: American Medical Association
 DOCUMENT TYPE: Journal
 LANGUAGE: English

AB Context: Peroxisome proliferator-activated receptors (PPARs) are nuclear transcription factors that modulate gene expression. Therapeutic agents targeting 2 distinct families of PPARs (α and γ) have been introduced in the United States. The first dual-PPAR agonist, muraglitazar, was reviewed by a US Food and Drug Administration (FDA) advisory committee on Sept. 9, 2005, resulting in a vote of 8:1 recommending approval for its use in controlling blood glucose levels in patients with type 2 diabetes. Objective: To evaluate the incidence of death, myocardial infarction (MI), stroke, congestive heart failure (CHF), and transient ischemic attack (TIA) in diabetic patients treated with muraglitazar compared with controls. Design, Setting, and Participants: The source material for this anal. consisted of documents about phase 2 and 3 clin. trials released under public disclosure laws

for the FDA advisory committee meeting. All reviewed trials were prospective, randomized, double-blind, multicenter studies enrolling patients with type 2 diabetes and Hb A_{1c} levels between 7% and 10%. Patients (N = 3725) were randomized to receive differing doses of muraglitazar, pioglitazone, or placebo as monotherapy or in combination with metformin or glyburide in trials ranging from 24 to 104 wk. Main Outcome Measures: The primary outcome was the incidence of death, non-fatal MI, or nonfatal stroke. A more comprehensive composite outcome included these events

plus the incidence of CHF and TIA. Results in the muraglitazar-treated patients, death, MI, or stroke occurred in 35 of 2374 (1.47%) patients compared with 9 of 1351 (0.67%) patients in the combined placebo and pioglitazone treatment groups (controls) [relative risk (RR), 2.23; 95% confidence interval (CI), 1.07 - 4.66; P = .03]. For the more comprehensive outcome measure that included TIA and CHF, the incidence


was 50 of 2374 (2.11%) for muraglitazar compared with 11 of 1351 (0.81%) for controls (RR, 2.62; 95% CI, 1.36 - 5.05; P = .004). Relative risks for each of the individual components of the composite end point exceeded 2.1 but were not statistically significant. Incidence of adjudicated CHF was 13 of 2374 (0.55%) muraglitazar-treated patients and 1 of 1351 controls (0.07%) (RR, 7.43; 95% CI, 0.97 - 56.8; P = .053). Conclusions: Compared with placebo or pioglitazone, muraglitazar was associated with an excess incidence of the composite end point of death, major adverse cardiovascular events (MI, stroke, TIA), and CHF. This agent should not

L7 ANSWER 26 OF 83 CAPLUS COPYRIGHT 2006 ACS on STN
 ACCESSION NUMBER: 2005:1260631 CAPLUS
 DOCUMENT NUMBER: 144:23127
 TITLE: Preparation of muraglitazar and its polymorphic forms for the treatment of dyslipidemia and diabetes
 INVENTOR(S): Manohar;
 PATENT ASSIGNEE(S): Chung, Hyei-Jha; Malley, Mary F.
 SOURCE: Bristol-Myers Squibb Company, USA
 PCT Int. Appl., 50 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005113521	A1	20051201	WO 2005-US17357	20050517
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SI, SM, SV, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CP, CO, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
US 2005288343	A1	20051229	US 2005-130048	20050516
PRIORITY APPLN. INFO.:			US 2004-572397P	P 20040519
			US 2005-130048	A 20050516

OTHER SOURCE(S): CASREACT 144:23127; MARPAT 144:23127

GI




AB An improved process of preparing muraglitazar (I) and crystalline forms, useful

for the treatment of dyslipidemia and diabetes, and intermediates are provided. I was prepared starting from 4-[2-(5-methyl-2-phenyloxazol-4-yl)ethoxy]benzaldehyde and glycine Me ester-HCl giving Me 4-[2-(5-methyl-2-phenyloxazol-4-yl)ethoxy]benzylaminoacetate-HCl which was treated with 4-methoxyphenyl chloroformate to give the Me ester of I and hydrolyzed to I. Polymorphic forms of I are provided.


IT 331746-67-9P 649761-25-1P
 RL: PRP (Properties); RCT (Reactant); SPN (Synthetic preparation); PREP

L7 ANSWER 25 OF 83 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
 be approved to treat diabetes based on lab. end points until safety is documented in a dedicated cardiovascular events trial.
 IT 331741-94-7, Muraglitazar
 RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (muraglitazar effect on death and major adverse cardiovascular events in patients with type 2 diabetes mellitus)
 RN 331741-94-7 CAPLUS
 CN Glycine, N-[(4-methoxyphenoxy)carbonyl]-N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- (9CI) (CA INDEX NAME)




REFERENCE COUNT: 22 THERE ARE 22 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE REFORMAT

L7 ANSWER 26 OF 83 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
 (Preparation); RACT (Reactant or reagent)
 (prepn. of muraglitazar and its polymorphic forms for the treatment of dyslipidemia and diabetes)
 RN 331746-67-9 CAPLUS
 CN Glycine, N-[(4-methoxyphenoxy)carbonyl]-N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-, methyl ester (9CI) (CA INDEX NAME)




RN 649761-25-1 CAPLUS
 CN Glycine, N-[(4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-, methyl ester, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

IT 331741-94-7P, Muraglitazar
 RL: PRP (Properties); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (preparation of muraglitazar and its polymorphic forms for the treatment of dyslipidemia and diabetes)
 RN 331741-94-7 CAPLUS
 CN Glycine, N-[(4-methoxyphenoxy)carbonyl]-N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- (9CI) (CA INDEX NAME)

L7 ANSWER 26 OF 83 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



REFERENCE COUNT: 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE

FORMAT


L7 ANSWER 27 OF 83 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2005:114338 CAPLUS
 DOCUMENT NUMBER: 144:120701
 TITLE: Muraglitazar: a dual peroxisome proliferator-activated receptor agonist
 AUTHOR(S): Kirwin, Jennifer; Van Amburgh, Jenny
 CORPORATE SOURCE: Northeastern University School of Pharmacy, Boston, MA, USA
 SOURCE: Formulary (2005), 40(9), 285-286, 288-289, 292-293
 CODEN: FORMF9; ISSN: 1082-801X
 PUBLISHER: Advantstar Communications, Inc.
 DOCUMENT TYPE: Journal; General Review
 LANGUAGE: English

AB A review. Muraglitazar (Bristol-Myers Squibb/Merck) is a new agent under investigation for the treatment of patients with type 2 diabetes. It belongs to a novel class of drugs that target the peroxisome proliferator-activated receptors, both alpha and gamma subtypes. Available clin. data describe improvements in glycemic parameters similar to available thiazolidinediones. In addition to improvements in blood glucose and HbA1c (HbA1c), muraglitazar treatment is associated with a substantial reduction in triglycerides (TGs), an increase in HDL-C, and a modest decrease in LDL-C levels. Safety data are limited, but in available abstrs., there are reports of moderately elevated rates of edema, weight gain, and hypoglycemia with muraglitazar compared with placebo or pioglitazone. When used in combination with metformin or glyburide, chronic heart failure events have been reported with muraglitazar. If approved, muraglitazar will provide a convenient alternative for the treatment of type 2 diabetes.

IT 331741-94-7, Muraglitazar
 RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (alpha- and beta-peroxisome proliferator-activated receptor agonist muraglitazar with insulin-sensitizing and lipid-lowering effect, reduced HbA1c, improved lipid parameter like TGs, HDL-C, LDL-C and effective in type 2 diabetes patient)

RN 331741-94-7 CAPLUS
 CN Glycine, N-[(4-methoxyphenoxy)carbonyl]-N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 28 THERE ARE 28 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE

FORMAT

L7 ANSWER 27 OF 83 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)

L7 ANSWER 28 OF 83 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2005:113885 CAPLUS
 DOCUMENT NUMBER: 144:121457
 TITLE: Muraglitazar, a dual (alpha/gamma) PPAR activator: a randomized, double-blind, placebo-controlled, 24-week monotherapy trial in adult patients with type 2 diabetes
 AUTHOR(S): Buse, John B.; Rubin, Cindy J.; Frederick, Robert; Virasami-Appana, Kalyanee; Lin, Kwo-Chuan; Montoro, Rafael; Shockey, Gerald; Davidson, Jaime A.
 CORPORATE SOURCE: University of North Carolina School of Medicine, Chapel Hill, NC, USA
 SOURCE: Clinical Therapeutics (2005), 27(8), 1181-1195
 CODEN: CLTHDG; ISSN: 0149-2918
 PUBLISHER: Excerpta Medica, Inc.
 DOCUMENT TYPE: Journal
 LANGUAGE: English

AB Background: Peroxisome proliferator-activated receptors (PPARs) present a therapeutic target, and simultaneous activation of PPAR-alpha and PPAR-gamma may provide improvements in glycemic control and dyslipidemia in patients with type 2 diabetes. Objective: The goal of this study was to evaluate the efficacy and safety of muraglitazar, a dual (alpha/gamma) PPAR activator, in adult patients with type 2 diabetes whose disease was inadequately controlled by diet and exercise. Methods: This was a randomized, double-blind, placebo-controlled, parallel-group, multicenter, 24-wk monotherapy study in drug-naive, type 2 diabetes patients with inadequate glycemic control. Men and women aged 18 to 70 years with a body mass index ≥ 27 kg/m² and serum triglyceride levels ≤ 600 mg/dL were eligible for study participation. The study included double-blind and open-label treatment phases. Patients with glycosylated Hb (HbA1c) levels $\geq 7.0\%$ and $\leq 10.0\%$ at screening were enrolled in the double-blind treatment phase. These patients received treatment with muraglitazar 2.5 mg, muraglitazar 5 mg, or placebo. Patients with HbA1c levels $>10.0\%$ and $\leq 12.0\%$ who met all other study criteria were eligible for enrollment in a 24-wk, open-label evaluation of muraglitazar 5 mg. The primary end point was the mean change from baseline in HbA1c levels after 24 wk of treatment. Results: A total of 340 patients (179 men, 161 women) participated in the double-blind treatment phase of the study. Patients had mean baseline HbA1c levels of 7.9% to 8.0%. Monotherapy with muraglitazar 2.5 mg and 5 mg significantly reduced HbA1c levels (-1.05% and -1.23%, resp.) compared with placebo (-0.32%; $P < 0.001$). At week 24, 58%, 72%, and 30% of the patients receiving muraglitazar 2.5 mg, muraglitazar 5 mg, and placebo, resp., achieved the American Diabetes Association-recommended HbA1c goal of $<7.0\%$. Fasting plasma glucose, free fatty acids, and fasting plasma insulin levels significantly decreased during muraglitazar treatment ($P < 0.001$), suggesting an increase in insulin sensitivity. Muraglitazar 2.5 and 5 mg provided improvements from baseline in triglyceride (-18% and -27%), high-density lipoprotein (HDL) cholesterol (10% and 16%), apolipoprotein B


(-7% and -12%), and non-HDL cholesterol levels (-3% and -5%) ($P < 0.05$ vs placebo for each). In a parallel, open-label cohort of 109 drug-naive patients (56 men, 53 women; mean baseline HbA1c level, 10.6%), muraglitazar 5 mg decreased the overall mean HbA1c level from baseline by 2.62% (last observation carried forward) and by 3.49% in the 62 patients completing 24 wk of study. Changes in lipid parameters during open-label treatment were similar to those observed during double-blind treatment. Muraglitazar was generally well tolerated. Edema-related adverse events

L7 ANSWER 28 OF 83 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
 of mild to moderate severity occurred in 5 % to 11 % of patients in all groups. Mean changes from baseline wt. in the double-blind treatment groups were 1.1 kg for muraglitazar 2.5 mg, 2.1 kg for muraglitazar 5 mg, and -0.8 kg for placebo (P < 0.001); there was a mean 2.9-kg increase in the open-label muraglitazar 5-mg group. Conclusion: In this study, 24 wk of treatment with muraglitazar 2.5 or 5 mg was an effective treatment option for these patients with type 2 diabetes whose disease was inadequately controlled with diet and exercise.

IT 331741-94-7, Muraglitazar
 RL: ADV (Adverse effect, including toxicity); PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses) (higher and lower doses of peroxisome proliferator-activated receptor muraglitazar were effective for treatment of type 2 diabetes in patient)

RN 331741-94-7 CAPLUS

CN Glycine, N-[(4-methoxyphenoxy)carbonyl]-N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 30 THERE ARE 30 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE REFORMAT

L7 ANSWER 29 OF 83 CAPLUS COPYRIGHT 2006 ACS on STN
 ACCESSION NUMBER: 2005:1075557 CAPLUS
 DOCUMENT NUMBER: 143:353392
 TITLE: Therapeutic agent for diabetes containing insulin resistance improving agent
 INVENTOR(S): Kanda, Shoichi; Araki, Kazuishi
 PATENT ASSIGNEE(S): Sankyo Company, Limited, Japan; Ohsami, Jun
 SOURCE: PCT Int. Appl., 36 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: Japanese
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005092382	A1	20051006	WO 2005-JP5526	20050325
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MY, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, BG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
JP 200514380	A2	20051110	JP 2005-88634	20050325
PRIORITY APPLN. INFO.:			JP 2004-94598	A 20040329


AB Disclosed is a therapeutic method for diseases that maintains excellent medicinal effects, suppressing any side effects (for example, edema or the like) to thereby ensure high safety. There is provided a pharmaceutical composition comprising an insulin resistance improving agent as an active ingredient, characterized in that an administration cycle of insulin resistance improving agent wherein the dosage thereof is reduced or discontinued during the administration period is repeated at least once.

IT 331741-94-7, BMS 298585
 RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses) (therapeutic agents for diabetes containing insulin resistance improving agents for use by specified method)

RN 331741-94-7 CAPLUS

CN Glycine, N-[(4-methoxyphenoxy)carbonyl]-N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- (9CI) (CA INDEX NAME)

L7 ANSWER 29 OF 83 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




REFERENCE COUNT: 10 THERE ARE 10 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE REFORMAT

L7 ANSWER 30 OF 83 CAPLUS COPYRIGHT 2006 ACS on STN
 ACCESSION NUMBER: 2005:1026924 CAPLUS
 DOCUMENT NUMBER: 143:326098
 TITLE: Preparation of tetrahydronaphthalenylcarboxamide derivatives as RXR (retinoid X receptor) function modulators and RXR/PPAR heterodimer function modulators
 INVENTOR(S): Ikeshita, Shinji; Yamamoto, Junji; Shinohara, Masashi
 PATENT ASSIGNEE(S): Sakai Chemical Industry Co., Ltd., Japan
 SOURCE: PCT Int. Appl., 60 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: Japanese
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005087713	A1	20050922	WO 2005-JP4357	20050311
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MY, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, BG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
PRIORITY APPLN. INFO.:			JP 2004-71741	A 20040312


OTHER SOURCE(S): MARPAT 143:326098
 GI



AB The title compds. I (R1, R2, R4 = H, alkyl; R3 = alkyl, halo, NH2, etc.; Ar = benzene ring, 5- or 6-membered heteroarom. ring, etc.; V = hydrocarbon; W = O, S, SO, etc.; Z = CO2H, PO3H, SO3H, etc.) are prepared Thus, 4-[(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)carboxamidomethyl]benzoic acid was prepared in a multistep process from 2,5-dimethyl-2,5-hexanediol. The bioactivities of compds. of this invention were demonstrated. Formulations are given.

IT 331741-94-7, BMS 298585
 RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses) (combination containing tetrahydronaphthalenylcarboxamide derive. and agents)

L7 ANSWER 30 OF 83 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
 RN 331741-94-7 CAPLUS
 CN Glycine, N-[(4-methoxyphenoxy)carbonyl]-N-[(4-{2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy}phenyl)methyl]- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 8 THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE
 FORMAT

L7 ANSWER 31 OF 83 CAPLUS COPYRIGHT 2006 ACS on STN
 ACCESSION NUMBER: 2005-732644 CAPLUS
 DOCUMENT NUMBER: 143:211899
 TITLE: Preparation of heterocyclic bicyclooctylcarboxamide derivatives as modulators of glucocorticoid receptor, AP-1, and/or NF-κB
 INVENTOR(S): Weinstein, David S.; Sheppeck, James; Gilmore, John L.
 PATENT ASSIGNEE(S): Bristol-Myers Squibb Company, USA
 SOURCE: PCT Int. Appl., 115 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005073203	A1	20050811	WO 2005-US1293	20050114
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
US 2005182083	A1	20050818	US 2005-35290	20050113
EP 1711488	A1	20061018	EP 2005-711486	20050114
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, TR, BG, CZ, EE, HU, PL, SK, HR, IS, YU			
PRIORITY APPLN. INFO.:			US 2004-537048P	P 20040116
			US 2005-35290	A 20050113
			WO 2005-US1293	W 20050114
OTHER SOURCE(S):		MARPAT 143:211899		
GI				


* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB Title compds. I (Y and W independently = C or N; X = CR3R4; R = H, alkyl, aryl, etc.; R1 = H, halo, alkenyl, etc.; R2 = H, alkoxy, aryloxy, etc.;
 R3 and R4 independently = H, alkenyl, alkoxy, etc. or R3 and R4 may optionally be taken together with the carbon that they are attached to form a 3-7 membered ring which may optionally include an O or N atom; Z = CONR5R6, CH2NR5R6, SONR5R6, etc.; R5 and R6 independently = H, amino,

L7 ANSWER 31 OF 83 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
 RN 258345-41-4 CAPLUS
 CN L-Tyrosine, N-[(12)-1-methyl-3-oxo-3-phenyl-1-propenyl]-O-[2-(5-methyl-2-phenyl-4-oxazolyl)ethyl]- (9CI) (CA INDEX NAME)
 less than 15 μM. I as modulator of glucocorticoid receptor, AP-1, and/or NF-κB should prove useful in the treatment of obesity, diabetes and inflammatory or immune assocd. diseases. Pharmaceutical compns. comprising I are disclosed.
 IT 258345-41-4, GW 409544
 RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (claimed co-drugs; preparation of heterocyclic bicyclooctylcarboxamide derivs. as modulators of glucocorticoid receptor, AP-1, and/or NF-κB)

RN 258345-41-4 CAPLUS
 CN L-Tyrosine, N-[(12)-1-methyl-3-oxo-3-phenyl-1-propenyl]-O-[2-(5-methyl-2-phenyl-4-oxazolyl)ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
 Double bond geometry as shown.




REFERENCE COUNT: 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE
 FORMAT

L7 ANSWER 32 OF 83 CAPLUS COPYRIGHT 2006 ACS on STN
 ACCESSION NUMBER: 2005-732629 CAPLUS
 DOCUMENT NUMBER: 143:211898
 TITLE: Preparation of heterocyclic bicyclooctylcarboxamide derivatives as modulators of glucocorticoid receptor, AP-1, and/or NF-κB
 INVENTOR(S): Yang, Bingwei Vera
 PATENT ASSIGNEE(S): Bristol-Myers Squibb Company, USA
 SOURCE: PCT Int. Appl., 69 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005073203	A1	20050811	WO 2005-US1794	20050114
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
US 2005176749	A1	20050811	US 2005-34635	20050113
EP 1706391	A1	20061004	EP 2005-705943	20050114
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, TR, BG, CZ, EE, HU, PL, SK, HR, IS, YU			
PRIORITY APPLN. INFO.:			US 2004-537468P	P 20040116
			WO 2005-US1794	W 20050114
OTHER SOURCE(S):		MARPAT 143:211898		
GI				

L7 ANSWER 32 OF 83 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



AB Title compds. I [X = CR5R6; R = H, alkyl, aryl, etc.; R1 and R2 independently = H, alkynyl, cycloalkyl, etc. or R1 and R2 together with the N atom that they are attached to can form 5-7 membered heteroaryl or cycloheteroalkyl ring which contains 1-3 heteroatoms selected from N, O or S; R3 = H, halo, OH, etc.; R4 = H, alkenyl, alkoxy, etc.; R5 and R6 independently = H, CN, aryloxy, etc. or R5 and R6 may optionally be taken together with the carbon that they are attached to form a 3-7 membered ring which may optionally include an O or N atom; A and B independently = (un)saturated 6-membered carbocyclic or heterocyclic ring; Z = S, O or NH] and their pharmaceutically acceptable salts, are prepared and disclosed as modulators of glucocorticoid receptor, AP-1, and/or NF- κ B. Thus, e.g., II was prepared by Diels-Alder reaction of anthracene with methacrylic acid followed by amidation with Et 2-amino-4-thiazole glyoxylate and subsequent hydrolysis/chlorination/coupling sequence with 1-(2-pyridinyl)piperazine. The activity of I to inhibit AP-1 was evaluated using cellular transrepression assays and it was revealed that compds. of the invention possessed an EC50 value of less than 15 μ M. I as modulator of glucocorticoid receptor, AP-1, and/or NF- κ B should prove useful in the treatment of obesity, diabetes and inflammatory or immune associated diseases. Pharmaceutical compns. comprising I are disclosed.

IT 258345-41-4, GW 409544
 RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses) (claimed co-drugs; preparation of heterocyclic bicyclooctylcarboxamide derivs. as modulators of glucocorticoid receptor, AP-1, and/or NF- κ B)

L7 ANSWER 33 OF 83 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2005:73507 CAPLUS
 DOCUMENT NUMBER: 143:211915
 TITLE: Preparation of azolylamino benzobicyclooctanecarboxamides as modulators of activator protein-1 (AP-1) and/or NF- κ B activity.
 INVENTOR(S): Weinstein, David S.; Yang, Bingwei; Vera, Kim; Soong-Hoon; Vaccaro, Wayne; Sheppeck, James; Gilmore, John
 PATENT ASSIGNEE(S): Bristol-Myers Squibb Company, USA
 SOURCE: PCT Int. Appl., 149 pp.
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005072132	A2	20050811	WO 2005-US1180	20050114
WO 2005072132	A3	20060302		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW,				
SM				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
US 2005187242	A1	20050825	US 2005-35176	20050113
EP 1703797	A2	20060927	EP 2005-705688	20050114
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, BA, HR, IS, YU				
PRIORITY APPLN. INFO.: US 2004-537469P P 20040116				
US 2005-35176 A 20050113				
WO 2005-US1180 W 20050114				

OTHER SOURCE(S): MARPAT 143:211915
 GI

L7 ANSWER 32 OF 83 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)


RN 258345-41-4 CAPLUS
 CN L-Tyrosine, N-[(12)-1-methyl-3-oxo-3-phenyl-1-propenyl]-O-[2-(5-methyl-2-phenyl-4-oxazolyl)ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
 Double bond geometry as shown.



REFERENCE COUNT: 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE
 FORMAT

L7 ANSWER 33 OF 83 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




AB Title compds. [I; dotted line = optional double bond; m, n = 1, 2; J, K = C, N, O, S; R = H, alkyl, alkenyl, alkynyl, alkoxy, cyano, aryl, aryloxy, heteroaryl, amino, etc.; R1 = H, halo, alkyl, alkenyl, alkynyl, cyano, cyanoalkyl, hydroxyaryl, NO2, amino, aryl, heteroaryl, etc.; R2 = H, alkyl, alkenyl, alkynyl, alkoxy, aryl, aryloxy, cyano, halo, NO2, cyanoalkyl, etc.; R3, R4 = H, alkyl, alkenyl, alkynyl, aryl, OH, heteroaryl, hydroxyaryl, aryloxyalkyl, etc.; R3R4 = atoms to form a 3-7 membered ring; R5, R6 = H, halo, OH, alkyl, alkenyl, alkynyl, alkoxy, aryl, aralkyl, aryloxy, heteroaryl, cyano, cyanoalkyl, NO2, amino, etc.; B = (substituted) carbocyclyl, heterocyclyl, were prepared Thus, title compound (II) was prepared in 21% yield via coupling of the corresponding bicyclooctanecarboxylic acid and thiazolylamine in the presence of HOBt/EDC/ET3N in MeCN at 85° for 5 h. I have glucocorticoid receptor/dexamethasone inhibition activity (>95% at 10 μ M) and/or AP-1 inhibition activity (EC50 <15 μ M).

IT 258345-41-4, GW 409544
 RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses) (coadministration; preparation of azolylamino benzobicyclooctanecarboxamides as modulators of AP-1 and/or NF- κ B activity)

RN 258345-41-4 CAPLUS
 CN L-Tyrosine, N-[(12)-1-methyl-3-oxo-3-phenyl-1-propenyl]-O-[2-(5-methyl-2-phenyl-4-oxazolyl)ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
 Double bond geometry as shown.



L7 ANSWER 34 OF 83 CAPLUS COPYRIGHT 2006 ACS on STN
 ACCESSION NUMBER: 2005:729529 CAPLUS
 DOCUMENT NUMBER: 143:211913
 TITLE: Preparation of bis(aryl)tricyclic modulators of glucocorticoid receptor, AP-1, and/or NFkB activity.
 INVENTOR(S): Yang, Bingwei Vera
 PATENT ASSIGNEE(S): Bristol-Myers Squibb Company, USA
 SOURCE: PCT Int. Appl., 87 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005072729	A1	20050811	WO 2005-US1229	20050114
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
US 2005182110	A1	20050818	US 2005-35119	20050113
EP 1708699	A1	20061011	EP 2005-711468	20050114
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, TR, BG, CZ, EE, HU, PL, SK, HR, IS, YU				
PRIORITY APPLN. INFO.:			US 2004-537470P	P 20040116
			WO 2005-US1229	W 20050114

OTHER SOURCE(S): MARPAT 143:211913
 GI


* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB Title compds. I [R = H, alk(en/yn)yl, cycloalkyl, etc.; R' = H, alk(en/yn)yl, cycloalkyl, etc.; R1-2 = H, halo, OH, etc.; R3-4 = H, alkyl, alk(en/yn)yl, alkoxy, etc.; Z = SO1-2-amino, carboxamido, etc.; A, B = (unsaturated 6-membered carbocyclic, heterocyclic ring) are prepared for instance II is prepared in several steps from 9-nitroanthracene, Me 2-acetamidocyclohexane and 2-amino-4-(naphthalen-1-yl)imidazole. I are glucocorticoid receptor modulators and are useful for the treatment of diseases associated with AP-1 or NF-kB-induced transcription [no data].


L7 ANSWER 35 OF 83 CAPLUS COPYRIGHT 2006 ACS on STN
 ACCESSION NUMBER: 2005:696690 CAPLUS
 DOCUMENT NUMBER: 143:186790
 TITLE: Fused aryl and heteroaryl bicyclo[2.2.2]octane derivative modulators of the glucocorticoid receptor, AP-1, and/or NF-kB activity, and therapeutic use thereof
 INVENTOR(S): Duan, Jingwu; Jiang, Bin; Sheppeck, James; Gilmore, John L.
 PATENT ASSIGNEE(S): Bristol-Myers Squibb Company, USA
 SOURCE: PCT Int. Appl., 74 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005070207	A1	20050804	WO 2005-US1411	20050114
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
US 2005176716	A1	20050811	US 2005-34652	20050113
EP 1705990	A1	20061004	EP 2005-711524	20050114
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, TR, BG, CZ, EE, HU, PL, SK, HR, IS, YU				
PRIORITY APPLN. INFO.:			US 2004-537467P	P 20040116
			US 2005-34652	A 20050113
			WO 2005-US1411	W 20050114

OTHER SOURCE(S): MARPAT 143:186790
 GI




L7 ANSWER 34 OF 83 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
 IT 258345-41-4, GW 409544
 RL: BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (combination pharmaceutical; preparation of bis(aryl)tricyclic imidazole/thiazole derivative modulators of glucocorticoid receptor, AP-1, and/or NFkB activity)
 RN 258345-41-4 CAPLUS
 CN L-Tyrosine, N-[(12)-1-methyl-3-oxo-3-phenyl-1-propenyl]-O-[2-(5-methyl-2-phenyl-4-oxazoly)ethyl]- (9CI) (CA INDEX NAME)
 Absolute stereochemistry.
 Double bond geometry as shown.



REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE
 FORMAT

L7 ANSWER 35 OF 83 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
 AB A class of non-steroidal compds. are provided which are useful in treating diseases associated with modulation of the glucocorticoid receptor, AP-1, and/or NF-kB activity including obesity, diabetes, inflammatory and immune diseases. The compds. of the invention are fused aryl and heteroaryl bicyclo[2.2.2]octane derivs. I [R = H, OH, alkyl, etc.; R1, R2 = H, halo, OH, alkyl, etc.; R3, R4 = H, alkyl, alkenyl, etc.; Z = S(O)tNR1R2, CONR1R2, CH2NR1R2; t = 1,2; R1, R2 = H, alkyl, etc.; X1-X8 = CR15, NR18, etc.; R15 = H, halo, OH, etc.; R18 = H, aryl, alkyl, etc.]. Also provided are pharmaceutical compns. and methods comprising the above compds. for treating obesity, diabetes and inflammatory or immune-associated diseases. Compound preparation is included.
 IT 258345-41-4, GW 409544
 RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (fused aryl and heteroaryl bicyclo[2.2.2]octane derivative modulators of glucocorticoid receptor, AP-1, and/or NF-kB activity, and therapeutic use)
 RN 258345-41-4 CAPLUS
 CN L-Tyrosine, N-[(12)-1-methyl-3-oxo-3-phenyl-1-propenyl]-O-[2-(5-methyl-2-phenyl-4-oxazoly)ethyl]- (9CI) (CA INDEX NAME)
 Absolute stereochemistry.
 Double bond geometry as shown.



REFERENCE COUNT: 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE
 FORMAT

L7 ANSWER 36 OF 83 CAPLUS COPYRIGHT 2006 ACS ON STN
 ACCESSION NUMBER: 2005:612299 CAPLUS
 DOCUMENT NUMBER: 143:133380
 TITLE: Preparation of azabicyclic heterocycles as
 cannabinoid
 INVENTOR(S): Gu, Guixue; Ewing, William R.; Mikkilineni, Amarendra
 B.; Pandri, Annapurna; Ellsworth, Bruce A.; Sher,
 Philip M.; Gerritz, Samuel; Sun, Chongqing;
 Murugesan,
 Natesan; Wu, Ximao
 PATENT ASSIGNEE(S): Bristol-Myers Squibb Company, USA
 SOURCE: PCT Int. Appl., 101 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 2
 PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005063762	A1	20050714	WO 2004-US42878	20041217
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MM, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CP, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2004309368	A1	20050714	AU 2004-309368	20041217
CA 2550375	AA	20050714	CA 2004-2550375	20041217
US 2005171110	A1	20050804	US 2004-16198	20041217
EP 1697371	A1	20060906	EP 2004-815007	20041217
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, HR, IS, YU				
EP 1699796	A1	20060913	EP 2004-814691	20041220
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, HR, IS, YU				
NO 2006002689	A	20060912	NO 2006-2689	20060612
NO 2006002691	A	20060914	NO 2006-2691	20060612
PRIORITY APPLN. INFO.:			US 2003-531451P	P 20031219
			US 2004-16198	A 20041217
			WO 2004-US42878	W 20041217
			WO 2004-US42542	W 20041220

OTHER SOURCE(S): MARPAT 143:133380
 GI


L7 ANSWER 37 OF 83 CAPLUS COPYRIGHT 2006 ACS ON STN
 ACCESSION NUMBER: 2005:572592 CAPLUS
 DOCUMENT NUMBER: 143:97378
 TITLE: Preparation of azabicyclic heterocycles as
 cannabinoid
 INVENTOR(S): Yu, Guixue; Ewing, William R.; Mikkilineni, Amarendra
 B.; Pandri, Annapurna; Sher, Philip M.; Gerritz,
 Samuel; Ellsworth, Bruce A.; Wu, Gang; Huang,
 Yanting;
 Sun, Chongqing; Murugesan, Natesan; Gu, Zhengxiang;
 Wang, Ying; Sitkoff, Doree; Johnson, Stephen R.; Wu,
 Ximao
 PATENT ASSIGNEE(S): Bristol-Myers Squibb Co, USA
 SOURCE: U.S. Pat. Appl. Publ., 196 pp.
 CODEN: USXXCO
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 2
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2005143381	A1	20050630	US 2004-16135	20041217
AU 2004309365	A1	20050714	AU 2004-309365	20041217
CA 2550435	AA	20050714	CA 2004-2550435	20041217
WO 2005063761	A1	20050714	WO 2004-US42820	20041217
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MM, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CP, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
US 2005192278	A1	20050901	US 2004-15876	20041217
US 7037910	B2	20060502		
EP 1697370	A1	20060906	EP 2004-814952	20041217
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, HR, IS, YU				
WO 2005061509	A1	20050707	WO 2004-US42542	20041220
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MM, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CP, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
EP 1699796	A1	20060913	EP 2004-814691	20041220
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, HR, IS, YU				

L7 ANSWER 36 OF 83 CAPLUS COPYRIGHT 2006 ACS ON STN (Continued)




AB The present application describes compds. I (R1, R2 = halo, CN, alkyl, etc.; R3 = H alkyl, alkenyl, cycloalkyl, etc.; R4 is absent when n is a double bond; R4 = H, alkyl, cycloalkyl, etc.; R5 = halo, (un)substituted OH, NH2, etc. when m is a single bond; R5 = O when m = a double bond; m, n = a single or double bond; when m is a single bond, n is a double bond; when m is a double bond, n is a single bond), pharmaceutical compns. comprising at least one compound I and optionally one or more addnl. therapeutic agents and methods of treatment using the compds. I both alone and in combination with one or more addnl. therapeutic agents. Over 40 compds. I were prepared E.g., a multi-step synthesis of II, starting from dichloromandelic anhydride, was given. The exemplified compds. I showed the CB-1 receptor binding Ki values in the range of 0.01 nM to 10000 nM.
 IT 331741-94-7
 RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses) (co-drug; preparation of azabicyclic heterocycles as cannabinoid receptor modulators)
 RN 331741-94-7 CAPLUS
 CN Glycine, N-[(4-methoxyphenoxy)carbonyl]-N-[(4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl)methyl]- (9CI) (CA INDEX NAME)




REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE
 FORMAT

L7 ANSWER 37 OF 83 CAPLUS COPYRIGHT 2006 ACS ON STN (Continued)
 NO 2006002704 A 20060905 NO 2006-2704 20060612
 NO 2006002689 A 20060912 NO 2006-2689 20060612
 PRIORITY APPLN. INFO.:

OTHER SOURCE(S): MARPAT 143:97378
 GI




AB The present application describes compds. I (R1, R2 = halo, CN, alkyl, etc.; R3 = alkyl, alkenyl, cycloalkyl, etc.; R6 = H, alkyl, cycloalkyl, etc.; R7 is absent when double bond; or R7 = H, alkyl, cycloalkyl, etc.), pharmaceutical compns. comprising at least one compound I and optionally one or more addnl. therapeutic agents and methods of treatment using the compds. I both alone and in combination with one or more addnl. therapeutic agents. Over 400 compds. I were prepared E.g., a multi-step synthesis of II, starting from dibromopyridazinone, was given. Representative compds. I showed the CB-1 receptor binding Ki values in the range of 0.01 nM to 10000 nM.
 IT 331741-94-7, Muraglitazar
 RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses) (co-drug; preparation of azabicyclic heterocycles as cannabinoid receptor modulators)
 RN 331741-94-7 CAPLUS
 CN Glycine, N-[(4-methoxyphenoxy)carbonyl]-N-[(4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl)methyl]- (9CI) (CA INDEX NAME)



L7 ANSWER 37 OF 83 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)

L7 ANSWER 38 OF 83 CAPLUS COPYRIGHT 2006 ACS on STN
 ACCESSION NUMBER: 2005:51192 CAPLUS
 DOCUMENT NUMBER: 143:165989
 TITLE: Construction of a virtual combinatorial library using SMILES strings to discover potential structure-diverse PPAR modulators
 AUTHOR(S): Liao, Chenzhong; Liu, Bing; Shi, Leming; Zhou, Jiaju; Lu, Xian-Ping
 CORPORATE SOURCE: Research Institute of Tsinghua University, ChipScreen Biosciences, Ltd., Guangdong, 518057, Peop. Rep. China
 SOURCE: European Journal of Medicinal Chemistry (2005), 40(7), 632-640
 CODEN: EJMCAS; ISSN: 0223-5234
 PUBLISHER: Elsevier Ltd.
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 AB Based on the structural characters of PPAR modulators, a virtual combinatorial library containing 1226,625 compds. was constructed using SMILES strings. Selected ADME filters were employed to compel compds. having poor drug-like properties from this library. This library was converted to sdf and mol2 files by CONCORD 4.0, and was then docked to PPAR γ by DOCK 4.0 to identify new chemical entities that may be potential drug leads against type 2 diabetes and other metabolic diseases. The method to construct virtual combinatorial library using SMILES strings was further visualized by Visual Basic.net that can facilitate the needs of generating other type virtual combinatorial libraries.
 IT 258345-41-4, GW 409544
 RL: PAC (Pharmacological activity); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (construction of a virtual combinatorial library using SMILES strings to discover potential structure-diverse PPAR modulators)
 RN 258345-41-4 CAPLUS
 CN L-Tyrosine, N-[(1Z)-1-methyl-3-oxo-3-phenyl-1-propenyl]-O-[2-(5-methyl-2-phenyl-4-oxazolyl)ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
 Double bond geometry as shown.



REFERENCE COUNT: 44 THERE ARE 44 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE REFORMAT

L7 ANSWER 38 OF 83 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)

L7 ANSWER 39 OF 83 CAPLUS COPYRIGHT 2006 ACS on STN
 ACCESSION NUMBER: 2005:493507 CAPLUS
 DOCUMENT NUMBER: 143:43869
 TITLE: Preparation of nitrogen containing bicyclic pyridine-based derivatives as inhibitors of HMG CoA reductase
 INVENTOR(S): O'Connor, Stephen P.; Robl, Jeffrey; Ahmad, Saleem; Bisaha, Sharon; Murugesan, Natesan; Ngu, Khehyong; Shi, Yan; Stein, Philip D.; Soundararajan, Nachimuthu;
 Natalie, Kenneth J., Jr.; Kolla, Laxma R.; Sausker, Justin; Quinlan, Sandra L.; Fan, Junying; Petsch, Dejah; Guo, Zhenrong
 PATENT ASSIGNEE(S): Bristol-Myers Squibb Company, USA
 SOURCE: PCT Int. Appl., 193 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005051386	A1	20050609	WO 2004-US39051	20041119
W: AB, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CI, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GR, GU, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, ME, MK, MN, MW, MX, MY, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CP, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
US 2005171140	A1	20050804	US 2004-989138	20041115
EP 1684754	A1	20060802	EP 2004-811719	20041119
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, HR, IS, YU				
PRIORITY APPLN. INFO.:			US 2003-523546P	P 20031120
			US 2004-989138	A 20041115
			WO 2004-US39051	W 20041119
OTHER SOURCE(S):		MARPAT 143:43869		
GI				

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *


AB Title compds. I [Het = 5- to 8-membered ring including at least one nitrogen atom with provisions; n = 0-1; R1 and R2 independently = H, alkyl, alkenyl, etc.; R3 = H, aryl, cycloalkyl, etc.; R4 and R5 independently = H, alkyl; X = -CR6R7-CR6aR7a-, -CR6-CR7-, R6, R7, R6a and R7a independently = H, alkyl] and their pharmaceutically acceptable salts.

10788996


11/26/06

L7 ANSWER 39 OF 83 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
are prepd. and disclosed as inhibitors of HMG CoA reductase. Thus, e.g.,
II was prepd. by cyclization of Et
2-amino-4-(4-fluorophenyl)-6-isopropyl-
5-methoxycarbonyl-3-pyridinepropanoate (prepn. given) followed by a
redn./sulfonylation/redn. sequence to give
(4-(4-fluorophenyl)-2-isopropyl-
8-methanesulfonyl-5,6,7,8-tetrahydro[1,8]naphthyridin-3-yl)-methanol
(III). III was oxidized to the resp. aldehyde and coupled with
1,1-dimethylethyl (4R,6S)-2,2-dimethyl-6-(1-phenyl-1H-tetrazole-5-
sulfonylmethyl)-[1,3]dioxan-4-yl-acetate followed by ring opening to give
II. I should display activity as inhibitors of HMG CoA reductase (no
data
given). I as inhibitors of HMG CoA reductase inhibitors should prove
useful in the treatment of, but not limited to, hyperlipidemia,
dyslipidemia, and atherosclerosis. Pharmaceutical compns. comprising I
are disclosed.
IT 258345-41-4, GW 409544 331741-94-7, Mureglitazar
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(claimed co-drug; preparation of nitrogen-containing bicyclic
pyridine-based
deriva. as inhibitors of HMG CoA reductase)
RN 258345-41-4 CAPLUS
CN L-Tyrosine, N-[(12)-1-methyl-3-oxo-3-phenyl-1-propenyl]-O-[2-(5-methyl-2-
phenyl-4-oxazolyl)ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.




RN 331741-94-7 CAPLUS
CN Glycine, N-[(4-methoxyphenoxy)carbonyl]-N-[[4-[2-(5-methyl-2-phenyl-4-
oxazolyl)ethoxy]phenyl]methyl]- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS
FORMAT RECORD. ALL CITATIONS AVAILABLE IN THE RE

L7 ANSWER 40 OF 83 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
ACCESSION NUMBER: 2005.472138 CAPLUS
DOCUMENT NUMBER: 143.26619
TITLE: Preparation of heterocyclic compounds as
hypolipidemic
agents
INVENTOR(S): Lohray, Braj Bhushan; Lohray, Vidya Bhushan
PATENT ASSIGNEE(S): Cadila Healthcare Limited, India
SOURCE: PCT Int. Appl., 75 pp.
CODEN: P1XXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:
PATENT NO. KIND DATE APPLICATION NO. DATE
WO 2005049589 A2 20050602 WO 2004-IN319 20041014
WO 2005049589 A3 20050915
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH,
CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD,
GE, GH, GM, GR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,
LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI,
NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY,
TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: BW, GH, GM, KE, LS, MW, ME, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM,
AZ, BY, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK,
EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE,
SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE,
SN, TD, TG
PRIORITY APPLN. INFO.: IN 2003-MU1064 A 20031014
OTHER SOURCE(S): MARPAT 143.26619
GI




AB Title compds. I [G = NR1(CH2)pY; A = (hetero)aryl, etc.; B = O, S; Ar =
optionally substituted divalent (hetero)aromatic, etc.; R1 = H,
alk(en)ynyl,
etc.; n, m, p = 1-3; Y = acyl, carboxy, etc.] are prepared For
instance, Et

[4-[2-(2,3-dihydrobenzo[1,4]oxazin-4-yl)ethoxy]benzylamino]acetate is
prepared by treatment of 4-[2-(2,3-dihydrobenzo[1,4]oxazin-4-
yl)ethoxy]benzaldehyde with glycine Et ester-HCl (MeOH, Et3N, NaBH4,
30°, 1 h). I showed good serum glucose, lipid and cholesterol
lowering activity; a selected example compound at 3 mg/kg/day showed a


57k reduction in serum glucose.
IT 852816-56-9P, Ethyl [ethoxycarbonylmethyl]-4-[2-(5-methyl-2-
phenyloxazol-4-yl)ethoxy]benzylamino]acetate 852817-49-3P,
[Carboxymethyl-4-[2-(5-methyl-2-phenyloxazol-4-
yl)ethoxy]benzylamino]acetic acid
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU
(Therapeutic use); BIOL (Biological study); PREP (Preparation); USES
(Uses)

L7 ANSWER 39 OF 83 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)


L7 ANSWER 40 OF 83 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
(prepn. of heterocyclic compds. as hypolipidemic agents)
RN 852816-56-9 CAPLUS
CN Glycine, N-(1-formylpropyl)-N-[[4-[2-(5-methyl-2-phenyl-4-
oxazolyl)ethoxy]phenyl]methyl]- (9CI) (CA INDEX NAME)



RN 852817-49-3 CAPLUS
CN Glycine, N-(carboxymethyl)-N-[[4-[2-(5-methyl-2-phenyl-4-
oxazolyl)ethoxy]phenyl]methyl]- (9CI) (CA INDEX NAME)



IT 331745-63-2, Ethyl [4-[2-(5-methyl-2-phenyloxazol-4-
yl)ethoxy]benzylamino]acetate
RL: RCT (Reactant); RACT (Reactant or reagent)
(preparation of heterocyclic compds. as hypolipidemic agents)
RN 331745-63-2 CAPLUS
CN Glycine, N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-,
ethyl ester (9CI) (CA INDEX NAME)



L7 ANSWER 41 OF 83 CAPLUS COPYRIGHT 2006 ACS ON STN
 ACCESSION NUMBER: 2005:451240 CAPLUS
 DOCUMENT NUMBER: 142:457108
 TITLE: Method of identifying responders to treatment with insulin sensitizers by measuring the ratio of HMW adiponectin to total or LMW adiponectin
 INVENTOR(S): Wagner, John A.; Scherer, Philipp E.; Pajvani, Utpal B.
 PATENT ASSIGNEE(S): Merck & Co., Inc., USA; Albert Einstein College of Medicine of Yeshiva University
 SOURCE: PCT Int. Appl., 20 pp.
 CODEN: PIXXD3
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005046734	A1	20050526	WO 2004-US36648	20041104
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GR, GU, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MY, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
AU 2004289237	A1	20050526	AU 2004-289237	20041104
CA 2545065	AA	20050526	CA 2004-2545065	20041104
EP 1684807	A1	20060802	EP 2004-810280	20041104
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK, HR, IS			
PRIORITY APPLN. INFO.:			US 2003-518390P	P 20031107
			WO 2004-US36648	W 20041104

AB A patient who is a responder to a therapeutic treatment for insulin resistance or for one or more diseases associated with type 2 diabetes can be identified by the method of measuring the amount of HMW adiponectin and the amount of total adiponectin or LMW adiponectin in the patient's tissue (usually plasma or serum) before the therapeutic treatment commences; then commencing the therapeutic treatment; and finally measuring the amount of HMW adiponectin and the amount of either total adiponectin or LMW adiponectin in the patient's plasma or serum one or more times after commencement of the therapeutic treatment. The patient is predicted to be a responder to the therapeutic treatment if the ratio of the amount of HMW adiponectin to the amount of total adiponectin or LMW adiponectin increases after the therapeutic treatment commences.


IT 331741-94-7, Muraglitazar
 RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL

L7 ANSWER 42 OF 83 CAPLUS COPYRIGHT 2006 ACS ON STN
 ACCESSION NUMBER: 2005:419336 CAPLUS
 DOCUMENT NUMBER: 143:125520
 TITLE: Muraglitazar Bristol-Myers Squibb/Merck
 AUTHOR(S): Barlocco, Daniela
 CORPORATE SOURCE: University of Milan Istituto di Chimica Farmaceutica e Tossicologica, Milan, 20131, Italy
 SOURCE: Current Opinion in Investigational Drugs (Thomson Scientific) (2005), 6(4), 427-434
 CODEN: COIDAZ; ISSN: 1472-4472
 PUBLISHER: Thomson Scientific
 DOCUMENT TYPE: Journal; General Review
 LANGUAGE: English

AB A review. Bristol-Myers Squibb and Merck & Co are co-developing muraglitazar, a dual peroxisome proliferator-activated receptor- α/γ agonist, for the potential treatment of type 2 diabetes and other metabolic disorders. In Nov. 2004, approval was anticipated as early as mid-2005.


IT 331741-94-7, Muraglitazar
 RL: ADV (Adverse effect, including toxicity); DMA (Drug mechanism of action); PAC (Pharmacological activity); PKT (Pharmacokinetics); THU (Therapeutic use); BIOL (Biological study); USES (Uses) (muraglitazar for potential treatment of patients with type 2 diabetes and metabolic disorders)

RN 331741-94-7 CAPLUS
 CN Glycine, N-[(4-methoxyphenoxy)carbonyl]-N-[(4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl)methyl]- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 56 THERE ARE 56 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE
 FORMAT

L7 ANSWER 41 OF 83 CAPLUS COPYRIGHT 2006 ACS ON STN (Continued)
 (Biological study); USES (Uses)
 TITLE: (method of identifying responders to treatment with insulin sensitizers by measuring the ratio of HMW adiponectin to total or LMW adiponectin)
 RN 331741-94-7 CAPLUS
 CN Glycine, N-[(4-methoxyphenoxy)carbonyl]-N-[(4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl)methyl]- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE
 FORMAT

L7 ANSWER 43 OF 83 CAPLUS COPYRIGHT 2006 ACS ON STN
 ACCESSION NUMBER: 2005:308435 CAPLUS
 DOCUMENT NUMBER: 142:373859
 TITLE: Preparation of pyrimidine and pyridine derivatives useful as HMG-CoA reductase inhibitors
 INVENTOR(S): Ahmad, Saleem; Robl, Jeffrey A.; Ngu, Khehyong
 PATENT ASSIGNEE(S): Bristol-Myers Squibb Company, USA
 SOURCE: PCT Int. Appl., 103 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005030758	A1	20050407	WO 2004-US31212	20040922
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GR, GU, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MY, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SH, TD, TG			
US 2005085497	A1	20050421	US 2004-946055	20040921
EP 1667997	A1	20060614	EP 2004-784885	20040922
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK			
PRIORITY APPLN. INFO.:			US 2003-505893P	P 20030925
			WO 2004-US31212	W 20040922

OTHER SOURCE(S): MARPAT 142:373859
 GI


* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB Title compds. I [X = N, CR5; R1-2 = H, alkyl, alkoxyalkyl, etc.; R3 = (hetero)aryl, cycloalkyl, etc.; R4 = H, (cyclo)alkyl, haloalkyl, etc.; R5 = H, alkyl; Z = hydroxyalkyl, etc.] are prepared. For instance, II is prepared in 5 steps from a substituted pyrimidine, 2-methyl-2H-[1,2,4]triazol-3-ylamine, and a prior art homochiral dihydroxy acetone derivative I are HMG-CoA reductase inhibitors and are active in inhibiting cholesterol biosynthesis, modulating blood serum lipids, for example, lowering LDL cholesterol and/or increasing HDL cholesterol, and treating hyperlipidemia, dyslipidemia, hormone replacement therapy, hypercholesterolemia, hypertriglyceridemia and atherosclerosis as well as Alzheimer's disease and osteoporosis (no data).


IT 258345-41-4, GW 409544 331741-94-7, Muraglitazar
 RL: BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

L7 ANSWER 43 OF 83 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
 (combination pharmaceutical; prepn. of pyrimidine and pyridine derivs.
 useful as HMG-CoA reductase inhibitors)
 RN 258345-41-4 CAPLUS
 CN L-Tyrosine, N-[(1Z)-1-methyl-3-oxo-3-phenyl-1-propenyl]-O-[2-(5-methyl-2-phenyl-4-oxazolyl)ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
 Double bond geometry as shown.



RN 331741-94-7 CAPLUS
 CN Glycine, N-[(4-methoxyphenoxy)carbonyl]-N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- (9CI) (CA INDEX NAME)




REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS
 RECORD. ALL CITATIONS AVAILABLE IN THE RE
 FORMAT

L7 ANSWER 44 OF 83 CAPLUS COPYRIGHT 2006 ACS on STN
 ACCESSION NUMBER: 2005:250021 CAPLUS
 DOCUMENT NUMBER: 142:475103
 TITLE: Muraglitazar; treatment of type 2 diabetes
 dual PPAR α /y agonist
 AUTHOR(S): McIntyre, J. A.; Castaner, J.
 CORPORATE SOURCE: Prous Science, Barcelona, 08080, Spain
 SOURCE: Drugs of the Future (2004), 29(11), 1084-1087
 CODEN: DRFUD4; ISSN: 0377-8282
 PUBLISHER: Prous Science
 DOCUMENT TYPE: Journal; General Review
 LANGUAGE: English

AB A review. Adult-onset, or type 2, diabetes is characterized by the body's inability to effectively utilize insulin, which leads to defects in carbohydrate, fat and protein metabolism. The peroxisome proliferator-activated receptors (PPARs) play a key role in the regulation of dietary fat storage and PPAR agonists, which act as insulin sensitizers, have shown therapeutic potential in the treatment of blood glucose and lipid abnormalities in patients with type 2 diabetes. Muraglitazar is a PPAR agonist with dual PPAR α /y subtype activity. In preclin. studies, diabetic db/db mice and hamsters fed a high-fat diet showed significant redns. in fasting and fed glucose, plasma insulin and triglycerides in response to muraglitazar administration. A significant reduction in both triglyceride and cholesterol content of the liver was also observed. In patients with type 2 diabetes, treatment with muraglitazar resulted in dose-dependent improvements in 24-h mean glucose concns., with corresponding decreases in fasting triglycerides, LDL cholesterol and total cholesterol. Muraglitazar is currently in phase III clin. development.

IT 331741-94-7, Muraglitazar
 RL: PAC (Pharmacological activity); PKT (Pharmacokinetics); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (treatment with muraglitazar resulted in dose-dependent improvement in 24-h mean glucose concentration with significant reduction in fasting triglycerides, LDL cholesterol and total cholesterol in liver of patient with type 2 diabetes)

RN 331741-94-7 CAPLUS
 CN Glycine, N-[(4-methoxyphenoxy)carbonyl]-N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 19 THERE ARE 19 CITED REFERENCES AVAILABLE FOR
 THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE
 FORMAT

L7 ANSWER 44 OF 83 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)

L7 ANSWER 45 OF 83 CAPLUS COPYRIGHT 2006 ACS on STN
 ACCESSION NUMBER: 2005:14148 CAPLUS
 DOCUMENT NUMBER: 142:107413
 TITLE: Combination therapy for the treatment of dyslipidemia
 INVENTOR(S): Erond, Ngozi E.; Fong, Tung M.; MacNeill, Douglas J.;
 Van Der Ploeg, Leonardus H. T.
 PATENT ASSIGNEE(S): Merck & Co., Inc., USA
 SOURCE: PCT Int. Appl., 106 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005000217	A2	20050106	WO 2004-US17120	20040602
WO 2005000217	A3	20050407		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LJ, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
EP 1635813	A2	20060322	EP 2004-753858	20040602
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK				
US 2006148721	A1	20060706	US 2005-555194	20051101
PRIORITY APPLN. INFO.:				US 2003-476387P P 20030606
				WO 2004-US17120 W 20040602

OTHER SOURCE(S): MARPAT 142:107413
 AB The invention relates to compns. comprising an anti-obesity agent and an anti-dyslipidemic agent useful for the treatment of dyslipidemia, dyslipidemia associated with obesity and dyslipidemia-related disorders.
 The invention further relates to methods of treating or preventing obesity, and obesity-related disorders, in a subject in need thereof by administering a composition of the present invention. The invention further provides pharmaceutical compns., medicaments, and kits useful in carrying out these methods.
 IT 331741-94-7, Muraglitazar
 RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (combination therapy for treatment of dyslipidemia)
 RN 331741-94-7 CAPLUS
 CN Glycine, N-[(4-methoxyphenoxy)carbonyl]-N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- (9CI) (CA INDEX NAME)

10788996

11/26/06



L7 ANSWER 45 OF 83 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



L7 ANSWER 46 OF 83 CAPLUS COPYRIGHT 2006 ACS on STN
 ACCESSION NUMBER: 2004:1127349 CAPLUS
 DOCUMENT NUMBER: 142:74574
 TITLE: Preparation of 1,2,4-triazolylethylamines as modulators of the glucocorticoid receptor
 INVENTOR(S): Robinson, Leslie; Rueter, Jaimie K.; Moree, Wilna J.
 PATENT ASSIGNEE(S): Bristol-Myers Squibb Company, USA
 SOURCE: PCT Int. Appl., 69 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004111015	A1	20041223	WO 2004-US18487	20040611
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MY, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SV, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
US 2004266831	A1	20041230	US 2004-865443	20040610
PRIORITY APPLN. INFO.:			US 2003-477545P	P 20030611
OTHER SOURCE(S):		CASREACT 142:74574; MARPAT 142:74574		
GI				

L7 ANSWER 46 OF 83 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



AB Title compds. I [A, B = cycloalkyl, aryl, heteroaryl; R1 = H, acyl, carboxy, etc.; R2-4 = H, alkyl, heteroalkyl, etc.; R5-6 = H, F, Cl, Br, etc.] are prepared General synthetic procedures are provided for the synthesis of 19 examples, e.g., II. Example compds. are tested in a glucocorticoid receptor binding assay in the range of 0.1 nM to 40 μM [no data]. I are glucocorticoid receptor modulators and are useful in treating diseases requiring glucocorticoid receptor agonist or antagonist therapy such as obesity, diabetes, inflammatory and immune disorders.


IT 258345-41-4
 RI: BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(combination pharmaceutical; preparation of 1,2,4-triazolylethylamines as modulators of glucocorticoid receptor)

RN 258345-41-4 CAPLUS

CN L-Tyrosine, N-[(12)-1-methyl-3-oxo-3-phenyl-1-propenyl]-O-[2-(5-methyl-2-phenyl-4-oxazolyl)ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
 Double bond geometry as shown.



REFERENCE COUNT: 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE
 FORMAT

10788996

11/26/06

L7 ANSWER 47 OF 83 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2004:112719 CAPLUS

DOCUMENT NUMBER: 142:74357

TITLE: Preparation of new benzamides for use in pharmaceutical compositions as peroxisome proliferator-activated receptor γ (PPAR γ) modulators

INVENTOR(S): Fernandez Serrat, Anna; Serra Comas, Carme; Balsa Lopez, Dolores; Llebaria Soldevila, Amadeu; Farrerons Gallem, Carles; Miquel Bono, Ignacio Jose; Cadenas Ruiz, Juan Lorenzo; Lagunes Arnal, Carmen; Cordomi Montoya, Anna; Salcedo Roca, Carolina; Toledo Mesa, Natividad; Marrero Gonzalez, Pedro; Haro Bautista, Diego; Fernandez Garcia, Andres

PATENT ASSIGNEE(S): Laboratorios S.A.L.V.A.T., S.A., Spain

SOURCE: PCT Int. Appl., 113 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004110983	A2	20041223	WO 2004-EP6330	20040611
WO 2004110983	C1	20050811		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
AU 2004247389	A1	20041223	AU 2004-247389	20040611
CA 2528231	AA	20041223	CA 2004-2528231	20040611
EP 1644321	A2	20060412	EP 2004-739820	20040611
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, HR			
BR 2004011412	A	20060725	BR 2004-11412	20040611
CN 1835914	A	20060920	CN 2004-80023119	20040611
US 2006160894	A1	20060720	US 2005-560533	20051213
PRIORITY APPLN. INFO.:			ES 2003-1461	A 20030613
			WO 2004-EP6330	W 20040611

OTHER SOURCE(S):

MARPAT 142:74357

GI

L7 ANSWER 48 OF 83 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2004:1124594 CAPLUS

DOCUMENT NUMBER: 142:79882

TITLE: Non-steroidal compound modulators of the glucocorticoid receptor and therapeutic uses for glucocorticoid receptor agonist or antagonist dependent diseases

INVENTOR(S): Hadide-Ruach, Sera Sabine; He, Xiaohui; Nagasawa, Johnny Yasuo

PATENT ASSIGNEE(S): Bristol-Myers Squibb Company, USA

SOURCE: PCT Int. Appl., 75 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1


PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004110385	A2	20041223	WO 2004-US18677	20040611
WO 2004110385	A3	20050127		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
US 2004266758	A1	20041230	US 2004-865444	20040610
PRIORITY APPLN. INFO.:			US 2003-477574P	P 20030611

OTHER SOURCE(S):

MARPAT 142:79882


GI



AB The present invention relates to new nonsteroidal compds. which are glucocorticoid receptor (GR) modulators (that is agonists and antagonists) and thus are useful in treating diseases requiring glucocorticoid receptor agonist or antagonist therapy such as obesity, diabetes and

Page 61 SAEED

L7 ANSWER 47 OF 83 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



AB Benzamides, such as I [R = OH, NH₂, alkoxy, alkylamino, etc.; R₁ = H, alkyl, benzyl, etc.; W = alkylene, aryl substituted alkylene; Z = benzyl, biphenylmethyl, phenylalkyl, etc.], were prepared for use in the prophylactic and/or curative treatment of a condition or a disease mediated by the PPAR γ . These benzamides are claimed for use in the treatment of metabolic diseases, such as non-insulin-dependent diabetes mellitus, obesity, hypercholesterolemia and other lipid-mediated pathologies, as well as for treatment of cardiovascular disease associated with metabolic syndrome, treatment of inflammation or

an inflammatory processes, such as rheumatoid arthritis, atherosclerosis, psoriasis and intestinal inflammatory disease, for treatment of cancer, skin wound healing or cutaneous disorders associated with an anomalous differentiation of epidermic cells, and for treatment of bone disease, particularly osteoporosis. Thus, the L-phenylalanine derivative, (S)-PhCH₂O-4-C₆H₄CH₂CH(CO₂Me)NHOOC₆H₄-4-OCH₂C₆H₄-4-OPh, is an example of the target benzamides prepared. The prepared benzamides were assayed for PPAR γ binding affinity and were evaluated for their PPAR γ agonist/antagonist functional activity.


IT 814922-13-9P
RI: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of new benzamides for use in pharmaceutical compns. as peroxisome proliferator-activated receptor γ (PPAR γ) modulators)

RN 814922-13-9 CAPLUS

CN L-Tyrosine, N-[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]benzoyl]-O-(phenylmethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L7 ANSWER 48 OF 83 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)

inflammatory or immune assocd. diseases, and to a method for using such compds. to treat these and related diseases. Specifically, the novel nonsteroidal compds. have the structure as formula (I), wherein R₁ through

R₆ are independently (i) hydrogen, F, Cl, Br, I, NO₂, CN, or OR₁₀, etc., (ii) C1-6-alkyl, C3-8-cycloalkyl, or C2-6-alkenyl, etc; R₇ is hydrogen, C1-6-alkyl, or C3-8-cycloalkyl, etc; R₈ and R₉ are independently hydrogen,

Cl-6-alkyl, or C3-8-cycloalkyl, etc; Y is O, S, or NR₁₄; Z is O, S, S(O), S(O)₂, or NR₁₅; and X is OC(R₁₆)R₁₇, SC(R₁₆)R₁₇, S(O)C(R₁₆)R₁₇, etc.


IT 258345-41-4

RI: THU (Therapeutic use); BIOL (Biological study); USES (Uses) (nonsteroidal compound modulators of glucocorticoid receptor and therapeutic uses for glucocorticoid receptor agonist or antagonist-dependent diseases)



RN 258345-41-4 CAPLUS

CN L-Tyrosine, N-[(12)-1-methyl-3-oxo-3-phenyl-1-propenyl]-O-[2-(5-methyl-2-phenyl-4-oxazolyl)ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



L7 ANSWER 50 OF 83 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



AB Title compds. I [X = alkanediyl, oxalkanediyl; X1 = cycloalkanedyl, cycloalkenedyl, oxacycloalkanedyl, oxacycloalkenedyl; Y1 = (un)substituted CH2, CH2CH2; Y2 = CH2, O, S, S(O), SO2, (un)substituted NH; R = (un)substituted or annulated Ph, pyridinyl, furyl, thienyl, pyrrolyl; R1 = H, alkyl, cycloalkyl, cycloalkylalkyl, Ph, aralkyl, heteroaryl, heteroarylalkyl, fluoroalkyl; R2, R3 = H, alkyl, F, (un)substituted NH; R4 = H, alkyl, F; R5 = H, F, alkyl, alkoxy, alkenyl, alkynyl, cycloalkyl, Ph, substituted alkyl; CR4R5 = cycloalkyl; R6 = H, alkyl] were prepared for use as PPAR modulators for treating disorders of the fatty acid metabolism and disorders of glucose utilization in addition to disorders, in which insulin resistance plays a part. Thus, the title compound II was prepared in a multi-stage synthesis and had EC50 for activation of the PPAR α receptor of 0.07 nM.

IT 754986-49-7P
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(Preparation of 3-(2-phenyloxazol-4-ylmethoxy)cyclohexylmethoxyacetic

acid derivs. and related compds. as PPAR agonists)


RN 754986-49-7 CAPLUS
CN Acetic acid, [[[(1R,3S)-3-[[[5-methyl-2-(4-methylphenyl)-4-oxazolyl]methoxy]cyclohexyl]methyl]thio]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.

L7 ANSWER 50 OF 83 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)


RN 754986-36-2 CAPLUS
CN Propanoic acid, 2-methyl-2-[[[(1R,3S)-3-[[[5-methyl-2-(4-(trifluoromethyl)phenyl]-4-oxazolyl]methoxy]cyclohexyl]methoxy]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 754986-51-1 CAPLUS
CN Butanoic acid, 2-[[[(1R,3S)-3-[[[5-methyl-2-(4-methylphenyl)-4-oxazolyl]methoxy]cyclohexyl]methyl]thio]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 754986-61-3 CAPLUS
CN Heptanoic acid, 2-[[[(1R,3S)-3-[[[5-methyl-2-(4-methylphenyl)-4-oxazolyl]methoxy]cyclohexyl]methyl]sulfinyl]-, rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 754986-66-8 CAPLUS
CN Heptanoic acid, 2-[[[(1R,3S)-3-[[[5-methyl-2-(4-methylphenyl)-4-oxazolyl]methoxy]cyclohexyl]methyl]sulfonyl]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.

L7 ANSWER 50 OF 83 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




IT 754986-13-5P 754986-20-4P 754986-36-2P
754986-51-1P 754986-61-3P 754986-66-8P
754986-72-6P 754986-83-9P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(Preparation of 3-(2-phenyloxazol-4-ylmethoxy)cyclohexylmethoxyacetic

acid derivs. and related compds. as PPAR agonists)


RN 754986-13-5 CAPLUS
CN Benzenepropanoic acid, α -[[[(1R,3S)-3-[[[5-methyl-2-(4-methylphenyl)-4-oxazolyl]methoxy]cyclohexyl]methoxy]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 754986-20-4 CAPLUS
CN Propanoic acid, 2-methyl-2-[[[(1R,3S)-3-[[[5-methyl-2-(4-methylphenyl)-4-oxazolyl]methoxy]cyclohexyl]methoxy]-, rel- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




L7 ANSWER 50 OF 83 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 754986-72-6 CAPLUS
CN L-Valine, N-[[[3-[[[5-methyl-2-(4-methylphenyl)-4-oxazolyl]methoxy]cyclohexyl]methyl]-, rel- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 754986-83-9 CAPLUS
CN L-Valine, N-[[[3-[[[5-methyl-2-(4-methylphenyl)-4-oxazolyl]methoxy]cyclohexyl]methyl]-N-(phenylmethyl)-, rel- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




IT 754986-09-9P 754986-18-0P 754986-29-3P
754986-48-6P 754986-71-5P 754986-86-2P
754987-30-9P 754987-31-0P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(Preparation of 3-(2-phenyloxazol-4-ylmethoxy)cyclohexylmethoxyacetic

acid derivs. and related compds. as PPAR agonists)

RN 754986-09-9 CAPLUS
CN Pentanoic acid, 2-[[[(1R,3S)-3-[[[5-methyl-2-(4-methylphenyl)-4-oxazolyl]methoxy]cyclohexyl]methoxy]-, 1,1-dimethylethyl ester, rel- (9CI)


L7 ANSWER 50 OF 83 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
(CA INDEX NAME)

Relative stereochemistry.




RN 754986-18-0 CAPLUS
CN Propanoic acid, 2-methyl-2-[[[1R,3S]-3-[[5-methyl-2-(4-methylphenyl)-4-oxazolyl]methoxy]cyclohexyl]methoxy]-, 1,1-dimethylethyl ester, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 754986-29-3 CAPLUS
CN Propanoic acid, 2-methyl-2-[[[1R,3S]-3-[[2-(4-fluorophenyl)-5-methyl-4-oxazolyl]methoxy]cyclohexyl]methoxy]-2-methyl-, 1,1-dimethylethyl ester, rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 754986-48-6 CAPLUS
CN Acetic acid, [[[(1R,3S)-3-[[5-methyl-2-(4-methylphenyl)-4-oxazolyl]methoxy]cyclohexyl]methyl]thio]-, ethyl ester, rel- (9CI) (CA INDEX NAME)


L7 ANSWER 50 OF 83 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
(CA INDEX NAME)

Absolute stereochemistry.



RN 754987-31-0 CAPLUS
CN L-Valine, N-[[[4-methoxyphenoxy]carbonyl]-N-[2-{3-[[5-methyl-2-(3-methylphenyl)-4-oxazolyl]methoxy]cyclohexyl]ethyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




IT 754986-52-2P 754986-53-3P 754986-54-4P
754986-57-7P
RL: RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use);
BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent);
USES (Uses)
(preparation of 3-(2-phenyloxazol-4-ylmethoxy)cyclohexylmethoxyacetic
acid
derivs. and related compds. as PPAR agonists)

RN 754986-52-2 CAPLUS
CN Heptanoic acid, 2-[[[(1R,3S)-3-[[5-methyl-2-(4-methylphenyl)-4-oxazolyl]methoxy]cyclohexyl]methyl]thio]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.


L7 ANSWER 50 OF 83 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
(CA INDEX NAME)

Relative stereochemistry.




RN 754986-71-5 CAPLUS
CN L-Valine, N-[[[3-[[5-methyl-2-(4-methylphenyl)-4-oxazolyl]methoxy]cyclohexyl]methyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 754986-86-2 CAPLUS
CN Glycine, N-[[[1R,3S]-3-[[5-methyl-2-(4-methylphenyl)-4-oxazolyl]methoxy]cyclohexyl]methyl]-N-(2-thienylmethyl)-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 754987-30-9 CAPLUS
CN L-Valine, N-[2-{3-[[5-methyl-2-(3-methylphenyl)-4-oxazolyl]methoxy]cyclohexyl]ethyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

L7 ANSWER 50 OF 83 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 754986-53-3 CAPLUS
CN Butanoic acid, 3-methyl-2-[[[(1R,3S)-3-[[5-methyl-2-(4-methylphenyl)-4-oxazolyl]methoxy]cyclohexyl]methyl]thio]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 754986-54-4 CAPLUS
CN Propanoic acid, 2-methyl-2-[[[(1R,3S)-3-[[5-methyl-2-(4-methylphenyl)-4-oxazolyl]methoxy]cyclohexyl]methyl]thio]-, rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 754986-57-7 CAPLUS
CN Pentanoic acid, 2-[[[(1R,3S)-3-[[5-methyl-2-(4-methylphenyl)-4-oxazolyl]methoxy]cyclohexyl]methyl]thio]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.

L7 ANSWER 50 OF 83 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




IT 754986-10-2P 754986-11-3P 754986-12-4P
 754986-14-6P 754986-15-7P 754986-16-8P
 754986-19-1P 754986-30-6P 754986-31-7P
 754986-32-8P 754986-34-0P 754986-35-1P
 754986-37-3P 754986-39-5P 754986-40-8P
 754986-41-9P 754986-50-0P 754986-55-5P
 754986-56-6P 754986-60-2P 754986-62-4P
 754986-63-5P 754986-64-6P 754986-65-7P
 754986-67-9P 754986-68-0P 754986-69-1P
 754986-73-7P 754986-74-8P 754986-75-9P
 754986-76-0P 754986-77-1P 754986-78-2P
 754986-80-6P 754986-82-8P 754986-85-1P
 754986-87-3P 754986-92-0P 754986-93-1P
 754986-95-3P 754986-96-4P 754986-98-6P
 754986-99-7P 754987-00-3P 754987-01-4P
 754987-03-6P 754987-04-7P 754987-12-1P
 754987-15-4P 754987-16-5P 754987-17-6P
 754987-18-7P
 RL: SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (preparation of 3-(2-phenyloxazol-4-ylmethoxy)cyclohexylmethoxyacetic acid

derivs. and related compds. as PPAR agonists)


RN 754986-10-2 CAPLUS
 CN Butanoic acid, 2-[[[(1R,3S)-3-[[5-methyl-2-(4-methylphenyl)-4-oxazolyl]methoxy]cyclohexyl]methoxy]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 754986-11-3 CAPLUS
 CN Propanoic acid, 2-[[[(1R,3S)-3-[[5-methyl-2-(4-methylphenyl)-4-oxazolyl]methoxy]cyclohexyl]methoxy]-, rel- (9CI) (CA INDEX NAME)

L7 ANSWER 50 OF 83 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 754986-16-8 CAPLUS
 CN Propanoic acid, 2-[[[(1R,3S)-3-[[5-methyl-2-(3-(trifluoromethyl)phenyl)-4-oxazolyl]methoxy]cyclohexyl]methoxy]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 754986-19-1 CAPLUS
 CN Propanoic acid, 2-methyl-2-[[[(1R,3S)-3-[[5-methyl-2-(4-methylphenyl)-4-oxazolyl]methoxy]cyclohexyl]methoxy]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 754986-30-6 CAPLUS
 CN Propanoic acid, 2-[[[(1R,3S)-3-[[2-(4-fluorophenyl)-5-methyl-4-oxazolyl]methoxy]cyclohexyl]methoxy]-2-methyl-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.


L7 ANSWER 50 OF 83 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)

Relative stereochemistry.




RN 754986-12-4 CAPLUS
 CN Butanoic acid, 2-[[[(1R,3S)-3-[[5-methyl-2-(4-methylphenyl)-4-oxazolyl]methoxy]cyclohexyl]methoxy]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 754986-14-6 CAPLUS
 CN Propanoic acid, 2-[[[(1R,3S)-3-[[2-(3-methoxyphenyl)-5-methyl-4-oxazolyl]methoxy]cyclohexyl]methoxy]-, rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 754986-15-7 CAPLUS
 CN Propanoic acid, 2-[[[(1R,3S)-3-[[5-methyl-2-(3-methylphenyl)-4-oxazolyl]methoxy]cyclohexyl]methoxy]-, rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.

L7 ANSWER 50 OF 83 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 754986-31-7 CAPLUS
 CN Propanoic acid, 2-[[[(1R,3S)-3-[[2-(3-methoxyphenyl)-5-methyl-4-oxazolyl]methoxy]cyclohexyl]methoxy]-2-methyl-, rel- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 754986-32-8 CAPLUS
 CN Propanoic acid, 2-methyl-2-[[[(1R,3S)-3-[[5-methyl-2-(3-(trifluoromethyl)phenyl)-4-oxazolyl]methoxy]cyclohexyl]methoxy]-, rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 754986-34-0 CAPLUS
 CN Propanoic acid, 2-[[[(1R,3S)-3-[[2-(3,4-dimethoxyphenyl)-5-methyl-4-oxazolyl]methoxy]cyclohexyl]methoxy]-2-methyl-, rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.

L7 ANSWER 50 OF 83 CAPLUS COPYRIGHT 2006 ACS ON STN (Continued)




RN 754986-35-1 CAPLUS
 CN Propanoic acid, 2-methyl-2-[[[(1R,3S)-3-[[2-(4-methylphenyl)-5-phenyl-4-oxazolyl]methoxy]cyclohexyl]methoxy]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 754986-37-3 CAPLUS
 CN Propanoic acid, 2-[[[(1R,3S)-3-[[2-(4-methoxyphenyl)-5-methyl-4-oxazolyl]methoxy]cyclohexyl]methoxy]-2-methyl-, rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 754986-39-5 CAPLUS
 CN Propanoic acid, 2-methyl-2-[[[(1R,3S)-3-[[5-methyl-2-(3-(trifluoromethoxy)phenyl)-4-oxazolyl]methoxy]cyclohexyl]methoxy]-, rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.

L7 ANSWER 50 OF 83 CAPLUS COPYRIGHT 2006 ACS ON STN (Continued)




RN 754986-55-5 CAPLUS
 CN Benzeneacetic acid, alpha-[[[(1R,3S)-3-[[5-methyl-2-(4-methylphenyl)-4-oxazolyl]methoxy]cyclohexyl]methyl]thio]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 754986-56-6 CAPLUS
 CN Cyclohexanecarboxylic acid, alpha-[[[(1R,3S)-3-[[5-methyl-2-(4-methylphenyl)-4-oxazolyl]methoxy]cyclohexyl]methyl]thio]-, rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 754986-60-2 CAPLUS
 CN Acetic acid, [[[(1R,3S)-3-[[5-methyl-2-(4-methylphenyl)-4-oxazolyl]methoxy]cyclohexyl]methyl]sulfinyl]-, rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.

L7 ANSWER 50 OF 83 CAPLUS COPYRIGHT 2006 ACS ON STN (Continued)




RN 754986-40-8 CAPLUS
 CN Propanoic acid, 2-methyl-2-[[[(1R,3S)-3-[[5-methyl-2-(4-(1-methylethyl)phenyl)-4-oxazolyl]methoxy]cyclohexyl]methoxy]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 754986-41-9 CAPLUS
 CN Propanoic acid, 2-methyl-2-[[[(1R,3S)-3-[[5-methyl-2-(3-methylphenyl)-4-oxazolyl]methoxy]cyclohexyl]methoxy]-, rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 754986-50-0 CAPLUS
 CN Propanoic acid, 2-[[[(1R,3S)-3-[[5-methyl-2-(4-methylphenyl)-4-oxazolyl]methoxy]cyclohexyl]methyl]thio]-, rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.

L7 ANSWER 50 OF 83 CAPLUS COPYRIGHT 2006 ACS ON STN (Continued)




RN 754986-62-4 CAPLUS
 CN Butanoic acid, 3-methyl-2-[[[(1R,3S)-3-[[5-methyl-2-(4-methylphenyl)-4-oxazolyl]methoxy]cyclohexyl]methyl]sulfinyl]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 754986-63-5 CAPLUS
 CN Butanoic acid, 3-methyl-2-[[[(1R,3S)-3-[[5-methyl-2-(4-methylphenyl)-4-oxazolyl]methoxy]cyclohexyl]methyl]sulfinyl]-, rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 754986-64-6 CAPLUS
 CN Pentanoic acid, 2-[[[(1R,3S)-3-[[5-methyl-2-(4-methylphenyl)-4-oxazolyl]methoxy]cyclohexyl]methyl]sulfinyl]-, rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.

L7 ANSWER 50 OF 83 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 754986-65-7 CAPLUS
CN Acetic acid, [[[(1R,3S)-3-[[[5-methyl-2-(4-methylphenyl)-4-oxazolyl]methoxy]cyclohexyl]methyl]sulfonyl]-, rel- (9CI) (CA INDEX NAME)]

Relative stereochemistry.



RN 754986-67-9 CAPLUS
CN Propanoic acid, 2-methyl-2-[[[(1R,3S)-3-[[[5-methyl-2-(4-methylphenyl)-4-oxazolyl]methoxy]cyclohexyl]methyl]sulfonyl]-, rel- (9CI) (CA INDEX NAME)]


Relative stereochemistry.



RN 754986-68-0 CAPLUS
CN Butanoic acid, 3-methyl-2-[[[(1R,3S)-3-[[[5-methyl-2-(4-methylphenyl)-4-oxazolyl]methoxy]cyclohexyl]methyl]sulfonyl]-, rel- (9CI) (CA INDEX NAME)]


Relative stereochemistry.

L7 ANSWER 50 OF 83 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 754986-75-9 CAPLUS
CN L-Valine, N-[[[3-[[[5-methyl-2-(4-methylphenyl)-4-oxazolyl]methoxy]cyclohexyl]methyl]-N-(methylsulfonyl)- (9CI) (CA INDEX NAME)]

Absolute stereochemistry.



RN 754986-76-0 CAPLUS
CN L-Valine, N-[[[3-[[[5-methyl-2-(4-methylphenyl)-4-oxazolyl]methoxy]cyclohexyl]methyl]-N-[[[methylsulfonyl]methyl]sulfonyl]- (9CI) (CA INDEX NAME)]


Absolute stereochemistry.



RN 754986-77-1 CAPLUS
CN L-Valine, N-[[[3-[[[5-methyl-2-(4-methylphenyl)-4-oxazolyl]methoxy]cyclohexyl]methyl]-N-[[[4-methylphenyl]sulfonyl]- (9CI) (CA INDEX NAME)]


Absolute stereochemistry.

L7 ANSWER 50 OF 83 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 754986-69-1 CAPLUS
CN Pentanoic acid, 2-[[[(1R,3S)-3-[[[5-methyl-2-(4-methylphenyl)-4-oxazolyl]methoxy]cyclohexyl]methyl]sulfonyl]-, rel- (9CI) (CA INDEX NAME)]

Relative stereochemistry.



RN 754986-73-7 CAPLUS
CN L-Valine, N-acetyl-N-[[[3-[[[5-methyl-2-(4-methylphenyl)-4-oxazolyl]methoxy]cyclohexyl]methyl]- (9CI) (CA INDEX NAME)]


Absolute stereochemistry.



RN 754986-74-8 CAPLUS
CN L-Valine, N-benzoyl-N-[[[3-[[[5-methyl-2-(4-methylphenyl)-4-oxazolyl]methoxy]cyclohexyl]methyl]- (9CI) (CA INDEX NAME)]


Absolute stereochemistry.

L7 ANSWER 50 OF 83 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 754986-78-2 CAPLUS
CN L-Valine, N-(methoxycarbonyl)-N-[[[3-[[[5-methyl-2-(4-methylphenyl)-4-oxazolyl]methoxy]cyclohexyl]methyl]- (9CI) (CA INDEX NAME)]

Absolute stereochemistry.




RN 754986-80-6 CAPLUS
CN Glycine, N-[[[(1R,3S)-3-[[[5-methyl-2-(4-methylphenyl)-4-oxazolyl]methoxy]cyclohexyl]methyl]-, rel-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)]

CN 1

CRN 754986-79-3
CHF C21 H28 N2 O4

Relative stereochemistry.



CN 2

CRN 76-05-1


L7 ANSWER 50 OF 83 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
CMP C2 H F3 O2

RN 754986-82-8 CAPLUS
CN L-Valine, N-methyl-N-[[3-[[5-methyl-2-(4-methylphenyl)-4-oxazolyl]methoxy]cyclohexyl]methyl]-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 754986-81-7
CMP C25 H36 N2 O4

Absolute stereochemistry.



CM 2

CRN 76-05-1
CMP C2 H F3 O2




RN 754986-85-1 CAPLUS
CN Glycine, N-[[[(1R,3S)-3-[[5-methyl-2-(4-methylphenyl)-4-oxazolyl]methoxy]cyclohexyl]methyl]-N-(phenylmethyl)-, rel-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1


CRN 754986-84-0

L7 ANSWER 50 OF 83 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 754986-93-1 CAPLUS
CN Butanoic acid, 2-methyl-2-[[[(1R,3S)-3-[[5-methyl-2-(4-methylphenyl)-4-oxazolyl]methoxy]methyl]cyclohexyl]methoxy]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 754986-95-3 CAPLUS
CN Propanoic acid, 2-[[[(1R,3S)-3-[[2-[[1,1'-biphenyl]-4-yl-5-methyl-4-oxazolyl]methoxy]methyl]cyclohexyl]methoxy]-2-methyl-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 754986-96-4 CAPLUS
CN Propanoic acid, 2-methyl-2-[[[(1R,3S)-3-[[5-methyl-2-phenyl-4-oxazolyl]methoxy]methyl]cyclohexyl]methoxy]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.

L7 ANSWER 50 OF 83 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
CMP C28 H34 N2 O4

Relative stereochemistry.




CM 2

CRN 76-05-1
CMP C2 H F3 O2




RN 754986-87-3 CAPLUS
CN Glycine, N-(cyclohexylmethyl)-N-[[[(1R,3S)-3-[[5-methyl-2-(4-methylphenyl)-4-oxazolyl]methoxy]cyclohexyl]methyl]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 754986-92-0 CAPLUS
CN Propanoic acid, 2-methyl-2-[[[(1R,3S)-3-[[5-methyl-2-(4-methylphenyl)-4-oxazolyl]methoxy]methyl]cyclohexyl]methoxy]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 754986-98-6 CAPLUS
CN Propanoic acid, 2-[[[(1R,3S)-3-[[5-ethyl-2-(3-methoxyphenyl)-4-oxazolyl]methoxy]methyl]cyclohexyl]methoxy]-2-methyl-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 754986-99-7 CAPLUS
CN Propanoic acid, 2-methyl-2-[[[(1R,3S)-3-[[5-methyl-2-[4-(1-methylethyl)phenyl]-4-oxazolyl]methoxy]methyl]cyclohexyl]methoxy]-, rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 754987-00-3 CAPLUS
CN Propanoic acid, 2-[[[(1R,3S)-3-[[5-cyclohexyl-2-(4-methylphenyl)-4-oxazolyl]methoxy]methyl]cyclohexyl]methoxy]-2-methyl-, rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.

L7 ANSWER 50 OF 83 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 754987-01-4 CAPLUS
 CN Propanoic acid, 2-[[[(1R,3S)-3-[[[5-ethyl-2-(4-methylethyl)phenyl]-4-oxazolyl]methoxy]methyl]cyclohexyl]methoxy]-2-methyl-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 754987-03-6 CAPLUS
 CN Propanoic acid, 2-[[[(1R,3S)-3-[[[5-ethyl-2-(4-methylphenyl)-4-oxazolyl]methoxy]methyl]cyclohexyl]methoxy]-2-methyl-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 754987-04-7 CAPLUS
 CN Propanoic acid, 2-[[[(1R,3S)-3-[[[5-ethyl-2-(4-methyl-3-(trifluoromethyl)phenyl]-4-oxazolyl]methoxy]methyl]cyclohexyl]methoxy]-2-methyl-, rel- (9CI) (CA INDEX NAME)


L7 ANSWER 50 OF 83 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)

PAGE 1-B

Me


RN 754987-36-5 CAPLUS
 CN Glycine, N-[2-[[[(1R,3R)-3-[[[5-methyl-2-(3-methylphenyl)-4-oxazolyl]methoxy]cyclohexyl]ethyl]-N-[(phenylmethoxy)carbonyl]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 754987-37-6 CAPLUS
 CN Glycine, N-[2-[[[(1R,3R)-3-[[[5-methyl-2-(3-methylphenyl)-4-oxazolyl]methoxy]cyclohexyl]ethyl]-N-(phenylacetyl)-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 754987-38-7 CAPLUS
 CN Glycine, N-[2-[[[(1R,3R)-3-[[[5-methyl-2-(3-methylphenyl)-4-oxazolyl]methoxy]cyclohexyl]ethyl]-N-[(phenylamino)carbonyl]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




L7 ANSWER 50 OF 83 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 754987-32-1 CAPLUS
 CN L-Valine, N-[[[(4-methoxyphenoxy)carbonyl]-N-[2-[[[5-methyl-2-(3-methylphenyl)-4-oxazolyl]methoxy]cyclohexyl]ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 754987-35-4 CAPLUS
 CN D-Phenylalanine, N-[[[(4-methoxyphenyl)methoxy]carbonyl]-α-methyl-N-[2-[[[5-methyl-2-(3-methylphenyl)-4-oxazolyl]methoxy]cyclohexyl]ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



PAGE 1-A

L7 ANSWER 50 OF 83 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)

REFERENCE COUNT: 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE
 FORMAT


L7 ANSWER 51 OF 83 CAPLUS COPYRIGHT 2006 ACS ON STN
 ACCESSION NUMBER: 2004.740306 CAPLUS
 DOCUMENT NUMBER: 141:243829
 TITLE: Synthesis of oxazol-4-yl-cyclohexanecarbonyl-amino acid derivatives as peroxisome proliferator activated receptor (ppar) modulators for the treatment of type 2 diabetes and atherosclerosis
 INVENTOR(S): Stapper, Christian; Gretzke, Dirk; Falk, Eugen; Goerlitz, Jochen; Kell, Stefanie; Schaefer, Hans-Ludwig; Glombik, Heiner; Wendler, Wolfgang
 PATENT ASSIGNEE(S): Aventis Pharma Deutschland GmbH, Germany
 SOURCE: PCT Int. Appl., 114 pp.
 DOCUMENT TYPE: CODEN: PIXXD2
 LANGUAGE: Patent
 FAMILY ACC. NUM. COUNT: 3
 PATENT INFORMATION: German

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004076426	A1	20040910	WO 2004-EP1578	20040219
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GR, GU, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MY, NA, NI, NG, NO, NZ, OM, PA, PE, PG, PH, PK, PL, PT, RO, RU, SA, SD, SE, SG, SI, SK, SL, SM, SN, SR, ST, SV, SW, SY, TD, TG, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VE, VN, YU, ZA, ZM, ZW, ZY, AA, AB, AC, AD, AE, AF, AG, AH, AI, AJ, AK, AL, AM, AN, AO, AP, AQ, AR, AS, AT, AU, AV, AW, AX, AY, AZ, BA, BB, BC, BD, BE, BF, BG, BH, BI, BJ, BK, BL, BM, BN, BO, BP, BQ, BR, BS, BT, BU, BV, BW, BX, BY, BZ, CA, CB, CC, CD, CE, CF, CG, CH, CI, CJ, CK, CL, CM, CN, CO, CP, CQ, CR, CS, CT, CU, CV, CW, CX, CY, CZ, DA, DB, DD, DE, DF, DG, DH, DI, DJ, DK, DL, DM, DN, DO, DP, DQ, DR, DS, DT, DU, DV, DW, DX, DY, DZ, EA, EB, EC, ED, EE, EF, EG, EH, EI, EJ, EK, EL, EM, EN, EO, EP, EQ, ER, ES, ET, EU, EV, EW, EX, EY, EZ, FA, FB, FC, FD, FE, FF, FG, FH, FI, FJ, FK, FL, FM, FN, FO, FP, FQ, FR, FS, FT, FU, FV, FW, FX, FY, FZ, GA, GB, GC, GD, GE, GF, GH, GI, GJ, GK, GL, GM, GN, GP, GQ, GR, GS, GT, GU, GV, GW, GX, GY, GZ, HA, HB, HC, HD, HE, HF, HG, HH, HI, HJ, HK, HL, HM, HN, HO, HP, HQ, HR, HS, HT, HU, HV, HW, HX, HY, HZ, IA, IB, IC, ID, IE, IF, IG, IH, II, IJ, IK, IL, IM, IN, IO, IP, IQ, IR, IS, IT, IU, IV, IW, IX, IY, IZ, JA, JB, JC, JD, JE, JF, JG, JH, JI, JJ, JK, JL, JM, JN, JO, JP, JQ, JR, JS, JT, JU, JV, JW, JX, JY, JZ, KA, KB, KC, KD, KE, KF, KG, KH, KI, KJ, KK, KL, KM, KN, KO, KP, KQ, KR, KS, KT, KU, KV, KW, KX, KY, KZ, LA, LB, LC, LD, LE, LF, LG, LH, LI, LJ, LK, LM, LN, LO, LP, LQ, LR, LS, LT, LU, LV, LW, LX, LY, LZ, MA, MB, MC, MD, ME, MF, MG, MH, MI, MJ, MK, ML, MN, MO, MP, MQ, MR, MS, MT, MU, MV, MW, MX, MY, MZ, NA, NB, NC, ND, NE, NF, NG, NH, NI, NJ, NK, NL, NM, NO, NP, NQ, NR, NS, NT, NU, NV, NW, NX, NY, NZ, OA, OB, OC, OD, OE, OF, OG, OH, OI, OJ, OK, OL, OM, ON, OO, OP, OQ, OR, OS, OT, OU, OV, OW, OX, OY, OZ, PA, PB, PC, PD, PE, PF, PG, PH, PI, PJ, PK, PL, PM, PN, PO, PP, PQ, PR, PS, PT, PU, PV, PW, PX, PY, PZ, QA, QB, QC, QD, QE, QF, QG, QH, QI, QJ, QK, QL, QM, QN, QO, QP, QQ, QR, QS, QT, QU, QV, QW, QX, QY, QZ, RA, RB, RC, RD, RE, RF, RG, RH, RI, RJ, RK, RL, RM, RN, RO, RP, RQ, RR, RS, RT, RU, RV, RW, RX, RY, RZ, SA, SB, SC, SD, SE, SF, SG, SH, SI, SJ, SK, SL, SM, SN, SO, SP, SQ, SR, SS, ST, SU, SV, SW, SX, SY, SZ, TA, TB, TC, TD, TE, TF, TG, TH, TI, TJ, TK, TL, TM, TN, TO, TP, TQ, TR, TS, TT, TU, TV, TW, TX, TY, TZ, UA, UB, UC, UD, UE, UF, UG, UH, UI, UJ, UK, UL, UM, UN, UO, UP, UQ, UR, US, UT, UV, UW, UX, UY, UZ, VA, VB, VC, VD, VE, VF, VG, VH, VI, VJ, VK, VL, VM, VN, VO, VP, VQ, VR, VS, VT, VU, VV, VW, VX, VY, VZ, WA, WB, WC, WD, WE, WF, WG, WH, WI, WJ, WK, WL, WM, WN, WO, WP, WQ, WR, WS, WT, WU, WV, WW, WX, WY, WZ, XA, XB, XC, XD, XE, XF, XG, XH, XI, XJ, XK, XL, XM, XN, XO, XP, XQ, XR, XS, XT, XU, XV, XW, XX, XY, XZ, YA, YB, YC, YD, YE, YF, YG, YH, YI, YJ, YK, YL, YM, YN, YO, YP, YQ, YR, YS, YT, YU, YV, YW, YX, YZ, ZA, ZB, ZC, ZD, ZE, ZF, ZG, ZH, ZI, ZJ, ZK, ZL, ZM, ZN, ZO, ZP, ZQ, ZR, ZS, ZT, ZU, ZV, ZW, ZX, ZY, ZZ				

OTHER SOURCE(S): MARPAT 141:243829
 GI


L7 ANSWER 51 OF 83 CAPLUS COPYRIGHT 2006 ACS ON STN (Continued)
 RL: BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (prepn. of amino acid derivs. as peroxisome proliferator activated receptor (ppar) modulators for the treatment of metabolic diseases)
 RN 752213-28-8 CAPLUS
 CN L-Alanine, N-[[3-[[[5-methyl-2-(4-methylphenyl)-4-oxazolyl]methoxy]cyclohexyl]carbonyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 752213-30-2 CAPLUS
 CN Alanine, 2-methyl-N-[[[3-[[[5-methyl-2-(4-methylphenyl)-4-oxazolyl]methoxy]cyclohexyl]carbonyl]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 752213-41-5 CAPLUS
 CN L-Valine, N-[[3-[[[5-methyl-2-(3-(trifluoromethyl)phenyl)-4-oxazolyl]methoxy]cyclohexyl]carbonyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 752214-13-4 CAPLUS
 CN L-Valine, N-[[3-[[[5-(1-methylethyl)-2-(4-(trifluoromethyl)phenyl)-4-oxazolyl]methoxy]methyl]cyclohexyl]carbonyl]- (9CI) (CA INDEX NAME)


Page 70 SAEED

L7 ANSWER 51 OF 83 CAPLUS COPYRIGHT 2006 ACS ON STN (Continued)

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB The invention relates to cis-cyclohexyl-substituted amino acid derivs., e.g. (I), and their physiol. acceptable salts and physiol. functional derivs., as suitable compds. for treatment and/or prevention of disturbances of fatty acid metabolism, impaired glucose utilization, and disturbances in which insulin resistance plays a role, for example. Intermediate (II) was prepared from Et 4-methyl-3-oxo-pentanoic acid, which was reacted with sodium nitrite in water to give Et 2-hydroxyimino-4-methyl-3-oxo-pentanoic acid, which was then reduced to the amine hydrochloride salt, reacted with 4-methylbenzoyl chloride, and the product cyclized to the substituted oxazole using phosphoroxochloride. The resulting intermediate was reduced to the 4-methanol derivative, which was iodinated to give II. Intermediate (III) was prepared from 6-oxabicyclo[3.2.1]octan-7-one by formation of the ring-opened Me ester diphenyl-methylsilyl ether derivative, which was coupled with H-L-Ala-OBu, and the product O-protected. Coupling of II and III gave title compds. Separation of the cis-cyclohexane isomers could be accomplished using HPLC techniques. Title compound (IV), prepared in the same fashion using H-L-Ala-OBu and III prepared from 3-oxabicyclo[3.3.1]nonane, had EC50 of 1.2 nM when tested in vitro against PPARα; similarly prepared I had EC50 99 nM.
 IT 752213-61-9P
 RL: BSU (Biological study, unclassified); PUR (Purification or recovery); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (preparation of amino acid derivs. as peroxisome proliferator activated receptor (ppar) modulators for the treatment of metabolic diseases)
 RN 752213-61-9 CAPLUS
 CN L-Valine, N-[[[3-[[[5-ethyl-2-(4-methylphenyl)-4-oxazolyl]methoxy]cyclohexyl]carbonyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



IT 752213-28-8P 752213-30-2P 752213-41-5P
 752214-13-4P 752214-14-5P 752214-21-4P


L7 ANSWER 51 OF 83 CAPLUS COPYRIGHT 2006 ACS ON STN (Continued)

Absolute stereochemistry.




RN 752214-14-5 CAPLUS
 CN L-Valine, N-[[3-[[[5-methyl-2-(3-(trifluoromethyl)phenyl)-4-oxazolyl]methoxy]methyl]cyclohexyl]carbonyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 752214-21-4 CAPLUS
 CN L-Valine, N-[[3-[[[5-ethyl-2-(4-(trifluoromethyl)phenyl)-4-oxazolyl]methoxy]methyl]cyclohexyl]carbonyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



IT 752213-21-1P 752213-59-5P
 RL: PEP (Physical, engineering or chemical process); PYP (Physical process); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); PROC (Process); USES (Uses)
 (preparation of amino acid derivs. as peroxisome proliferator activated receptor (ppar) modulators for the treatment of metabolic diseases)
 RN 752213-21-1 CAPLUS
 CN L-Valine, N-[[3-[[[5-methyl-2-(4-methylphenyl)-4-oxazolyl]methoxy]methyl]cyclohexyl]carbonyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L7 ANSWER 51 OF 83 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 752213-59-5 CAPLUS
CN L-Valine, N-[[3-[[5-ethyl-2-(4-methylphenyl)-4-oxazolyl]methoxy]cyclohexyl]carbonyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



IT 752213-23-3P 752213-25-5P
RL: PUR (Purification or recovery); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of amino acid derivs. as peroxisome proliferator activated receptor (ppar) modulators for the treatment of metabolic diseases)

RN 752213-23-3 CAPLUS
CN L-Valine, N-[[3-[[5-methyl-2-(4-methylphenyl)-4-oxazolyl]methoxy]cyclohexyl]carbonyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 752213-25-5 CAPLUS
CN L-Valine, N-[[3-[[5-methyl-2-(4-methylphenyl)-4-oxazolyl]methoxy]cyclohexyl]carbonyl]- (9CI) (CA INDEX NAME)


L7 ANSWER 51 OF 83 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)

Absolute stereochemistry.




RN 752213-29-9 CAPLUS
CN L-Phenylalanine, N-[[3-[[5-methyl-2-(4-methylphenyl)-4-oxazolyl]methoxy]cyclohexyl]carbonyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 752213-32-4 CAPLUS
CN D-Valine, N-[[3-[[5-methyl-2-(4-methylphenyl)-4-oxazolyl]methoxy]cyclohexyl]carbonyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 752213-38-0 CAPLUS
CN L-Valine, N-[[3-[[2-(3-methoxyphenyl)-5-methyl-4-oxazolyl]methoxy]cyclohexyl]carbonyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L7 ANSWER 51 OF 83 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)


Absolute stereochemistry.



IT 752213-20-0P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of amino acid derivs. as peroxisome proliferator activated receptor (ppar) modulators for the treatment of metabolic diseases)

RN 752213-20-0 CAPLUS
CN L-Valine, N-[[3-[[5-methyl-2-(4-methylphenyl)-4-oxazolyl]methoxy]methyl]cyclohexyl]carbonyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



IT 752213-26-6P 752213-29-9P 752213-32-4P
752213-38-0P 752213-40-4P 752213-43-7P
752213-45-9P 752213-47-1P 752213-49-3P
752213-51-7P 752213-53-9P 752213-55-1P
752213-57-3P 752213-63-1P 752213-65-3P
752213-79-9P 752213-83-5P 752213-87-9P
752214-10-1P 752214-11-2P 752214-15-6P
752214-16-7P 752214-17-8P 752214-18-9P
752214-20-3P
RL: SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of amino acid derivs. as peroxisome proliferator activated receptor (ppar) modulators for the treatment of metabolic diseases)


RN 752213-26-6 CAPLUS
CN L-Leucine, N-[[3-[[5-methyl-2-(4-methylphenyl)-4-oxazolyl]methoxy]cyclohexyl]carbonyl]- (9CI) (CA INDEX NAME)

L7 ANSWER 51 OF 83 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 752213-40-4 CAPLUS
CN L-Valine, N-[[3-[[2-(3-bromophenyl)-5-methyl-4-oxazolyl]methoxy]cyclohexyl]carbonyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 752213-43-7 CAPLUS
CN L-Valine, N-[[3-[[5-(1-methylethyl)-2-(4-methylphenyl)-4-oxazolyl]methoxy]cyclohexyl]carbonyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 752213-45-9 CAPLUS
CN L-Valine, N-[[3-[[2-(3-methoxyphenyl)-5-(1-methylethyl)-4-oxazolyl]methoxy]cyclohexyl]carbonyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



L7 ANSWER 51 OF 83 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)


RN 752213-47-1 CAPLUS
 CN L-Valine, N-[[3-[[2-(3-methoxyphenyl)-5-(trifluoromethyl)-4-oxazolyl]methoxy]cyclohexyl]carbonyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 752213-49-3 CAPLUS
 CN L-Valine, N-[[3-[[5-(trifluoromethyl)-2-[3-(trifluoromethyl)phenyl]-4-oxazolyl]methoxy]cyclohexyl]carbonyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 752213-51-7 CAPLUS
 CN L-Valine, N-[[3-[[2-(4-methylphenyl)-5-(trifluoromethyl)-4-oxazolyl]methoxy]cyclohexyl]carbonyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 752213-53-9 CAPLUS
 CN L-Valine, N-[[3-[[2-(4-methylphenyl)-5-phenyl-4-oxazolyl]methoxy]cyclohexyl]carbonyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L7 ANSWER 51 OF 83 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 752213-65-3 CAPLUS
 CN L-Valine, N-[[3-[[5-cyclohexyl-2-(4-methylphenyl)-4-oxazolyl]methoxy]cyclohexyl]carbonyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 752213-79-9 CAPLUS
 CN L-Valine, N-methyl-N-[[3-[[5-methyl-2-(4-methylphenyl)-4-oxazolyl]methoxy]cyclohexyl]carbonyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 752213-83-5 CAPLUS
 CN L-Valine, N-[[3-[[5-methyl-2-(4-methylphenyl)-4-oxazolyl]methoxy]cyclohexyl]carbonyl]-N-(phenylmethyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L7 ANSWER 51 OF 83 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 752213-55-1 CAPLUS
 CN L-Valine, N-[[3-[[2-(3-methoxyphenyl)-5-phenyl-4-oxazolyl]methoxy]cyclohexyl]carbonyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 752213-57-3 CAPLUS
 CN L-Valine, N-[[3-[[5-ethyl-2-(3-methoxyphenyl)-4-oxazolyl]methoxy]cyclohexyl]carbonyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 752213-63-1 CAPLUS
 CN L-Valine, N-[[3-[[5-cyclohexyl-2-(3-methoxyphenyl)-4-oxazolyl]methoxy]cyclohexyl]carbonyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L7 ANSWER 51 OF 83 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 752213-87-9 CAPLUS
 CN L-Valine, N-[[3-[[5-methyl-2-(4-methylphenyl)-4-oxazolyl]methoxy]cyclohexyl]carbonyl]-N-propyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 752214-10-1 CAPLUS
 CN L-Valine, N-[[3-[[5-methyl-2-(4-methylphenyl)-4-oxazolyl]methoxy]methyl]cyclohexyl]carbonyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 752214-11-2 CAPLUS
 CN L-Valine, N-[[3-[[2-(3,4-dimethylphenyl)-5-ethyl-4-oxazolyl]methoxy]methyl]cyclohexyl]carbonyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


10788996 11/26/06

L7 ANSWER 51 OF 83 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 752214-15-6 CAPLUS
 CN L-Valine, N-[[3-[[[5-ethyl-2-[4-(1-methylethyl)phenyl]-4-oxazoly]methoxymethyl]cyclohexyl]carbonyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 752214-16-7 CAPLUS
 CN L-Valine, N-[[3-[[[5-ethyl-2-(4-methylphenyl)-4-oxazoly]methoxymethyl]cyclohexyl]carbonyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 752214-17-8 CAPLUS
 CN L-Valine, N-[[3-[[[5-cyclohexyl-2-(3-methoxyphenyl)-4-oxazoly]methoxymethyl]cyclohexyl]carbonyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


L7 ANSWER 52 OF 83 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)

ACCESSION NUMBER: 2004:589248 CAPLUS
 DOCUMENT NUMBER: 141:140474
 TITLE: Triglyceride and triglyceride-like prodrugs of glycogen phosphorylase inhibiting compounds
 INVENTOR(S): Sher, Philip M.; Ellsworth, Bruce A.
 PATENT ASSIGNEE(S): Bristol-Myers Squibb Co., USA
 SOURCE: U.S. Pat. Appl. Publ., 43 pp.
 CODEN: USXXCO
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2004142938	A1	20040722	US 2003-712823	20031113
US 7098235	B2	20060829		

PRIORITY APPLN. INFO.: US 2002-426465P P 20021114


OTHER SOURCE(S): MARPAT 141:140474
 GI




I



= W1




= W2



= W3


AB Prodrugs of glycogen phosphorylase inhibiting compds. are provided, said prodrug compds., G(-O2CR')m(-OH)n(-O2C(CH2)pCH3)q [G = branched or straight C3-5-carbon chain and (-O2CR'), (-OH) and (-O2C(CH2)pCH3) are attached to any available carbon atom along G; m = 1-4; n = 0-3; p = 0-16; q = 0-3; where m + n + q = 3 or 4; and -O2CR' is a fragment of a compound I wherein W = W1, W2, W3; X = O, S, SO2, CHR5, CHRSO, CHR5S, CHR5SO2, CHR5CO, CH2CHR5; Y = bond, CHR6; Z = aryl, heteroaryl; R1 = H, alkyl, alkenyl; R2 = H, alkyl, aryl, arylalkyl, heteroarylalkyl, alkenyl; R3, R4 = H, halo, CF3, CN, alkyl, alkoxy; R5, R6 = H, alkyl, aryl, alkenyl, CN, CN4R9A (tetrazole), CO2R9A, CONR9AOR9B, CONR9AOR9B; A = CH, N; B = O, S; wherein R1, R2, R5, R6, R7, R8 = alkyl, aryl, alkenyl, arylalkyl, heteroarylalkyl, alkoxy, aryloxy and each may be substituted with 1-3 hydrogen bonding groups). Thus, 3-[(5-

L7 ANSWER 51 OF 83 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 752214-18-9 CAPLUS
 CN L-Valine, N-[[3-[[[2-(3-methoxyphenyl)-5-methyl-4-oxazoly]methoxymethyl]cyclohexyl]carbonyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 752214-20-3 CAPLUS
 CN L-Valine, N-[[3-[[[5-methyl-2-[4-(1-methylethyl)phenyl]-4-oxazoly]methoxymethyl]cyclohexyl]carbonyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 52 OF 83 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
 chloroindolecarbonyl)amino]-3,4-dihydrocarbostyryl I (R1 = R2 = H, W = 5-chloroindole, X = CH2, YZ = benzo) was prepd. from 3-amino-3,4-dihydrocarbostyryl via acylation with 5-chloroindolecarboxylic acid resin-bound 2,3,5,6-tetrafluorophenyl ester. Further provided are pharmaceutical compns. and methods for treating diabetes and related diseases employing compds. above, either alone or in combination with another therapeutic agent.
 IT 258345-41-4, CW-409544
 RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses) (companion therapeutic agent (antidiabetic); preparation of triglyceride and triglyceride-like prodrugs of glycogen phosphorylase inhibiting compds.)
 RN 258345-41-4 CAPLUS
 CN L-Tyrosine, N-[(12)-1-methyl-3-oxo-3-phenyl-1-propenyl]-O-[2-(5-methyl-2-phenyl-4-oxazoly]ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
 Double bond geometry as shown.



REFERENCE COUNT: 167 THERE ARE 167 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 53 OF 83 CAPLUS COPYRIGHT 2006 ACS ON STN
 ACCESSION NUMBER: 2004:53962 CAPLUS
 DOCUMENT NUMBER: 141:82335
 TITLE: Human glucagon-like-peptide-1 mimics and their antidiabetic effects
 INVENTOR(S): Natarajan, Seshia Iyer; Mapelli, Claudio; Bastos, Margarita M.; Bernatowicz, Michael; Lee, Ving; Ewing, William R.
 PATENT ASSIGNEE(S): USA
 SOURCE: U.S. Pat. Appl. Publ., 73 pp., Cont.-in-part of U.S. Ser. No. 273,975.
 CODEN: USXXCO
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 2
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2004127423	A1	20040701	US 2003-419399	20030421
US 2003195157	A1	20031016	US 2002-273975	20021018
WO 2004094461	A2	20041104	WO 2004-US12374	20040421
WO 2004094461	A3	20050915		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MY, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SV, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
 R: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 1615653	A2	20060118	EP 2004-760098	20040421
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK,				

HR
 PRIORITY APPLN. INFO.:
 US 2001-342015P P 20011018
 US 2002-273975 A2 20021018
 US 2003-419399 A 20030421
 WO 2004-US12374 W 20040421

AB The invention discloses human glucagon-like peptide-1 (GLP-1) peptide mimics that mimic the biol. activity of the native GLP-1 peptide and thus are useful for the treatment or prevention of diseases or disorders associated with GLP activity. Further, the invention provides novel, chemical modified peptides that not only stimulate insulin secretion in type II diabetics, but also produce other beneficial insulinotropic responses. These synthetic peptide GLP-1 mimics exhibit increased stability to proteolytic cleavage making them ideal therapeutic candidates for oral or parenteral administration.

L7 ANSWER 54 OF 83 CAPLUS COPYRIGHT 2006 ACS ON STN
 ACCESSION NUMBER: 2004:392331 CAPLUS
 DOCUMENT NUMBER: 140:406798
 TITLE: Preparation of benzoxepinopyridines as HMG-CoA reductase inhibitors
 INVENTOR(S): Robl, Jeffrey A.; Chen, Bang-chi; Sun, Chong-qing
 PATENT ASSIGNEE(S): Bristol-Myers Squibb Company, USA
 SOURCE: U.S. Pat. Appl. Publ., 44 pp., Cont.-in-part of U.S. Ser. No. 875,155, abandoned.
 CODEN: USXXCO
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 3
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2004092573	A1	20040513	US 2003-602752	20030624
US 6812345	B2	20041102		
US 2002013324	A1	20020131	US 2001-875155	20010606
PRIORITY APPLN. INFO.:			US 2000-211595P	P 20000615
			US 2001-875155	B2 20010606

OTHER SOURCE(S): MARPAT 140:406798
 GI


* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB Title compds. I [X = O, S, SO, SO₂, NR₇; Z = HOCHCH₂CH(OH)CH₂CO₂R₃, 4-hydroxy-2-oxopyran-6-yl, etc.; n = 0, 1; R₁, R₂ = alkyl, arylalkyl, cycloalkyl, alkenyl, cycloalkenyl, aryl, heteroaryl, cycloheteroalkyl; R₃ = H, alkyl, metal ion; R₄ = H, halo, CF₃, etc.; R₇ = H, alkyl, aryl, alkanoyl, aroyl, alkoxy-carbonyl, etc.; R₉, R₁₀ = H, alkyl], were prepared as HMG CoA reductase inhibitors active in inhibiting cholesterol biosynthesis, modulating blood serum lipids such as lowering LDL cholesterol and/or increasing HDL cholesterol, and treating hyperlipidemia, hypercholesterolemia, hypertriglyceridemia and atherosclerosis (no data). A multistep synthesis of II is reported.
 IT 258345-41-4, GW-409544
 RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (coadministered agents; preparation of benzoxepinopyridines as HMG-CoA reductase inhibitors for treatment of hyperlipidemia, hypercholesterolemia, hypertriglyceridemia, atherosclerosis, and other disorders)
 RN 258345-41-4 CAPLUS
 CN L-Tyrosine, N-[(12)-1-methyl-3-oxo-3-phenyl-1-propenyl]-O-[2-(5-methyl-2-phenyl-4-oxazolyl)ethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.
 Double bond geometry as shown.

L7 ANSWER 53 OF 83 CAPLUS COPYRIGHT 2006 ACS ON STN (Continued)
 IT 258345-41-4, GW-409544
 RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (human glucagon-like-peptide-1 mimics and their antidiabetic effects)
 RN 258345-41-4 CAPLUS
 CN L-Tyrosine, N-[(12)-1-methyl-3-oxo-3-phenyl-1-propenyl]-O-[2-(5-methyl-2-phenyl-4-oxazolyl)ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
 Double bond geometry as shown.



L7 ANSWER 54 OF 83 CAPLUS COPYRIGHT 2006 ACS ON STN (Continued)



REFERENCE COUNT: 16 THERE ARE 16 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE
 FORMAT


L7 ANSWER 55 OF 83 CAPLUS COPYRIGHT 2006 ACS on STN
 ACCESSION NUMBER: 2004:368874 CAPLUS
 DOCUMENT NUMBER: 140:357672
 TITLE: Preparation of glycinenitrile-based inhibitors of dipeptidyl peptidase IV
 INVENTOR(S): Magnin, David R.; Hamann, Lawrence G.
 PATENT ASSIGNEE(S): Bristol-Myers Squibb Company, USA
 SOURCE: PCT Int. Appl., 57 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004037181	A2	20040506	WO 2003-US33385	20031021
WO 2004037181	A3	20041021		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SV, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CP, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2003282983	A1	20040513	AU 2003-282983	20031021
US 2004259919	A1	20041233	US 2003-690173	20031021
US 6995180	B2	20060207		
EP 1553937	A2	20050720	EP 2003-774915	20031021
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
PRIORITY APPLN. INFO.: US 2002-420603P P 20021023				
WO 2003-US33385 W 20031021				

OTHER SOURCE(S): MARPAT 140:357672
 AB Glycinenitrile derivs. R₁NHCHR₁CONR₂CH(R₁)N [R₁ is H, alk(en)(yn)yl or (cyclo)alk(en)yl; R₂ is (un)substituted alk(en)(yn)yl, (cyclo)alk(en)yl or arylalk(en)(yn)yl; R₃ is group given for R₂ or cycloalkylalkyl, alkylthioalkyl, arylalkylthioalkyl, (hetero)aryl, heteroarylalkyl, cycloheteroalkyl or cycloheteroalkylalkyl, which may be substituted; R₄ is H or can combine with R₃ to form a 4- to 5-membered heterocyclic ring] were prepared for use in pharmaceutical compns. for the treatment of diabetes and related diseases. Thus, (S)-H₂NCH(Ad)CONeCH₂CH₂CO₂H was prepared by condensation of (S)-Boc-NHCH(Ad)CO₂H (Boc = tert-butoxycarbonyl) with EtNHCH₂CH₂CO₂H (syntheses given), followed by deprotection using trifluoroacetic acid.
 IT 258345-41-4, GW 409544
 RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses) (antidiabetic agent; preparation of glycinenitrile amino acid derivs.)

L7 ANSWER 56 OF 83 CAPLUS COPYRIGHT 2006 ACS on STN
 ACCESSION NUMBER: 2004:262735 CAPLUS
 DOCUMENT NUMBER: 140:417258
 TITLE: Molecular modeling study of species-selective peroxisome proliferator-activated receptor (PPAR) α agonist; possible mechanism(s) of human PPARα selectivity of an α-substituted phenylpropanoic acid derivative (KCL)
 AUTHOR(S): Uchiki, Hideharu; Miyachi, Hiroyuki
 CORPORATE SOURCE: Discovery Research Laboratories, Kyorin Pharmaceutical Co., Ltd., Tochigi, 329-0114, Japan
 SOURCE: Chemical & Pharmaceutical Bulletin (2004), 52(3), 365-367
 CODEN: CPBTAL; ISSN: 0009-2363
 PUBLISHER: Pharmaceutical Society of Japan
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 AB In order to investigate the reason why phenylpropanoic acid derivative (KCL), a potent, human peroxisome proliferator-activated receptor (PPAR) α-selective agonist, shows this selectivity, we analyzed the binding modes of KCL and a related compound to the ligand-binding domain of human PPARα and rat PPARα by means of computer-aided mol. modeling. We concluded that the characteristic specificity of KCL is due to a specific hydrophobic contact between the hydrophobic tail part (the 4-trifluoromethyl group) and the key amino acid Ile272 located on the helix three region of the human PPARα ligand binding domain. We propose a possible binding mode of KCL with the ligand-binding domain of human PPARα. This binding model should offer important insights for further structural design of subtype-selective PPARα agonists for the treatment of altered metabolic homeostasis, such as dyslipidemia, obesity, and diabetes.
 IT 258345-41-4, GW 409544
 RL: DMA (Drug mechanism of action); PAC (Pharmacological activity); BIOL (Biological study) (mol. modeling study of species-selective peroxisome proliferator-activated receptor (PPAR) α agonist and possible mechanism(s) of human PPARα selectivity of an α-substituted phenylpropanoic acid derivative (KCL))
 RN 258345-41-4 CAPLUS
 CN L-Tyrosine, N-[(1Z)-1-methyl-3-oxo-3-phenyl-1-propenyl]-O-[2-(5-methyl-2-phenyl-4-oxazolyl)ethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.
 Double bond geometry as shown.



REFERENCE COUNT: 17 THERE ARE 17 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RECORD.
 FORMAT

L7 ANSWER 55 OF 83 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
 RN 258345-41-4 CAPLUS
 CN L-Tyrosine, N-[(1Z)-1-methyl-3-oxo-3-phenyl-1-propenyl]-O-[2-(5-methyl-2-phenyl-4-oxazolyl)ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
 Double bond geometry as shown.



L7 ANSWER 56 OF 83 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)

L7 ANSWER 57 OF 83 CAPLUS COPYRIGHT 2006 ACS on STM
 ACCESSION NUMBER: 2004.145835 CAPLUS
 DOCUMENT NUMBER: 140.145835
 TITLE: Preparation of dibenzofused bicyclo[2.2.2]octane-derived amides as modulators of the glucocorticoid receptor
 INVENTOR(S): Vaccaro, Wayne; Yang, Bingwei Vera; Kim, Soong-hoon; Huynh, Tram; Tortolani, David R.; Leavitt, Kenneth J.;
 Li, Wenying; Doweyko, Arthur M.; Chen, Xiao-tao; Doweyko, Lidie
 PATENT ASSIGNEE(S): Bristol-Myers Squibb Company, USA; et al.
 SOURCE: PCT Int. Appl., 265 pp.
 CODEN: PIXX22
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004009017	A2	20040129	WO 2003-US22300	20030717
WO 2004009017	A3	20040708		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	GH, GM, KE, LS, MM, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BP, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
AU 2003251970	A1	20040209	AU 2003-251970	20030717
US 2004132758	A1	20040708	US 2003-621909	20030717
US 6995181	B2	20060207		
EP 1534273	A2	20050601	EP 2003-765638	20030717
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK			
JP 2006508042	T2	20060309	JP 2004-523482	20030717
NO 2005000074	A	20050309	NO 2005-74	20050106
US 2005171136	A1	20050804	US 2005-85347	20050321
PRIORITY APPLN. INFO.:			US 2002-396877P	P 20030718
			US 2003-621909	A1 20030717
			WO 2003-US22300	W 20030717

OTHER SOURCE(S): MARPAT 140:145835
 GI


L7 ANSWER 58 OF 83 CAPLUS COPYRIGHT 2006 ACS on STM
 ACCESSION NUMBER: 2004.111429 CAPLUS
 DOCUMENT NUMBER: 140.111429
 TITLE: Preparation of substituted heterocyclic derivatives useful as antidiabetic and antiobesity agents
 INVENTOR(S): Cheng, Peter T. W.; Chen, Sean; Devasthale, Pratik; Ding, Charles Z.; Herpin, Timothy F.; Wu, Shung; Zhang, Hao; Wang, Wei; Ye, Xiang-Yang
 PATENT ASSIGNEE(S): Bristol-Myers Squibb Company, USA
 SOURCE: PCT Int. Appl., 543 pp.
 CODEN: PIXX22
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004004665	A2	20040115	WO 2003-US22149	20030702
WO 2004004665	A3	20040325		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	GH, GM, KE, LS, MM, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BP, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
AU 2003259131	A1	20040123	AU 2003-259131	20030702
JP 2005536494	T2	20051202	JP 2004-520148	20030702
EP 1656368	A2	20060517	EP 2003-763485	20030702
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK			
US 2004063700	A1	20040401	US 2003-616365	20030708
NO 2005000077	A	20050203	NO 2005-77	20050106
PRIORITY APPLN. INFO.:			US 2002-394508P	P 20020709
			WO 2003-US22149	W 20030702

OTHER SOURCE(S): MARPAT 140:111429
 GI




L7 ANSWER 57 OF 83 CAPLUS COPYRIGHT 2006 ACS on STM (Continued)



AB Title compds. I [R-R4 = H, alk(en/yn)yl, alkoxy, aryl, etc.; Z = carboxamido, alkylamino, etc.] are prepared For instance, 2-amino-4,5-dimethylthiazole is coupled to the acid derived from the cycloaddn. of methacrylic acid and anthracene (CH3CN, EDCI, Et3N, HOAc,
 18 h) to give II. I are glucocorticoid receptor modulators which are useful in treating diseases requiring glucocorticoid receptor agonist or antagonist therapy such as obesity, diabetes, inflammatory and immune disorders.
 IT 258345-41-4, GW-409544
 RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (combination pharmaceutical; preparation of dibenzofused bicyclo[2.2.2]octane-derived amides as modulators of glucocorticoid receptor)
 RN 258345-41-4 CAPLUS
 CN L-Tyrosine, N-[(12)-1-methyl-3-oxo-3-phenyl-1-propenyl]-O-[2-(5-methyl-2-phenyl-4-oxazolyl)ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
 Double bond geometry as shown.




L7 ANSWER 58 OF 83 CAPLUS COPYRIGHT 2006 ACS on STM (Continued)
 AB The title compds. (I) [Z1 = (CH2)m, CO, Z2 = (CH2)p, CO; D = CH, CO, (CH2)x (where m = 0-3; p = 1, 2; q = 0-2); n = 0-2; Q = C, N; A = (CH2)x (where x = 1-5); A = (CH2)x1 (where x1 = 1-5) with an alkenyl bond or an alkynyl bond embedded anywhere in the chain; or A = -(CH2)x2-O-(CH2)x3- (where x2, x3 = 0 to 5, provided that at least one of x2 and x3 is other than 0); B = a bond or (CH2)x4 (where x4 = 1-5); X = CH, N; X2-X6 = C, N, O, or S and at least one of X2-X6 is C; R1 = H, alkyl; R2 = H, alkyl, alkoxy, halogen, (un)substituted amino; R2a, R2b, R2c = H, alkyl, alkoxy, halogen, (un)substituted amino, cyano; R3 = H, alkyl, arylalkyl, arylalkoxycarbonyl, alkylalkoxycarbonyl, alkylalkoxycarbonyl, alkenylalkoxycarbonyl, arylalkoxycarbonyl, aryl, heteroaryl, cycloheteroalkyl, etc.; E = CH, N; Z = (CH2)x5 (where x5 is 0, i.e. a single or a double bond, 1, 2), or Z is (CH2)x6 (where x6 = 2-5), where (CH2)x6 includes an alkenyl (C=C) bond embedded within the chain or Z = -(CH2)x7-O-(CH2)x8- (where x7, x8 = 0-4); (CH2)x9 to (CH2)x10, (CH2)m, (CH2)n, (CH2)p and (CH2)q may be optionally substituted; Y = CO2R4 (where R4 = H, alkyl, or a prodrug ester), or Y = a C-linked 1-tetrazole, a phosphonic acid of the structure P(O)(OR4a)R5 [where R4a = H, a prodrug ester; R5 = alkyl or aryl, or a phosphonic acid of the structure P(O)(OR4a)2] including all stereoisomers, prodrug esters, and pharmaceutically acceptable salts thereof are prepared These compds. e.g.
 cis-1-ethoxycarbonyl-4-[3-[2-(2-phenyl-5-methylloxazol-4-yl)ethoxyphenyl]pyrrolidin-3-yl]acetic acid and
 cis-1-[6-(trifluoromethyl)pyrimidin-2-yl]-4-[3-[2-(2-phenyl-5-methylloxazol-4-yl)ethoxyphenyl]pyrrolidin-3-carboxylic acid, modulate serum levels of blood glucose, triglyceride, insulin, and nonesterified fatty acid (NEFA) levels, and thus are particularly useful in the treatment of diabetes and obesity, especially Type 2 diabetes, as well as hyperglycemia, hyperinsulinemia, hyperlipidemia, obesity, atherosclerosis, and related diseases employing such substituted acid derivs. alone or in combination with another antidiabetic agent and/or a hypolipidemic agent and/or other therapeutic agents. Disclosed is a method for treating diabetes, especially Type 2 diabetes, and related diseases such as insulin resistance, hyperglycemia, hyperinsulinemia, elevated blood levels of fatty acids or glycerol, hyperlipidemia, obesity, hypertriglyceridemia, inflammation, Syndrome X, diabetic complications, dysmetabolic syndrome, atherosclerosis, and related diseases, which comprises administering to a patient in need of treatment a therapeutically effective amount of the compound I. Also disclosed is a method for treating early malignant lesions (such as ductal carcinoma in situ of the breast and lobular carcinoma in situ of the breast), premalignant lesions including fibroadenoma of the breast and prostatic intraepithelial neoplasia (PIN), liposarcomas and various other epithelial tumors (including breast, prostate, colon, ovarian, gastric and lung), irritable bowel syndrome, Crohn's disease, gastric ulceritis, and osteoporosis and proliferative diseases such as psoriasis, which comprises administering to a patient in need of treatment a therapeutically effective amount of the compound I.
 IT 258345-41-4, GW-409544
 RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (combination therapy; preparation of substituted heterocyclic derivs. as antidiabetic and antiobesity agents)

10788996 11/26/06

L7 ANSWER 58 OF 83 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
 RN 258345-41-4 CAPLUS
 CN L-Tyrosine, N-[(1Z)-1-methyl-3-oxo-3-phenyl-1-propenyl]-O-[2-(5-methyl-2-phenyl-4-oxazolyl)ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
 Double bond geometry as shown.




L7 ANSWER 59 OF 83 CAPLUS COPYRIGHT 2006 ACS on STN
 ACCESSION NUMBER: 2004:41224 CAPLUS
 DOCUMENT NUMBER: 140:111417
 TITLE: Preparation of substituted heterocyclic derivatives useful as antidiabetic and antiobesity agents
 INVENTOR(S): Cheng, Peter T. W.; Chen, Sean; Ding, Charles Z.; Herpin, Timothy F.
 PATENT ASSIGNEE(S): Bristol-Myers Squibb Company, USA
 SOURCE: PCT Int. Appl., 160 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004004655	A2	20040115	WO 2003-US21331	20030708
WO 2004004655	A3	20041014		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MY, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SV, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2490972	AA	20040115	CA 2003-2490972	20030708
AU 2003248861	A1	20040123	AU 2003-248861	20030708
US 2004063762	A1	20040401	US 2003-616283	20030708
US 6875782	B2	20050405		
EP 1531810	A2	20050525	EP 2003-763345	20030708
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
CN 1665500	A	20050907	CN 2003-816038	20030708
JP 2006501187	T2	20060112	JF 2004-520018	20030708
NO 2004005529	A	20050203	NO 2004-5529	20041217
US 2005119312	A1	20050602	US 2004-16183	20041217
PRIORITY APPLN. INFO.:				
			US 2002-394553P	P 20020709
			US 2003-616283	A3 20030708
			WO 2003-US21331	W 20030708

OTHER SOURCE(S): MARPAT 140:111417
 GI


L7 ANSWER 59 OF 83 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



AB Comps. having general structure (I) [Q = C, N; A = (un)substituted (CH2)x (where x = 1-5) with an alkenyl bond or an alkynyl bond embedded anywhere in the chain, or A = (un)substituted -(CH2)x3-O-(CH2)x3- (where x2, x3 = 0-5, provided that at least one of x2 and x3 is other than 0); B = a bond, (un)substituted (CH2)x4 (where x4 = 1-5); X = CH, N; X2-X6 = C, N, O, or S, provided that at least one of X2-X6 is N; and at least one of X2, X3, X4, X5 and X6 is C; R1 = H, alkyl; R2, R2a, R2b, R2c = H, alkyl, alkoxy, halogen, (un)substituted amino, cyano; R3 = H, alkyl, arylalkyl, arylalkoxycarbonyl, alkylalkoxycarbonyl, alkynylalkoxycarbonyl, alkenylalkoxycarbonyl, alkylcarbonyl, aryl, heteroaryl, cycloheteroalkyl, heteroarylcarbonyl, heteroarylheteroarylalkyl, alkylcarbonylamino, arylcarbonylamino, heteroarylcarbonylamino, alkoxyalkylamino, arylalkoxycarbonylamino, etc.; Y = CO2R (where R = H, alkyl, or a prodrug ester), or Y = a C-linked 1-tetrazole, a phosphonic acid of the structure P(O)(OR4a)R5 (where R4a = H, a prodrug ester; R5 = alkyl, aryl, or a phosphonic acid of the structure P(O)(OR4a)2)] including all stereoisomers thereof, prodrug esters thereof, and pharmaceutically acceptable salts thereof. These compts. such as N-[[4-[(1,2,3-triazol-4-yl)methoxy]benzyl][4-methoxyphenoxy]amino]acetic acid N-[[4-[[2-(1,2,3-triazol-4-yl)ethoxy]benzyl][4-methoxyphenoxy]amino]acetic acid, N-[[1-(4-(2- or 4-imidazolyl)methoxy)phenyl]isopentyl][4-methoxyphenoxy]amino]acetic acid, N-[[1-(4-(1,2,4-oxadiazol-3-yl)methoxy)phenyl]isopentyl][4-methoxyphenoxy]amino]acetic acid, N-[[4-[(1,2,4-oxadiazol-3-yl)methoxy]phenethyl]isobutoxy]amino]acetic acid derivs. modulate serum levels of blood glucose, triglyceride, insulin, and nonesterified fatty acid (NEFA) and thus are particularly useful in the treatment of diabetes and obesity, especially Type 2 diabetes, as well as hyperglycemia, hyperinsulinemia, hyperlipidemia, obesity, atherosclerosis, and related diseases.
 IT 258345-41-4, GW-409544
 RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses) (combination therapy; preparation of substituted heterocyclic derivs. as antidiabetic and antiobesity agents)
 RN 258345-41-4 CAPLUS
 CN L-Tyrosine, N-[(1Z)-1-methyl-3-oxo-3-phenyl-1-propenyl]-O-[2-(5-methyl-2-phenyl-4-oxazolyl)ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L7 ANSWER 59 OF 83 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
 Double bond geometry as shown.




10788996

11/26/06

L7 ANSWER 60 OF 83 CAPLUS COPYRIGHT 2006 ACS on STN
 ACCESSION NUMBER: 2004:3661 CAPLUS
 DOCUMENT NUMBER: 140:73181
 TITLE: Lactam glycogen phosphorylase inhibitors and their use
 INVENTOR(S): in disease treatment
 Sher, Philip; Wu, Gang; Stouch, Terry; Ellsworth, Bruce
 PATENT ASSIGNEE(S): Bristol-Myers Squibb Company, USA
 SOURCE: U.S. Pat. Appl. Publ., 51 pp.
 CODEN: USXXCO
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2004002495	A1	20040101	US 2003-440851	20030519
US 7057046	B2	20060606		
US 2006128687	A1	20060615	US 2006-352867	20060213
PRIORITY APPLN. INFO.:			US 2002-382002P	P 20020520
			US 2003-440851	A3 20030519

OTHER SOURCE(S): MARPAT 140:73181
 GI



AB Lactams I (W = bicyclic heteroaryl; X = O, S, SO₂, CHR₃, CHR₃O, CHR₃S, CHR₃SO₂, CHR₃CO, CH₂CHR₃; Y = bond, CHR₃; Z = aryl, heteroaryl; R₁ = H, alkyl, aryl, alkenyl; R₂ = H, alkyl, aryl, arylalkyl, heteroarylalkyl, alkenyl; R₃ = H, alkyl, aryl, alkenyl, CN, tetrazole derivative, CO₂R₄, CONR₄R₄, CONR₄OR₄; R₄ = H, alkyl, aryl, arylalkyl, heteroarylalkyl, etc.) which are glycogen phosphorylase inhibitors are disclosed. Further provided is a method for treating diabetes and related diseases employing a glycogen phosphorylase inhibiting amount of the above compound,

either alone or in combination with another therapeutic agent. Thus, the syntheses of 3-(5-chloroindole-2-carboxylamino)-5-methoxy-3,4-dihydrocarbostyryl and 3-(5-chloroindole-2-carboxylamino)-2,3,4,5-tetrahydro-1H-1-benzazepin-2-one, and numerous other related compounds, are described.

IT 258345-41-4, GW-409544
 RU: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (lactam glycogen phosphorylase inhibitors and)
 RN 258345-41-4 CAPLUS

L7 ANSWER 61 OF 83 CAPLUS COPYRIGHT 2006 ACS on STN
 ACCESSION NUMBER: 2003:737571 CAPLUS
 DOCUMENT NUMBER: 139:255357
 TITLE: Use of PPAR alpha agonists for the treatment of vascular and renal diseases
 INVENTOR(S): Zahradka, Peter; Taylor, Carla
 PATENT ASSIGNEE(S): Can.
 SOURCE: PCT Int. Appl., 33 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003075911	A1	20030918	WO 2003-CA335	20030311
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GW, GQ, GN, ML, MR, NE, SN, TD, TG				
CA 2481371	AA	20030918	CA 2003-2481371	20030311
AU 2003208238	A1	20030922	AU 2003-208238	20030311
US 2006052457	A1	20060309	US 2005-507495	20050817
PRIORITY APPLN. INFO.:			US 2002-362243P	P 20020311
			WO 2003-CA335	W 20030311

AB Activation of peroxisome proliferator activated receptor alpha (PPARα) by administration of therapeutic amounts of a PPARα agonist, WY-14643, inhibits the proliferation of vascular smooth muscle cells, hepatoma cells and human renal proximal tubule cells. WY-14643

may be applicable as a medicament for the treatment of proliferative vascular disease (atherosclerosis, hypertension), revascularization-induced injury (restenosis) and chronic renal failure.


IT 258345-41-4, GW-409544
 RU: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (PPARα agonist; PPARα agonists for treatment of vascular and renal diseases)
 RN 258345-41-4 CAPLUS

CN L-Tyrosine, N-[(1Z)-1-methyl-3-oxo-3-phenyl-1-propenyl]-O-[2-(5-methyl-2-phenyl-4-oxazolyl)ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
 Double bond geometry as shown.


L7 ANSWER 60 OF 83 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
 CN L-Tyrosine, N-[(1Z)-1-methyl-3-oxo-3-phenyl-1-propenyl]-O-[2-(5-methyl-2-phenyl-4-oxazolyl)ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
 Double bond geometry as shown.



REFERENCE COUNT: 174 THERE ARE 174 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 61 OF 83 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



REFERENCE COUNT: 14 THERE ARE 14 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT


10788996

11/26/06


L7 ANSWER 62 OF 83 CAPLUS COPYRIGHT 2006 ACS on STN
 ACCESSION NUMBER: 2003:65431 CAPLUS
 DOCUMENT NUMBER: 139:197489
 TITLE: Preparation of azolecarboxylic acids useful as antidiabetic and antiobesity agents
 INVENTOR(S): Cheng, Peter T.; Zhang, Hao; Hariharan, Narayanan
 PATENT ASSIGNEE(S): Bristol-Myers Squibb Company, USA
 SOURCE: U.S. Pat. Appl. Publ., 81 pp., Cont.-in-part of U.S. Ser. No. 153,454.
 CODEN: USXXCO
 Patent
 DOCUMENT TYPE: English
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 2
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2003158232	A1	20030821	US 2002-294525	20021114
US 6967212	B2	20051122		
US 2003092736	A1	2002-153454	US 2002-153454	20020522
US 2005124661	A1	20050609	US 2004-12810	20041215
PRIORITY APPLN. INFO.:			US 2001-294380P	P 20010530
			US 2002-153454	A2 20020522
			US 2002-294525	A3 20021114

OTHER SOURCE(S): MARPAT 139:197489
 GI



L7 ANSWER 62 OF 83 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
 AB Title compds. [I: m, n = 0-2; Q = C, H; A = (CH2)x, (CH2)x1, (CH2)x2, (CH2)x3; x = 1-5; x1 = 2-5; x2, x3 = 0-5; 21 of x2, x3 = 0; x1 = CH, N; X2, X3, X4, X5, X7 = C, N, O, S; in each of X1-X7, C may include CH; R1 = H, alkyl; R2 = H, alkyl, alkoxy, halo, (substituted) amino; R2a, R2b and R2c = H, alkyl, alkoxy, halo, (substituted) amino; R3, R3a = H, alkyl, arylalkyl, aryloxy, carbonyl, alkyloxy, carbonyl, alkynyloxy, carbonyl, alkenyloxy, carbonyl, aryl, carbonyl, etc.; Y = CO2R4, 1-tetrazolyl, P(O)(OR4a)R5, P(O)(OR4a)2; R4 = H, alkyl, prodrug ester; R4a = H, prodrug ester; R5 = alkyl, aryl; with proviso(s), were prepared as simultaneous inhibitors of peroxisome proliferator activated receptor-γ (PPARγ) and stimulators of peroxisome proliferator activated receptor-α (PPARα). Thus, title compound (II) (prepared starting from Meldrum's acid 3-methoxyphenylacetyl chloride) bound to human PPARα and to PPARγ ligand binding domains with IC50 = 69 nM.
 IT 258345-41-4, GW-409544
 RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses) (coadministration; preparation of azolecarboxylic acids useful as antidiabetic and antiobesity agents)
 RN 258345-41-4 CAPLUS
 CN L-Tyrosine, N-[(12)-1-methyl-3-oxo-3-phenyl-1-propenyl]-O-[2-(5-methyl-2-phenyl-4-oxazolyl)ethyl]- (9CI) (CA INDEX NAME)
 Absolute stereochemistry.
 Double bond geometry as shown.




REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE
 FORMAT


L7 ANSWER 63 OF 83 CAPLUS COPYRIGHT 2006 ACS on STN
 ACCESSION NUMBER: 2003:396869 CAPLUS
 DOCUMENT NUMBER: 138:401724
 TITLE: Preparation of carboxylic acid derivatives as peroxisome proliferator activated receptor regulators
 INVENTOR(S): Tajima, Hisao; Nakayama, Yoshisuke
 PATENT ASSIGNEE(S): Ono Pharmaceutical Co., Ltd., Japan
 SOURCE: PCT Int. Appl., 86 pp.
 CODEN: PIXXDX
 Patent
 DOCUMENT TYPE: Japanese
 LANGUAGE: Japanese
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003042194	A1	20030522	WO 2002-JP1729	20021111
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MY, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RN: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GH, GO, GW, ML, MR, NE, NG, TD, TG				
CA 2465861	AA	20030522	CA 2002-2465861	20021111
EP 1445256	A1	20040811	EP 2002-803104	20021111
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK				
BR 2002014049	A	20041013	BR 2002-14049	20021111
NZ 532812	A	20050225	NZ 2002-532812	20021111
HU 200402072	A2	20050228	HU 2004-2072	20021111
CN 1608056	A	20050420	CN 2002-826264	20021111
NO 2004001878	A	20040812	NO 2004-1878	20040507
ZA 2004003594	A	20041202	ZA 2004-3594	20040511
US 2004254370	A1	20041216	US 2004-495158	20040511
PRIORITY APPLN. INFO.:			JP 2001-346583	A 20011112
			WO 2002-JP1729	W 20021111


OTHER SOURCE(S): MARPAT 138:401724
 GI



L7 ANSWER 63 OF 83 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
 alkanyl; A = O, S; D = Q1, etc.; ring A1 = satd. heteroaryl; R6 = H, alkyl, etc.; m = 1-3 are prepd. I are useful in the treatment of diabetes, obesity, syndrome X, hypercholesterolemia, etc. The peroxisome proliferator activated receptor regulating activity of one compd. of this invention was demonstrated. Formulations are given.
 IT 530130-12-2P
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses) (preparation and bioeffect of carboxylic acid derivs. as peroxisome proliferator activated receptor regulators)
 RN 530130-12-2 CAPLUS
 CN Glycine, N-[(3-[2-[5-methyl-2-[4-(1,2,3-thiadiazol-4-yl)phenyl]-4-oxazolyl]ethoxy]phenyl)methyl]-N-2-propenyl- (9CI) (CA INDEX NAME)




IT 530129-62-5P 530129-63-6P 530129-64-7P
 530129-66-9P 530129-68-1P 530129-69-2P
 530129-74-9P 530129-76-1P
 RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses) (preparation of carboxylic acid derivs. as peroxisome proliferator activated receptor regulators)
 RN 530129-62-5 CAPLUS
 CN Glycine, N-[(3-[2-[2-(4-cyclohexylphenyl)-5-methyl-4-oxazolyl]ethoxy]phenyl)methyl]-N-2-propenyl-, ethyl ester (9CI) (CA INDEX NAME)




RN 530129-63-6 CAPLUS
 CN Glycine, N-[(3-[2-[2-(4-cyclohexylphenyl)-5-methyl-4-oxazolyl]ethoxy]phenyl)methyl]-N-2-propenyl-, ethyl ester (9CI) (CA INDEX NAME)

AB The title compds. I [X, Y = alkylene; Z = O, S; R1 - R4 = H, alkyl; R5 =


L7 ANSWER 63 OF 83 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 530129-64-7 CAPLUS
CN Glycine, N-[[3-[2-[5-methyl-2-[4-(tetrahydro-2H-pyran-4-yl)phenyl]-4-oxazolyloxy]phenyl]methyl]-N-2-propenyl-, ethyl ester (9CI) (CA INDEX NAME)




RN 530129-66-9 CAPLUS
CN Glycine, N-[[3-[2-[5-methyl-2-phenyl-4-oxazolyloxy]phenyl]methyl]-N-2-propenyl-, ethyl ester (9CI) (CA INDEX NAME)




RN 530129-68-1 CAPLUS
CN Glycine, N-[[3-[2-[4-(dimethylamino)phenyl]-5-methyl-4-oxazolyloxy]phenyl]methyl]-N-2-propenyl-, ethyl ester (9CI) (CA INDEX NAME)

L7 ANSWER 63 OF 83 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




IT 530129-81-8P 530129-83-0P 530129-85-2P
530129-88-5P 530129-89-6P 530129-91-0P
530129-92-1P 530129-93-2P 530129-99-8P
530130-00-8P 530130-03-1P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of carboxylic acid derivs. as peroxisome proliferator activated receptor regulators)
RN 530129-81-8 CAPLUS
CN Glycine, N-[[3-[2-[5-methyl-2-[4-(1,2,3-thiadiazol-4-yl)phenyl]-4-oxazolyloxy]phenyl]methyl]-N-2-propenyl-, sodium salt (9CI) (CA INDEX NAME)




● Na

RN 530129-83-0 CAPLUS
CN Glycine, N-[[3-[2-[2-(4-cyclohexylphenyl)-5-methyl-4-oxazolyloxy]phenyl]methyl]-N-2-propenyl-, sodium salt (9CI) (CA INDEX NAME)




RN 530129-85-2 CAPLUS


L7 ANSWER 63 OF 83 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 530129-69-2 CAPLUS
CN Alanine, 2-methyl-N-[[3-[2-[5-methyl-2-phenyl-4-oxazolyloxy]phenyl]methyl]-N-2-propenyl-, methyl ester (9CI) (CA INDEX NAME)




RN 530129-74-9 CAPLUS
CN Glycine, N-[[3-[2-[5-methyl-2-[4-(4-morpholinyl)phenyl]-4-oxazolyloxy]phenyl]methyl]-N-2-propenyl-, ethyl ester (9CI) (CA INDEX NAME)




RN 530129-76-1 CAPLUS
CN Glycine, N-[[4-[2-[5-methyl-2-phenyl-4-oxazolyloxy]phenyl]methyl]-N-2-propenyl-, ethyl ester (9CI) (CA INDEX NAME)


L7 ANSWER 63 OF 83 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
CN Glycine, N-[[3-[2-[5-methyl-2-[4-(tetrahydro-2H-pyran-4-yl)phenyl]-4-oxazolyloxy]phenyl]methyl]-N-2-propenyl-, sodium salt (9CI) (CA INDEX NAME)



RN 530129-88-5 CAPLUS
CN Glycine, N-[[3-[2-[5-methyl-2-phenyl-4-oxazolyloxy]phenyl]methyl]-N-2-propenyl-, sodium salt (9CI) (CA INDEX NAME)




RN 530129-89-6 CAPLUS
CN Glycine, N-[[3-[2-[5-methyl-2-phenyl-4-oxazolyloxy]phenyl]methyl]-N-2-propenyl-, sodium salt (9CI) (CA INDEX NAME)




● Na

RN 530129-91-0 CAPLUS
CN Glycine, N-[[3-[2-[2-(4-(dimethylamino)phenyl)-5-methyl-4-oxazolyloxy]phenyl]methyl]-N-2-propenyl-, sodium salt (9CI) (CA INDEX NAME)




10788996 11/26/06

L7 ANSWER 63 OF 83 CAPLUS COPYRIGHT 2006 ACS ON STN (Continued)
 RN 530129-92-1 CAPLUS
 CN Alanine, 2-methyl-N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-N-2-propenyl- (9CI) (CA INDEX NAME)




RN 530129-93-2 CAPLUS
 CN Alanine, 2-methyl-N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-N-2-propenyl-, sodium salt (9CI) (CA INDEX NAME)



• Na

RN 530129-99-8 CAPLUS
 CN Glycine, N-[[3-[2-(5-methyl-2-[4-(4-morpholinyl)phenyl]-4-oxazolyl)ethoxy]phenyl]methyl]-N-2-propenyl-, monohydrochloride (9CI) (CA INDEX NAME)



• HCl

RN 530130-00-8 CAPLUS


L7 ANSWER 64 OF 83 CAPLUS COPYRIGHT 2006 ACS ON STN

ACCESSION NUMBER: 2003:320036 CAPLUS
 DOCUMENT NUMBER: 138:138498
 TITLE: Preparation of human glucagon-like-peptide-1 mimics and their use in the treatment of diabetes and related conditions
 INVENTOR(S): Natarajan, Sesha I.; Bastos, Margarita M.; Bernatowicz, Michael S.; Mapelli, Claudio; Lee, Ving; Ewing, William R.
 PATENT ASSIGNEE(S): Bristol-Myers Squibb Company, USA
 SOURCE: PCT Int. Appl., 153 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 2
 PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003033671	A2	20030424	WO 2002-US33386	20021018
WO 2003033671	A3	20051229		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MY, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, T2, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2463908	AA	20030424	CA 2002-2463908	20021018
JP 2005514337	T2	20050519	JP 2003-536401	20021018
CN 1630709	A	20050642	CN 2002-820558	20021018
EP 1572892	A2	20050914	EP 2002-782185	20021018
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK				
BR 2002013377	A	20060523	BR 2002-13377	20021018
NO 2004001203	A	20040610	NO 2004-1203	20040323
ZA 2004002846	A	20050816	ZA 2004-2846	20040415
PRIORITY APPLN. INFO.:			US 2001-342015P	P 20011018
			WO 2002-US33386	W 20021018

OTHER SOURCE(S): MARPAT 138:138498
 AB The invention provides novel human glucagon-like peptide-1 (GLP-1) peptide mimics A-Xaa1-Xaa2-Xaa3-Xaa4-Xaa5-Xaa6-Xaa7-Xaa8-Xaa9-Y-Z-B [Xaa1-Xaa9 are naturally or non-naturally occurring amino acid residues; Y and Z are amino acid residues which may be substituted; A and B are optionally present; A is H, an amino acid or peptide containing approx. 1-15 amino acid residues, an R group [H, (cyclo)alkyl, cycloalkylalkyl, heterocyclyl, heterocycloalkyl, (hetero)aryl, arylalkyl, aryloxyalkyl, heteroarylalkyl, or heteroarylalkoxy], an RCO (amide) group, a carbamate group, a urea, a sulfonamido, or an aminosulfonyl group; B is OH, alkoxy, etc., an amino acid residue, or a peptide containing from 1-15 amino acid

L7 ANSWER 63 OF 83 CAPLUS COPYRIGHT 2006 ACS ON STN (Continued)
 CN Glycine, N-[[3-[2-(5-methyl-2-[4-(4-morpholinyl)phenyl]-4-oxazolyl)ethoxy]phenyl]methyl]-N-2-propenyl- (9CI) (CA INDEX NAME)




RN 530130-03-1 CAPLUS
 CN Glycine, N-[[3-[2-(5-methyl-2-[4-(4-morpholinyl)phenyl]-4-oxazolyl)ethoxy]phenyl]methyl]-N-2-propenyl- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 12 THERE ARE 12 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE REFORMAT

L7 ANSWER 64 OF 83 CAPLUS COPYRIGHT 2006 ACS ON STN (Continued)
 terminating at the C-terminus as a carboxamide, ester, carboxyl, or an amino alc.] that mimic the biol. activity of the native GLP-1 peptide and thus are useful for the treatment or prevention of diseases or disorders assocd. with GLP activity. These chem.-modified peptides stimulate insulin secretion in type II diabetics and produce other beneficial insulinotropic responses, while exhibiting increased stability to proteolytic cleavage making them ideal therapeutic candidates for oral or parenteral administration. A method of prepg. the polypeptides comprises replacing the message sequence of the polypeptide with a variant message sequence capable of inducing receptor mediated signal transduction. An example is claimed peptide H-ARGTPTSD-Bip(2-Et)-Bip(2-Me)-NH2 (Bip = biphenylalanine residue).
 IT 258345-41-4, GW-409544
 RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses) (preparation of human glucagon-like-peptide-1 mimics for use in treatment of diabetes and related conditions)
 RN 258345-41-4 CAPLUS
 CN L-Tyrosine, N-[[12]-1-methyl-3-oxo-3-phenyl-1-propenyl]-O-[2-(5-methyl-2-phenyl-4-oxazolyl)ethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.
 Double bond geometry as shown.



L7 ANSWER 65 OF 83 CAPLUS COPYRIGHT 2006 ACS on STN
 ACCESSION NUMBER: 2003:202655 CAPLUS
 DOCUMENT NUMBER: 138:221784
 TITLE: Preparation of O-pyrazole glucoside SGLT2 inhibitors as antidiabetic agents
 INVENTOR(S): Washburn, William N.
 PATENT ASSIGNEE(S): Bristol-Myers Squibb Company, USA
 SOURCE: PCT Int. Appl., 51 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003020737	A1	20030313	WO 2002-US28480	20020905
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MY, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
US 2003087843	A1	20030508	US 2002-235336	20020905
EP 1432720	A1	20040630	EP 2002-761586	20020905
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK				
PRIORITY APPLN. INFO.:			US 2001-317280P	P 20010905
			WO 2002-US28480	W 20020905

OTHER SOURCE(S): MARPAT 138:221784
 GI



I

L7 ANSWER 66 OF 83 CAPLUS COPYRIGHT 2006 ACS on STN
 ACCESSION NUMBER: 2003:173582 CAPLUS
 DOCUMENT NUMBER: 138:221586
 TITLE: Preparation of azoles as oral antidiabetic agents.
 INVENTOR(S): Biggs, Christopher Franklin; Bridges, Alexander James;
 Casimiro-Garcia, Augustin; Fakhoury, Stephen Alan;
 Lee, Helen Tsenwei; Reed, Jessica Elizabeth; Schaum, Robert Philipp; Schlosser, Kevin Matthew; Sexton, Karen Elaine; Zhou, Hairong
 PATENT ASSIGNEE(S): Warner Lambert Co., USA
 SOURCE: PCT Int. Appl., 333 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003018553	A1	20030306	WO 2002-1B2843	20020715
WO 2003018553	C1	20040408		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MY, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2458621	A1	20030306	CA 2002-2458621	20020715
EP 1423363	A1	20040602	EP 2002-745739	20020715
EP 1423363	B1	20060419		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK				
BR 2002012069	A	20040720	BR 2002-12069	20020715
EE 200400075	A	20040816	EE 2004-75	20020715
HU 200401620	A2	20041129	HU 2004-1620	20020715
CN 1558897	A	20041229	CN 2002-621635	20020715
JP 2005504778	T2	20050217	JP 2003-523217	20020715
EP 1577305	A1	20050921	EP 2005-104581	20020715
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK				
AT 323674	E	20060515	AT 2002-745739	20020715
US 2003171377	A1	20030911	US 2002-225716	20020822
ZA 2004000374	A	20050117	ZA 2004-374	20040119
BG 108597	A	20050331	BG 2004-108597	20040224
NO 2004000881	A	20040419	NO 2004-881	20040227
PRIORITY APPLN. INFO.:			US 2001-315728P	P 20010829
			US 2001-322123P	P 20010914
			US 2002-369788P	P 20020403
			EP 2002-745739	A3 20020715
			WO 2002-1B2843	W 20020715

L7 ANSWER 65 OF 83 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)

AB O-pyrazole glucosides I, wherein A is CH₂ or (CH₂)₂; R₁ is hydrogen, arylalkyl, alkenyl, or alkyl; R₂ is alkyl or perfluoroalkyl; and R₃ and R₄ are independently hydrogen, OH, alkoxy, O-aryl, OCH₂-aryl, alkyl, cycloalkyl, CF₃, -OCHF₂, -3,4-(OCH₂)₂, -OCF₃, halogen, -CN, carboxylate, -CO₂H, acyl, amide, sulfonamide, aryl, sulfide, sulfoxide; R₃ and R₄ together with the carbons to which they are attached form an annulated 5-, 6-, or 7-membered carbocycle or heterocycle which may contain 1-4 heteroatoms in the ring which are N, O, S, SO, and SO₂. Further provided are methods of using such compds. for the treatment of diabetes and related diseases, and to pharmaceutical compns. containing such compds.

Thus I (A = CH₂; R₁ = R₃ = R₄ = H; R₂ = Me) was prepared as an antidiabetic, antiobesity, antihypertensive, antiatherosclerotic, and lipid-lowering agent.
 IT 258345-41-4, GW 409544
 RI: BSU (Biological study, unclassified); BIOL (Biological study) (preparation of O-pyrazole glucoside SGLT2 inhibitors as antidiabetic agents)
 RN 258345-41-4 CAPLUS
 CN L-Tyrosine, N-[(1Z)-1-methyl-3-oxo-3-phenyl-1-propenyl]-O-[2-(5-methyl-2-phenyl-4-oxazolyl)ethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.
 Double bond geometry as shown.



REFERENCE COUNT: 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE
 FORMAT


L7 ANSWER 66 OF 83 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)

OTHER SOURCE(S): MARPAT 138:221586
 AB AXQVC(B) (D)ZE [A = (substituted) (fused) aryl, heteroaryl, cycloalkyl, haloalkyl, alkoxy; D = H, (substituted) arylamino, alkanoyl, PhCO, aryl, heteroaryl, cycloalkyl, heterocycloalkyl; E = COR₅; R₅ = alkyl, OH, alkoxy, amino, sulfonylamino, substituted heteroaryl, dioxothiazolyl, etc.; with provisos], were prepared. Thus, (S)-tyrosine Me ester, 2,5-dimethoxytetrahydrofuran, and NaOAc were heated in aqueous HOAc at 100° for 20 min. to give 35% pyrrolotyrosine Me ester. This was stirred with 2-(5-methyl-2-phenyloxazol-4-yl)ethanol, Ph3P, and di-Et azodicarboxylate in THF for 18 h to give 51% (S)-3-[4-[2-(5-methyl-2-phenyloxazol-4-yl)ethoxy]phenyl]-2-pyrrol-1-ylpropionate. The latter was stirred with LiOH in THF/H₂O to give 51% (S)-3-[4-[2-(5-methyl-2-phenyloxazol-4-yl)ethoxy]phenyl]-2-pyrrol-1-ylpropionic acid. In a 3T3-L1 adipocyte differentiation assay, title compds. at 5 μM showed 2-183% of the activity of BRL 49653 pos. control. A drug formulation is given.
 IT 501030-36-0P
 RI: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses) (claimed compound; preparation of azoles as oral antidiabetic agents)
 RN 501030-36-0 CAPLUS
 CN Benzeneacetic acid, α-[methyl[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]amino]-, methyl ester (9CI) (CA INDEX NAME)




IT 501029-25-0P 501029-26-1P 501029-27-2P
 RI: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses) (claimed compound; preparation of azoles as oral antidiabetic agents)
 RN 501029-25-0 CAPLUS
 CN Benzeneacetic acid, α-[[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]amino]- (9CI) (CA INDEX NAME)


L7 ANSWER 66 OF 83 CAPLUS COPYRIGHT 2006 ACS ON STN (Continued)



RN 501029-26-1 CAPLUS
 CN Benzeneacetic acid, α -[([4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl)amino]-, methyl ester (9CI) (CA INDEX NAME)



RN 501029-27-2 CAPLUS
 CN Benzeneacetic acid, α -[methyl([4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl)amino]- (9CI) (CA INDEX NAME)



IT 501031-82-9P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (preparation of azoles as oral antidiabetic agents)
 RN 501031-82-9 CAPLUS
 CN Benzeneacetic acid, α -[acetyl([4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl)amino]-, methyl ester (9CI) (CA INDEX NAME)

L7 ANSWER 67 OF 83 CAPLUS COPYRIGHT 2006 ACS ON STN

ACCESSION NUMBER: 2002:964190 CAPLUS
 DOCUMENT NUMBER: 138:39272
 TITLE: Preparation of 3-(oxazolylalkoxyphenyl)propionic acids

and analogs as modulators of peroxisome proliferator activated receptors for treatment of diabetes and related conditions

INVENTOR(S): Gosssett, Lynn Stacy; Green, Jonathan Edward; Henry, James Robert; Jones, Winton Dennis, Jr.; Matthews, Donald Paul; Shen, Quan Rong; Smith, Daryl Lynn; Vance, Jennifer Ann; Warshawsky, Alan M.


PATENT ASSIGNEE(S): Eli Lilly and Company, USA
 SOURCE: PCT Int. Appl., 438 pp.
 CODEN: PIXXD2

DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002100403	A1	20021219	WO 2002-US15143	20020524
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2448552	AA	20021219	CA 2002-2448552	20020524
NZ 529550	A	20031219	NZ 2002-529550	20020524
EP 1401434	A1	20040331	EP 2002-746380	20020524
EP 1401434	B1	20061115		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
BR 2002010167	A	20040406	BR 2002-10167	20020524
HU 200400268	A2	20040728	HU 2004-268	20020524
JP 200502600	T2	20050127	JP 2003-503224	20020524
CN 1578659	A	20050209	CN 2002-815453	20020524
US 2005075378	A1	200509407	US 2003-477405	20031112
ZA 200309059	A	20050810	ZA 2003-9059	20031120
PRIORITY APPLN. INFO:			US 2001-296701P	P 20010607
			WO 2002-US15143	W 20020524


OTHER SOURCE(S): MARPAT 138:39272
 GI

L7 ANSWER 66 OF 83 CAPLUS COPYRIGHT 2006 ACS ON STN (Continued)



REFERENCE COUNT: 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE
 FORMAT

L7 ANSWER 67 OF 83 CAPLUS COPYRIGHT 2006 ACS ON STN (Continued)



AB Title compds. I [wherein n = 2-5; V = a bond or O; X = CH2 or O; p = 0 or 1; m = 1-4; Y1 = (un)substituted (hetero)aryl; Y2 and Y3 = independently H, alkyl, or alkoxy; Y4 = (un)substituted alk(en/yn)ylaminoalkyl, carboxyalkyl, (thio)ureidoalkyl, carbamoylalkyl, aminoalkyl, alkoxyalkyl, alkylthioalkyl, or CN; R5 = H or alkyl; and pharmaceutically acceptable salts, solvates, hydrates, or stereoisomers thereof] were prepared as peroxisome proliferator activated receptor (PPAR) modulators

(no data). For example, 3-[2-(1,3-dioxo-1,3-dihydroisindolo-2-ylmethyl)-4-hydroxyphenyl]propionic acid tert-Bu ester was coupled with toluene-4-sulfonic acid 2-(5-methyl-2-phenyloxazol-4-yl)ethyl ester in the presence of Cs2CO3 in DMF. Deprotection of the amine using NaBH4 in isopropanol followed by conversion to the carbamate and deesterification gave II. I are useful for the treatment of Syndrome X, Type II diabetes, hyperglycemia, hyperlipidemia, obesity, coagulopathy, hypertension, arteriosclerosis, and other disorders related to Syndrome X,


as well as cardiovascular diseases (no data).
 IT 478545-03-8P, (S)-3-[2-[(Carboxyphenylmethyl)carbamoyl]-4-[2-(5-methyl-2-phenyloxazol-4-yl)ethoxy]phenyl]propionic acid
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(PPAR modulator; preparation of (oxazolylalkoxyphenyl)propionic acids and analogs as PPAR modulators for treatment of diabetes and related conditions)

RN 478545-03-8 CAPLUS
 CN Benzenepropanoic acid, 2-[[[(S)-carboxyphenylmethyl]amino]carbonyl]-4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]- (9CI) (CA INDEX NAME)

11/26/06

L7 ANSWER 67 OF 83 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
Absolute stereochemistry.



REFERENCE COUNT: 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS
FORMAT RECORD. ALL CITATIONS AVAILABLE IN THE RE


FORMAT

L7 ANSWER 68 OF 83 CAPLUS COPYRIGHT 2006 ACS ON STN
ACCESSION NUMBER: 2002:927185 CAPLUS
DOCUMENT NUMBER: 138:24716
TITLE: Preparation of azolecarboxylic acids useful as
antiidiabetic and antiobesity agents
INVENTOR(S): Cheng, Peter T.; Zhang, Hao; Hariharan, Narayanan
PATENT ASSIGNEE(S): Bristol-Myers Squibb Company, USA
SOURCE: PCT Int. Appl., 169 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002096358	A2	20021205	WO 2002-US16633	20020523
WO 2002096358	A3	20030327		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, EA, EC, EE, ES, FI, GB, GD, GE, GH, GM, GR, HU, IL, ID, IN, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW			
RW:	GH, GM, KE, LS, MM, MZ, SD, SI, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, QA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
CA 2449160	AA	20021205	CA 2002-2449160	20020523
EP 1390363	A3	20020325	EP 2002-739306	20020523
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR			
TR 200400650	T3	20040621	TR 2004-650	20020523
HU 200401504	A2	20041129	HU 2004-1504	20020523
JP 2004536070	T	20041202	JP 2002-592871	20020523
TW 235061	B1	20050701	TW 2002-91111100	20020524
PRIORITY APPLN. INFO.:			WO 2001-294380P	P 20010530
			WO 2002-US16633	W 20020523

OTHER SOURCE(S) : MARPAT 138:24716
GI

L7 ANSWER 68 OF 83 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)


[illegible]

R4a = H, prodrug ester; R5 = alkyl, aryl; with proviso(s), were prepared as simultaneous inhibitors of peroxisome proliferator activated receptor- γ (PPAR γ) and stimulators of peroxisome proliferator activated receptor- α (PPAR α). Thus, title compound (II) (prepared starting from Meldrum's acid 3-methoxyphenylacetyl chloride) bound to human PPAR α and to PPAR γ ligand binding domains with IC50 = 69


IT 258345-41-4, Gw-409544

LN	RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses) (coadministration; preparation of azolecarboxylic acids useful as antidiabetic and antiobesity agents)
RN	258345-41-4 CAPLUS
CN	L-Tyrosine, N-[(12Z)-1-methyl-3-oxo-3-phenyl-1-propenyl]-O-[2-(5-methyl-2- oxo-4-oxazolyloxy)ethyl]- (9CI) (CA INDEX NAME)

L7 ANSWER 68 OF 83 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
Absolute stereochemistry.
Double bond geometry as shown.



L7 ANSWER 70 OF 83 CAPLUS COPYRIGHT 2006 ACS ON STN (Continued)



AB The present invention relates to carboxylic acid substituted oxazole derivs. (shown as I; e.g.
 (S)-2-methoxy-3-(4-(2-(5-methyl-2-phenyloxazol-4-yl)ethoxy)benzo(b)thiophen-7-yl)propionic acid) wherein R1 to R7 are as defined below, and pharmaceutically acceptable salts and esters thereof. The compds. are useful for the treatment of diseases such as diabetes, non-insulin dependent diabetes mellitus, elevated blood pressure, increased lipid and cholesterol levels, atherosclerotic diseases or metabolic syndrome. In I: R1 = aryl or heteroaryl; R2, R3, R4 and R6 = H, hydroxy, lower-alkenyl, halogen, lower-alkyl or lower-alkoxy, wherein at least one of R2, R3, R4 and R6 is not H, or R3 and R4 are bonded to each other to form a ring together with the C atoms to which they are attached, and R3 and R4 together are -CH:CH-S-, -S-CH:CH-, -CH:CH-O-, -O-CH:CH-, -CH:CH-CH:CH-, -(CH2)3-S-, -O-(CH2)2-S- or -O-(CH2)2-S-O-; R5 is lower-alkoxy, lower-alkenyloxy, 2-benzoylanilino, NHCR8; CR9C(R10); R7, R8, R9 = H or lower-alkyl; R10 is aryl; n = 1-3; wherein the bond between the C atom C6 and the C atom Cb


is a single or double bond. About 160 example preps. are included. I exhibit IC50 values of 0.1 nM to 50 μM, preferably 1 nM to 10 μM, particularly 1-3500 nM, more preferred 1-500 nM, for PPARα and PPARγ. The compds. further exhibit EC50 values of 0.1 nM to 50 μM, preferably 1 nM to 10 μM, more preferably 1-3500 nM, particularly 1-500 nM, for PPARα and PPARγ.

IT 475480-37-6P, 3-[3-Methyl-4-[2-(5-methyl-2-phenyloxazol-4-yl)ethoxy]phenyl]-2-((Z)-1-methyl-3-oxo-3-phenyl-1-propenylamino)propionic acid
 RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
 (drug candidate; preparation of carboxylic acid substituted oxazole derivs. as PPAR-α and -γ activators for treatment of type II diabetes)

RN 475480-37-6 CAPLUS
 CN Tyrosine, 3-methyl-N-[(1Z)-1-methyl-3-oxo-3-phenyl-1-propenyl]-O-[2-(5-methyl-2-phenyl-4-oxazolyl)ethyl]- (9CI) (CA INDEX NAME)


Double bond geometry as shown.

L7 ANSWER 70 OF 83 CAPLUS COPYRIGHT 2006 ACS ON STN (Continued)
 Double bond geometry as shown.



REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE
 FORMAT


L7 ANSWER 70 OF 83 CAPLUS COPYRIGHT 2006 ACS ON STN (Continued)



IT 475481-75-5P, 3-[3-Methyl-4-[2-(5-methyl-2-phenyloxazol-4-yl)ethoxy]phenyl]-2-((Z)-1-methyl-3-oxo-3-phenyl-1-propenylamino)propionic acid calcium salt (2:1)
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (drug candidate; preparation of carboxylic acid substituted oxazole derivs. as PPAR-α and -γ activators for treatment of type II diabetes)

RN 475481-75-5 CAPLUS
 CN Tyrosine, 3-methyl-N-[(1Z)-1-methyl-3-oxo-3-phenyl-1-propenyl]-O-[2-(5-methyl-2-phenyl-4-oxazolyl)ethyl]-, calcium salt (2:1) (9CI) (CA INDEX NAME)

Double bond geometry as shown.



● 1/2 Ca



IT 475481-73-3P, 3-[3-Methyl-4-[2-(5-methyl-2-phenyloxazol-4-yl)ethoxy]phenyl]-2-((Z)-1-methyl-3-oxo-3-phenyl-1-propenylamino)propionic acid methyl ester
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (preparation of carboxylic acid substituted oxazole derivs. as PPAR-α and -γ activators for treatment of type II diabetes)

RN 475481-73-3 CAPLUS
 CN Tyrosine, 3-methyl-N-[(1Z)-1-methyl-3-oxo-3-phenyl-1-propenyl]-O-[2-(5-methyl-2-phenyl-4-oxazolyl)ethyl]-, methyl ester (9CI) (CA INDEX NAME)

L7 ANSWER 71 OF 83 CAPLUS COPYRIGHT 2006 ACS ON STN
 ACCESSION NUMBER: 2002:813924 CAPLUS
 DOCUMENT NUMBER: 137:311200
 TITLE: Preparation of 2,1-oxazoline and 1,2-pyrazoline-based inhibitors of dipeptidyl peptidase IV
 INVENTOR(S): Sulsky, Richard B.; Robl, Jeffrey A.
 PATENT ASSIGNEE(S): Bristol-Myers Squibb Company, USA
 SOURCE: PCT Int. Appl., 61 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002081128	A1	20021024	WO 2002-US10936	20020405
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MY, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW			
RM:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, T2, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
US 2002183367	A1	20021205	US 2002-107279	20020326
US 6573287	B2	20030603		
CA 2444465	AA	20021024	CA 2002-2444465	20020405
EP 1377288	A1	20040107	EP 2002-723791	20020405
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR			
JP 2004532220	T2	20041021	JP 2002-580932	20020405
HU 200401423	A2	20041129	HU 2004-1423	20020504
PRIORITY APPLN. INFO.:			US 2001-283438P	P 20010412
			WO 2002-US10936	W 20020405

OTHER SOURCE(S): MARPAT 137:311200
 GI



L7 ANSWER 71 OF 83 CAPLUS COPYRIGHT 2006 ACS ON STN (Continued)

AB The invention describes dipeptidyl peptidase IV (DP 4) inhibiting compds. I [n is 0 or 1; X is H or CN; Y is N, NH or O; Z is CH₂ when Y is O or


NH, with Y-Z forming a single bond, and Z is CH when Y is N, with Y-Z forming a double bond; R₁-R₄ = H, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkylalkyl, bicyclicalkyl, bicyclicalkylalkyl, alkylthioalkyl, arylalkylthioalkyl, cycloalkenyl, aryl, aralkyl, heteroaryl, heteroarylalkyl, cycloheteroalkyl or cycloheteroalkylalkyl, which may be substituted; R₁ may combine with R₃ or R₄ to form a ring (CR₅R₆)₂₋₆ or (CR₇R₈)₃₋₆, resp., where R₅-R₈ = H, OH, alkoxy, alkyl, aryl, etc.] and their pharmaceutically-acceptable salts or prodrug esters. A method is also provided for treating diabetes and related diseases, employing a DP 4 inhibitor I, optionally in combination with other therapeutic agents, including an antidiabetic, hypolipidemic, or anti-obesity agent. Thus, coupling of sultam-protected 1,2-pyrazoline-3-carboxamide with (S)-N-(tert-butoxycarbonyl)cyclohexylglycine (HOGAT, Et₃N, and EDAC in CH₂Cl₂), followed by sultam cleavage with methanolic ammonia, amide conversion to nitrile using imidazole, and deprotection, afforded II.TFA.

IT 258345-41-4, GW-409544

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses) (antidiabetic agent; preparation of oxazoline and pyrazoline-based inhibitors of dipeptidyl peptidase IV)

RN 258345-41-4 CAPLUS
CN L-Tyrosine, N-[(12)-1-methyl-3-oxo-3-phenyl-1-propenyl]-O-[2-(5-methyl-2-phenyl-4-oxazolyl)ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE

FORMAT


L7 ANSWER 72 OF 83 CAPLUS COPYRIGHT 2006 ACS ON STN

ACCESSION NUMBER: 2002-813874 CAPLUS
DOCUMENT NUMBER: 137.311199
TITLE: Amino acid complexes of C-aryl glucosides for treatment of diabetes
INVENTOR(S): Gougoutas, Jack Z.
PATENT ASSIGNEE(S): Bristol-Myers Squibb Company, USA
SOURCE: PCT Int. Appl., 80 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002083066	A2	20021024	WO 2002-US11066	20020408
WO 2002083066	A3	20030306		
W:	AB, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, HW, IL, IR, KE, MG, MN, MR, NE, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW			
CA 2444481	AA	20021024	CA 2002-244481	20020408
US 2003064935	A1	20030403	US 2002-117914	20020408
EP 6774112	B2	20040810		
EP 1385856	A2	20040204	EP 2002-723801	20020408
EP 1385856	B1	20060222		
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR			
JP 2004536047	T2	20041202	JP 2002-580871	20020408
AT 318272	E	20060315	AT 2002-723801	20020408
ES 2258141	T3	20060816	ES 2002-2723801	20020408
PRIORITY APPLN. INFO.:			US 2001-283097P	P 20010411
			WO 2002-US11066	W 20020408

OTHER SOURCE(S): MARPAT 137.311199
OI

L7 ANSWER 72 OF 83 CAPLUS COPYRIGHT 2006 ACS ON STN (Continued)



AB Crystalline complexes are obtained from 1:1 or 2:1 mixts. of either the (D) or (L) enantiomer of natural amino acids and compds. of formula I [R₁, R₂, R₃ = H, OH, ORS, alkyl, OCHF₂, OCF₃, SR_{5a}, halogen; R₄ = H, OH, ORS,

alkyl, cycloalkyl, CF₃, OCHF₂, OCF₃, halogen, CONR₆R_{6a}, CO₂R_{5c}, CO₂H, COR_{6b}, CH(OH)R_{6c}, CH(OR_{5d})R_{6d}, CN, NHCOR_{5e}, NHCOR_{5f}, NHCOR_{5g}, SR_{5h}, SO₂R_{5i}, or a five, six or seven membered heterocycle which may contain 1 to 4 heteroatoms (N, O, S, SO, and/or SO₂), or R₃ and R₄ together with the carbons to which they are attached form an annelated five, six or seven membered carbocycle or heterocycle which may contain 1 to 4 heteroatoms in the ring; R₅, R_{5a}-R_{5i} are independently alkyl; R₆, R_{6a}-R_{6d} are independently H, alkyl, aryl, alkylaryl or cycloalkyl, or NR₆R_{6a} form an annelated five, six or seven membered heterocycle which

may contain 1 to 4 heteroatoms in the ring]. A method is also provided for treating diabetes and related diseases employing an SGLT2 (sodium dependent glucose transporters found in the intestine and kidney) inhibiting amount of the above complex alone or in combination with

another antidiabetic agent or other therapeutic agent. Thus, I (R₁ = 4-Me, R₄ = 4-OCHF₂, R₂, R₃ = H) was prepared by a multistep procedure starting from o-toluic acid, anisole, 2,3,4,6-tetra-O-benzyl-β-D-glucolactone, and CHF₂Cl and treated with L-phenylalanine to form the crystalline 1:1 complex.


IT 258345-41-4, GW-409544

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses) (preparation of amino acid/C-aryl glucoside complexes for treatment of diabetes and related diseases)

RN 258345-41-4 CAPLUS

CN L-Tyrosine, N-[(12)-1-methyl-3-oxo-3-phenyl-1-propenyl]-O-[2-(5-methyl-2-phenyl-4-oxazolyl)ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



L7 ANSWER 73 OF 83 CAPLUS COPYRIGHT 2006 ACS ON STN

ACCESSION NUMBER: 2002:754366 CAPLUS

DOCUMENT NUMBER: 137:279197

TITLE: Preparation of five-membered heterocyclic alkanolic acid derivatives as remedies for diabetes and hyperlipidemia

INVENTOR(S): Momose, Yu; Maekawa, Tatsuoshi; Imoto, Hiroshi; Odaka, Hiroyuki; Kimura, Hiroyuki

PATENT ASSIGNEE(S): Takeda Chemical Industries, Ltd., Japan

SOURCE: PCT Int. Appl., 165 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: Japanese


FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002076959	A1	20021003	WO 2002-JP2741	20020322
W: AS, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TO				
JP 2002348281	A2	20021204	JP 2002-81621	20020322
EP 1394154	A1	20040303	EP 2002-705433	20020322
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
US 2004063775	A1	20040401	US 2003-472159	20030922
PRIORITY APPLN. INFO.:			JP 2001-85572	A 20010323
			WO 2002-JP2741	W 20020322

OTHER SOURCE(S): MARPAT 137:279197

Q1



AB The title compds. I [R1 represents an optionally substituted five-membered heterocyclic group; X represents a bond, etc.; Q represents a C1-20 divalent hydrocarbon group; Y represents a bond, etc.; Ring A represents an aromatic ring optionally having one to three substituents; Z represents (CH2)nZ1 (n is an integer of 0 to 8 and Z1 represents a bond, etc.), etc.;

L7 ANSWER 74 OF 83 CAPLUS COPYRIGHT 2006 ACS ON STN

ACCESSION NUMBER: 2002:736927 CAPLUS

DOCUMENT NUMBER: 137:247879

TITLE: Preparation of antidiabetic agents C-aryl glucoside as

INVENTOR(S): Ellsworth, Bruce; Washburn, William N.; Sher, Philip M.; Wu, Gang; Meng, Wei

PATENT ASSIGNEE(S): U.S. Pat. Appl. Publ., 17 pp., Cont.-in-part of U.S. 6,414,126.

SOURCE: CODEN: USXXCO

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 2

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2002137903	A1	20020926	US 2002-151436	20020520
US 6515117	B2	20030204		
US 6414126	B1	20020702	US 2000-679027	20001004
ZA 2002002604	A	20030703	ZA 2002-2604	20020403
CA 2486539	AA	20031204	CA 2003-2486539	20030515
WO 2003099836	A1	20031204	WO 2003-US15591	20030515
W: AS, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TO				
AU 2003237886	A1	20031212	AU 2003-237886	20030515
EP 1506211	A1	20050216	EP 2003-736643	20030515
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
BR 2003011323	A	20050315	BR 2003-11323	20030515
CN 1653075	A	20050810	CN 2003-811353	20030515
JP 200531588	T2	20051020	JP 2004-507493	20030515
NO 200404915	A	20041216	NO 2004-4915	20041111
ZA 2004009295	A	20060222	ZA 2004-9295	20041118
PRIORITY APPLN. INFO.:			US 1999-158773P	P 19991012
			US 2000-194615P	P 20000405
			US 2000-679027	A2 20001004
			US 2002-151436	A 20020520
			WO 2003-US15591	W 20030515

Q1

L7 ANSWER 73 OF 83 CAPLUS COPYRIGHT 2006 ACS ON STN (Continued)

ring B represents a five-membered heterocycle optionally having one to three substituents; W represents a C1-20 divalent satd. hydrocarbon group;

and R2 represents OH, etc.] are prepd. A process for prep. I is disclosed. Comps. of this invention at 0.01% in feed given to diabetic mice for 4 days caused 43% to 42% decrease of blood sugar. Formulations are given.


IT 464184-99-4P 464185-00-0P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation of five-membered heterocyclic alkanolic acid derivs. as remedies for diabetes and hyperlipidemia)


RN 464184-99-4 CAPLUS

CN Benzenepentanoic acid, γ-[[[4-[(5-methyl-2-phenyl-4-oxazolyl)methoxy]phenyl]acetyl]oxy]-δ-oxo-, methyl ester (9CI) (CA INDEX NAME)



RN 464185-00-0 CAPLUS


CN Benzenepentanoic acid, γ-[[[4-[(5-methyl-2-phenyl-4-oxazolyl)methoxy]phenyl]acetyl]amino]-δ-oxo-, methyl ester (9CI) (CA INDEX NAME)



REFERENCE COUNT: 88 THERE ARE 88 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE

FORMAT

L7 ANSWER 74 OF 83 CAPLUS COPYRIGHT 2006 ACS ON STN (Continued)



AB A SGLT2-inhibiting compound is provided having the formula I method is also

provided for treating diabetes and related diseases employing a SGLT2-inhibiting amount of the above compound alone or in combination

with

another antidiabetic agent or other therapeutic agent (no data). 1A pharmaceutical combination comprising a SGLT2 inhibitor compound and an antidiabetic agent other than a SGLT2 inhibitor, for treating the complications of diabetes, an antiobesity agent, an antihypertensive agent, an antiplatelet agent, an antiatherosclerotic agent, and/or a lipid-lowering agent (no data). A method for treating or delaying the progression or onset of diabetes, diabetic retinopathy, diabetic neuropathy, diabetic nephropathy, delayed wound healing, insulin resistance, hyperglycemia, hyperinsulinemia, elevated blood levels of fatty acids or glycerol, hyperlipidemia, obesity, hypertriglyceridemia, Syndrome X, diabetic complications, atherosclerosis or hypertension, or for increasing high-d. lipoprotein levels, which comprises administering to a mammalian species in need of treatment a therapeutically effective amount of a compd (no data).

IT 258345-41-4, GW 409544

RL: BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)


(preparation of antidiabetic agents C-aryl glucosides as human SGLT2 inhibitors)

RN 258345-41-4 CAPLUS

CN L-Tyrosine, N-[(12)-1-methyl-3-oxo-3-phenyl-1-propenyl]-O-[2-(5-methyl-2-phenyl-4-oxazolyl)ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry as shown.



10788996

11/26/06

L7 ANSWER 75 OF 83 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2002:540258 CAPLUS
DOCUMENT NUMBER: 137:109267
TITLE: Preparation of benzoxepinopyridines as HMG-CoA
reductase inhibitors
INVENTOR(S): Robt. Jeffrey A.; Chen, Bang-chi; Sun, Chong-qing
PATENT ASSIGNEE(S): USA
SOURCE: U.S. Pat. Appl. Publ., 42 pp., Cont.-in-part of U.S.
Ser. No. 875,155.
CODEN: USXXCO
Patent
English

DOCUMENT TYPE:
LANGUAGE:
FAMILY ACC. NUM. COUNT: 3
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2002094977	A1	20020718	US 2001-7407	20011204
US 6627636	B2	20030930		
US 2002013334	A1	20020131	US 2001-875155	20010606
PRIORITY APPLN. INFO.:			US 2000-211595P	P 20000615
			US 2001-875155	A2 20010606

OTHER SOURCE(S): MARPAT 137:109267
GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB Title compds. I [X = O, S, SO, SO₂, NR₇; Z = HOCHCH₂CH(OH)CH₂CO₂R₃, 4-hydroxy-2-oxopyran-6-yl, etc.; n = 0, 1; R₁, R₂ = alkyl, arylalkyl, cycloalkyl, alkenyl, cycloalkenyl, aryl, heteroaryl, cycloheteroalkyl; R₃ = H, alkyl, metal ion; R₄ = H, halo, CF₃, etc.; R₇ = H, alkyl, aryl, alkanoyl, aryl, alkoxycarbonyl, etc.; R₉, R₁₀ = H, alkyl], were prepared as

HMG CoA reductase inhibitors active in inhibiting cholesterol biosynthesis, modulating blood serum lipids such as lowering LDL cholesterol and/or increasing HDL cholesterol, and treating hyperlipidemia, hypercholesterolemia, hypertriglyceridemia, and atherosclerosis (no data). A multistep synthesis of II is reported.


IT 258345-41-4, GW 409544
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(coadministered agents; preparation of benzoxepinopyridines as HMG-CoA reductase inhibitors for treatment of hyperlipidemia, hypercholesterolemia, hypertriglyceridemia, atherosclerosis, and other disorders)

RN 258345-41-4 CAPLUS

CN L-Tyrosine, N-[(12)-1-methyl-3-oxo-3-phenyl-1-propenyl]-O-(2-(5-methyl-2-phenyl-4-oxazolyl)ethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.

L7 ANSWER 75 OF 83 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



L7 ANSWER 76 OF 83 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2002:504648 CAPLUS
DOCUMENT NUMBER: 137:83637
TITLE: Medicinal compositions containing diuretic and
insulin
INVENTOR(S): Takaoaka, Masaya; Arai, Kazuishi; Kanda, Shoichi
PATENT ASSIGNEE(S): Sankyo Company, Limited, Japan
SOURCE: PCT Int. Appl., 183 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002051441	A1	20020704	WO 2001-JP11296	20011221
W: AU, BR, CA, CN, CO, CZ, HU, ID, IL, IN, KR, MX, NO, NZ, PH, PL, RU, SG, SK, US, VN, ZA				
RM: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR				
JP 2002255854	A2	20020911	JP 2001-386861	20011220
EP 1354602	A1	20031022	EP 2001-271867	20011221
EP 1354602	B1	20061004		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI, CY, TR				
EP 1695716	A2	20060830	EP 2006-12545	20011221
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
AT 341343	E	20061015	AT 2001-271867	20011221
US 2004053974	A1	20040318	US 2003-606632	20030626
US 2005288339	A1	20051229	US 2005-165743	20050624
PRIORITY APPLN. INFO.:			JP 2000-394424	A 20001226

OTHER SOURCE(S): MARPAT 137:83637


AB Disclosed are medicinal compns. containing a diuretic and an insulin resistance-improving agent whereby side effects associating the administration of an insulin resistance-improving agent (for example, megalocardia, edema, body fluid retention, pleural effusion) can be prevented or treated. Oral administration of furosemide prevented increases of heart weight and blood plasma, and edema due to administration of 5-[4-(6-methoxy-1-methyl-1H-benzimidazol-2-ylmethoxy)benzyl]thiazolidine-2,4-dione hydrochloride.

IT 331741-94-7, BMS 298585
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(medicinal compns. containing diuretics and insulin resistance-improving agents)

RN 331741-94-7 CAPLUS

CN Glycine, N-[(4-methoxyphenoxy)carbonyl]-N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- (9CI) (CA INDEX NAME)

L7 ANSWER 76 OF 83 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



REFERENCE COUNT: 22 THERE ARE 22 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE
FORMAT

4-oxazoly]ethoxy]phenyl]methyl]- 331739-93-6P, Glycine,
N-[(3-[2-(5-methyl-2-phenyl-4-oxazoly]ethoxy]phenyl]methyl]-N-[(4-
phenyl)methoxy]phenyl]methyl]- 331739-94-7P, Glycine,
N-[(4-[(1,1-dimethylethyl)-2-thiazoly]phenyl]methyl]-N-[(3-[2-(5-methyl-
2-phenyl-4-oxazoly]ethoxy]phenyl]methyl]- 331739-95-8P, Glycine,
N-[(3-[2-(5-methyl-2-phenyl-4-oxazoly]ethoxy]phenyl]methyl]-N-
[(3-phenoxy-2-thienyl)methyl]- 331739-96-9P, Glycine,
N-(22)-3-(2-furanyl)-2-propenyl]-N-[(3-[2-(5-methyl-2-phenyl-4-
oxazoly]ethoxy]phenyl]methyl]- 331739-97-0P, Glycine,
N-[(4-(fluorophenyl)methyl)-N-[(3-[2-(5-methyl-2-phenyl-4-
oxazoly]ethoxy]phenyl]methyl]- 331739-98-1P, Glycine,
N-[(2-[(4-chlorophenyl)thio]phenyl]methyl]-N-[(3-[2-(5-methyl-2-phenyl-4-
oxazoly]ethoxy]phenyl]methyl]- 331739-99-2P, Glycine,
N-[(3-[3,5-dimethoxyphenoxy]phenyl]methyl]-N-[(3-[2-(5-methyl-2-phenyl-4-
oxazoly]ethoxy]phenyl]methyl]- 331740-00-2P, Glycine,
N-[(3-[2-(5-methyl-2-phenyl-4-oxazoly]ethoxy]phenyl]methyl]-N-(1-
naphthalenyl)- 331740-01-3P, Glycine,
phenyl-4-oxazoly]ethoxy]phenyl]methyl]-N-(2-naphthalenyl)- 331740-02-4P, Glycine,
N-(1H-indol-2-yl)methyl]-N-[(3-[2-(5-methyl-2-phenyl-4-oxazoly]ethoxy]phenyl]methyl]- 331740-03-5P, Glycine,
N-[(3-benzoyl-2,4-dichlorophenyl]methyl]-N-[(3-[2-(5-methyl-2-phenyl-4-oxazoly]ethoxy]phenyl]methyl]- 331740-04-6P, Glycine,
N-[(3-[2-(5-methyl-2-phenyl-4-oxazoly]ethoxy]phenyl]methyl]-N-[(5-[2-(trifluoromethyl)phenyl]methyl)-N-[(3-[2-(5-methyl-2-phenyl-4-oxazoly]ethoxy]phenyl]methyl]-N-[(3-[2-(5-methyl-2-phenyl-4-oxazoly]ethoxy]phenyl]methyl]-N-[(5-[3-nitrophenyl)-2-furanyl]methyl]- 331740-06-8P, Glycine,
N-[(5-[2-chloro-5-(trifluoromethyl)phenyl]-2-furanyl]methyl]-N-[(3-[2-(5-methyl-2-phenyl-4-oxazoly]ethoxy]phenyl]methyl]- 331740-07-9P, Glycine,
N-[(3-[2-(5-methyl-2-phenyl-4-oxazoly]ethoxy]phenyl]methyl]-N-[(3-[2-(5-methyl-2-phenyl-4-oxazoly]ethoxy]phenyl]methyl]-N-[(5-[2-(trifluoromethyl)phenyl]-2-furanyl]methyl)- 331740-08-0P, Glycine,
N-[(3-[2-(5-methyl-2-phenyl-4-oxazoly]ethoxy]phenyl]methyl]-N-[(5-[2-nitrophenyl)-2-furanyl]methyl]- 331740-09-1P, 1H-Pyrrole-2-carboxylic acid,
5-[(1-carboxymethyl)[3-(2-(5-methyl-2-phenyl-4-oxazoly]ethoxy]phenyl]methyl]amino]methyl]-4-ethyl-3-methyl-2-(phenylmethyl) ester 331740-10-4P, Glycine,
N-[(3-(4-bromophenyl)-2-furanyl]methyl]-N-[(3-[2-(5-methyl-2-phenyl-4-oxazoly]ethoxy]phenyl]methyl]- 331740-11-5P, Glycine,
N-[(5-[3-chlorophenyl]-2-furanyl]methyl]-N-[(3-[2-(5-methyl-2-phenyl-4-oxazoly]ethoxy]phenyl]methyl)- 331740-12-6P, Glycine,
N-[(5-[3,6-dioxolan-2-yl]-2-furanyl]methyl]-N-[(3-[2-(5-methyl-2-phenyl-4-oxazoly]ethoxy]phenyl]methyl)- 331740-13-7P, Glycine,
N-[(1-[3-chloro-5-(trifluoromethyl)-2-pyridyl]methyl)-2-indol-3-yl]methyl]-N-[(3-[2-(5-methyl-2-phenyl-4-oxazoly]ethoxy]phenyl]methyl)- 331740-14-8P, Glycine,
N-[(5-[2,4-dichlorophenyl]-2-furanyl]methyl]-N-[(3-[2-(5-methyl-2-phenyl-4-oxazoly]ethoxy]phenyl]methyl)- 331740-15-9P, Glycine,
N-[(4-(2,6-difluorobenzoyl)-1-methyl-1H-pyrrol-2-yl]methyl]-N-[(3-[2-(5-methyl-2-phenyl-4-oxazoly]ethoxy]phenyl]methyl)- 331740-16-0P, Glycine,
N-[(4-benzoyl-1-methyl-1H-pyrrol-2-yl]methyl)-N-[(3-[2-(5-methyl-2-phenyl-4-oxazoly]ethoxy]phenyl]methyl)- 331740-17-1P, Glycine,
N-[(2,2'-bithiophen-5-yl)methyl]-N-[(3-[2-(5-methyl-2-phenyl-4-oxazoly]ethoxy]phenyl]methyl)- 331740-18-2P, Glycine,
N-[(5-bromo-3,4-dimethylthieno[3,3-b]thien-2-yl]methyl)-N-[(3-[2-(5-methyl-2-phenyl-4-oxazoly]ethoxy]phenyl]methyl)- 331740-18-3P, Glycine,
N-[(5-bromo-3,4-dimethylthieno[3,3-b]thien-2-yl]methyl)-N-[(3-[2-(5-methyl-2-phenyl-4-oxazoly]ethoxy]phenyl]methyl)- 331740-18-4P, Glycine,
N-[(5-bromo-3,4-dimethylthieno[3,3-b]thien-2-yl]methyl)-N-[(3-[2-(5-methyl-2-phenyl-4-oxazoly]ethoxy]phenyl]methyl)- 331740-18-5P, Glycine,
N-[(5-bromo-3,4-dimethylthieno[3,3-b]thien-2-yl]methyl)-N-[(3-[2-(5-methyl-2-phenyl-4-oxazoly]ethoxy]phenyl]methyl)- 331740-18-6P, Glycine,
N-[(5-bromo-3,4-dimethylthieno[3,3-b]thien-2-yl]methyl)-N-[(3-[2-(5-methyl-2-phenyl-4-oxazoly]ethoxy]phenyl]methyl)- 331740-18-7P, Glycine,
N-[(5-bromo-3,4-dimethylthieno[3,3-b]thien-2-yl]methyl)-N-[(3-[2-(5-methyl-2-phenyl-4-oxazoly]ethoxy]phenyl]methyl)- 331740-18-8P, Glycine,
N-[(5-bromo-3,4-dimethylthieno[3,3-b]thien-2-yl]methyl)-N-[(3-[2-(5-methyl-2-phenyl-4-oxazoly]ethoxy]phenyl]methyl)- 331740-18-9P, Glycine,
N-[(5-bromo-3,4-dimethylthieno[3,3-b]thien-2-yl]methyl)-N-[(3-[2-(5-methyl-2-phenyl-4-oxazoly]ethoxy]phenyl]methyl)- 331740-19-0P, Glycine,
N-[(5-bromo-3,4-dimethylthieno[3,3-b]thien-2-yl]methyl)-N-[(3-[2-(5-methyl-2-phenyl-4-oxazoly]ethoxy]phenyl]methyl)- 331740-19-1P, Glycine,
N-[(5-bromo-3,4-dimethylthieno[3,3-b]thien-2-yl]methyl)-N-[(3-[2-(5-methyl-2-phenyl-4-oxazoly]ethoxy]phenyl]methyl)- 331740-19-2P, Glycine,
N-[(5-bromo-3,4-dimethylthieno[3,3-b]thien-2-yl]methyl)-N-[(3-[2-(5-methyl-2-phenyl-4-oxazoly]ethoxy]phenyl]methyl)- 331740-19-3P, Glycine,
N-[(5-bromo-3,4-dimethylthieno[3,3-b]thien-2-yl]methyl)-N-[(3-[2-(5-methyl-2-phenyl-4-oxazoly]ethoxy]phenyl]methyl)- 331740-19-4P, Glycine,
N-[(5-bromo-3,4-dimethylthieno[3,3-b]thien-2-yl]methyl)-N-[(3-[2-(5-methyl-2-phenyl-4-oxazoly]ethoxy]phenyl]methyl)- 331740-19-5P, Glycine,
N-[(5-bromo-3,4-dimethylthieno[3,3-b]thien-2-yl]methyl)-N-[(3-[2-(5-methyl-2-phenyl-4-oxazoly]ethoxy]phenyl]methyl)- 331740-19-6P, Glycine,
N-[(5-bromo-3,4-dimethylthieno[3,3-b]thien-2-yl]methyl)-N-[(3-[2-(5-methyl-2-phenyl-4-oxazoly]ethoxy]phenyl]methyl)- 331740-19-7P, Glycine,
N-[(5-bromo-3,4-dimethylthieno[3,3-b]thien-2-yl]methyl)-N-[(3-[2-(5-methyl-2-phenyl-4-oxazoly]ethoxy]phenyl]methyl)- 331740-19-8P, Glycine,
N-[(5-bromo-3,4-dimethylthieno[3,3-b]thien-2-yl]methyl)-N-[(3-[2-(5-methyl-2-phenyl-4-oxazoly]ethoxy]phenyl]methyl)- 331740-19-9P, Glycine,
N-[(5-bromo-3,4-dimethylthieno[3,3-b]thien-2-yl]methyl)-N-[(3-[2-(5-methyl-2-phenyl-4-oxazoly]ethoxy]phenyl]methyl)- 331740-20-0P, Glycine,
N-[(5-bromo-3,4-dimethylthieno[3,3-b]thien-2-yl]methyl)-N-[(3-[2-(5-methyl-2-phenyl-4-oxazoly]ethoxy]phenyl]methyl)- 331740-20-1P, Glycine,
N-[(5-bromo-3,4-dimethylthieno[3,3-b]thien-2-yl]methyl)-N-[(3-[2-(5-methyl-2-phenyl-4-oxazoly]ethoxy]phenyl]methyl)- 331740-20-2P, Glycine,
N-[(5-bromo-3,4-dimethylthieno[3,3-b]thien-2-yl]methyl)-N-[(3-[2-(5-methyl-2-phenyl-4-oxazoly]ethoxy]phenyl]methyl)- 331740-20-3P, Glycine,
N-[(5-bromo-3,4-dimethylthieno[3,3-b]thien-2-yl]methyl)-N-[(3-[2-(5-methyl-2-phenyl-4-oxazoly]ethoxy]phenyl]methyl)- 331740-20-4P, Glycine,
N-[(5-bromo-3,4-dimethylthieno[3,3-b]thien-2-yl]methyl)-N-[(3-[2-(5-methyl-2-phenyl-4-oxazoly]ethoxy]phenyl]methyl)- 331740-20-5P, Glycine,
N-[(5-bromo-3,4-dimethylthieno[3,3-b]thien-2-yl]methyl)-N-[(3-[2-(5-methyl-2-phenyl-4-oxazoly]ethoxy]phenyl]methyl)- 331740-20-6P, Glycine,
N-[(5-bromo-3,4-dimethylthieno[3,3-b]thien-2-yl]methyl)-N-[(3-[2-(5-methyl-2-phenyl-4-oxazoly]ethoxy]phenyl]methyl)- 331740-20-7P, Glycine,
N-[(5-bromo-3,4-dimethylthieno[3,3-b]thien-2-yl]methyl)-N-[(3-[2-(5-methyl-2-phenyl-4-oxazoly]ethoxy]phenyl]methyl)- 331740-20-8P, Glycine,
N-[(5-bromo-3,4-dimethylthieno[3,3-b]thien-2-yl]methyl)-N-[(3-[2-(5-methyl-2-phenyl-4-oxazoly]ethoxy

L7 ANSWER 77 OF 83 CAPLUS COPYRIGHT 2006 ACS ON STN (Continued)

Glycine, N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-N-[[5-(phenylethynyl)-2-thienyl]methyl]- 331740-90-6P, Glycine, N-[[4-(2,4-dichlorobenzoyl)-1-methyl-1H-pyrazol-2-yl]methyl]-N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- 331740-21-7P, Glycine.

N-[[1-(4-chlorophenyl)-1H-pyrazol-2-yl]methyl]-N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- 331740-22-8P, Glycine, N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-N-[[4-(phenylethynyl)-2-thienyl]methyl]- 331740-23-9P, Glycine.

N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-N-[[3-nitro-4-phenoxyphenyl]methyl]- 331740-24-0P, Glycine, N-[[3-methyl-4-phenoxyphenyl]methyl]-N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- 331740-25-1P, Glycine, N-[[3-chloro-4-phenoxyphenyl]methyl]-N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- 331740-26-2P, Glycine, N-[[2-chloro-4-phenoxyphenyl]methyl]-N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- 331740-27-3P, Glycine.

N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-N-[[4-nitro-3-phenoxyphenyl]methyl]- 331740-28-4P, Glycine.

N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-N-[[2-nitro-5-phenoxyphenyl]methyl]- 331740-29-5P, Glycine.

N-[[5-chloro-3-methyl-1-phenyl-1H-pyrazol-4-yl]methyl]-N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- 331740-30-6P, Glycine, N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-N-[[5-[1-methyl-5-(trifluoromethyl)-1H-pyrazol-3-yl]-2-thienyl]methyl]- 331740-31-9P, Glycine, N-[[6-methoxy-2-naphthalenyl]methyl]-N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- 331740-32-0P, Glycine, N-[[4-methoxy-1-naphthalenyl]methyl]-N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- 331740-33-1P, Glycine, N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-N-[[5-[2-nitro-4-(trifluoromethyl)phenyl]-2-furanyl]methyl]- 331740-34-2P, Glycine, N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-N-[[4-(2-pyridinyl)phenyl]methyl]- 331740-35-3P, Glycine, N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-N-[[2-(phenylmethyl)phenyl]methyl]- 331740-36-4P, Glycine, N-heptyl-N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- 331740-37-5P, Glycine, N-[[1,1'-biphenyl]-4-yl]methyl]-N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- 331740-38-6P, Glycine, N-[[2-hydroxyphenyl]methyl]-N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- 331740-39-7P, Glycine, N-[[5-(2-chlorophenyl)-2-furanyl]methyl]-N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- 331740-40-0P, Glycine, N-[[3,5-dimethoxyphenyl]methyl]-N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- 331740-41-1P, Glycine, N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-N-[[3-phenoxyphenyl]methyl]- 331740-42-2P, Glycine, N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-N-[[4-phenoxyphenyl]methyl]- 331740-43-3P, Glycine.

L7 ANSWER 77 OF 83 CAPLUS COPYRIGHT 2006 ACS ON STN (Continued)

oxazolyl)ethoxy]phenyl]methyl]-N-[[5-[2-nitro-4-(trifluoromethyl)phenyl]-2-furanyl]methyl]- 331740-34-2P, Glycine, N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-N-[[4-(2-pyridinyl)phenyl]methyl]- 331740-35-3P, Glycine, N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-N-[[2-(phenylmethyl)phenyl]methyl]- 331740-36-4P, Glycine, N-heptyl-N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- 331740-37-5P, Glycine, N-[[1,1'-biphenyl]-4-yl]methyl]-N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- 331740-38-6P, Glycine, N-[[2-hydroxyphenyl]methyl]-N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- 331740-39-7P, Glycine, N-[[5-(2-chlorophenyl)-2-furanyl]methyl]-N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- 331740-40-0P, Glycine, N-[[3,5-dimethoxyphenyl]methyl]-N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- 331740-41-1P, Glycine, N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-N-[[3-phenoxyphenyl]methyl]- 331740-42-2P, Glycine, N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-N-[[4-phenoxyphenyl]methyl]- 331740-43-3P, Glycine.

N-[[3,5'-dichloro(1,1'-biphenyl)-4-yl]methyl]-N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- 331740-72-8P, Glycine, N-[[3-methoxy(1,1'-biphenyl)-4-yl]methyl]-N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- 331740-73-9P, Glycine.

N-[[3,4'-difluoro(1,1'-biphenyl)-4-yl]methyl]-N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- 331740-74-0P, Glycine, N-[[3-fluoro(1,1'-biphenyl)-4-yl]methyl]-N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- 331740-75-1P, Glycine, N-[[4-(3-furanyl)phenyl]methyl]-N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- 331740-76-2P, Glycine, N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-N-[[4-(2-thienyl)phenyl]methyl]- 331740-77-3P, Glycine, N-[[3-methoxy-4-phenoxyphenyl]methyl]-N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- 331740-78-4P, Glycine.

N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-N-[[3-nitro-4-phenoxyphenyl]methyl]- 331740-79-5P, Glycine, N-[[3-methyl-4-phenoxyphenyl]methyl]-N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- 331740-80-6P, Glycine, N-[[3-chloro-4-phenoxyphenyl]methyl]-N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- 331740-81-9P, Glycine, N-[[2-methoxy-4-phenoxyphenyl]methyl]-N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- 331740-82-0P, Glycine, N-[[2-chloro-4-phenoxyphenyl]methyl]-N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- 331740-83-1P, Glycine.

N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-N-[[4-nitro-3-phenoxyphenyl]methyl]- 331740-84-2P, Glycine.

N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-N-[[2-nitro-5-phenoxyphenyl]methyl]- 331740-85-3P, Glycine, N-[[6-methoxy-2-naphthalenyl]methyl]-N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- 331740-86-4P, Glycine, N-[[4-methoxy-1-naphthalenyl]methyl]-N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- 331740-87-5P, Glycine, N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-N-[[4-(2-pyrimidinyl)phenyl]methyl]- 331740-88-6P, Glycine, N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-N-[[4-(5-pyrimidinyl)phenyl]methyl]- 331740-89-7P, Glycine, N-[[1H-indol-2-yl]methyl]-N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- 331740-90-0P, Glycine, N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-N-[[1R]-1-phenylethyl]- 331740-91-1P, D-Alanine, N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-N-[[4-phenoxyphenyl]methyl]- 331740-94-4P, D-Phenylalanine, N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-N-[[4-phenoxyphenyl]methyl]- 331740-95-5P, L-Phenylalanine, N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-N-[[4-phenoxyphenyl]methyl]- 331740-96-6P, D-Valine,

L7 ANSWER 77 OF 83 CAPLUS COPYRIGHT 2006 ACS ON STN (Continued)

N-[[3-(4-chlorophenoxy)phenyl]methyl]-N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- 331740-44-4P, Glycine, N-[[3-(3,5-dichlorophenoxy)phenyl]methyl]-N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- 331740-45-5P, Glycine, N-[[3-(4-methylphenoxy)phenyl]methyl]-N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- 331740-46-6P, Glycine.

N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-N-[[4-(1E)-2-phenylethenyl]phenyl]methyl]- 331740-47-7P, Glycine.

N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-N-[[4-(2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- 331740-48-8P, Glycine, N-[[3-benzoyl-2,4-dichlorophenyl]methyl]-N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- 331740-49-9P, Glycine, N-[[3-(4-(1,1-dimethylethyl)phenoxy)phenyl]methyl]-N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- 331740-50-2P, Glycine, N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-N-[[4-(phenylmethoxy)phenyl]methyl]- 331740-51-3P, Glycine.

N-[[4-[2-(1,1-dimethylethyl)-2-thiazolyl]phenyl]methyl]-N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- 331740-52-4P, Glycine, N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-N-[[2-phenoxyphenyl]methyl]- 331740-53-5P, Glycine, N-[[4-(3-methoxyphenoxy)phenyl]methyl]-N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- 331740-54-6P, Glycine, N-[[4-(4-bromophenoxy)phenyl]methyl]-N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- 331740-55-7P, Glycine, N-[[4-(4-chlorophenoxy)phenyl]methyl]-N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- 331740-56-8P, Glycine, N-[[4-(4-methylphenoxy)phenyl]methyl]-N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- 331740-57-9P, Glycine, N-[[4-(4-methoxyphenoxy)phenyl]methyl]-N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- 331740-58-0P, Glycine, N-[[4-(2-chlorophenoxy)phenyl]methyl]-N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- 331740-59-1P, Glycine, N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-N-[[4-(4-(trifluoromethyl)phenoxy)phenyl]methyl]- 331740-60-4P, Glycine, N-[[4-(3,5-dichlorophenoxy)phenyl]methyl]-N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- 331740-61-5P, Glycine, N-[[4-(4-fluorophenoxy)phenyl]methyl]-N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- 331740-62-6P, Glycine, N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-N-[[4-(3-thienyloxy)phenyl]methyl]- 331740-63-7P, Glycine, N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-N-[[4-(4-methylthio)phenoxy]phenyl]methyl]- 331740-64-8P, Glycine.


N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-N-[[3-phenoxy-2-thienyl]methyl]- 331740-65-9P, Glycine, N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-N-[[4-(3-(trifluoromethyl)phenoxy)phenyl]methyl]- 331740-66-0P, Glycine, N-[[4-(2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-N-[[4-(3-nitrophenoxy)phenyl]methyl]- 331740-67-1P, Glycine, N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-N-[[4-(phenylamino)phenyl]methyl]- 331740-68-2P, Glycine, N-[[4-(1H-imidazol-1-yl)phenyl]methyl]-N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-N-[[4-(3-phenyl-1-propenyl)oxy]carbonyl]- 331741-25-4P, Glycine,

N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-N-[[3-phenyl-

L7 ANSWER 77 OF 83 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)


2-propynyl)oxy)carbonyl]- 331741-26-5P, Glycine,
 N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-N-[[2-phenylethoxy)carbonyl]- 331741-27-6P, Glycine,
 N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-N-[[3-phenylpropoxy)carbonyl]- 331741-28-7P, Glycine,
 N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-N-[[[(22)-3-phenyl-2-propenyl]oxy]carbonyl]- 331741-29-8P, Glycine,
 N-[[4-fluoro-3-methylphenoxy)carbonyl]-N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- 331741-30-1P, Glycine,
 N-[[3-methoxyphenoxy)carbonyl]-N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- 331741-31-2P, Glycine,
 N-[[3,4-dimethoxyphenoxy)carbonyl]-N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- 331741-32-3P, Glycine,
 N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-N-[[3,4,5-trimethoxyphenoxy)carbonyl]- 331741-33-4P, Glycine,
 N-[[3-(3-methoxyphenyl)methoxy]carbonyl]-N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- 331741-34-5P, Glycine,
 N-[[4-methoxyphenyl)methoxy]carbonyl]-N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- 331741-35-6P, Glycine,
 N-[[1,3-benzodioxol-5-ylmethoxy]carbonyl]-N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- 331741-36-7P, Glycine,
 N-[[1,3-benzodioxol-5-ylxy]carbonyl]-N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- 331741-37-8P, Glycine,
 N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-N-[[4-(trifluoromethoxy)phenoxy]carbonyl]- 331741-38-9P, Glycine,
 N-[[4-methoxy-1-naphthalenyl]oxy]carbonyl]-N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- 331741-39-0P, Glycine,
 N-[[2,3-dimethoxyphenoxy)carbonyl]-N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- 331741-40-3P, Benzoic acid,
 4-[[[carboxymethyl] [3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]amino]carbonyl]oxy]-, 1-methyl ester 331741-41-4P, Glycine, N-[[4-bromo-3-methylphenoxy]carbonyl]-N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- 331741-42-5P, Glycine, N-[[4-(1,3-dithiolan-2-yl)phenoxy]carbonyl]-N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- 331741-43-6P, Glycine, N-[[4-chloro-3-methylphenoxy]carbonyl]-N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- 331741-44-7P, Glycine, N-[[4-fluorophenoxy]carbonyl]-N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- 331741-45-8P, Glycine, N-[[4-chlorophenoxy]carbonyl]-N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- 331741-46-9P, Glycine, N-[[4-bromophenoxy]carbonyl]-N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- 331741-47-0P, Glycine, N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-N-[[3-(trifluoromethoxy)phenoxy]carbonyl]- 331741-48-1P, Glycine, N-[[3-fluorophenoxy]carbonyl]-N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- 331741-49-2P, Glycine, N-[[3-chlorophenoxy]carbonyl]-N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- 331741-50-3P, Glycine, N-[[3-bromophenoxy]carbonyl]-N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- 331741-51-6P, Glycine, N-[[3-(acetyloxy)phenoxy]carbonyl]-N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- 331741-52-7P, Glycine, N-[[4-acetylphenoxy]carbonyl]-N-[[3-[2-(5-methyl-2-phenyl-4-

L7 ANSWER 77 OF 83 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 331739-68-5 CAPLUS
 CN Glycine,
 N,N-bis[4-(2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- (9CI) (CA INDEX NAME)


PAGE 1-A



PAGE 1-B



RN 331739-70-9 CAPLUS
 CN Glycine,
 N-[[4-(2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-N-2-propynyl]- (9CI) (CA INDEX NAME)



RN 331739-71-0 CAPLUS
 CN Glycine, N-2-benzoxazolyl-N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- (9CI) (CA INDEX NAME)


L7 ANSWER 77 OF 83 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)

oxazolyl)ethoxy]phenyl]methyl]- 331741-53-8P, Glycine,
 N-[[3-(acetylphenoxy)carbonyl]-N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- 331741-54-9P, Glycine,
 N-[[[(2,3-dihydro-3-oxo-6-benzofuranyl)oxy]carbonyl]-N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- 331741-55-0P, Glycine,
 N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-N-[[4-(1,2,3-thiadiazol-4-yl)phenoxy]carbonyl]- 331741-56-1P, Glycine,
 N-[[3-hydroxyphenoxy]carbonyl]-N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- 331741-57-2P, Glycine,
 N-[[3-methylphenoxy]carbonyl]-N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- 331741-58-3P, Glycine,
 N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-N-[[4,5-trimethylphenoxy]carbonyl]- 331741-59-4P, Glycine,
 N-[[4-ethoxyphenoxy]carbonyl]-N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- 331741-60-7P, Glycine,
 N-[[3-ethoxy-4-methoxyphenoxy]carbonyl]-N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- 331741-61-8P, Glycine,
 N-[[4-cyclopentylphenoxy]carbonyl]-N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- 331741-62-0P, Glycine,
 N-[[4-ethenylphenoxy]carbonyl]-N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- 331741-64-1P, Glycine,
 N-[[4-(3-methylbutyl)phenoxy]carbonyl]-N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- 331741-65-2P, Glycine,
 N-[[4-butylphenoxy]carbonyl]-N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- 331741-66-3P, Glycine,
 N-[[4-hexylphenoxy]carbonyl]-N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- 331741-67-4P, Glycine,
 N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-N-[[3-(4-morpholinyl)phenoxy]carbonyl]- 331741-68-5P, Glycine,


N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-N-[[[(5,6,7,8-tetrahydro-2-naphthalenyl)oxy]carbonyl]- 331741-69-6P, Glycine,
 N-[[3-(1,1-dimethylethyl)phenoxy]carbonyl]-N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- 331741-70-9P, Glycine,
 N-[[3-(1-methylethyl)phenoxy]carbonyl]-N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- 331741-71-0P, Glycine,
 N-[[3-(4-dimethylphenoxy)carbonyl]-N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- 331741-72-1P, Glycine,
 N-[[3-(5-dimethylphenoxy)carbonyl]-N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(prepn. of oxazolyl- and thiazolylalkoxybenzylglycines and related comds. as antidiabetic and antiobesity agents)
 RN 331739-67-4 CAPLUS
 CN Glycine, N-[[4-(2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-N-(phenylmethyl)- (9CI) (CA INDEX NAME)


L7 ANSWER 77 OF 83 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 331739-72-1 CAPLUS
 CN Glycine, N-2-benzoxazolyl-N-[[4-(2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- (9CI) (CA INDEX NAME)



RN 331739-73-2 CAPLUS
 CN Glycine, N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-N-[[4-phenoxyphenyl]methyl]- (9CI) (CA INDEX NAME)




RN 331739-74-3 CAPLUS
 CN Glycine,
 N-[[4-(2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-N-(2-naphthalenylmethyl)- (9CI) (CA INDEX NAME)




RN 331739-75-4 CAPLUS
 CN Glycine,
 N-[[3-(4-chlorophenoxy)phenyl]methyl]-N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- (9CI) (CA INDEX NAME)


L7 ANSWER 77 OF 83 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 331739-76-5 CAPLUS
CN Glycine, N-([5-(4-chlorophenyl)-2-furanyl]methyl)-N-([3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl)- (9CI) (CA INDEX NAME)



RN 331739-77-6 CAPLUS
CN Glycine, N-([4-(3-fluorophenoxy)phenyl]methyl)-N-([3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl)- (9CI) (CA INDEX NAME)




RN 331739-78-7 CAPLUS
CN Glycine, N-([4-(3-methylphenoxy)phenyl]methyl)-N-([3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl)- (9CI) (CA INDEX NAME)




RN 331739-79-8 CAPLUS

L7 ANSWER 77 OF 83 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)


RN 331739-83-4 CAPLUS
CN Glycine, N-([3-(3,4-dichlorophenoxy)phenyl]methyl)-N-([3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl)- (9CI) (CA INDEX NAME)




RN 331739-84-5 CAPLUS
CN Glycine, N-([3-(2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl)-N-([3-(2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl)- (9CI) (CA INDEX NAME)



RN 331739-85-6 CAPLUS
CN Glycine, N-([1,1'-biphenyl]-4-ylmethyl)-N-([3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl)- (9CI) (CA INDEX NAME)




RN 331739-86-7 CAPLUS
CN Glycine, N-([5-(2-chlorophenyl)-2-furanyl]methyl)-N-([3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl)- (9CI) (CA INDEX NAME)




RN 331739-87-8 CAPLUS
CN Glycine, N-([3-(2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl)-N-([3-(2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl)- (9CI) (CA INDEX NAME)

L7 ANSWER 77 OF 83 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)


CN Glycine, N-([4-(2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl)-N-([4-(3-pyridinyl)phenyl]methyl)- (9CI) (CA INDEX NAME)




RN 331739-80-1 CAPLUS
CN Glycine, N-([3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl)-N-([3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl)- (9CI) (CA INDEX NAME)



RN 331739-81-2 CAPLUS
CN Glycine, N-([3-(2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl)-N-([3-(2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl)- (9CI) (CA INDEX NAME)




RN 331739-82-3 CAPLUS
CN Glycine, N-([3-(2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl)-N-([3-(2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl)- (9CI) (CA INDEX NAME)



L7 ANSWER 77 OF 83 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)


PAGE 1-A



PAGE 1-B


CF₃

RN 331739-88-9 CAPLUS
CN Glycine, N-([3-(4-methylphenoxy)phenyl]methyl)-N-([3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl)- (9CI) (CA INDEX NAME)



RN 331739-89-0 CAPLUS
CN Glycine, N-([3-(4-methoxyphenoxy)phenyl]methyl)-N-([3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl)- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 1-B

OMe


RN 331739-90-3 CAPLUS
CN Glycine, N-([3-(2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl)-N-([3-(2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl)- (9CI) (CA INDEX NAME)

L7 ANSWER 77 OF 83 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)

Double bond geometry as shown.




RN 331739-91-4 CAPLUS
CN Glycine, N-[[4-[(2-chloro-6-fluorophenyl)methoxy]phenyl]methyl]-N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- (9CI) (CA INDEX NAME)



RN 331739-92-5 CAPLUS
CN Glycine, N-[[3-(2,7-dimethyl-2,6-octadienyl)-N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- (9CI) (CA INDEX NAME)


Double bond geometry as shown.




RN 331739-93-6 CAPLUS
CN Glycine, N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-N-[[4-(phenylmethoxy)phenyl]methyl]- (9CI) (CA INDEX NAME)

L7 ANSWER 77 OF 83 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)


oxazolyl]ethoxy]phenyl]methyl]- (9CI) (CA INDEX NAME)



RN 331739-98-1 CAPLUS
CN Glycine, N-[[2-[(4-chlorophenyl)thio]phenyl]methyl]-N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- (9CI) (CA INDEX NAME)




RN 331739-99-2 CAPLUS
CN Glycine, N-[[3-(3,5-dimethoxyphenoxy)phenyl]methyl]-N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- (9CI) (CA INDEX NAME)




RN 331740-00-2 CAPLUS
CN Glycine, N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-N-[[1-naphthalenyl]methyl]- (9CI) (CA INDEX NAME)


L7 ANSWER 77 OF 83 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 331739-94-7 CAPLUS
CN Glycine, N-[[4-[1,1-dimethylethyl]-2-thiazolyl]phenyl]methyl]-N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- (9CI) (CA INDEX NAME)




RN 331739-95-8 CAPLUS
CN Glycine, N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-N-[[3-phenoxy-2-thienyl]methyl]- (9CI) (CA INDEX NAME)




RN 331739-96-9 CAPLUS
CN Glycine, N-[(2Z)-3-(2-furanyl)-2-propenyl]-N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 331739-97-0 CAPLUS
CN Glycine, N-[(4-fluorophenyl)methyl]-N-[[3-[2-(5-methyl-2-phenyl-4-


L7 ANSWER 77 OF 83 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 331740-01-3 CAPLUS
CN Glycine, N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-N-[[2-naphthalenyl]methyl]- (9CI) (CA INDEX NAME)




RN 331740-02-4 CAPLUS
CN Glycine, N-[(1H-indol-2-yl)methyl]-N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- (9CI) (CA INDEX NAME)




RN 331740-03-5 CAPLUS
CN Glycine, N-[(3-benzoyl-2,4-dichlorophenyl)methyl]-N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- (9CI) (CA INDEX NAME)


L7 ANSWER 77 OF 83 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 331740-04-6 CAPLUS
CN Glycine, N-([3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl)-N-([5-[2-(trifluoromethyl)phenyl]-2-furanyl]methyl)- (9CI) (CA INDEX NAME)



RN 331740-05-7 CAPLUS
CN Glycine, N-([3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl)-N-([5-[2-(nitrophenyl)-2-furanyl]methyl]- (9CI) (CA INDEX NAME)




RN 331740-06-8 CAPLUS
CN Glycine, N-([3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl)-N-([3-[2-(2-chloro-5-(trifluoromethyl)phenyl)-2-furanyl]methyl]- (9CI) (CA INDEX NAME)




RN 331740-07-9 CAPLUS

L7 ANSWER 77 OF 83 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)


RN 331740-11-5 CAPLUS
CN Glycine, N-([5-[3-chlorophenyl]-2-furanyl]methyl)-N-([3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl)- (9CI) (CA INDEX NAME)



RN 331740-12-6 CAPLUS
CN Glycine, N-([5-[1,3-dioxolan-2-yl]-2-furanyl]methyl)-N-([3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl)- (9CI) (CA INDEX NAME)




RN 331740-13-7 CAPLUS
CN Glycine, N-([1-[3-chloro-5-(trifluoromethyl)-2-pyridinyl]-1H-indol-3-yl]methyl)-N-([3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl)- (9CI) (CA INDEX NAME)




RN 331740-14-8 CAPLUS
CN Glycine, N-([5-[2,4-dichlorophenyl]-2-furanyl]methyl)-N-([3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl)- (9CI) (CA INDEX NAME)


L7 ANSWER 77 OF 83 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
CN Glycine, N-([3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl)-N-([5-[3-(trifluoromethyl)phenyl]-2-furanyl]methyl)- (9CI) (CA INDEX NAME)




RN 331740-08-0 CAPLUS
CN Glycine, N-([3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl)-N-([5-[2-(nitrophenyl)-2-furanyl]methyl]- (9CI) (CA INDEX NAME)




RN 331740-09-1 CAPLUS
CN 1H-Pyrrole-2-carboxylic acid, 5-[[[carboxymethyl][3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]amino]methyl]-4-ethyl-3-methyl-, 2-(phenylmethyl) ester (9CI) (CA INDEX NAME)




RN 331740-10-4 CAPLUS
CN Glycine, N-([5-[2-(4-bromophenyl)-2-furanyl]methyl]-N-([3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl)- (9CI) (CA INDEX NAME)




L7 ANSWER 77 OF 83 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 331740-15-9 CAPLUS
CN Glycine, N-([4-(2,6-difluorobenzoyl)-1-methyl-1H-pyrrol-2-yl]methyl)-N-([3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl)- (9CI) (CA INDEX NAME)




RN 331740-16-0 CAPLUS
CN Glycine, N-([4-benzoyl-1-methyl-1H-pyrrol-2-yl]methyl)-N-([3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl)- (9CI) (CA INDEX NAME)




RN 331740-17-1 CAPLUS
CN Glycine, N-([2,2'-bithiophen]-5-ylmethyl)-N-([3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl)- (9CI) (CA INDEX NAME)


L7 ANSWER 77 OF 83 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 331740-18-2 CAPLUS
CN Glycine,
N-[(5-bromo-3,4-dimethylthieno[2,3-b]thien-2-yl)methyl]-N-[(3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl)methyl]- (9CI) (CA INDEX NAME)




RN 331740-19-3 CAPLUS
CN Glycine, N-[(3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl)methyl]-N-[(5-(phenylethynyl)-2-thienyl)methyl]- (9CI) (CA INDEX NAME)




RN 331740-20-6 CAPLUS
CN Glycine,
N-[(2,4-dichlorobenzoyl)-1-methyl-1H-pyrrol-2-yl)methyl]-N-[(3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl)methyl]- (9CI) (CA INDEX NAME)


L7 ANSWER 77 OF 83 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 331740-24-0 CAPLUS
CN Glycine,
N-[(3-methyl-4-phenoxyphenyl)methyl]-N-[(3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl)methyl]- (9CI) (CA INDEX NAME)



RN 331740-25-1 CAPLUS
CN Glycine,
N-[(3-chloro-4-phenoxyphenyl)methyl]-N-[(3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl)methyl]- (9CI) (CA INDEX NAME)




RN 331740-26-2 CAPLUS
CN Glycine,
N-[(2-chloro-4-phenoxyphenyl)methyl]-N-[(3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl)methyl]- (9CI) (CA INDEX NAME)




RN 331740-27-3 CAPLUS
CN Glycine, N-[(3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl)methyl]-N-[(4-nitro-3-phenoxyphenyl)methyl]- (9CI) (CA INDEX NAME)


L7 ANSWER 77 OF 83 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 331740-21-7 CAPLUS
CN Glycine,
N-[(1-(4-chlorophenyl)-1H-pyrrol-2-yl)methyl]-N-[(3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl)methyl]- (9CI) (CA INDEX NAME)




RN 331740-22-8 CAPLUS
CN Glycine, N-[(3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl)methyl]-N-[(4-(phenylethynyl)-2-thienyl)methyl]- (9CI) (CA INDEX NAME)




RN 331740-23-9 CAPLUS
CN Glycine, N-[(3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl)methyl]-N-[(3-nitro-4-phenoxyphenyl)methyl]- (9CI) (CA INDEX NAME)


L7 ANSWER 77 OF 83 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 331740-28-4 CAPLUS
CN Glycine, N-[(3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl)methyl]-N-[(2-nitro-5-phenoxyphenyl)methyl]- (9CI) (CA INDEX NAME)



RN 331740-29-5 CAPLUS
CN Glycine, N-[(5-chloro-3-methyl-1-phenyl-1H-pyrazol-4-yl)methyl]-N-[(3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl)methyl]- (9CI) (CA INDEX NAME)




RN 331740-30-8 CAPLUS
CN Glycine, N-[(3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl)methyl]-N-[(5-[1-methyl-5-(trifluoromethyl)-1H-pyrazol-3-yl]-2-thienyl)methyl]- (9CI) (CA INDEX NAME)




RN 331740-31-9 CAPLUS
CN Glycine,
N-[(6-methoxy-2-naphthalenyl)methyl]-N-[(3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl)methyl]- (9CI) (CA INDEX NAME)


L7 ANSWER 77 OF 83 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
4-oxazolyl)ethoxy]phenyl)methyl]- (9CI) (CA INDEX NAME)



RN 331740-32-0 CAPLUS
CN Glycine,
N-[(4-methoxy-1-naphthalenyl)methyl]-N-[(3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl)methyl]- (9CI) (CA INDEX NAME)




RN 331740-33-1 CAPLUS
CN Glycine, N-[(3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl)methyl]-N-[[5-[2-nitro-4-(trifluoromethyl)phenyl]-2-furanyl)methyl]- (9CI) (CA INDEX NAME)




RN 331740-34-2 CAPLUS
CN Glycine, N-[(4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl)methyl]-N-[[4-(2-pyridinyl)phenyl)methyl]- (9CI) (CA INDEX NAME)

L7 ANSWER 77 OF 83 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)


RN 331740-38-6 CAPLUS
CN Glycine, N-[(2-hydroxyphenyl)methyl]-N-[(4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl)methyl]- (9CI) (CA INDEX NAME)




RN 331740-39-7 CAPLUS
CN Glycine, N-[(5-(2-chlorophenyl)-2-furanyl)methyl]-N-[(4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl)methyl]- (9CI) (CA INDEX NAME)




RN 331740-40-0 CAPLUS
CN Glycine, N-[(3,5-dimethoxyphenyl)methyl]-N-[(4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl)methyl]- (9CI) (CA INDEX NAME)




RN 331740-41-1 CAPLUS
CN Glycine, N-[(4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl)methyl]-N-[(3-phenoxyphenyl)methyl]- (9CI) (CA INDEX NAME)




L7 ANSWER 77 OF 83 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 331740-35-3 CAPLUS
CN Glycine, N-[(4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl)methyl]-N-[[2-(phenylmethyl)phenyl)methyl]- (9CI) (CA INDEX NAME)



RN 331740-36-4 CAPLUS
CN Glycine, N-heptyl-N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl)methyl]- (9CI) (CA INDEX NAME)




RN 331740-37-5 CAPLUS
CN Glycine, N-[(1,1'-biphenyl)-4-ylmethyl]-N-[(4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl)methyl]- (9CI) (CA INDEX NAME)




L7 ANSWER 77 OF 83 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)


RN 331740-42-2 CAPLUS
CN Glycine, N-[(4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl)methyl]-N-[[4-(phenoxyphenyl)methyl]- (9CI) (CA INDEX NAME)



RN 331740-43-3 CAPLUS
CN Glycine,
N-[(3-(4-chlorophenoxy)phenyl)methyl]-N-[(4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl)methyl]- (9CI) (CA INDEX NAME)




RN 331740-44-4 CAPLUS
CN Glycine, N-[(3-(3,5-dichlorophenoxy)phenyl)methyl]-N-[(4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl)methyl]- (9CI) (CA INDEX NAME)




RN 331740-45-5 CAPLUS
CN Glycine,
N-[(3-(4-methylphenoxy)phenyl)methyl]-N-[(4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl)methyl]- (9CI) (CA INDEX NAME)

L7 ANSWER 77 OF 83 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 331740-46-6 CAPLUS
 CN Glycine, N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-N-[[4-[(1E)-2-phenylethenyl]phenyl]methyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 331740-47-7 CAPLUS
 CN Glycine, N-[[4-[(2-chloro-6-fluorophenyl)methoxy]phenyl]methyl]-N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- (9CI) (CA INDEX NAME)




RN 331740-48-8 CAPLUS
 CN Glycine, N-[[3-benzoyl-2,4-dichlorophenyl]methoxy]phenyl]methyl]-N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- (9CI) (CA INDEX NAME)


L7 ANSWER 77 OF 83 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 331740-52-4 CAPLUS
 CN Glycine, N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-N-[[2-phenoxyphenyl]methyl]- (9CI) (CA INDEX NAME)




RN 331740-53-5 CAPLUS
 CN Glycine, N-[[4-(3-methoxyphenoxy)phenyl]methyl]-N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- (9CI) (CA INDEX NAME)




RN 331740-54-6 CAPLUS
 CN Glycine, N-[[4-(4-bromophenoxy)phenyl]methyl]-N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- (9CI) (CA INDEX NAME)

L7 ANSWER 77 OF 83 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 331740-49-9 CAPLUS
 CN Glycine, N-[[3-(4-(1,1-dimethylethyl)phenoxy)phenyl]methyl]-N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 1-B

RN 331740-50-2 CAPLUS
 CN Glycine, N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-N-[[4-(phenylmethoxy)phenyl]methyl]- (9CI) (CA INDEX NAME)




RN 331740-51-3 CAPLUS
 CN Glycine, N-[[4-(4-(1,1-dimethylethyl)-2-thiazolyl)phenyl]methyl]-N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- (9CI) (CA INDEX NAME)


L7 ANSWER 77 OF 83 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 331740-55-7 CAPLUS
 CN Glycine, N-[[4-(4-chlorophenoxy)phenyl]methyl]-N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- (9CI) (CA INDEX NAME)




RN 331740-56-8 CAPLUS
 CN Glycine, N-[[4-(4-methylphenoxy)phenyl]methyl]-N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- (9CI) (CA INDEX NAME)



RN 331740-57-9 CAPLUS
 CN Glycine, N-[[4-(4-methoxyphenoxy)phenyl]methyl]-N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- (9CI) (CA INDEX NAME)


L7 ANSWER 77 OF 83 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




—OMe

PAGE 1-B


RN 331740-58-0 CAPLUS
CN Glycine, N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- (9CI) (CA INDEX NAME)




RN 331740-59-1 CAPLUS
CN Glycine, N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-N-[[4-[2-(3-chlorophenoxy)phenyl]phenyl]methyl]- (9CI) (CA INDEX NAME)



L7 ANSWER 77 OF 83 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 331740-63-7 CAPLUS
CN Glycine, N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- (9CI) (CA INDEX NAME)



—SMe

PAGE 1-B

RN 331740-64-8 CAPLUS
CN Glycine, N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-N-[[4-[2-(3-phenoxy-2-thienyl)methyl]phenyl]methyl]- (9CI) (CA INDEX NAME)




RN 331740-65-9 CAPLUS
CN Glycine, N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-N-[[4-[2-(3-(trifluoromethyl)phenoxy)phenyl]methyl]phenyl]methyl]- (9CI) (CA INDEX NAME)

L7 ANSWER 77 OF 83 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)


—CF₃

PAGE 1-B

RN 331740-60-4 CAPLUS
CN Glycine, N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- (9CI) (CA INDEX NAME)




RN 331740-61-5 CAPLUS
CN Glycine, N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- (9CI) (CA INDEX NAME)



RN 331740-62-6 CAPLUS
CN Glycine, N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-N-[[4-[2-(3-fluorophenoxy)phenyl]methyl]phenyl]methyl]- (9CI) (CA INDEX NAME)


L7 ANSWER 77 OF 83 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



—CF₃

PAGE 1-B

RN 331740-66-0 CAPLUS
CN Glycine, N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-N-[[4-[2-(3-nitrophenoxy)phenyl]methyl]phenyl]methyl]- (9CI) (CA INDEX NAME)




—NO₂


PAGE 1-B

RN 331740-67-1 CAPLUS
CN Glycine, N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-N-[[4-[2-(3-phenylamino)phenyl]methyl]phenyl]methyl]- (9CI) (CA INDEX NAME)


L7 ANSWER 77 OF 83 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 331740-68-2 CAPLUS
 CN Glycine, N-[[4-(1H-imidazol-1-yl)phenyl]methyl]-N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- (9CI) (CA INDEX NAME)




RN 331740-69-3 CAPLUS
 CN Glycine, N-[[4-(2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl)methyl]-N-[[4-(4-pyridinyl)phenyl]methyl]- (9CI) (CA INDEX NAME)




RN 331740-70-6 CAPLUS
 CN Glycine, N-[[4'-(aminocarbonyl)[1,1'-biphenyl]-4-yl]methyl]-N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- (9CI) (CA INDEX NAME)


L7 ANSWER 77 OF 83 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 331740-74-0 CAPLUS
 CN Glycine, N-[[4'-(3-fluoro[1,1'-biphenyl]-4-yl)methyl]-N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- (9CI) (CA INDEX NAME)




RN 331740-75-1 CAPLUS
 CN Glycine, N-[[4-(3-furanyl)phenyl]methyl]-N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- (9CI) (CA INDEX NAME)




RN 331740-76-2 CAPLUS
 CN Glycine, N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-N-[[4-(2-thienyl)phenyl]methyl]- (9CI) (CA INDEX NAME)




L7 ANSWER 77 OF 83 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 331740-71-7 CAPLUS
 CN Glycine, N-[[3',5'-dichloro[1,1'-biphenyl]-4-yl]methyl]-N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- (9CI) (CA INDEX NAME)




RN 331740-72-8 CAPLUS
 CN Glycine, N-[[3-methoxy[1,1'-biphenyl]-4-yl]methyl]-N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- (9CI) (CA INDEX NAME)




RN 331740-73-9 CAPLUS
 CN Glycine, N-[[3',4'-difluoro[1,1'-biphenyl]-4-yl]methyl]-N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- (9CI) (CA INDEX NAME)

L7 ANSWER 77 OF 83 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)


RN 331740-77-3 CAPLUS
 CN Glycine, N-[[3-methoxy-4-phenoxyphenyl]methyl]-N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- (9CI) (CA INDEX NAME)



RN 331740-78-4 CAPLUS
 CN Glycine, N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-N-[[3-nitro-4-phenoxyphenyl]methyl]- (9CI) (CA INDEX NAME)




RN 331740-79-5 CAPLUS
 CN Glycine, N-[[3-methyl-4-phenoxyphenyl]methyl]-N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- (9CI) (CA INDEX NAME)




RN 331740-80-8 CAPLUS
 CN Glycine, N-[[3-chloro-4-phenoxyphenyl]methyl]-N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- (9CI) (CA INDEX NAME)


L7 ANSWER 77 OF 83 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 331740-81-9 CAPLUS
CN Glycine, N-[(2-methoxy-4-phenoxyphenyl)methyl]-N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- (9CI) (CA INDEX NAME)




RN 331740-82-0 CAPLUS
CN Glycine, N-[(2-chloro-4-phenoxyphenyl)methyl]-N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- (9CI) (CA INDEX NAME)




RN 331740-83-1 CAPLUS
CN Glycine, N-[(4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl)methyl]-N-[[4-(4-nitro-3-phenoxyphenyl)methyl]- (9CI) (CA INDEX NAME)

L7 ANSWER 77 OF 83 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)

PAGE 1-A




RN 331740-87-5 CAPLUS
CN Glycine, N-[(4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl)methyl]-N-[[4-(2-pyrimidinyl)phenyl]methyl]- (9CI) (CA INDEX NAME)




RN 331740-88-6 CAPLUS
CN Glycine, N-[(4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl)methyl]-N-[[4-(5-pyrimidinyl)phenyl]methyl]- (9CI) (CA INDEX NAME)


L7 ANSWER 77 OF 83 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 331740-84-2 CAPLUS
CN Glycine, N-[(4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl)methyl]-N-[[2-nitro-5-phenoxyphenyl]methyl]- (9CI) (CA INDEX NAME)




RN 331740-85-3 CAPLUS
CN Glycine, N-[(6-methoxy-2-naphthalenyl)methyl]-N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- (9CI) (CA INDEX NAME)




RN 331740-86-4 CAPLUS
CN Glycine, N-[(4-methoxy-1-naphthalenyl)methyl]-N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- (9CI) (CA INDEX NAME)

L7 ANSWER 77 OF 83 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 331740-89-7 CAPLUS
CN Glycine, N-[(1H-indol-2-yl)methyl]-N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- (9CI) (CA INDEX NAME)




RN 331740-90-0 CAPLUS
CN Glycine, N-[(3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl)methyl]-N-[(1R)-1-phenylethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 331740-91-1 CAPLUS
CN D-Alanine, N-[(3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl)methyl]-N-[(1R)-1-phenylethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 331740-92-2 CAPLUS
CN D-Phenylalanine, N-[(3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl)methyl]-N-[(1R)-1-phenylethyl]- (9CI) (CA INDEX NAME)


L7 ANSWER 77 OF 83 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)

Absolute stereochemistry.




RN 331740-93-3 CAPLUS
 CN D-Alanine,
 N-([3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl)-N-
 ([4-phenoxyphenyl]methyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 331740-94-4 CAPLUS
 CN D-Phenylalanine, N-([3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl)-N-([4-phenoxyphenyl]methyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 331740-95-5 CAPLUS
 CN L-Phenylalanine, N-([3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl)-N-([4-phenoxyphenyl]methyl)- (9CI) (CA INDEX NAME)


L7 ANSWER 77 OF 83 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)

[[4-phenoxyphenyl]methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 331740-99-9 CAPLUS
 CN Glycine, N-([3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl)-N-
 ([4-phenoxyphenyl]methyl)- (9CI) (CA INDEX NAME)




RN 331741-00-5 CAPLUS
 CN Glycine, N-([3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl)-N-
 ([4-phenoxyphenyl]methyl)- (9CI) (CA INDEX NAME)



RN 331741-01-6 CAPLUS
 CN Glycine, N-([3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl)-N-([4-phenoxyphenyl]methyl)- (9CI) (CA INDEX NAME)


L7 ANSWER 77 OF 83 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)

Absolute stereochemistry.




RN 331740-96-6 CAPLUS
 CN D-Valine, N-([3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl)-N-
 ([4-phenoxyphenyl]methyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 331740-97-7 CAPLUS
 CN Acetic acid, (2,2-dimethylpropoxy) [[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]amino]-, (2R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 331740-98-8 CAPLUS
 CN D-Serine, N-([3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl)-N-
 ([4-phenoxyphenyl]methyl)- (9CI) (CA INDEX NAME)


L7 ANSWER 77 OF 83 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 331741-02-7 CAPLUS
 CN Glycine, N-([3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl)-N-([4-phenoxyphenyl]methyl)- (9CI) (CA INDEX NAME)



RN 331741-03-8 CAPLUS
 CN Glycine, N-([3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl)-N-([4-phenoxyphenyl]methyl)- (9CI) (CA INDEX NAME)




RN 331741-04-9 CAPLUS
 CN Glycine, N-([3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl)-N-([4-phenoxyphenyl]methyl)- (9CI) (CA INDEX NAME)




RN 331741-05-0 CAPLUS
 CN Glycine, N-([3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl)-N-([4-phenoxyphenyl]methyl)- (9CI) (CA INDEX NAME)


L7 ANSWER 77 OF 83 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 331741-06-1 CAPLUS
CN Glycine, N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-N-[[4-(phenylmethoxy)phenoxy]carbonyl]- (9CI) (CA INDEX NAME)



RN 331741-07-2 CAPLUS
CN Glycine, N-[[4-(hydroxyphenoxy)carbonyl]-N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- (9CI) (CA INDEX NAME)




RN 331741-08-3 CAPLUS
CN Glycine, N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-N-(phenoxycarbonyl)- (9CI) (CA INDEX NAME)




RN 331741-09-4 CAPLUS
CN Glycine, N-[[4-(chloro-3-fluorophenoxy)carbonyl]-N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- (9CI) (CA INDEX NAME)


L7 ANSWER 77 OF 83 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 331741-14-1 CAPLUS
CN Glycine, N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-N-[[2-(nitrophenoxy)carbonyl]- (9CI) (CA INDEX NAME)




RN 331741-15-2 CAPLUS
CN Glycine, N-[[3-(9H-fluoren-9-ylmethoxy)carbonyl]-N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- (9CI) (CA INDEX NAME)




RN 331741-16-3 CAPLUS
CN Glycine, N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-N-[[4-(nitrophenyl)methoxy]carbonyl]- (9CI) (CA INDEX NAME)


L7 ANSWER 77 OF 83 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 331741-10-7 CAPLUS
CN Glycine, N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-N-[[3-(phenoxyphenyl)methoxy]carbonyl]- (9CI) (CA INDEX NAME)



RN 331741-11-8 CAPLUS
CN Glycine, N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-N-[[2-(propynyloxy)carbonyl]- (9CI) (CA INDEX NAME)




RN 331741-12-9 CAPLUS
CN Glycine, N-[[4-(methylphenoxy)carbonyl]-N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- (9CI) (CA INDEX NAME)




RN 331741-13-0 CAPLUS
CN Glycine, N-[[4-(methoxyphenoxy)carbonyl]-N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- (9CI) (CA INDEX NAME)


L7 ANSWER 77 OF 83 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 331741-17-4 CAPLUS
CN Glycine, N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-N-[[4-(nitrophenoxy)carbonyl]- (9CI) (CA INDEX NAME)



RN 331741-18-5 CAPLUS
CN Glycine, N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-N-[[4-(phenoxyphenoxy)carbonyl]- (9CI) (CA INDEX NAME)




RN 331741-19-6 CAPLUS
CN Glycine, N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-N-[[2-(phenoxyphenyl)methoxy]carbonyl]- (9CI) (CA INDEX NAME)




RN 331741-20-9 CAPLUS
CN Glycine, N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-N-[[4-(phenoxyphenyl)methoxy]carbonyl]- (9CI) (CA INDEX NAME)


L7 ANSWER 77 OF 83 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 331741-21-0 CAPLUS
CN Glycine, N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-N-[[3-phenoxyphenoxy]carbonyl]- (9CI) (CA INDEX NAME)



RN 331741-22-1 CAPLUS
CN Glycine, N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-N-[[2-phenoxyphenoxy]carbonyl]- (9CI) (CA INDEX NAME)




RN 331741-23-2 CAPLUS
CN Glycine, N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-N-[[2-phenoxyethoxy]carbonyl]- (9CI) (CA INDEX NAME)




RN 331741-24-3 CAPLUS
CN Glycine, N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-N-[[[(2E)-3-phenyl-2-propenyl]oxy]carbonyl]- (9CI) (CA INDEX NAME)

L7 ANSWER 77 OF 83 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)


Double bond geometry as shown.




RN 331741-29-8 CAPLUS
CN Glycine, N-[[4-(4-fluoro-3-methylphenoxy)carbonyl]-N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- (9CI) (CA INDEX NAME)



RN 331741-30-1 CAPLUS
CN Glycine, N-[[3-methoxyphenoxy]carbonyl]-N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- (9CI) (CA INDEX NAME)




RN 331741-31-2 CAPLUS
CN Glycine, N-[[3,4-dimethoxyphenoxy]carbonyl]-N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- (9CI) (CA INDEX NAME)




RN 331741-32-3 CAPLUS
CN Glycine, N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-N-[[3,4,5-trimethoxyphenoxy]carbonyl]- (9CI) (CA INDEX NAME)

L7 ANSWER 77 OF 83 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)


Double bond geometry as shown.




RN 331741-25-4 CAPLUS
CN Glycine, N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-N-[[3-phenyl-2-propynyl]oxy]carbonyl]- (9CI) (CA INDEX NAME)



RN 331741-26-5 CAPLUS
CN Glycine, N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-N-[[2-phenylethoxy]carbonyl]- (9CI) (CA INDEX NAME)




RN 331741-27-6 CAPLUS
CN Glycine, N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-N-[[3-phenylpropoxy]carbonyl]- (9CI) (CA INDEX NAME)




RN 331741-28-7 CAPLUS
CN Glycine, N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-N-[[[(2Z)-3-phenyl-2-propenyl]oxy]carbonyl]- (9CI) (CA INDEX NAME)


L7 ANSWER 77 OF 83 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 331741-33-4 CAPLUS
CN Glycine, N-[[3-methoxyphenyl]methoxy]carbonyl]-N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- (9CI) (CA INDEX NAME)



RN 331741-34-5 CAPLUS
CN Glycine, N-[[4-methoxyphenyl]methoxy]carbonyl]-N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- (9CI) (CA INDEX NAME)




RN 331741-35-6 CAPLUS
CN Glycine, N-[[1,3-benzodioxol-5-ylmethoxy]carbonyl]-N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- (9CI) (CA INDEX NAME)




RN 331741-36-7 CAPLUS
CN Glycine, N-[[1,3-benzodioxol-5-ylmethoxy]carbonyl]-N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- (9CI) (CA INDEX NAME)


L7 ANSWER 77 OF 83 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 331741-37-8 CAPLUS
CN Glycine, N-[(3-{2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy}phenyl)methyl]-N-[[4-(trifluoromethoxy)phenoxy]carbonyl]- (9CI) (CA INDEX NAME)




RN 331741-38-9 CAPLUS
CN Glycine, N-[(4-methoxy-1-naphthalenyl)oxy]carbonyl-N-[(3-{2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy}phenyl)methyl]- (9CI) (CA INDEX NAME)




RN 331741-39-0 CAPLUS
CN Glycine, N-[(2,3-dimethoxyphenoxy)carbonyl]-N-[(3-{2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy}phenyl)methyl]- (9CI) (CA INDEX NAME)


L7 ANSWER 77 OF 83 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 331741-44-7 CAPLUS
CN Glycine, N-[(4-fluorophenoxy)carbonyl]-N-[(3-{2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy}phenyl)methyl]- (9CI) (CA INDEX NAME)



RN 331741-45-8 CAPLUS
CN Glycine, N-[(4-chlorophenoxy)carbonyl]-N-[(3-{2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy}phenyl)methyl]- (9CI) (CA INDEX NAME)




RN 331741-46-9 CAPLUS
CN Glycine, N-[(4-bromophenoxy)carbonyl]-N-[(3-{2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy}phenyl)methyl]- (9CI) (CA INDEX NAME)




RN 331741-47-0 CAPLUS
CN Glycine, N-[(3-(trifluoromethoxy)phenoxy)carbonyl]-N-[(3-{2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy}phenyl)methyl]- (9CI) (CA INDEX NAME)


L7 ANSWER 77 OF 83 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 331741-40-3 CAPLUS
CN Benzoic Acid, 4-[[[(carboxymethyl)[(3-{2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy}phenyl)methyl]amino]carbonyl]oxy]-, 1-methyl ester (9CI) (CA INDEX NAME)



RN 331741-41-4 CAPLUS
CN Glycine, N-[(4-bromo-3-methylphenoxy)carbonyl]-N-[(3-{2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy}phenyl)methyl]- (9CI) (CA INDEX NAME)




RN 331741-42-5 CAPLUS
CN Glycine, N-[(4-(1,3-dithiolan-2-yl)phenoxy)carbonyl]-N-[(3-{2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy}phenyl)methyl]- (9CI) (CA INDEX NAME)




RN 331741-43-6 CAPLUS
CN Glycine, N-[(4-chloro-3-methylphenoxy)carbonyl]-N-[(3-{2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy}phenyl)methyl]- (9CI) (CA INDEX NAME)


L7 ANSWER 77 OF 83 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 331741-48-1 CAPLUS
CN Glycine, N-[(3-fluorophenoxy)carbonyl]-N-[(3-{2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy}phenyl)methyl]- (9CI) (CA INDEX NAME)



RN 331741-49-2 CAPLUS
CN Glycine, N-[(3-chlorophenoxy)carbonyl]-N-[(3-{2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy}phenyl)methyl]- (9CI) (CA INDEX NAME)




RN 331741-50-5 CAPLUS
CN Glycine, N-[(3-bromophenoxy)carbonyl]-N-[(3-{2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy}phenyl)methyl]- (9CI) (CA INDEX NAME)




RN 331741-51-6 CAPLUS
CN Glycine, N-[(3-acetyloxy)phenoxy]carbonyl-N-[(3-{2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy}phenyl)methyl]- (9CI) (CA INDEX NAME)


L7 ANSWER 77 OF 83 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 331741-52-7 CAPLUS
CN Glycine, N-((4-acetylphenoxy)carbonyl)-N-([3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl)- (9CI) (CA INDEX NAME)



RN 331741-53-8 CAPLUS
CN Glycine, N-((3-acetylphenoxy)carbonyl)-N-([3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl)- (9CI) (CA INDEX NAME)




RN 331741-54-9 CAPLUS
CN Glycine, N-((2,3-dihydro-3-oxo-6-benzofuranyl)oxy)carbonyl)-N-([3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl)- (9CI) (CA INDEX NAME)




RN 331741-55-0 CAPLUS
CN Glycine, N-([4-(1,2,3-thiadiazol-4-yl)phenoxy]carbonyl)-N-([3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl)- (9CI) (CA INDEX NAME)


L7 ANSWER 77 OF 83 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 331741-60-7 CAPLUS
CN Glycine, N-([3-ethoxy-4-methoxyphenoxy]carbonyl)-N-([3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl)- (9CI) (CA INDEX NAME)



RN 331741-61-8 CAPLUS
CN Glycine, N-((4-cyclopentylphenoxy)carbonyl)-N-([3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl)- (9CI) (CA INDEX NAME)




RN 331741-63-0 CAPLUS
CN Glycine, N-((4-ethenylphenoxy)carbonyl)-N-([3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl)- (9CI) (CA INDEX NAME)




RN 331741-64-1 CAPLUS
CN Glycine, N-([4-(3-methylbutyl)phenoxy]carbonyl)-N-([3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl)- (9CI) (CA INDEX NAME)


L7 ANSWER 77 OF 83 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 331741-56-1 CAPLUS
CN Glycine, N-((3-hydroxyphenoxy)carbonyl)-N-([3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl)- (9CI) (CA INDEX NAME)



RN 331741-57-2 CAPLUS
CN Glycine, N-((3-methylphenoxy)carbonyl)-N-([3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl)- (9CI) (CA INDEX NAME)




RN 331741-58-3 CAPLUS
CN Glycine, N-([3,4,5-trimethylphenoxy]carbonyl)-N-([3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl)- (9CI) (CA INDEX NAME)



RN 331741-59-4 CAPLUS
CN Glycine, N-((4-ethoxyphenoxy)carbonyl)-N-([3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl)- (9CI) (CA INDEX NAME)

L7 ANSWER 77 OF 83 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




PAGE 1-A


-CHMe2

PAGE 1-B


RN 331741-65-2 CAPLUS
CN Glycine, N-((4-butylphenoxy)carbonyl)-N-([3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl)- (9CI) (CA INDEX NAME)



RN 331741-66-3 CAPLUS
CN Glycine, N-((4-hexylphenoxy)carbonyl)-N-([3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl)- (9CI) (CA INDEX NAME)




RN 331741-67-4 CAPLUS
CN Glycine, N-([3-(4-morpholinyl)phenoxy]carbonyl)-N-([3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl)- (9CI) (CA INDEX NAME)



L7 ANSWER 77 OF 83 CAPLUS COPYRIGHT 2006 ACS ON STN (Continued)


RN 331741-68-5 CAPLUS

CN Glycine, N-[(3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl)methyl]-N-[[[(5,6,7,8-tetrahydro-2-naphthalenyl)oxy]carbonyl]- (9CI) (CA INDEX NAME)




RN 331741-69-6 CAPLUS

CN Glycine, N-[(3-[1,1-dimethylethyl]phenoxy]carbonyl]-N-[(3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl)methyl]- (9CI) (CA INDEX NAME)




RN 331741-70-9 CAPLUS

CN Glycine, N-[(3-[1-methylethyl]phenoxy]carbonyl]-N-[(3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl)methyl]- (9CI) (CA INDEX NAME)



RN 331741-71-0 CAPLUS

CN Glycine, N-[(3,4-dimethylphenoxy]carbonyl]-N-[(3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl)methyl]- (9CI) (CA INDEX NAME)



L7 ANSWER 77 OF 83 CAPLUS COPYRIGHT 2006 ACS ON STN (Continued)

propynyloxy]carbonyl]- 331741-93-6P, Glycine, N-[(4-methylphenoxy]carbonyl]-N-[(4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl)methyl]- 331741-94-7P, Glycine, N-[(4-methoxyphenoxy]carbonyl]-N-[(4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl)methyl]- 331741-95-8P, Glycine, N-[(4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl)methyl]-N-[(2-nitrophenoxy]carbonyl]- 331741-96-9P, Glycine, N-[(4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl)methyl]-N-[(4-phenoxy]carbonyl]- 331741-97-0P, Glycine, N-[(4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl)methyl]-N-[(4-nitrophenyl)methoxy]carbonyl]- 331741-98-1P, Glycine, N-[(4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl)methyl]-N-[(4-nitrophenoxy]carbonyl]- 331741-99-2P, Glycine, N-[(4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl)methyl]-N-[(4-phenoxyphenoxy]carbonyl]- 331742-00-8P, Glycine, N-[(4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl)methyl]-N-[(2-phenoxyphenyl)methoxy]carbonyl]- 331742-01-9P, Glycine, N-[(4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl)methyl]-N-[(4-phenoxyphenyl)methoxy]carbonyl]- 331742-02-0P, Glycine, N-[(4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl)methyl]-N-[(3-phenoxyphenoxy]carbonyl]- 331742-03-1P, Glycine, N-[(4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl)methyl]-N-[(2-phenoxyphenoxy]carbonyl]- 331742-04-2P, Glycine, N-[(4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl)methyl]-N-[(2-phenoxyethoxy]carbonyl]- 331742-05-3P, Glycine, N-[(4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl)methyl]-N-[(1,2,3,4-tetrahydro-2H-pyridin-2-yl)oxy]carbonyl]- 331742-06-4P, Glycine,


N-[(4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl)methyl]-N-[(3-phenyl-2-propenyl)oxy]carbonyl]- 331742-07-5P, Glycine, N-[(4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl)methyl]-N-[(2-phenylethoxy]carbonyl]- 331742-08-6P, Glycine, N-[(4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl)methyl]-N-[(3-phenylpropoxy]carbonyl]- 331742-09-7P, Glycine, N-[(4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl)methyl]-N-[(1,2,3,4-tetrahydro-2H-pyridin-2-yl)oxy]carbonyl]- 331742-10-0P, Glycine, N-[(2-methoxyphenoxy]carbonyl]- 331742-11-1P, Glycine, N-[(3-methoxyphenoxy]carbonyl]- 331742-12-2P, Glycine, N-[(3,4-dimethoxyphenoxy]carbonyl]- 331742-13-3P, Glycine, N-[(4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl)methyl]-N-[(3,4,5-trimethoxyphenoxy]carbonyl]- 331742-14-4P, Glycine, N-[(3-acetylphenoxy]carbonyl]- 331742-15-5P, Glycine, N-[(4-methoxyphenyl)methoxy]carbonyl]- 331742-16-6P, Glycine, N-[(1,3-benzodioxol-5-yl)methoxy]carbonyl]- 331742-17-7P, Glycine, N-[(1,3-benzodioxol-5-yl)oxy]carbonyl]- 331742-18-8P, Glycine, N-[(4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl)methyl]-N-[(4-(trifluoromethoxy)phenoxy]carbonyl]- 331742-19-9P, Glycine,

N-[(4-methoxy-1-naphthalenyl)oxy]carbonyl]-N-[(4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl)methyl]- 331742-20-2P, Glycine, N-[(2,3-dimethoxyphenoxy]carbonyl]-N-[(4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl)methyl]- 331742-21-3P, Benzoic acid,

L7 ANSWER 77 OF 83 CAPLUS COPYRIGHT 2006 ACS ON STN (Continued)

RN 331741-72-1 CAPLUS

CN Glycine, N-[(3,5-dimethylphenoxy]carbonyl]-N-[(3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl)methyl]- (9CI) (CA INDEX NAME)



IT 331741-73-2P, Glycine, N-[(3-ethylphenoxy]carbonyl]-N-[(3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl)methyl]- 331741-74-3P, Glycine, N-[(4-[1,1-dimethylethyl]phenoxy]carbonyl]-N-[(3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl)methyl]- 331741-75-4P, Glycine, N-[(4-[1-methylethyl]phenoxy]carbonyl]-N-[(3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl)methyl]- 331741-76-5P, Glycine, N-[(3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl)methyl]-N-[(4-(phenylmethyl)phenoxy]carbonyl]- 331741-77-6P, Glycine, N-[(4-ethylphenoxy]carbonyl]-N-[(3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl)methyl]- 331741-78-7P, Glycine, N-[(3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl)methyl]-N-[(4-propylphenoxy]carbonyl]- 331741-79-8P, Glycine,

N-[(2,3-dihydro-1H-inden-5-yl)oxy]carbonyl]-N-[(3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl)methyl]- 331741-80-1P, Glycine, N-[(3-ethoxyphenoxy]carbonyl]-N-[(3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl)methyl]- 331741-81-2P, Glycine, N-[(3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl)methyl]-N-[(4-pentylphenoxy]carbonyl]- 331741-82-3P, Glycine, N-[(4-fluoro-3-(trifluoromethyl)phenoxy]carbonyl]-N-[(3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl)methyl]- 331741-83-4P, Glycine, N-[(3-fluorophenyl)methoxy]carbonyl]-N-[(3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl)methyl]- 331741-84-5P, Glycine, N-[(3-chlorophenyl)methoxy]carbonyl]-N-[(3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl)methyl]- 331741-85-6P, Glycine, N-[(3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl)methyl]-N-[(3-(trifluoromethoxy)phenyl)methoxy]carbonyl]- 331741-86-7P, Glycine, N-[(4-fluorophenyl)methoxy]carbonyl]-N-[(3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl)methyl]- 331741-87-8P, Glycine, N-[(4-chlorophenyl)methoxy]carbonyl]-N-[(3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl)methyl]- 331741-88-9P, Glycine, N-[(3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl)methyl]-N-[(4-(trifluoromethoxy)phenyl)methoxy]carbonyl]- 331741-89-0P, Glycine, N-[(3,5-dimethoxyphenyl)methoxy]carbonyl]-N-[(3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl)methyl]- 331741-90-3P, Glycine, N-[(3-acetylphenoxy]carbonyl)-N-[(4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl)methyl]- 331741-91-4P, Glycine, N-[(4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl)methyl]-N-[(3-phenoxyphenyl)methoxy]carbonyl]- 331741-92-5P, Glycine, N-[(4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl)methyl]-N-[(2-

L7 ANSWER 77 OF 83 CAPLUS COPYRIGHT 2006 ACS ON STN (Continued)

4-[[[(carboxymethyl)[(4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl)methyl]amino]carbonyl]oxy]-1-methyl ester 331742-22-4P, Glycine, N-[(4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl)methyl]-N-[(4-phenylmethoxy]phenoxy]carbonyl]- 331742-23-5P, Glycine, N-[(4-hydroxyphenoxy]carbonyl)-N-[(4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl)methyl]- 331742-24-6P, Glycine, N-[(4-bromo-3-methylphenoxy]carbonyl)-N-[(4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl)methyl]- 331742-25-7P, Glycine, N-[(4-fluorophenoxy]carbonyl)-N-[(4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl)methyl]- 331742-26-8P, Glycine, N-[(4-chlorophenoxy]carbonyl)-N-[(4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl)methyl]- 331742-27-9P, Glycine, N-[(4-bromophenoxy]carbonyl)-N-[(4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl)methyl]- 331742-28-0P, Glycine, N-[(4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl)methyl]-N-[(3-(trifluoromethoxy)phenoxy]carbonyl]- 331742-29-1P, Glycine, N-[(3-fluorophenoxy]carbonyl)-N-[(4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl)methyl]- 331742-30-4P, Glycine, N-[(3-chlorophenoxy]carbonyl)-N-[(4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl)methyl]- 331742-31-5P, Glycine, N-[(3-bromophenoxy]carbonyl)-N-[(4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl)methyl]- 331742-32-6P, Glycine, N-[(3,5-difluorophenoxy]carbonyl)-N-[(4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl)methyl]- 331742-33-7P, Glycine, N-[(3-methylphenoxy]carbonyl)-N-[(4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl)methyl]- 331742-34-8P, Glycine, N-[(3-chloro-4-fluorophenoxy]carbonyl)-N-[(4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl)methyl]- 331742-35-9P, Glycine, N-[(4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl)methyl]-N-[(3,4,5-trimethylphenoxy]carbonyl)- 331742-36-0P, Glycine, N-[(4-chloro-3,5-dimethylphenoxy]carbonyl)-N-[(4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl)methyl]- 331742-37-1P, Glycine, N-[(3,4-difluorophenoxy]carbonyl)-N-[(4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl)methyl]- 331742-38-2P, Glycine, N-[(4-ethenylphenoxy]carbonyl)-N-[(4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl)methyl]- 331742-39-3P, Glycine, N-[(4-fluoro-3-methylphenoxy]carbonyl)-N-[(4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl)methyl]- 331742-40-6P, Glycine, N-[(4-chloro-3-fluorophenoxy]carbonyl)-N-[(4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl)methyl]- 331742-41-7P, Glycine,

N-[(3-methyl-4-(methylthio)phenoxy]carbonyl)-N-[(4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl)methyl]- 331742-42-8P, Glycine, N-[(4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl)methyl]-N-[(4-(1H-pyrrrol-1-yl)phenoxy]carbonyl)- 331742-43-9P, Glycine,

N-[(4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl)methyl]-N-[(5,6,7,8-tetrahydro-2-naphthalenyl)oxy]carbonyl]- 331742-44-0P, Glycine, N-[(1,1'-biphenyl)-3-yloxy]carbonyl)-N-[(4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl)methyl]- 331742-45-1P, Glycine, N-[(4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl)methyl]-N-[(3-(trifluoromethyl)phenoxy]carbonyl)- 331742-46-2P, Glycine, N-[(3-[1,1-dimethylethyl]phenoxy]carbonyl)-N-[(4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl)methyl]- 331742-47-3P, Glycine, N-[(3-[1-methylethyl]phenoxy]carbonyl)-N-[(4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl)methyl]- 331742-48-4P, Glycine, N-[(3,4-dimethylphenoxy]carbonyl)-N-[(4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl)methyl]- 331742-49-5P, Glycine,

ANSWER 77 OF 83 CAPLUS COPYRIGHT 2006 ACS ON STN (Continued)

oxazoyl)ethoxy]phenyl]methyl]- 331743-06-7P, Glycine,
N-(4-fluorobenzoyl)-N-[[3-[2-(5-methyl-2-phenyl-4-oxazoyl)ethoxy]phenyl]methyl]- 331743-07-8P, Glycine,
N-(3,4-dichlorobenzoyl)-N-[[3-[2-(5-methyl-2-phenyl-4-oxazoyl)ethoxy]phenyl]methyl]- 331743-08-9P, Glycine,
N-[[3-[2-(5-methyl-2-phenyl-4-oxazoyl)ethoxy]phenyl]-N-(4-propoxybenzoyl)- 331743-09-0P, Glycine, N-(4-ethoxybenzoyl)-N-[[3-[2-(5-methyl-2-phenyl-4-oxazoyl)ethoxy]phenyl]methyl]- 331743-10-3P, Glycine, N-(3-methylbenzoyl)-N-[[3-[2-(5-methyl-2-phenyl-4-oxazoyl)ethoxy]phenyl]methyl]- 331743-11-4P, Glycine, N-(4-methoxybenzoyl)-N-[[3-[2-(5-methyl-2-phenyl-4-oxazoyl)ethoxy]phenyl]methyl]- 331743-12-5P, Glycine, N-(3-chlorobenzoyl)-N-[[3-[2-(5-methyl-2-phenyl-4-oxazoyl)ethoxy]phenyl]methyl]- 331743-13-6P, Glycine, N-(4-chlorobenzoyl)-N-[[3-[2-(5-methyl-2-phenyl-4-oxazoyl)ethoxy]phenyl]methyl]- 331743-14-7P, Glycine, N-(4-butylbenzoyl)-N-[[3-[2-(5-methyl-2-phenyl-4-oxazoyl)ethoxy]phenyl]methyl]- 331743-15-8P, Glycine, N-(3,5-dichlorobenzoyl)-N-[[3-[2-(5-methyl-2-phenyl-4-oxazoyl)ethoxy]phenyl]methyl]- 331743-16-9P, Glycine, N-(3-fluorobenzoyl)-N-[[3-[2-(5-methyl-2-phenyl-4-oxazoyl)ethoxy]phenyl]methyl]- 331743-17-0P, Glycine, N-(3-chloro-4-fluorobenzoyl)-N-[[3-[2-(5-methyl-2-phenyl-4-oxazoyl)ethoxy]phenyl]methyl]- 331743-18-1P, Glycine, N-(3-ethoxybenzoyl)-N-[[3-[2-(5-methyl-2-phenyl-4-oxazoyl)ethoxy]phenyl]methyl]- 331743-19-2P, Glycine, N-(5-chloro-2-phenylcarboxyl)-N-[[3-[2-(5-methyl-2-phenyl-4-oxazoyl)ethoxy]phenyl]methyl]- 331743-20-3P, Glycine, N-[[3-[2-(5-methyl-2-phenyl-4-oxazoyl)ethoxy]phenyl]methyl]-N-[[5-(methylthio)-2-thienyl]carbonyl]- 331743-21-6P, Glycine, N-[[4-(methylphenyl)acetyl]-N-[[3-[2-(5-methyl-2-phenyl-4-oxazoyl)ethoxy]phenyl]methyl]- 331743-22-7P, Glycine, N-[[3-(fluorophenyl)acetyl]-N-[[3-[2-(5-methyl-2-phenyl-4-oxazoyl)ethoxy]phenyl]methyl]- 331743-23-8P, Glycine, N-[[3-(5-difluorophenyl)acetyl]-N-[[3-[2-(5-methyl-2-phenyl-4-oxazoyl)ethoxy]phenyl]methyl]- 331743-24-9P, Glycine, N-(1,3-benzodioxol-5-ylacetyl)-N-[[3-[2-(5-methyl-2-phenyl-4-oxazoyl)ethoxy]phenyl]methyl]- 331743-25-0P, Glycine, N-[[4-(ethoxyphenyl)acetyl]-N-[[3-[2-(5-methyl-2-phenyl-4-oxazoyl)ethoxy]phenyl]methyl]- 331743-26-1P, Glycine, N-[[3-[2-(5-methyl-2-phenyl-4-oxazoyl)ethoxy]phenyl]methyl]-N-[[3-(4-methylphenyl)carboxyl]- 331743-27-2P, Glycine, N-[[3-(4-methylphenyl-4-oxazoyl)ethoxy]phenyl]methyl]-N-[[4-nitrophenyl]acetyl]- 331743-28-3P
Glycine, N-[[4-[2-(5-methyl-2-phenyl-4-oxazoyl)ethoxy]phenyl]methyl]-N-(1-oxo-3-phenylpropyl)- 331743-29-4P, Glycine, N-[[1,1'-biphenyl]-2-ylcarbonyl]-N-[[4-[2-(5-methyl-2-phenyl-4-oxazoyl)ethoxy]phenyl]methyl]- 331743-30-7P, Glycine, N-[[4-[2-(5-methyl-2-phenyl-4-oxazoyl)ethoxy]phenyl]methyl]-N-(4-phenoxybenzoyl)- 331743-31-8P
Glycine, N-[[4-[2-(5-methyl-2-phenyl-4-oxazoyl)ethoxy]phenyl]methyl]-N-[[2-(phenylmethyl)benzoyl]- 331743-32-9P, Glycine, N-[[4-[2-(5-methyl-2-phenyl-4-oxazoyl)ethoxy]phenyl]methyl]-N-[[3-(phenylsulfinyl)benzoyl]- 331743-33-0P, Glycine, N-[[4-[2-(5-methyl-2-phenyl-4-oxazoyl)ethoxy]phenyl]methyl]-N-[[2-[4-(methylphenyl)thiolbenzoyl]- 331743-34-1P, Glycine, N-[[4-[2-(5-methyl-2-phenyl-4-oxazoyl)ethoxy]phenyl]methyl]-N-[[2-(phenylsulfinyl)benzoyl]- 331743-35-2P, Glycine, N-(5-chloro-2-phenoxybenzoyl)-N-[[4-[2-(5-methyl-2-phenyl-4-

ANSWER 77 OF 83 CAPLUS COPYRIGHT 2006 ACS ON STN (Continued)

oxazoly] ethoxy[phenyl]methyl]-N- [317343-36-3P, Glycine,
N-[[4-[2-(5-methyl-2-phenyl-4-oxazoly]ethoxy[phenyl]methyl]-N-(2-
phenylbenzoyl)- 317343-37-4P, Glycine, N-[[1,1'-biphenyl-4-
yl]carbonyl]-N-[4-[2-(5-methyl-2-phenyl-4-oxazoly]ethoxy[phenyl]methyl]-
317343-38-5P, Glycine, N-[[4-[2-(5-methyl-2-phenyl-4-oxazoly]ethoxy[phenyl]methyl]-N-(3-phenoxybenzoyl)- 317343-39-6P
Glycine,
N-[[4-[2-(5-methyl-2-phenyl-4-oxazoly]ethoxy[phenyl]methyl]-N-
[[2-phenoxyphenyl]acetyl]- 317343-40-9P, Glycine,
N-[[1,1'-biphenyl-4-yl]acetyl]-N-[[4-[2-(5-methyl-2-phenyl-4-
oxazoly]ethoxy[phenyl]methyl]-N-317343-41-0P, Glycine,
N-[[4-[2-(5-methyl-2-phenyl-4-oxazoly]ethoxy[phenyl]methyl]-N-[4-
[[3-methylbenzoyl]amino]carbonyl]-N-317343-42-1P, Glycine,
N-[[4-[2-(5-methyl-2-phenyl-4-oxazoly]ethoxy[phenyl]methyl]-N-[2-(1H-
pyrrol-1-yl)benzoyl]- 317343-43-2P, Glycine,
N-[[4-[2-(5-methyl-2-phenyl-4-oxazoly]ethoxy[phenyl]methyl]-N-[[4-
phenoxyphenyl]acetyl]- 317343-44-3P, Glycine,
N-[[4-[2-(5-methyl-2-phenyl-4-oxazoly]ethoxy[phenyl]methyl]-N-[[3-
phenoxyphenyl]acetyl]- 317343-45-4P, Glycine,
N-[[2'-biphenylbenzoyl]amino]carbonyl]-N-[[4-[2-(5-methyl-2-phenyl-4-
oxazoly]ethoxy[phenyl]methyl]- 317343-46-5P, Glycine,
N-(3,4-dimethylbenzoyl)-N-[[4-[2-(5-methyl-2-phenyl-4-
oxazoly]ethoxy[phenyl]methyl]-N-317343-47-6P, Glycine,
N-(4-chloro-3-methylbenzoyl)-N-[[4-[2-(5-methyl-2-phenyl-4-
oxazoly]ethoxy[phenyl]methyl]-N- 317343-48-7P, Glycine,
N-(3,4-difluorobenzoyl)-N-[[4-[2-(5-methyl-2-phenyl-4-
oxazoly]ethoxy[phenyl]methyl]-N-317343-49-8P, Glycine,
N-[[3-(4-dimethylbenzoyl)-N-[[4-[2-(5-methyl-2-phenyl-4-
oxazoly]ethoxy[phenyl]methyl]-N-317343-50-1P, Glycine,
N-(3-chlorobenzoyl)-N-[[4-[2-(5-methyl-2-phenyl-4-
oxazoly]ethoxy[phenyl]methyl]-N-317343-51-2P, Glycine,
N-(4-chlorobenzoyl)-N-[[4-[2-(5-methyl-2-phenyl-4-
oxazoly]ethoxy[phenyl]methyl]-N-317343-52-3P, Glycine,
N-(3-chloro-4-fluorobenzoyl)-N-[[4-[2-(5-methyl-2-phenyl-4-
oxazoly]ethoxy[phenyl]methyl]-N-317343-53-4P, Glycine,
N-[[4-(1-methyl-2-phenylbenzoyl)-N-[[4-[2-(5-methyl-2-phenyl-4-
oxazoly]ethoxy[phenyl]methyl]-N-317343-54-5P, Glycine,
N-[[4-[2-(5-methyl-2-phenyl-4-oxazoly]ethoxy[phenyl]methyl]-N-[[4-(2-
methylpropyl)benzoyl]- 317343-55-6P, Glycine,
N-[[4-[2-(5-methyl-2-phenyl-4-oxazoly]ethoxy[phenyl]methyl]-N-(4-
propoxybenzoyl)- 317343-56-7P, Glycine, N-(4-butylbenzoyl)-N-[[4-
2-phenyl-4-oxazoly]ethoxy[phenyl]methyl]-N-317343-57-8P, Glycine, N-[[4-[2-(5-methyl-2-phenyl-4-
oxazoly]ethoxy[phenyl]methyl]-N-[[5-(methylthio)-2-thienyl]carbonyl]-
317343-58-9P, Glycine, N-[[4-[2-(5-methyl-2-phenyl-4-
oxazoly]ethoxy[phenyl]methyl]-N-[[[phenylmethyl]amino]carbonyl]-
317343-59-0P, Glycine, N-[[[4-methylphenyl]amino]carbonyl]-N-[[3-
2-(5-methyl-2-phenyl-4-oxazoly]ethoxy[phenyl]methyl]-N-
317343-60-3P, Glycine, N-[[[4-methoxyphenyl]methylamino]carbonyl]-N-
[[3-2-(5-methyl-2-phenyl-4-oxazoly]ethoxy[phenyl]methyl]-N-
317343-61-4P, Glycine, N-[[1,1'-biphenyl-4-yl]carbonyl]-N-
[[2-[2-(5-methyl-2-phenyl-4-oxazoly]ethoxy[phenyl]methyl]-N-
317343-62-5P, Glycine, N-[[[3-(5-dimethoxyphenyl)amino]carbonyl]-N-
[[3-2-(5-methyl-2-phenyl-4-oxazoly]ethoxy[phenyl]methyl]-N-
317343-63-6P, Glycine, N-[[[3-(5-dichlorophenyl)amino]carbonyl]-N-
[[3-2-(5-methyl-2-phenyl-4-oxazoly]ethoxy[phenyl]methyl]-N-
317343-64-7P, Glycine, N-[[[3-(5-methyl-2-phenyl-4-
oxazoly]ethoxy[phenyl]methyl]-N-[[[3-(5-methyl-2-phenyl-4-
oxazoly]ethoxy[phenyl]methyl]-N-[[[3-(5-methyl-2-phenyl-4-
oxazoly]ethoxy[phenyl]methyl]-N-[[[2,4-difluorobenzoyl]amino]carbonyl]-N-
317343-65-8P, Glycine, N-[[[2,4-difluorobenzoyl]amino]carbonyl]-N-

L7 ANSWER 77 OF 83 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)

331743-66-9P, Glycine, N-[[[3-(2,4-dimethoxyphenyl)amino]carbonyl]-N-[[3-(2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy)phenyl]methyl]-

331743-67-0P, Glycine, N-[[[2-(methoxyphenyl)amino]carbonyl]-N-[[3-(2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy)phenyl]methyl]-

331743-68-1P, Glycine, N-[[[1,1'-biphenyl]-4-ylamino]carbonyl]-N-[[4-(2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy)phenyl]methyl]-

331743-69-2P, Glycine, N-[[[3-(5-dimethoxyphenyl)amino]carbonyl]-N-[[4-(2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy)phenyl]methyl]-

331743-70-5P, Glycine, N-[[[3-(5-dichlorophenyl)amino]carbonyl]-N-[[4-(2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy)phenyl]methyl]-

331743-71-6P, Glycine, N-[[[4-(2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy)phenyl]methyl]-N-[[[3-(methylthio)phenyl]amino]carbonyl]-

331743-72-7P, Glycine, N-[[[2,4-difluorophenyl]amino]carbonyl]-N-[[4-(2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy)phenyl]methyl]-

331743-73-8P, Glycine, N-[[[2,4-dimethoxyphenyl]amino]carbonyl]-N-[[4-(2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy)phenyl]methyl]-

331743-74-9P, Glycine, N-[[[4-methoxyphenyl]amino]carbonyl]-N-[[4-(2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy)phenyl]methyl]-

331743-75-0P, Glycine, N-[[[2-(methoxyphenyl)amino]carbonyl]-N-[[4-(2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy)phenyl]methyl]-

331743-76-1P, Glycine, N-[[[4-(2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy)phenyl]methyl]-N-(1-naphthalenylsulfonyl)-

331743-77-2P, Glycine, N-[[[4-fluorophenyl]methyl]sulfonyl]-N-[[3-(2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy)phenyl]methyl]-

331743-78-3P, Glycine, N-[[[3-(2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy)phenyl]methyl]-N-(phenylsulfonyl)-

331743-79-4P, Glycine, N-[[[2,5-dichlorophenyl]sulfonyl]-N-[[3-(2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy)phenyl]methyl]-

331743-80-7P, Glycine, N-[[[4-fluorophenyl]sulfonyl]-N-[[3-(2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy)phenyl]methyl]-

331743-81-8P, Glycine, N-[[[3-(2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy)phenyl]methyl]-N-[[phenylmethyl]sulfonyl]-

331743-82-9P, Glycine, N-[[[3-(2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy)phenyl]methyl]-N-[[[1E]-2-phenylethenyl]sulfonyl]-

331743-83-0P, Glycine, N-[[[3-(2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy)phenyl]methyl]-N-[[2,2,2-trifluoroethyl]sulfonyl]-

331743-84-1P, Glycine, N-[[[2,5-dimethylphenyl]sulfonyl]-N-[[3-(2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy)phenyl]methyl]-


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(prepn. of oxazolyl- and thiazolylalkoxybenzylglycines and related compds. as antidiabetic and antiobesity agents)

RN 331741-73-2 CAPLUS


CN Glycine, N-[[[3-ethylphenoxy]carbonyl]-N-[[3-(2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy)phenyl]methyl]- (9CI) (CA INDEX NAME)

L7 ANSWER 77 OF 83 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 331741-78-7 CAPLUS

CN Glycine, N-[[[3-(2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy)phenyl]methyl]-N-[[4-propylphenoxy]carbonyl]- (9CI) (CA INDEX NAME)




RN 331741-79-8 CAPLUS

CN Glycine, N-[[[3-(2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy)phenyl]methyl]-N-[[4-(2,3-dihydro-1H-inden-5-yl)oxy]carbonyl]- (9CI) (CA INDEX NAME)



RN 331741-80-1 CAPLUS


CN Glycine, N-[[[3-(2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy)phenyl]methyl]-N-[[4-(2-ethoxyphenoxy)carbonyl]- (9CI) (CA INDEX NAME)



RN 331741-81-2 CAPLUS


CN Glycine, N-[[[3-(2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy)phenyl]methyl]-N-[[4-(2-pentylphenoxy)carbonyl]- (9CI) (CA INDEX NAME)

L7 ANSWER 77 OF 83 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 331741-74-3 CAPLUS

CN Glycine, N-[[[4-(1,1-dimethylethyl)phenoxy]carbonyl]-N-[[3-(2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy)phenyl]methyl]- (9CI) (CA INDEX NAME)




RN 331741-75-4 CAPLUS

CN Glycine, N-[[[4-(1-methylethyl)phenoxy]carbonyl]-N-[[3-(2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy)phenyl]methyl]- (9CI) (CA INDEX NAME)



RN 331741-76-5 CAPLUS


CN Glycine, N-[[[3-(2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy)phenyl]methyl]-N-[[4-(phenylmethyl)phenoxy]carbonyl]- (9CI) (CA INDEX NAME)



RN 331741-77-6 CAPLUS


CN Glycine, N-[[[4-(2-ethylphenoxy)carbonyl]-N-[[3-(2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy)phenyl]methyl]- (9CI) (CA INDEX NAME)

L7 ANSWER 77 OF 83 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 331741-82-3 CAPLUS

CN Glycine, N-[[[4-fluoro-3-(trifluoromethyl)phenoxy]carbonyl]-N-[[3-(2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy)phenyl]methyl]- (9CI) (CA INDEX NAME)




RN 331741-83-4 CAPLUS

CN Glycine, N-[[[3-(3-fluorophenyl)methoxy]carbonyl]-N-[[3-(2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy)phenyl]methyl]- (9CI) (CA INDEX NAME)



RN 331741-84-5 CAPLUS


CN Glycine, N-[[[3-(3-chlorophenyl)methoxy]carbonyl]-N-[[3-(2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy)phenyl]methyl]- (9CI) (CA INDEX NAME)




RN 331741-85-6 CAPLUS

CN Glycine, N-[[[3-(2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy)phenyl]methyl]-N-[[[3-(trifluoromethoxy)phenyl]methoxy]carbonyl]- (9CI) (CA INDEX NAME)


L7 ANSWER 77 OF 83 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 331741-86-7 CAPLUS
CN Glycine, N-[[[4-(trifluorophenyl)methoxy]carbonyl]-N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- (9CI) (CA INDEX NAME)



RN 331741-87-8 CAPLUS
CN Glycine, N-[[[4-(chlorophenyl)methoxy]carbonyl]-N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- (9CI) (CA INDEX NAME)




RN 331741-88-9 CAPLUS
CN Glycine, N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-N-[[[4-(trifluoromethoxy)phenyl]methoxy]carbonyl]- (9CI) (CA INDEX NAME)




RN 331741-89-0 CAPLUS
CN Glycine, N-[[[3,5-dimethoxyphenyl]methoxy]carbonyl]-N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- (9CI) (CA INDEX NAME)


L7 ANSWER 77 OF 83 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 331741-93-6 CAPLUS
CN Glycine, N-[[[4-(methoxyphenoxy)carbonyl]-N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- (9CI) (CA INDEX NAME)




RN 331741-94-7 CAPLUS
CN Glycine, N-[[[4-(methoxyphenoxy)carbonyl]-N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- (9CI) (CA INDEX NAME)




RN 331741-95-8 CAPLUS
CN Glycine, N-[[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-N-[[[2-(nitrophenoxy)carbonyl]- (9CI) (CA INDEX NAME)




L7 ANSWER 77 OF 83 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 331741-90-3 CAPLUS
CN Glycine, N-[[[3-(acetyloxy)phenoxy]carbonyl]-N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- (9CI) (CA INDEX NAME)




RN 331741-91-4 CAPLUS
CN Glycine, N-[[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-N-[[[3-(phenoxyphenoxy)carbonyl]- (9CI) (CA INDEX NAME)




RN 331741-92-5 CAPLUS
CN Glycine, N-[[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-N-[[[2-(propynyloxy)carbonyl]- (9CI) (CA INDEX NAME)

L7 ANSWER 77 OF 83 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)


RN 331741-96-9 CAPLUS
CN Glycine, N-[[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-N-[[[phenoxy]carbonyl]- (9CI) (CA INDEX NAME)



RN 331741-97-0 CAPLUS
CN Glycine, N-[[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-N-[[[4-(nitrophenyl)methoxy]carbonyl]- (9CI) (CA INDEX NAME)




RN 331741-98-1 CAPLUS
CN Glycine, N-[[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-N-[[[4-(nitrophenoxy)carbonyl]- (9CI) (CA INDEX NAME)




RN 331741-99-2 CAPLUS
CN Glycine, N-[[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-N-[[[4-(phenoxyphenoxy)carbonyl]- (9CI) (CA INDEX NAME)


L7 ANSWER 77 OF 83 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 331742-00-8 CAPLUS
CN Glycine, N-([4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl)-N-((2-phenoxyphenyl)methoxy)carbonyl- (9CI) (CA INDEX NAME)



RN 331742-01-9 CAPLUS
CN Glycine, N-([4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl)-N-((4-phenoxyphenyl)methoxy)carbonyl- (9CI) (CA INDEX NAME)




RN 331742-02-0 CAPLUS
CN Glycine, N-([4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl)-N-((3-phenoxyphenyl)methoxy)carbonyl- (9CI) (CA INDEX NAME)




L7 ANSWER 77 OF 83 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)

RN 331742-03-1 CAPLUS
CN Glycine, N-([4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl)-N-((2-phenoxyphenoxy)carbonyl)- (9CI) (CA INDEX NAME)




RN 331742-04-2 CAPLUS
CN Glycine, N-([4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl)-N-((2-phenoxyethoxy)carbonyl)- (9CI) (CA INDEX NAME)




RN 331742-05-3 CAPLUS
CN Glycine, N-([4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl)-N-(((2E)-3-phenyl-2-propenyl)oxy)carbonyl- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 331742-06-4 CAPLUS
CN Glycine, N-([4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl)-N-((3-phenyl-2-propynyl)oxy)carbonyl- (9CI) (CA INDEX NAME)


L7 ANSWER 77 OF 83 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 331742-07-5 CAPLUS
CN Glycine, N-([4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl)-N-((2-phenylethoxy)carbonyl)- (9CI) (CA INDEX NAME)




RN 331742-08-6 CAPLUS
CN Glycine, N-([4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl)-N-((3-phenylpropoxy)carbonyl)- (9CI) (CA INDEX NAME)




RN 331742-09-7 CAPLUS
CN Glycine, N-([4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl)-N-(((2Z)-3-phenyl-2-propenyl)oxy)carbonyl- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




L7 ANSWER 77 OF 83 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)


RN 331742-10-0 CAPLUS
CN Glycine, N-((2-methoxyphenoxy)carbonyl)-N-([4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl)- (9CI) (CA INDEX NAME)



RN 331742-11-1 CAPLUS
CN Glycine, N-((3-methoxyphenoxy)carbonyl)-N-([4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl)- (9CI) (CA INDEX NAME)




RN 331742-12-2 CAPLUS
CN Glycine, N-((3,4-dimethoxyphenoxy)carbonyl)-N-([4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl)- (9CI) (CA INDEX NAME)




RN 331742-13-3 CAPLUS
CN Glycine, N-([4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl)-N-((3,4,5-trimethoxyphenoxy)carbonyl)- (9CI) (CA INDEX NAME)


L7 ANSWER 77 OF 83 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 331742-14-4 CAPLUS
CN Glycine, N-[(3-acetylphenoxy)carbonyl]-N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- (9CI) (CA INDEX NAME)



RN 331742-15-5 CAPLUS
CN Glycine, N-[[4-methoxyphenyl]methoxy]carbonyl]-N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- (9CI) (CA INDEX NAME)




RN 331742-16-6 CAPLUS
CN Glycine, N-[(1,3-benzodioxol-5-ylmethoxy)carbonyl]-N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- (9CI) (CA INDEX NAME)




L7 ANSWER 77 OF 83 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)


PAGE 1-A



PAGE 2-A




RN 331742-20-2 CAPLUS
CN Glycine, N-[(2,3-dimethoxyphenoxy)carbonyl]-N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- (9CI) (CA INDEX NAME)




L7 ANSWER 77 OF 83 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)

RN 331742-17-7 CAPLUS
CN Glycine, N-[(1,3-benzodioxol-5-yl)oxy]carbonyl]-N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- (9CI) (CA INDEX NAME)




RN 331742-18-8 CAPLUS
CN Glycine, N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-N-[[4-(trifluoromethoxy)phenoxy]carbonyl]- (9CI) (CA INDEX NAME)




RN 331742-19-9 CAPLUS
CN Glycine, N-[[4-methoxy-1-naphthalenyl]oxy]carbonyl]-N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- (9CI) (CA INDEX NAME)

L7 ANSWER 77 OF 83 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)


RN 331742-21-3 CAPLUS
CN Benzoic acid, 4-[[[(carboxymethyl)[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]amino]carbonyl]oxy]-, 1-methyl ester (9CI) (CA INDEX NAME)



RN 331742-22-4 CAPLUS
CN Glycine, N-[[4-(phenylmethoxy)phenoxy]carbonyl]-N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- (9CI) (CA INDEX NAME)




RN 331742-23-5 CAPLUS
CN Glycine, N-[(4-hydroxyphenoxy)carbonyl]-N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- (9CI) (CA INDEX NAME)




RN 331742-24-6 CAPLUS
CN Glycine, N-[(4-bromo-3-methylphenoxy)carbonyl]-N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- (9CI) (CA INDEX NAME)


L7 ANSWER 77 OF 83 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 331742-25-7 CAPLUS
 CN Glycine, N-([4-(4-fluorophenoxy)carbonyl]-N-([4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl)methyl]- (9CI) (CA INDEX NAME)



RN 331742-26-8 CAPLUS
 CN Glycine, N-([4-(4-chlorophenoxy)carbonyl]-N-([4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl)methyl]- (9CI) (CA INDEX NAME)




RN 331742-27-9 CAPLUS
 CN Glycine, N-([4-(4-bromophenoxy)carbonyl]-N-([4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl)methyl]- (9CI) (CA INDEX NAME)




L7 ANSWER 77 OF 83 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)


RN 331742-28-0 CAPLUS
 CN Glycine, N-([4-(4-chlorophenoxy)carbonyl]-N-([4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl)methyl]- (9CI) (CA INDEX NAME)



RN 331742-29-1 CAPLUS
 CN Glycine, N-([4-(4-fluorophenoxy)carbonyl]-N-([4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl)methyl]- (9CI) (CA INDEX NAME)




RN 331742-30-4 CAPLUS
 CN Glycine, N-([4-(4-bromophenoxy)carbonyl]-N-([4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl)methyl]- (9CI) (CA INDEX NAME)




RN 331742-31-5 CAPLUS
 CN Glycine, N-([4-(4-chlorophenoxy)carbonyl]-N-([4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl)methyl]- (9CI) (CA INDEX NAME)


L7 ANSWER 77 OF 83 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 331742-32-6 CAPLUS
 CN Glycine, N-([4-(4-bromophenoxy)carbonyl]-N-([4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl)methyl]- (9CI) (CA INDEX NAME)



RN 331742-33-7 CAPLUS
 CN Glycine, N-([4-(4-fluorophenoxy)carbonyl]-N-([4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl)methyl]- (9CI) (CA INDEX NAME)




RN 331742-34-8 CAPLUS
 CN Glycine, N-([4-(4-chlorophenoxy)carbonyl]-N-([4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl)methyl]- (9CI) (CA INDEX NAME)




RN 331742-35-9 CAPLUS
 CN Glycine, N-([4-(4-fluorophenoxy)carbonyl]-N-([4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl)methyl]- (9CI) (CA INDEX NAME)


L7 ANSWER 77 OF 83 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 331742-36-0 CAPLUS
 CN Glycine, N-([4-(4-chlorophenoxy)carbonyl]-N-([4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl)methyl]- (9CI) (CA INDEX NAME)



RN 331742-37-1 CAPLUS
 CN Glycine, N-([4-(4-fluorophenoxy)carbonyl]-N-([4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl)methyl]- (9CI) (CA INDEX NAME)




RN 331742-38-2 CAPLUS
 CN Glycine, N-([4-(4-ethenylphenoxy)carbonyl]-N-([4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl)methyl]- (9CI) (CA INDEX NAME)




RN 331742-39-3 CAPLUS
 CN Glycine, N-([4-(4-fluorophenoxy)carbonyl]-N-([4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl)methyl]- (9CI) (CA INDEX NAME)


L7 ANSWER 77 OF 83 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
phenyl-4-oxazolyl)ethoxy]phenyl)methyl]- (9CI) (CA INDEX NAME)



RN 331742-40-6 CAPLUS
CN Glycine, N-[(4-chloro-3-fluorophenoxy)carbonyl]-N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl)methyl]- (9CI) (CA INDEX NAME)




RN 331742-41-7 CAPLUS
CN Glycine, N-[[3-methyl-4-(methylthio)phenoxy]carbonyl]-N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl)methyl]- (9CI) (CA INDEX NAME)




RN 331742-42-8 CAPLUS
CN Glycine, N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl)methyl]-N-[[4-(1H-pyrrol-1-yl)phenoxy]carbonyl]- (9CI) (CA INDEX NAME)


L7 ANSWER 77 OF 83 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 331742-46-2 CAPLUS
CN Glycine, N-[[3-(1,1-dimethylethyl)phenoxy]carbonyl]-N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl)methyl]- (9CI) (CA INDEX NAME)



RN 331742-47-3 CAPLUS
CN Glycine, N-[[3-(1-methylethyl)phenoxy]carbonyl]-N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl)methyl]- (9CI) (CA INDEX NAME)




RN 331742-48-4 CAPLUS
CN Glycine, N-[[3,4-dimethylphenoxy]carbonyl]-N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl)methyl]- (9CI) (CA INDEX NAME)




RN 331742-49-5 CAPLUS
CN Glycine, N-[[3,5-dimethylphenoxy]carbonyl]-N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl)methyl]- (9CI) (CA INDEX NAME)


L7 ANSWER 77 OF 83 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 331742-43-9 CAPLUS
CN Glycine, N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl)methyl]-N-[[5,6,7,8-tetrahydro-2-naphthalenyl]oxy]carbonyl]- (9CI) (CA INDEX NAME)




RN 331742-44-0 CAPLUS
CN Glycine, N-[[1,1'-biphenyl]-3-yloxy]carbonyl]-N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl)methyl]- (9CI) (CA INDEX NAME)




RN 331742-45-1 CAPLUS
CN Glycine, N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl)methyl]-N-[[3-(trifluoromethyl)phenoxy]carbonyl]- (9CI) (CA INDEX NAME)


L7 ANSWER 77 OF 83 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 331742-50-8 CAPLUS
CN Glycine, N-[[3-ethylphenoxy]carbonyl]-N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl)methyl]- (9CI) (CA INDEX NAME)



RN 331742-51-9 CAPLUS
CN Glycine, N-[[4-chloro-3-methylphenoxy]carbonyl]-N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl)methyl]- (9CI) (CA INDEX NAME)




RN 331742-52-0 CAPLUS
CN Glycine, N-[[4-(1-methylethyl)phenoxy]carbonyl]-N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl)methyl]- (9CI) (CA INDEX NAME)




RN 331742-53-1 CAPLUS
CN Glycine, N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl)methyl]-N-


L7 ANSWER 77 OF 83 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
[[4-(phenylmethyl)phenoxy]carbonyl]- (9CI) (CA INDEX NAME)



RN 331742-54-2 CAPLUS
CN Glycine, N-[[4-(4-ethylphenoxy)carbonyl]-N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- (9CI) (CA INDEX NAME)




RN 331742-55-3 CAPLUS
CN Glycine, N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-N-[[4-(propylphenoxy)carbonyl]- (9CI) (CA INDEX NAME)




RN 331742-56-4 CAPLUS
CN Glycine, N-[[2,3-dihydro-1H-inden-5-yl]oxy]carbonyl]-N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- (9CI) (CA INDEX NAME)

L7 ANSWER 77 OF 83 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)


RN 331742-60-0 CAPLUS
CN Glycine, N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-N-[[4-(1,2,3-thiadiazol-4-yl)phenoxy]carbonyl]- (9CI) (CA INDEX NAME)



RN 331742-61-1 CAPLUS
CN Glycine, N-[[4-fluoro-3-(trifluoromethyl)phenoxy]carbonyl]-N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- (9CI) (CA INDEX NAME)




RN 331742-62-2 CAPLUS
CN Glycine, N-[[3-methoxy-5-methylphenoxy]carbonyl]-N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- (9CI) (CA INDEX NAME)




RN 331742-63-3 CAPLUS
CN Glycine, N-[[3-fluorophenyl]methoxy]carbonyl]-N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- (9CI) (CA INDEX NAME)


L7 ANSWER 77 OF 83 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 331742-57-5 CAPLUS
CN Glycine, N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-N-[[2-(naphthalenyloxy)carbonyl]- (9CI) (CA INDEX NAME)




RN 331742-58-6 CAPLUS
CN Glycine, N-[[3-ethoxyphenoxy]carbonyl]-N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- (9CI) (CA INDEX NAME)




RN 331742-59-7 CAPLUS
CN Glycine, N-[[3,5-dichlorophenoxy]carbonyl]-N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- (9CI) (CA INDEX NAME)




L7 ANSWER 77 OF 83 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 331742-64-4 CAPLUS
CN Glycine, N-[[3-chlorophenyl]methoxy]carbonyl]-N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- (9CI) (CA INDEX NAME)



RN 331742-65-5 CAPLUS
CN Glycine, N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-N-[[3-(trifluoromethoxy)phenyl]methoxy]carbonyl]- (9CI) (CA INDEX NAME)




RN 331742-66-6 CAPLUS
CN Glycine, N-[[4-fluorophenyl]methoxy]carbonyl]-N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- (9CI) (CA INDEX NAME)




RN 331742-67-7 CAPLUS


L7 ANSWER 77 OF 83 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
 CN Glycine,
 N-[[[4-(chlorophenyl)methoxy]carbonyl]-N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- (9CI) (CA INDEX NAME)



RN 331742-68-8 CAPLUS
 CN Glycine, N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-N-[[[4-(trifluoromethoxy)phenyl]methoxy]carbonyl]- (9CI) (CA INDEX NAME)




RN 331742-69-9 CAPLUS
 CN Glycine, N-[[[3,5-dimethoxyphenyl]methoxy]carbonyl]-N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- (9CI) (CA INDEX NAME)




RN 331742-70-2 CAPLUS
 CN Glycine, N-[[[3-(difluoromethoxy)phenoxy]carbonyl]-N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- (9CI) (CA INDEX NAME)


L7 ANSWER 77 OF 83 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
 (phenoxythioxomethyl)- (9CI) (CA INDEX NAME)




RN 331742-75-7 CAPLUS
 CN Glycine,
 N-[[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-N-(4-phenoxybenzoyl)- (9CI) (CA INDEX NAME)



RN 331742-76-8 CAPLUS
 CN Glycine,
 N-[[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-N-(2-naphthalenylcarbonyl)- (9CI) (CA INDEX NAME)




RN 331742-77-9 CAPLUS
 CN Glycine,
 N-[[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-N-(2-thienylcarbonyl)- (9CI) (CA INDEX NAME)




RN 331742-78-0 CAPLUS
 CN Glycine, N-(3,5-dimethoxybenzoyl)-N-[[3-[2-(5-methyl-2-phenyl-4-


L7 ANSWER 77 OF 83 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 331742-71-3 CAPLUS
 CN Glycine, N-[[[3-(difluoromethoxy)phenoxy]carbonyl]-N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- (9CI) (CA INDEX NAME)



RN 331742-72-4 CAPLUS
 CN Glycine, N-[[[3-hydroxyphenoxy]carbonyl]-N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- (9CI) (CA INDEX NAME)




RN 331742-73-5 CAPLUS
 CN Glycine, N-[[[3-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-N-(phenoxythioxomethyl)- (9CI) (CA INDEX NAME)




RN 331742-74-6 CAPLUS
 CN Glycine, N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-N-


L7 ANSWER 77 OF 83 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
 oxazolyl)ethoxy]phenyl]methyl]- (9CI) (CA INDEX NAME)



RN 331742-79-1 CAPLUS
 CN Glycine,
 N-[[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-N-(1-naphthalenylcarbonyl)- (9CI) (CA INDEX NAME)




RN 331742-80-4 CAPLUS
 CN Glycine, N-(3,4-difluorobenzoyl)-N-[[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- (9CI) (CA INDEX NAME)




RN 331742-81-5 CAPLUS
 CN Glycine,
 N-[[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-N-(3-phenoxybenzoyl)- (9CI) (CA INDEX NAME)


L7 ANSWER 77 OF 83 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 331742-82-6 CAPLUS
CN Glycine, N-([3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl)-N-(4-(phenylmethyl)benzoyl)- (9CI) (CA INDEX NAME)



RN 331742-83-7 CAPLUS
CN Glycine, N-([3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl)-N-(4-(3-phenylpropyl)benzoyl)- (9CI) (CA INDEX NAME)




RN 331742-84-8 CAPLUS
CN Glycine, N-([3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl)-N-(4-(3,5-dimethylbenzoyl)- (9CI) (CA INDEX NAME)




RN 331742-85-9 CAPLUS
CN Glycine, N-([3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl)-N-(4-(5-methyl-2-thienyl)benzoyl)- (9CI) (CA INDEX NAME)


L7 ANSWER 77 OF 83 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 331742-90-6 CAPLUS
CN Glycine, N-([3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl)-N-(4-(3-chloro-4-methoxybenzoyl)- (9CI) (CA INDEX NAME)



RN 331742-91-7 CAPLUS
CN Glycine, N-([3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl)-N-(4-(3,4-dimethylbenzoyl)- (9CI) (CA INDEX NAME)




RN 331742-92-8 CAPLUS
CN Glycine, N-([3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl)-N-(4-(2-methylpropyl)benzoyl)- (9CI) (CA INDEX NAME)




RN 331742-93-9 CAPLUS
CN Glycine, N-([3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl)-N-(4-(3-fluoro-4-methylbenzoyl)- (9CI) (CA INDEX NAME)


L7 ANSWER 77 OF 83 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 331742-86-0 CAPLUS
CN Glycine, N-([3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl)-N-(4-(5-nitro-2-thienyl)benzoyl)- (9CI) (CA INDEX NAME)



RN 331742-87-1 CAPLUS
CN Glycine, N-([3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl)-N-(4-(4-methyl-2-thienyl)benzoyl)- (9CI) (CA INDEX NAME)




RN 331742-88-2 CAPLUS
CN Glycine, N-([3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl)-N-(4-butoxybenzoyl)- (9CI) (CA INDEX NAME)




RN 331742-69-3 CAPLUS
CN Glycine, N-([3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl)-N-(4-methoxy-3-methylbenzoyl)- (9CI) (CA INDEX NAME)


L7 ANSWER 77 OF 83 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 331742-94-0 CAPLUS
CN Glycine, N-([3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl)-N-(4-(methylthio)benzoyl)- (9CI) (CA INDEX NAME)



RN 331742-95-1 CAPLUS
CN Glycine, N-([3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl)-N-(4-(1-methylethyl)benzoyl)- (9CI) (CA INDEX NAME)




RN 331742-96-2 CAPLUS
CN Glycine, N-([3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl)-N-(4-(2-methylpropyl)benzoyl)- (9CI) (CA INDEX NAME)




RN 331742-97-3 CAPLUS
CN Glycine, N-([3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl)-N-(4-chloro-3-methylbenzoyl)- (9CI) (CA INDEX NAME)


L7 ANSWER 77 OF 83 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 331742-98-4 CAPLUS
CN Glycine, N-(3-methoxy-4-methylbenzoyl)-N-([3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl)methyl]- (9CI) (CA INDEX NAME)



RN 331742-99-5 CAPLUS
CN Glycine, N-(1,3-benzodioxol-5-ylcarbonyl)-N-([3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl)methyl]- (9CI) (CA INDEX NAME)




RN 331743-00-1 CAPLUS
CN Glycine, N-(4-(1-methylethoxy)benzoyl)-N-([3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl)methyl]- (9CI) (CA INDEX NAME)




RN 331743-02-3 CAPLUS
CN Glycine, N-((3,4-dichlorobenzoyl)-N-([3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl)methyl])-(9CI) (CA INDEX NAME)


L7 ANSWER 77 OF 83 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 331743-08-9 CAPLUS
CN Glycine, N-((3-chlorobenzoyl)-N-([3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl)methyl])-(9CI) (CA INDEX NAME)



RN 331743-09-0 CAPLUS
CN Glycine, N-(4-ethoxybenzoyl)-N-([3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl)methyl]- (9CI) (CA INDEX NAME)




RN 331743-10-3 CAPLUS
CN Glycine, N-(3-methylbenzoyl)-N-([3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl)methyl]- (9CI) (CA INDEX NAME)




RN 331743-11-4 CAPLUS
CN Glycine, N-(4-methoxybenzoyl)-N-([3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl)methyl]- (9CI) (CA INDEX NAME)


L7 ANSWER 77 OF 83 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 331743-04-5 CAPLUS
CN Glycine, N-(3-methoxybenzoyl)-N-([3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl)methyl]- (9CI) (CA INDEX NAME)



RN 331743-05-6 CAPLUS
CN Glycine, N-(3-methoxybenzoyl)-N-([3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl)methyl]- (9CI) (CA INDEX NAME)




RN 331743-06-7 CAPLUS
CN Glycine, N-(4-fluorobenzoyl)-N-([3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl)methyl]- (9CI) (CA INDEX NAME)




RN 331743-07-8 CAPLUS
CN Glycine, N-(3,4-dichlorobenzoyl)-N-([3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl)methyl]- (9CI) (CA INDEX NAME)


L7 ANSWER 77 OF 83 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 331743-12-5 CAPLUS
CN Glycine, N-(3-chlorobenzoyl)-N-([3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl)methyl]- (9CI) (CA INDEX NAME)



RN 331743-13-6 CAPLUS
CN Glycine, N-(4-chlorobenzoyl)-N-([3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl)methyl]- (9CI) (CA INDEX NAME)




RN 331743-14-7 CAPLUS
CN Glycine, N-(4-butybenzoyl)-N-([3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl)methyl]- (9CI) (CA INDEX NAME)




RN 331743-15-8 CAPLUS
CN Glycine, N-(3,5-dichlorobenzoyl)-N-([3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl)methyl]- (9CI) (CA INDEX NAME)


L7 ANSWER 77 OF 83 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 331743-16-9 CAPLUS
CN Glycine, N-((3-fluorobenzoyl)-N-([3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl)methyl]- (9CI) (CA INDEX NAME)



RN 331743-17-0 CAPLUS
CN Glycine, N-((3-chloro-4-fluorobenzoyl)-N-([3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl)methyl]- (9CI) (CA INDEX NAME)




RN 331743-18-1 CAPLUS
CN Glycine, N-((3-ethoxybenzoyl)-N-([3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl)methyl]- (9CI) (CA INDEX NAME)




RN 331743-19-2 CAPLUS
CN Glycine, N-((5-chloro-2-thienyl)carbonyl)-N-([3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl)methyl]- (9CI) (CA INDEX NAME)


L7 ANSWER 77 OF 83 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 331743-24-9 CAPLUS
CN Glycine, N-((1,3-benzodioxol-5-yl)acetyl)-N-([3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl)methyl]- (9CI) (CA INDEX NAME)



RN 331743-25-0 CAPLUS
CN Glycine, N-((4-ethoxyphenyl)acetyl)-N-([3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl)methyl]- (9CI) (CA INDEX NAME)




RN 331743-26-1 CAPLUS
CN Glycine, N-((3-nitrophenyl)acetyl)-N-([3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl)methyl]- (9CI) (CA INDEX NAME)




RN 331743-27-2 CAPLUS
CN Glycine, N-((4-nitrophenyl)acetyl)-N-([3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl)methyl]- (9CI) (CA INDEX NAME)


L7 ANSWER 77 OF 83 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 331743-20-5 CAPLUS
CN Glycine, N-([3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl)methyl]-N-([5-(methylthio)-2-thienyl]carbonyl)- (9CI) (CA INDEX NAME)



RN 331743-21-6 CAPLUS
CN Glycine, N-((4-methylphenyl)acetyl)-N-([3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl)methyl]- (9CI) (CA INDEX NAME)




RN 331743-22-7 CAPLUS
CN Glycine, N-((3-fluorophenyl)acetyl)-N-([3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl)methyl]- (9CI) (CA INDEX NAME)




RN 331743-23-8 CAPLUS
CN Glycine, N-((3,5-difluorophenyl)acetyl)-N-([3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl)methyl]- (9CI) (CA INDEX NAME)


L7 ANSWER 77 OF 83 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 331743-28-3 CAPLUS
CN Glycine, N-([4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl)methyl]-N-([1-oxo-3-phenylpropyl]- (9CI) (CA INDEX NAME)



RN 331743-29-4 CAPLUS
CN Glycine, N-((1,1'-biphenyl)-2-yl)carbonyl)-N-([4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl)methyl]- (9CI) (CA INDEX NAME)




RN 331743-30-7 CAPLUS
CN Glycine, N-([4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl)methyl]-N-([4-phenoxybenzoyl]- (9CI) (CA INDEX NAME)




RN 331743-31-8 CAPLUS
CN Glycine, N-([4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl)methyl]-N-([2-(phenylmethyl)benzoyl]- (9CI) (CA INDEX NAME)


L7 ANSWER 77 OF 83 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 331743-32-9 CAPLUS
CN Glycine,
N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-N-[3-(phenylsulfinyl)benzoyl]- (9CI) (CA INDEX NAME)




RN 331743-33-0 CAPLUS
CN Glycine,
N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-N-[2-[(4-methylphenyl)thio]benzoyl]- (9CI) (CA INDEX NAME)




RN 331743-34-1 CAPLUS
CN Glycine,
N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-N-[2-(phenylsulfinyl)benzoyl]- (9CI) (CA INDEX NAME)


L7 ANSWER 77 OF 83 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 331743-38-5 CAPLUS
CN Glycine,
N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-N-[3-phenoxybenzoyl]- (9CI) (CA INDEX NAME)



RN 331743-39-6 CAPLUS
CN Glycine, N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-N-[(2-phenoxyphenyl)acetyl]- (9CI) (CA INDEX NAME)




RN 331743-40-9 CAPLUS
CN Glycine, N-[[1,1'-biphenyl]-4-ylacetyl]-N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- (9CI) (CA INDEX NAME)




RN 331743-41-0 CAPLUS
CN Glycine,
N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-N-[4-


L7 ANSWER 77 OF 83 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 331743-35-2 CAPLUS
CN Glycine, N-(5-chloro-2-phenoxybenzoyl)-N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- (9CI) (CA INDEX NAME)




RN 331743-36-3 CAPLUS
CN Glycine,
N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-N-[2-phenoxybenzoyl]- (9CI) (CA INDEX NAME)




RN 331743-37-4 CAPLUS
CN Glycine, N-[(1,1'-biphenyl)-4-ylcarbonyl]-N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- (9CI) (CA INDEX NAME)


L7 ANSWER 77 OF 83 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 331743-42-1 CAPLUS
CN Glycine,
N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-N-[2-(1H-pyrrol-1-yl)benzoyl]- (9CI) (CA INDEX NAME)



RN 331743-43-2 CAPLUS
CN Glycine, N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-N-[(4-phenoxyphenyl)acetyl]- (9CI) (CA INDEX NAME)



RN 331743-44-3 CAPLUS
CN Glycine, N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-N-[(3-phenoxyphenyl)acetyl]- (9CI) (CA INDEX NAME)




RN 331743-45-4 CAPLUS
CN Glycine,
N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-N-[4-

L7 ANSWER 77 OF 83 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)


RN 331743-45-4 CAPLUS

CN Glycine, N-[(2,2'-bithiophen-5-ylcarbonyl)-N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- (9CI) (CA INDEX NAME)




RN 331743-46-5 CAPLUS

CN Glycine, N-(3,4-dimethylbenzoyl)-N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- (9CI) (CA INDEX NAME)



RN 331743-47-6 CAPLUS

CN Glycine, N-(4-chloro-3-methylbenzoyl)-N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- (9CI) (CA INDEX NAME)



RN 331743-48-7 CAPLUS


CN Glycine, N-(3,4-difluorobenzoyl)-N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- (9CI) (CA INDEX NAME)



L7 ANSWER 77 OF 83 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)


RN 331743-52-3 CAPLUS

CN Glycine, N-(3-chloro-4-fluorobenzoyl)-N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- (9CI) (CA INDEX NAME)




RN 331743-53-4 CAPLUS

CN Glycine, N-(4-(1-methylethyl)benzoyl)-N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- (9CI) (CA INDEX NAME)



RN 331743-54-5 CAPLUS

CN Glycine, N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-N-(4-(2-methylpropyl)benzoyl)- (9CI) (CA INDEX NAME)




RN 331743-55-6 CAPLUS

CN Glycine, N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-N-(4-propoxybenzoyl)- (9CI) (CA INDEX NAME)




L7 ANSWER 77 OF 83 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 331743-49-8 CAPLUS

CN Glycine, N-(3,4-dichlorobenzoyl)-N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- (9CI) (CA INDEX NAME)




RN 331743-50-1 CAPLUS

CN Glycine, N-(3-chlorobenzoyl)-N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- (9CI) (CA INDEX NAME)




RN 331743-51-2 CAPLUS

CN Glycine, N-(4-chlorobenzoyl)-N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- (9CI) (CA INDEX NAME)




L7 ANSWER 77 OF 83 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 331743-56-7 CAPLUS

CN Glycine, N-(4-butylbenzoyl)-N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- (9CI) (CA INDEX NAME)




RN 331743-57-8 CAPLUS

CN Glycine, N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-N-[[5-(methylthio)-2-thienyl]carbonyl]- (9CI) (CA INDEX NAME)



RN 331743-58-9 CAPLUS


CN Glycine, N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-N-[[phenylmethyl]amino]carbonyl]- (9CI) (CA INDEX NAME)




RN 331743-59-0 CAPLUS

CN Glycine, N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-N-[[4-methoxyphenyl]amino]carbonyl]- (9CI) (CA INDEX NAME)


L7 ANSWER 77 OF 83 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
4-oxazolyl)ethoxy]phenyl)methyl]- (9CI) (CA INDEX NAME)




RN 331743-60-3 CAPLUS
CN Glycine, N-([[(4-methoxyphenyl)methylamino]carbonyl]-N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl)methyl]]- (9CI) (CA INDEX NAME)



RN 331743-61-4 CAPLUS
CN Glycine, N-([[(1,1'-biphenyl)-4-ylamino]carbonyl]-N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl)methyl]]- (9CI) (CA INDEX NAME)




RN 331743-62-5 CAPLUS
CN Glycine, N-([[(3,5-dimethoxyphenyl)amino]carbonyl]-N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl)methyl]]- (9CI) (CA INDEX NAME)




RN 331743-63-6 CAPLUS
CN Glycine, N-([[(3,5-dichlorophenyl)amino]carbonyl]-N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl)methyl]]- (9CI) (CA INDEX NAME)


L7 ANSWER 77 OF 83 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
4-oxazolyl)ethoxy]phenyl)methyl]- (9CI) (CA INDEX NAME)




RN 331743-68-1 CAPLUS
CN Glycine, N-([[(1,1'-biphenyl)-4-ylamino]carbonyl]-N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl)methyl]]- (9CI) (CA INDEX NAME)



RN 331743-69-2 CAPLUS
CN Glycine, N-([[(3,5-dimethoxyphenyl)amino]carbonyl]-N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl)methyl]]- (9CI) (CA INDEX NAME)




RN 331743-70-5 CAPLUS
CN Glycine, N-([[(3,5-dichlorophenyl)amino]carbonyl]-N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl)methyl]]- (9CI) (CA INDEX NAME)




RN 331743-71-6 CAPLUS
CN Glycine, N-([[(4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl)amino]carbonyl]-N-[[3-(methylthio)phenyl]methyl]]- (9CI) (CA INDEX NAME)


L7 ANSWER 77 OF 83 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
phenyl-4-oxazolyl)ethoxy]phenyl)methyl]- (9CI) (CA INDEX NAME)




RN 331743-64-7 CAPLUS
CN Glycine, N-([[(3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl)amino]carbonyl]-N-[[3-(methylthio)phenyl]methyl]]- (9CI) (CA INDEX NAME)



RN 331743-65-8 CAPLUS
CN Glycine, N-([[(2,4-difluorophenyl)amino]carbonyl]-N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl)methyl]]- (9CI) (CA INDEX NAME)




RN 331743-66-9 CAPLUS
CN Glycine, N-([[(2,4-dimethoxyphenyl)amino]carbonyl]-N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl)methyl]]- (9CI) (CA INDEX NAME)




RN 331743-67-0 CAPLUS
CN Glycine, N-([[(2-methoxyphenyl)amino]carbonyl]-N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl)methyl]]- (9CI) (CA INDEX NAME)


L7 ANSWER 77 OF 83 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 331743-72-7 CAPLUS
CN Glycine, N-([[(2,4-difluorophenyl)amino]carbonyl]-N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl)methyl]]- (9CI) (CA INDEX NAME)



RN 331743-73-8 CAPLUS
CN Glycine, N-([[(2,4-dimethoxyphenyl)amino]carbonyl]-N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl)methyl]]- (9CI) (CA INDEX NAME)




RN 331743-74-9 CAPLUS
CN Glycine, N-([[(4-methoxyphenyl)amino]carbonyl]-N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl)methyl]]- (9CI) (CA INDEX NAME)




RN 331743-75-0 CAPLUS

L7 ANSWER 77 OF 83 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
 CN Glycine,
 N-[[[2-methoxyphenyl]amino]carbonyl]-N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- (9CI) (CA INDEX NAME)




RN 331743-76-1 CAPLUS
 CN Glycine,
 N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-N-(1-naphthalenylsulfonyl)- (9CI) (CA INDEX NAME)

PAGE 1-A




L7 ANSWER 77 OF 83 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)

RN 331743-80-7 CAPLUS
 CN Glycine, N-[[4-(4-fluorophenyl)sulfonyl]-N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- (9CI) (CA INDEX NAME)




RN 331743-81-8 CAPLUS
 CN Glycine, N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-N-[[phenylmethyl]sulfonyl]- (9CI) (CA INDEX NAME)




RN 331743-82-9 CAPLUS
 CN Glycine, N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-N-[[1E]-2-phenylethenyl]sulfonyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 331743-83-0 CAPLUS
 CN Glycine, N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-N-[[2,2,2-trifluoroethyl]sulfonyl]- (9CI) (CA INDEX NAME)




RN 331743-84-1 CAPLUS

L7 ANSWER 77 OF 83 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)


PAGE 2-A




RN 331743-77-2 CAPLUS
 CN Glycine,
 N-[[[4-(4-fluorophenyl)methyl]sulfonyl]-N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- (9CI) (CA INDEX NAME)



RN 331743-78-3 CAPLUS
 CN Glycine, N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-N-(phenylsulfonyl)- (9CI) (CA INDEX NAME)




RN 331743-79-4 CAPLUS
 CN Glycine, N-[[2,5-dichlorophenyl]sulfonyl]-N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- (9CI) (CA INDEX NAME)



L7 ANSWER 77 OF 83 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)

RN 331743-85-2P, Glycine, N-[[3,4-dichlorophenyl]sulfonyl]-N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- (9CI) (CA INDEX NAME)



IT 331743-85-2P, Glycine, N-[[3,4-dichlorophenyl]sulfonyl]-N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- 331743-86-3P, Glycine, N-[[2,5-dichloro-3-thienyl]sulfonyl]-N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- 331743-87-4P, Glycine, N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-N-[[5-(2-pyridinyl)ethyl]sulfonyl]- 331743-88-5P, Glycine, N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-N-[[3-(trifluoromethyl)phenyl]methyl]sulfonyl]- 331743-89-6P, Glycine, N-[[3-(2-methylphenyl)methyl]sulfonyl]-N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- 331743-90-9P, Glycine, N-[[2-(4-fluorophenyl)methyl]sulfonyl]-N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- 331743-91-0P, Glycine, N-[[4-chlorophenyl]sulfonyl]-N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- 331743-92-1P, Glycine, N-[[3,4-dichlorophenyl]sulfonyl]-N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- 331743-93-2P, Glycine,


N-[[[2-chloro-6-fluorophenyl]methyl]sulfonyl]-N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- 331743-94-3P, Glycine, N-[[4-chlorophenyl]sulfonyl]-N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- 331743-95-4P, Glycine, N-[[2-chlorophenyl]sulfonyl]-N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- 331743-96-5P, Glycine, N-[[2,4-dichlorophenyl]sulfonyl]-N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- 331743-97-6P, Glycine, N-[[2-methylphenyl]sulfonyl]-N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- 331743-98-7P, Glycine, N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-N-[[4-(trifluoromethoxy)phenyl]methyl]sulfonyl]- 331743-99-8P, Glycine, N-[[[4-(1,1-dimethylethyl)phenyl]methyl]sulfonyl]-N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- 331744-00-4P, Glycine, N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-N-[[4-(propylphenyl)sulfonyl]- 331744-01-5P, Glycine, N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-N-(2-naphthalenylsulfonyl)- 331744-02-6P, Glycine, N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-N-[[4-(2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-N-[[4-(2,6-trimethylphenyl)sulfonyl]- 331744-04-8P, Glycine, N-[[4-chlorophenyl]sulfonyl]-N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- 331744-05-9P, Glycine, N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-N-[[4-(phenylmethyl)sulfonyl]- 331744-06-0P, Glycine,

L7 ANSWER 77 OF 83 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)

439276-49-0P 439276-50-3P 439276-51-4P
439276-54-7P 439276-55-8P 439276-57-0P
439276-58-1P 439276-61-6P 439276-62-7PRL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU
(Therapeutic use); BIOL (Biological study); PREP (Preparation); USES
(Uses)(prepn. of oxazolyl- and thiazolylalkoxybenzylglycines and related
compds. as antidiabetic and antiobesity agents)


RN 331743-85-2 CAPLUS

CN Glycine, N-[[[3,4-dichlorophenyl]sulfonyl]-N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- (9CI) (CA INDEX NAME)




RN 331743-86-3 CAPLUS

CN Glycine, N-[[[2,5-dichloro-3-thienyl]sulfonyl]-N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- (9CI) (CA INDEX NAME)




RN 331743-87-4 CAPLUS

CN Glycine, N-[[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-N-[[5-(2-pyridinylsulfonyl)-2-thienyl]sulfonyl]- (9CI) (CA INDEX NAME)




L7 ANSWER 77 OF 83 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 331743-92-1 CAPLUS

CN Glycine, N-[[[3,4-dichlorophenyl]methyl]sulfonyl]-N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- (9CI) (CA INDEX NAME)




RN 331743-93-2 CAPLUS

CN Glycine, N-[[[2-chloro-6-fluorophenyl]methyl]sulfonyl]-N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- (9CI) (CA INDEX NAME)



RN 331743-94-3 CAPLUS


CN Glycine, N-[[[4-chlorophenyl]methyl]sulfonyl]-N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- (9CI) (CA INDEX NAME)



L7 ANSWER 77 OF 83 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)


RN 331743-88-5 CAPLUS

CN Glycine, N-[[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-N-[[[3-(trifluoromethyl)phenyl]methyl]sulfonyl]- (9CI) (CA INDEX NAME)




RN 331743-89-6 CAPLUS

CN Glycine, N-[[[3-methylphenyl]methyl]sulfonyl]-N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- (9CI) (CA INDEX NAME)



RN 331743-90-9 CAPLUS

CN Glycine, N-[[[2-fluorophenyl]methyl]sulfonyl]-N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- (9CI) (CA INDEX NAME)




RN 331743-91-0 CAPLUS

CN Glycine, N-[[[4-chlorophenyl]sulfonyl]-N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- (9CI) (CA INDEX NAME)

L7 ANSWER 77 OF 83 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)


RN 331743-95-4 CAPLUS

CN Glycine, N-[[[2-chlorophenyl]methyl]sulfonyl]-N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- (9CI) (CA INDEX NAME)




RN 331743-96-5 CAPLUS

CN Glycine, N-[[[2,4-dichlorophenyl]methyl]sulfonyl]-N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- (9CI) (CA INDEX NAME)



RN 331743-97-6 CAPLUS


CN Glycine, N-[[[2-methylphenyl]methyl]sulfonyl]-N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- (9CI) (CA INDEX NAME)




RN 331743-98-7 CAPLUS

CN Glycine, N-[[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-N-[[[4-(trifluoromethoxy)phenyl]methyl]sulfonyl]- (9CI) (CA INDEX NAME)


L7 ANSWER 77 OF 83 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 331743-99-8 CAPLUS
CN Glycine, N-[[[4-(1,1-dimethylethyl)phenyl]methyl]sulfonyl]-N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- (9CI) (CA INDEX NAME)




RN 331744-00-4 CAPLUS
CN Glycine, N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-N-[[4-(propylphenyl)sulfonyl]- (9CI) (CA INDEX NAME)




RN 331744-01-5 CAPLUS
CN Glycine, N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-N-(2-naphthalenylsulfonyl)- (9CI) (CA INDEX NAME)

L7 ANSWER 77 OF 83 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 331744-05-9 CAPLUS
CN Glycine, N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-N-[[phenylmethyl]sulfonyl]- (9CI) (CA INDEX NAME)




RN 331744-06-0 CAPLUS
CN Glycine, N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-N-[[1E]-2-phenylethenyl]sulfonyl]- (9CI) (CA INDEX NAME)


Double bond geometry as shown.




RN 331744-07-1 CAPLUS
CN Glycine, N-[[2,5-dimethylphenyl]sulfonyl]-N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- (9CI) (CA INDEX NAME)




L7 ANSWER 77 OF 83 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 331744-02-6 CAPLUS
CN Glycine, N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-N-(phenylsulfonyl)- (9CI) (CA INDEX NAME)




RN 331744-03-7 CAPLUS
CN Glycine, N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-N-[[2,4,6-trimethylphenyl]sulfonyl]- (9CI) (CA INDEX NAME)




RN 331744-04-8 CAPLUS
CN Glycine, N-[[4-chlorophenyl]sulfonyl]-N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- (9CI) (CA INDEX NAME)

L7 ANSWER 77 OF 83 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)


RN 331744-08-2 CAPLUS
CN Glycine, N-[[3,4-dichlorophenyl]sulfonyl]-N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- (9CI) (CA INDEX NAME)



RN 331744-09-3 CAPLUS
CN Glycine, N-[[4-(2-chloro-6-nitrophenoxy)phenyl]sulfonyl]-N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- (9CI) (CA INDEX NAME)




RN 331744-10-6 CAPLUS
CN Glycine, N-(2-dibenzofuranyl)sulfonyl]-N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- (9CI) (CA INDEX NAME)




RN 331744-11-7 CAPLUS
CN Glycine, N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-N-[[3-(trifluoromethyl)phenyl]methyl]sulfonyl]- (9CI) (CA INDEX NAME)


L7 ANSWER 77 OF 83 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 331744-12-8 CAPLUS
CN Glycine,
N-[[[(3-methylphenyl)methyl]sulfonyl]-N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- (9CI) (CA INDEX NAME)




RN 331744-13-9 CAPLUS
CN Glycine,
N-[[[(2-fluorophenyl)methyl]sulfonyl]-N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- (9CI) (CA INDEX NAME)




RN 331744-14-0 CAPLUS
CN Glycine,
N-[[[(4-fluorophenyl)methyl]sulfonyl]-N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- (9CI) (CA INDEX NAME)


L7 ANSWER 77 OF 83 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 331744-18-4 CAPLUS
CN Glycine,
N-[[[(2-chlorophenyl)methyl]sulfonyl]-N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- (9CI) (CA INDEX NAME)




RN 331744-19-5 CAPLUS
CN Glycine, N-[[[(2,4-dichlorophenyl)methyl]sulfonyl]-N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- (9CI) (CA INDEX NAME)




RN 331744-20-8 CAPLUS
CN Glycine,
N-[[[(2-methylphenyl)methyl]sulfonyl]-N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- (9CI) (CA INDEX NAME)


L7 ANSWER 77 OF 83 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 331744-15-1 CAPLUS
CN Glycine, N-[[[(3,4-dichlorophenyl)methyl]sulfonyl]-N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- (9CI) (CA INDEX NAME)




RN 331744-16-2 CAPLUS
CN Glycine,
N-[[[(2-chloro-6-fluorophenyl)methyl]sulfonyl]-N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- (9CI) (CA INDEX NAME)




RN 331744-17-3 CAPLUS
CN Glycine,
N-[[[(4-chlorophenyl)methyl]sulfonyl]-N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- (9CI) (CA INDEX NAME)


L7 ANSWER 77 OF 83 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 331744-21-9 CAPLUS
CN Glycine, N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-N-[[4-[2-(trifluoromethoxy)phenyl]methyl]sulfonyl]- (9CI) (CA INDEX NAME)



RN 331744-22-0 CAPLUS
CN Glycine, N-[[[(1,1-dimethylethyl)phenyl]methyl]sulfonyl]-N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- (9CI) (CA INDEX NAME)




RN 331744-25-3 CAPLUS
CN Glycine, N-[[2-[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]ethyl]-N-[[4-(phenoxyphenyl)methyl]- (9CI) (CA INDEX NAME)



L7 ANSWER 77 OF 83 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)


RN 331744-26-4 CAPLUS

CN Glycine, N-[(5-[2-chlorophenyl]-2-furanyl)methyl]-N-[2-[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]ethyl]- (9CI) (CA INDEX NAME)




RN 331744-27-5 CAPLUS

CN Glycine, N-[2-[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]ethyl]-N-[(phenylmethoxy)carbonyl]- (9CI) (CA INDEX NAME)



RN 331744-28-6 CAPLUS

CN Glycine, N-[2-[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]ethyl]-N-(phenylmethyl)- (9CI) (CA INDEX NAME)



RN 331744-30-0 CAPLUS


CN Glycine, N-[(4-methoxyphenoxy)carbonyl]-N-[(2-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl)methyl]- (9CI) (CA INDEX NAME)



L7 ANSWER 77 OF 83 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)


RN 331744-34-4 CAPLUS

CN β-Alanine, N-[(3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl)methyl]-N-[(4-phenoxyphenyl)methyl]- (9CI) (CA INDEX NAME)




RN 331744-35-5 CAPLUS

CN β-Alanine, N-[(3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl)methyl]-N-[(phenylmethoxy)carbonyl]- (9CI) (CA INDEX NAME)




RN 331744-36-6 CAPLUS

CN β-Alanine, N-[(4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl)methyl]-N-(phenoxycarbonyl)- (9CI) (CA INDEX NAME)




RN 331744-37-7 CAPLUS

CN β-Alanine, N-[(4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl)methyl]-N-[(4-phenoxyphenyl)methyl]- (9CI) (CA INDEX NAME)




L7 ANSWER 77 OF 83 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 331744-31-1 CAPLUS

CN β-Alanine, N-[(3-chlorophenoxy)carbonyl]-N-[(4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl)methyl]- (9CI) (CA INDEX NAME)




RN 331744-32-2 CAPLUS

CN β-Alanine, N-[(3-chlorophenoxy)carbonyl]-N-[(3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl)methyl]- (9CI) (CA INDEX NAME)




RN 331744-33-3 CAPLUS

CN β-Alanine, N-[(3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl)methyl]-N-(phenoxycarbonyl)- (9CI) (CA INDEX NAME)




L7 ANSWER 77 OF 83 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 331744-38-8 CAPLUS

CN β-Alanine, N-[(3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl)methyl]-N-[(phenylmethoxy)carbonyl]- (9CI) (CA INDEX NAME)




RN 331744-39-9 CAPLUS

CN Glycine, N-[(3-(cyclopropylphenoxy)carbonyl)-N-[(4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl)methyl]- (9CI) (CA INDEX NAME)




RN 331744-40-2 CAPLUS

CN Glycine, N-[(3-(cyclopropylphenoxy)carbonyl)-N-[(3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl)methyl]- (9CI) (CA INDEX NAME)




RN 331744-41-3 CAPLUS


L7 ANSWER 77 OF 83 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
 CN Glycine, N-[(3-(cyclopropyloxy)phenoxy)carbonyl]-N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- (9CI) (CA INDEX NAME)



RN 331744-42-4 CAPLUS
 CN Glycine, N-[(3-fluoro-4-methylphenoxy)carbonyl]-N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- (9CI) (CA INDEX NAME)



RN 331744-43-5 CAPLUS
 CN Glycine, N-[(3-chloro-4-methylphenoxy)carbonyl]-N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- (9CI) (CA INDEX NAME)




RN 331744-44-6 CAPLUS
 CN Glycine, N-[(3-bromo-4-methylphenoxy)carbonyl]-N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- (9CI) (CA INDEX NAME)




L7 ANSWER 77 OF 83 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)


RN 331744-48-0 CAPLUS
 CN Glycine, N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-N-[(3-propylphenoxy)carbonyl]- (9CI) (CA INDEX NAME)



RN 331744-49-1 CAPLUS
 CN Glycine, N-[(4-cyclopropylphenoxy)carbonyl]-N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- (9CI) (CA INDEX NAME)




RN 331744-50-4 CAPLUS
 CN Glycine, N-[(4-(cyclopropyloxy)phenoxy)carbonyl]-N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- (9CI) (CA INDEX NAME)




RN 331744-51-5 CAPLUS
 CN Glycine, N-[(3-fluoro-4-methylphenoxy)carbonyl]-N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- (9CI) (CA INDEX NAME)




L7 ANSWER 77 OF 83 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 331744-45-7 CAPLUS
 CN Glycine, N-[(3-fluoro-4-methoxyphenoxy)carbonyl]-N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- (9CI) (CA INDEX NAME)



RN 331744-46-8 CAPLUS
 CN Glycine, N-[(3-chloro-4-methoxyphenoxy)carbonyl]-N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- (9CI) (CA INDEX NAME)





RN 331744-47-9 CAPLUS
 CN Glycine, N-[(3-bromo-4-methoxyphenoxy)carbonyl]-N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- (9CI) (CA INDEX NAME)




L7 ANSWER 77 OF 83 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)


RN 331744-52-6 CAPLUS
 CN Glycine, N-[(3-chloro-4-methylphenoxy)carbonyl]-N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- (9CI) (CA INDEX NAME)



RN 331744-53-7 CAPLUS
 CN Glycine, N-[(3-bromo-4-methylphenoxy)carbonyl]-N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- (9CI) (CA INDEX NAME)




RN 331744-54-8 CAPLUS
 CN Glycine, N-[(3-fluoro-4-methoxyphenoxy)carbonyl]-N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- (9CI) (CA INDEX NAME)




RN 331744-55-9 CAPLUS
 CN Glycine, N-[(3-chloro-4-methoxyphenoxy)carbonyl]-N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- (9CI) (CA INDEX NAME)




L7 ANSWER 77 OF 83 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 331744-56-0 CAPLUS
 CN Glycine, N-[(3-bromo-4-methoxyphenoxy)carbonyl]-N-[(3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl)methyl]- (9CI) (CA INDEX NAME)



RN 331744-57-1 CAPLUS
 CN Glycine, N-[(3-bromo-4-methoxyphenoxy)carbonyl]-N-[(3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl)methyl]-N-[(3-propylphenoxy)carbonyl]- (9CI) (CA INDEX NAME)




RN 331744-58-2 CAPLUS
 CN Glycine, N-[(3-cyclopropylphenoxy)carbonyl]-N-[(3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl)methyl]- (9CI) (CA INDEX NAME)




RN 331744-59-3 CAPLUS
 CN Glycine, N-[(4-cyclopropylphenoxy)carbonyl]-N-[(3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl)methyl]- (9CI) (CA INDEX NAME)

L7 ANSWER 77 OF 83 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
 CN Glycine, N-[(4-methylphenoxy)carbonyl]-N-[(1-[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl)ethyl]- (9CI) (CA INDEX NAME)




RN 331744-64-0 CAPLUS
 CN Glycine, N-[(4-methoxyphenoxy)carbonyl]-N-[(1S)-1-[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 331744-65-1 CAPLUS
 CN Glycine, N-[(4-methoxyphenoxy)carbonyl]-N-[(1R)-1-[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 331744-66-2 CAPLUS
 CN Glycine, N-[(4-methoxyphenoxy)carbonyl]-N-[(1-4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl)pentyl]- (9CI) (CA INDEX NAME)


L7 ANSWER 77 OF 83 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 331744-60-6 CAPLUS
 CN Glycine, N-[(4-(cyclopropyloxy)phenoxy)carbonyl]-N-[(3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl)methyl]- (9CI) (CA INDEX NAME)



RN 331744-61-7 CAPLUS
 CN Benzoic acid, 2-(carboxymethyl)-2-[(4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl)methyl]hydrazide (9CI) (CA INDEX NAME)




RN 331744-62-8 CAPLUS
 CN Benzoic acid, 2-(carboxymethyl)-2-[(3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl)methyl]hydrazide (9CI) (CA INDEX NAME)




RN 331744-63-9 CAPLUS


L7 ANSWER 77 OF 83 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 331744-67-3 CAPLUS
 CN Glycine, N-[(4-methoxyphenoxy)carbonyl]-N-[(1-4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl)-3-butenyl]- (9CI) (CA INDEX NAME)



RN 331744-68-4 CAPLUS
 CN Glycine, N-[(4-methoxyphenoxy)carbonyl]-N-[(1-4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl)butyl]- (9CI) (CA INDEX NAME)




RN 331744-72-0 CAPLUS
 CN Glycine, N-[(4-methoxyphenoxy)carbonyl]-N-[(1-4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl)ethyl]- (9CI) (CA INDEX NAME)




RN 331744-73-1 CAPLUS
 CN Glycine, N-[(4-methylphenoxy)carbonyl]-N-[(1-4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl)ethyl]- (9CI) (CA INDEX NAME)


L7 ANSWER 77 OF 83 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 331744-74-2 CAPLUS
CN Glycine, N-[(4-methylphenoxy)carbonyl]-N-[1-[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]pentyl]- (9CI) (CA INDEX NAME)



RN 331744-75-3 CAPLUS
CN Glycine, N-[(4-methoxyphenoxy)carbonyl]-N-[1-[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]propyl]- (9CI) (CA INDEX NAME)




RN 331744-76-4 CAPLUS
CN Glycine, N-[(4-methoxyphenoxy)carbonyl]-N-[3-methyl-1-[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]butyl]- (9CI) (CA INDEX NAME)



RN 331744-77-5 CAPLUS
CN Glycine, N-[(4-methoxyphenoxy)carbonyl]-N-[1-[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]ethyl]- (9CI) (CA INDEX NAME)


L7 ANSWER 77 OF 83 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
CN Glycine,
N-[(4-methylphenoxy)carbonyl]-N-[(1R)-1-[4-[(5-methyl-2-phenyl-4-oxazolyl)methoxy]phenyl]ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 331744-81-1 CAPLUS
CN Glycine,
N-[(4-methylphenoxy)carbonyl]-N-[(1S)-1-[4-[(5-methyl-2-phenyl-4-oxazolyl)methoxy]phenyl]ethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 331744-82-2 CAPLUS
CN Glycine,
N-[(4-methoxyphenoxy)carbonyl]-N-[(1R)-1-[4-[(5-methyl-2-phenyl-4-oxazolyl)methoxy]phenyl]ethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L7 ANSWER 77 OF 83 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 331744-78-6 CAPLUS
CN Glycine,
N-[(3-methoxyphenoxy)carbonyl]-N-[(1R)-1-[4-[(5-methyl-2-phenyl-4-oxazolyl)methoxy]phenyl]ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 331744-79-7 CAPLUS
CN Glycine,
N-[(3-methoxyphenoxy)carbonyl]-N-[(1S)-1-[4-[(5-methyl-2-phenyl-4-oxazolyl)methoxy]phenyl]ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 331744-80-0 CAPLUS

L7 ANSWER 77 OF 83 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 331744-83-3 CAPLUS
CN Glycine,
N-[(4-methoxyphenoxy)carbonyl]-N-[(1S)-1-[4-[(5-methyl-2-phenyl-4-oxazolyl)methoxy]phenyl]ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 331744-84-4 CAPLUS
CN Alanine, N-[(4-methoxyphenoxy)carbonyl]-2-methyl-N-[(4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl)methyl]- (9CI) (CA INDEX NAME)




L7 ANSWER 77 OF 83 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
 RN 331744-87-7 CAPLUS
 CN L-Alanine, N-[(4-methoxyphenoxy)carbonyl]-N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 331744-88-8 CAPLUS
 CN L-Alanine, N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-N-[(phenylmethoxy)carbonyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 331744-89-9 CAPLUS
 CN D-Alanine, N-[(4-methoxyphenoxy)carbonyl]-N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 331744-90-2 CAPLUS

L7 ANSWER 77 OF 83 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 331744-96-8 CAPLUS
 CN D-Alanine, N-[(4-methylphenoxy)carbonyl]-N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 331744-97-9 CAPLUS
 CN D-Alanine, N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-N-[(phenylmethoxy)carbonyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 331744-98-0 CAPLUS
 CN L-Alanine, N-[(4-methoxyphenoxy)carbonyl]-N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


L7 ANSWER 77 OF 83 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
 CN D-Alanine, N-[(4-methylphenoxy)carbonyl]-N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 331744-91-3 CAPLUS
 CN D-Alanine, N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-N-[(phenylmethoxy)carbonyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 331744-94-6 CAPLUS
 CN Alanine, N-[(4-methoxyphenoxy)carbonyl]-2-methyl-N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- (9CI) (CA INDEX NAME)



RN 331744-95-7 CAPLUS
 CN D-Alanine, N-[(4-methoxyphenoxy)carbonyl]-N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L7 ANSWER 77 OF 83 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 331744-99-1 CAPLUS
 CN L-Alanine, N-[(4-methylphenoxy)carbonyl]-N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 331745-00-7 CAPLUS
 CN L-Alanine, N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-N-[(phenylmethoxy)carbonyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 331745-01-8 CAPLUS
 CN L-Alanine, N-[(4-methoxyphenoxy)carbonyl]-N-[(1R)-1-[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]ethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L7 ANSWER 77 OF 83 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 331745-02-9 CAPLUS
 CN D-Alanine, N-[(4-methoxyphenoxy)carbonyl]-N-[(1R)-1-[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 331745-03-0 CAPLUS
 CN L-Alanine, N-[(4-methoxyphenoxy)carbonyl]-N-[(1S)-1-[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 331745-04-1 CAPLUS
 CN D-Alanine, N-[(4-methoxyphenoxy)carbonyl]-N-[(1S)-1-[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]ethyl]- (9CI) (CA INDEX NAME)


L7 ANSWER 77 OF 83 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 331745-13-2 CAPLUS
 CN Glycine, N-[(4-methoxyphenoxy)carbonyl]-N-[(4-[(5-methyl-2-phenyl-4-oxazolyl)methoxy]phenyl)methyl]- (9CI) (CA INDEX NAME)



RN 331745-14-3 CAPLUS
 CN Glycine, N-[(4-methoxyphenoxy)carbonyl]-N-[(3-[(5-methyl-2-phenyl-4-oxazolyl)propoxy]phenyl)methyl]-N-[(4-methylphenoxy)carbonyl]- (9CI) (CA INDEX NAME)




RN 331745-15-4 CAPLUS
 CN Glycine, N-[(4-methoxyphenoxy)carbonyl]-N-[(4-[2-(5-methyl-2-phenyl-4-oxazolyl)propoxy]phenyl)methyl]- (9CI) (CA INDEX NAME)




RN 331745-16-5 CAPLUS
 CN Glycine, N-[(4-methylphenoxy)carbonyl]-N-[(4-[2-(5-methyl-2-phenyl-4-oxazolyl)propoxy]phenyl)methyl]- (9CI) (CA INDEX NAME)

L7 ANSWER 77 OF 83 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)


Absolute stereochemistry.



RN 331745-06-3 CAPLUS
 CN Glycine, N-[(4-methylphenoxy)carbonyl]-N-[(4-[(5-methyl-2-phenyl-4-oxazolyl)methoxy]phenyl)methyl]- (9CI) (CA INDEX NAME)




RN 331745-08-5 CAPLUS
 CN Glycine, N-[(4-methoxyphenoxy)carbonyl]-N-[(4-[2-methyl-2-(5-methyl-2-phenyl-4-oxazolyl)propoxy]phenyl)methyl]- (9CI) (CA INDEX NAME)




RN 331745-10-9 CAPLUS
 CN Glycine, N-[(4-methoxyphenoxy)carbonyl]-N-[(3-[2-methyl-2-(5-methyl-2-phenyl-4-oxazolyl)propoxy]phenyl)methyl]- (9CI) (CA INDEX NAME)


L7 ANSWER 77 OF 83 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 331745-18-7 CAPLUS
 CN Glycine, N-[(4-methylphenoxy)carbonyl]-N-[(3-[(5-methyl-2-phenyl-4-oxazolyl)methoxy]phenyl)methyl]- (9CI) (CA INDEX NAME)



RN 331745-19-8 CAPLUS
 CN Glycine, N-[(4-methoxyphenoxy)carbonyl]-N-[(3-[(5-methyl-2-phenyl-4-oxazolyl)methoxy]phenyl)methyl]- (9CI) (CA INDEX NAME)




RN 331745-22-3 CAPLUS
 CN Glycine, N-(5-methyl-2-benzoxazolyl)-N-[(3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl)methyl]- (9CI) (CA INDEX NAME)




RN 331745-23-4 CAPLUS
 CN Glycine, N-(5-methyl-2-benzoxazolyl)-N-[(4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl)methyl]- (9CI) (CA INDEX NAME)


L7 ANSWER 77 OF 83 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 331745-24-5 CAPLUS
CN Glycine, N-[(4-methoxyphenoxy)carbonyl]-N-[[4-[2-[2-(4-methoxyphenyl)-5-methyl-4-oxazolyl]ethoxy]phenyl]methyl]- (9CI) (CA INDEX NAME)



RN 331745-43-8 CAPLUS
CN Glycine, N-[(3-[2-[2-(4-methoxyphenyl)-5-methyl-4-oxazolyl]ethoxy]phenyl]methyl]-N-[(4-methylphenoxy)carbonyl]- (9CI) (CA INDEX NAME)




RN 331745-44-9 CAPLUS
CN Glycine, N-[(3-[2-[2-(2-chlorophenyl)-5-methyl-4-oxazolyl]ethoxy]phenyl]methyl]-N-[(4-methylphenoxy)carbonyl]- (9CI) (CA INDEX NAME)




RN 331745-45-0 CAPLUS

L7 ANSWER 77 OF 83 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 331745-60-9 CAPLUS
CN Glycine, N-[(3-methylphenoxy)carbonyl]-N-[(1S)-1-[4-[(5-methyl-2-phenyl-4-oxazolyl)methoxy]phenyl]ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 331745-69-8 CAPLUS
CN Glycine, N-[(3-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-N-[(1S)-1-phenylethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.




RN 331746-91-9 CAPLUS
CN Glycine, N-[(4-methoxyphenoxy)carbonyl]-N-[(3-methyl-1-[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]-3-butenyl]- (9CI) (CA INDEX NAME)

L7 ANSWER 77 OF 83 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)


CN Glycine, N-[(4-[2-[2-(2-chlorophenyl)-5-methyl-4-oxazolyl]ethoxy]phenyl]methyl]-N-[(4-methoxyphenoxy)carbonyl]- (9CI) (CA INDEX NAME)



RN 331745-46-1 CAPLUS
CN Glycine, N-[(4-[2-[2-(2-chlorophenyl)-5-methyl-4-oxazolyl]ethoxy]phenyl]methyl]-N-[(4-methoxyphenoxy)carbonyl]- (9CI) (CA INDEX NAME)




RN 331745-47-2 CAPLUS
CN Glycine, N-[(3-[2-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-N-[(4-methoxyphenoxy)carbonyl]- (9CI) (CA INDEX NAME)




RN 331745-49-4 CAPLUS
CN Glycine, N-[(4-methoxyphenoxy)carbonyl]-N-[(3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- (9CI) (CA INDEX NAME)

L7 ANSWER 77 OF 83 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 331746-92-0 CAPLUS
CN Glycine, N-[(4-methoxyphenoxy)carbonyl]-N-[(4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- (9CI) (CA INDEX NAME)




RN 331746-93-1 CAPLUS
CN L-Alanine, N-[(3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-N-[(4-phenoxyphenyl)methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 331746-95-3 CAPLUS
CN Glycine, N-[(6-methyl-2-benzoxazolyl)-N-[(3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- (9CI) (CA INDEX NAME)




L7 ANSWER 77 OF 83 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)

RN 439276-48-9 CAPLUS

CN Glycine,

N-[(4-methoxyphenoxy)carbonyl]-N-[(1R)-1-[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]hexyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 439276-49-0 CAPLUS

CN Glycine,

N-[(4-methoxyphenoxy)carbonyl]-N-[(1S)-1-[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]hexyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 439276-50-3 CAPLUS

CN Glycine,

N-[(4-methoxyphenoxy)carbonyl]-N-[(4-[2-[2-(3-chlorophenyl)-5-methyl-4-oxazolyl]ethoxy]phenyl)methyl]- (9CI) (CA INDEX NAME)


L7 ANSWER 77 OF 83 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 439276-57-0 CAPLUS

CN Glycine,


N-[(3-[2-[2-(3-chlorophenyl)-5-methyl-4-oxazolyl]ethoxy]phenyl)methyl]-N-[(4-methoxyphenoxy)carbonyl]- (9CI) (CA INDEX NAME)



RN 439276-58-1 CAPLUS

CN Glycine,


N-[(3-[2-[2-(2-methoxyphenyl)-5-methyl-4-oxazolyl]ethoxy]phenyl)methyl]-N-[(4-methoxyphenoxy)carbonyl]- (9CI) (CA INDEX NAME)



RN 439276-61-6 CAPLUS

CN Glycine,

N-[(3-[2-[2-(5-methyl-2-(3-(trifluoromethyl)phenyl)-4-oxazolyl]ethoxy]phenyl)methyl]-N-[(4-methoxyphenoxy)carbonyl]- (9CI) (CA INDEX NAME)




RN 439276-62-7 CAPLUS

CN Glycine,

N-[(3-[2-[2-(5-methyl-2-(4-(trifluoromethyl)phenyl)-4-oxazolyl]ethoxy]phenyl)methyl]-N-[(4-methoxyphenoxy)carbonyl]- (9CI) (CA INDEX NAME)


L7 ANSWER 77 OF 83 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 439276-51-4 CAPLUS

CN Glycine,


N-[(4-methoxyphenoxy)carbonyl]-N-[(4-[2-[2-(2-methoxyphenyl)-5-methyl-4-oxazolyl]ethoxy]phenyl)methyl]- (9CI) (CA INDEX NAME)



RN 439276-54-7 CAPLUS

CN Glycine,

N-[(4-methoxyphenoxy)carbonyl]-N-[(4-[2-[2-(5-methyl-2-(3-(trifluoromethyl)phenyl)-4-oxazolyl]ethoxy]phenyl)methyl]- (9CI) (CA INDEX NAME)




RN 439276-55-8 CAPLUS

CN Glycine,

N-[(4-methoxyphenoxy)carbonyl]-N-[(4-[2-[2-(5-methyl-2-(4-(trifluoromethyl)phenyl)-4-oxazolyl]ethoxy]phenyl)methyl]- (9CI) (CA INDEX NAME)

L7 ANSWER 77 OF 83 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



IT 331746-63-5, Glycine, N-[(4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl)methyl]-, 1,1-dimethylethyl ester

331746-64-6, Glycine, N-[(3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl)methyl]-, methyl ester 331746-65-7, Glycine, N-[(4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl)methyl]-, methyl ester 331746-66-8, Glycine, N-[(4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl)methyl]-, mono(trifluoroacetate) 331746-68-0, Glycine, N-[(3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl)methyl]-N-[(3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl)methyl]-, 1,1-dimethylethyl ester 331746-69-1, Glycine, N-[(3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl)methyl]-N-(4-phenoxybenzoyl)-, 1,1-dimethylethyl ester 331746-70-4, Glycine, N-[(3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl)methyl]-N-(2-naphthalenylcarbonyl)-, 1,1-dimethylethyl ester 331746-71-5, Glycine, N-[(4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl)methyl]-N-(1-naphthalenylsulfonyl)-, 1,1-dimethylethyl ester 331746-74-8, β-Alanine, N-[(3-chlorophenoxy)carbonyl]-N-[(4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl)methyl]-, methyl ester 331746-75-9, Glycine, N-(chlorocarbonyl)-N-[(4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl)methyl]-, methyl ester 331746-76-0, Glycine, N-[(3-(cyclopropyloxy)phenoxy)carbonyl]-N-[(3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl)methyl]-, methyl ester


RL: RCT (Reactant); RACT (Reactant or reagent)
(preparation of oxazolyl- and thiazolylalkoxybenzylglycines and related

compds. as antidiabetic and antiobesity agents)

RN 331746-63-5 CAPLUS

CN Glycine,

N-[(4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl)methyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 331746-64-6 CAPLUS


CN Glycine,

N-[(3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl)methyl]-, methyl ester (9CI) (CA INDEX NAME)

L7 ANSWER 77 OF 83 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 331746-65-7 CAPLUS
CN Glycine, N-([4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl)-, methyl ester (9CI) (CA INDEX NAME)



RN 331746-66-8 CAPLUS
CN Glycine, N-([4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl)-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 331739-69-6
CMF C21 H22 N2 O4




CM 2

CRN 76-05-1
CMF C2 H F3 O2



L7 ANSWER 77 OF 83 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)


PAGE 1-A



PAGE 2-A




RN 331746-74-8 CAPLUS
CN β-Alanine, N-((3-chlorophenoxy)carbonyl)-N-([4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl)-, methyl ester (9CI) (CA INDEX NAME)




RN 331746-75-9 CAPLUS
CN Glycine, N-(chlorocarbonyl)-N-([4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl)-, methyl ester (9CI) (CA INDEX NAME)

L7 ANSWER 77 OF 83 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)


RN 331746-68-0 CAPLUS
CN Glycine, N-([3-(difluoromethoxy)phenoxy]carbonyl)-N-([3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl)-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 331746-69-1 CAPLUS
CN Glycine, N-([3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl)-N-(4-phenoxybenzoyl)-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 331746-70-4 CAPLUS
CN Glycine, N-([3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl)-N-(2-naphthalenylcarbonyl)-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 331746-71-5 CAPLUS
CN Glycine, N-([4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl)-N-(1-naphthalenylsulfonyl)-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

L7 ANSWER 77 OF 83 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 331746-76-0 CAPLUS
CN Glycine, N-([3-(cyclopropyloxy)phenoxy]carbonyl)-N-([3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl)-, methyl ester (9CI) (CA INDEX NAME)



IT 331745-61-0P, Glycine, N-([4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl)-N-(phenylmethyl)-, ethyl ester
331745-62-1P, Glycine, N,N-bis([4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl)-, ethyl ester 331745-63-2P, Glycine, N-([4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl)-, ethyl ester 331745-64-3P, Glycine, N-([3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl)-, 1,1-dimethylethyl ester
331745-65-4P, Glycine, N-([3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl)-N-([4-phenoxyphenyl]methyl)-, 1,1-dimethylethyl ester 331745-66-5P, Glycine, N-([3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl)-N-([3-(4-hydroxyphenyl)carbonyl]-N-([3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl)-, 1,1-dimethylethyl ester

ester 331745-68-7P, Glycine, N-([4-(boronophenyl)methyl]-N-([4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl)-, 1-(1,1-dimethylethyl) ester 331745-71-2P, Glycine, N-(chlorocarbonyl)-N-([3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl)-, 1,1-dimethylethyl ester


331745-72-3P, Glycine, N-([3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl)-N-([4-(phenylmethoxy)phenoxy]carbonyl)-, 1,1-dimethylethyl ester 331745-73-4P, Glycine, N-([4-(hydroxyphenoxy)carbonyl]-N-([3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl)-, 1,1-dimethylethyl ester 331745-75-6P, Glycine, N-([3-(acetyloxy)phenoxy]carbonyl)-N-([3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl)-, 1,1-dimethylethyl ester 331745-76-7P, Glycine, N-([4-(methoxyphenyl)amino]carbonyl)-N-([3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl)-, methyl ester 331745-77-8P, Glycine, N-([4-(methoxyphenyl)methylamino]carbonyl)-N-([3-[2-(5-methyl-2-

L7 ANSWER 77 OF 83 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)


phenyl-4-oxazolylethoxy]phenyl]methyl]-, methyl ester 331745-88-1P, Glycine, N-[(2,4-dinitrophenyl)sulfonyl]-N-[2-[4-[2-(5-methyl-2-phenyl-4-oxazolylethoxy]phenyl]ethyl]-, 1,1-dimethylethyl ester 331745-89-2P, Glycine, N-[2-[4-[2-(5-methyl-2-phenyl-4-oxazolylethoxy]phenyl]ethyl]-, 1,1-dimethylethyl ester 331745-90-5P, Carbamic acid, 2-[(2-cyanoethyl)amino]-2-oxoethyl] [(4-[2-(5-methyl-2-phenyl-4-oxazolylethoxy]phenyl]methyl]-, 4-methoxyphenyl ester 331745-93-8P, Glycine, N-[(4-methoxyphenoxy)carbonyl]-N-[2-[2-(5-methyl-2-phenyl-4-oxazolylethoxy]phenyl]methyl]-, methyl ester 331745-95-0P, Glycine, N-[(3-cyclopropylphenoxy)carbonyl]-N-[4-[2-(5-methyl-2-phenyl-4-oxazolylethoxy]phenyl]methyl]-, methyl ester 331746-04-4P, Benzoic acid, 2-(2-ethoxy-2-oxoethyl)-2-[(4-[2-(5-methyl-2-phenyl-4-oxazolylethoxy]phenyl]methyl]hydrazide 331746-06-6P, Glycine, N-[1-[3-[2-(5-methyl-2-phenyl-4-oxazolylethoxy]phenyl]ethyl]-, methyl ester 331746-07-7P, Glycine, N-[(4-methylphenoxy)carbonyl]-N-[1-[3-[2-(5-methyl-2-phenyl-4-oxazolylethoxy]phenyl]ethyl]-, methyl ester 331746-10-2P, Glycine, N-[(4-methoxyphenoxy)carbonyl]-N-[15]-1-[4-[2-(5-methyl-2-phenyl-4-oxazolylethoxy]phenyl]ethyl]-, methyl ester 331746-12-4P, Glycine, N-[1-[4-[2-(5-methyl-2-phenyl-4-oxazolylethoxy]phenyl]pentyl]-, methyl ester 331746-13-5P, Glycine, N-[(4-methoxyphenoxy)carbonyl]-N-[1-[4-[2-(5-methyl-2-phenyl-4-oxazolylethoxy]phenyl]-3-butenyl]-, methyl ester 331746-14-6P, Glycine, N-[(4-methoxyphenoxy)carbonyl]-N-[1-[4-[2-(5-methyl-2-phenyl-4-oxazolylethoxy]phenyl]butyl]-, methyl ester 331746-21-5P, Alanine, 2-methyl-N-[(4-[2-(5-methyl-2-phenyl-4-oxazolylethoxy]phenyl]methyl]-, methyl ester 331746-22-6P, Alanine, 2-methyl-N-[(4-[2-(5-methyl-2-phenyl-4-oxazolylethoxy]phenyl]methyl]- 331746-26-0P, L-Alanine, N-[(4-methoxyphenoxy)carbonyl]-N-[(1R)-1-[4-[2-(5-methyl-2-phenyl-4-oxazolylethoxy]phenyl]ethyl]-, methyl ester 331746-32-8P, Glycine, N-[(4-methylphenoxy)carbonyl]-N-[(4-[5-methyl-2-phenyl-4-oxazolylethoxy]phenyl]methyl]-, methyl ester 331746-43-1P, Glycine, N-[(4-[2-methyl-2-(5-methyl-2-phenyl-4-oxazolylethoxy]phenyl]propoxy]phenyl]methyl]-, methyl ester 331746-44-2P, Glycine, N-[(4-methoxyphenoxy)carbonyl]-N-[4-[2-methyl-2-(5-methyl-2-phenyl-4-oxazolylethoxy]phenyl]methyl]-, methyl ester 331746-52-2P, Glycine, N-[(4-methoxyphenoxy)carbonyl]-N-[4-[2-(4-methoxyphenyl)-5-methyl-4-oxazolylethoxy]phenyl]methyl]-, methyl ester 331746-67-9P, Glycine, N-[(4-methoxyphenoxy)carbonyl]-N-[4-[2-(5-methyl-2-phenyl-4-oxazolylethoxy]phenyl]methyl]-, methyl ester 331746-79-3P, Glycine, N-[1-[4-[2-(5-methyl-2-phenyl-4-oxazolylethoxy]phenyl]-3-butenyl]-, methyl ester 331746-94-2P, Glycine, N-[4-[2-(5-methyl-2-phenyl-4-oxazolylethoxy]phenyl]methyl]-N-[(phenylmethyl)amino]carbonyl]-, ethyl ester 439573-67-8P, R₁: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent) (prepn. of oxazolyl- and thiazolylalkoxybenzylglycines and related compds. as antidiabetic and antiobesity agents)

RN 331745-61-0 CAPLUS
CN Glycine, N-[(4-[2-(5-methyl-2-phenyl-4-oxazolylethoxy]phenyl]methyl]-N-(phenylmethyl)-, ethyl ester (9CI) (CA INDEX NAME)


L7 ANSWER 77 OF 83 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 331745-64-3 CAPLUS
CN Glycine, N-[(3-[2-(5-methyl-2-phenyl-4-oxazolylethoxy]phenyl]methyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 331745-65-4 CAPLUS
CN Glycine, N-[(3-[2-(5-methyl-2-phenyl-4-oxazolylethoxy]phenyl]methyl]-N-[(4-phenoxyphenyl)methyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 331745-66-5 CAPLUS
CN Glycine, N-[(3-[2-(5-methyl-2-phenyl-4-oxazolylethoxy]phenyl]methyl]-N-[(4-phenoxyphenyl)methyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 331745-67-6 CAPLUS
CN Glycine, N-[(4-hydroxyphenyl)methyl]-N-[(3-[2-(5-methyl-2-phenyl-4-oxazolylethoxy]phenyl]methyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

L7 ANSWER 77 OF 83 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 331745-62-1 CAPLUS
CN Glycine, N-[(3-[2-(5-methyl-2-phenyl-4-oxazolylethoxy]phenyl]methyl]-N-[(4-phenoxyphenyl)methyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 1-B




RN 331745-63-2 CAPLUS
CN Glycine, N-[(3-[2-(5-methyl-2-phenyl-4-oxazolylethoxy]phenyl]methyl]-N-[(4-phenoxyphenyl)methyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)


L7 ANSWER 77 OF 83 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 331745-68-7 CAPLUS
CN Glycine, N-[(3-[2-(5-methyl-2-phenyl-4-oxazolylethoxy]phenyl]methyl]-N-[(4-phenoxyphenyl)methyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 331745-71-2 CAPLUS
CN Glycine, N-[(3-[2-(5-methyl-2-phenyl-4-oxazolylethoxy]phenyl]methyl]-N-[(4-phenoxyphenyl)methyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 331745-72-3 CAPLUS
CN Glycine, N-[(3-[2-(5-methyl-2-phenyl-4-oxazolylethoxy]phenyl]methyl]-N-[(4-phenoxyphenyl)methyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




L7 ANSWER 77 OF 83 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
 RN 331745-73-4 CAPLUS
 CN Glycine, N-[(4-hydroxyphenoxy)carbonyl]-N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 331745-75-6 CAPLUS
 CN Glycine
 N-[[3-(acetyloxy)phenoxy]carbonyl]-N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 331745-76-7 CAPLUS
 CN Glycine
 N-[[[4-(methoxyphenyl)amino]carbonyl]-N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-, methyl ester (9CI) (CA INDEX NAME)




RN 331745-77-8 CAPLUS
 CN Glycine, N-[[[4-(methoxyphenyl)methylamino]carbonyl]-N-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-, methyl ester (9CI) (CA INDEX NAME)


L7 ANSWER 77 OF 83 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 331745-93-8 CAPLUS
 CN Glycine, N-[(4-methoxyphenoxy)carbonyl]-N-[[2-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-, methyl ester (9CI) (CA INDEX NAME)




RN 331745-95-0 CAPLUS
 CN Glycine,
 N-[(3-cyclopropylphenoxy)carbonyl]-N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-, methyl ester (9CI) (CA INDEX NAME)




RN 331746-04-4 CAPLUS
 CN Benzoic acid, 2-(2-ethoxy-2-oxoethyl)-2-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]hydrazide (9CI) (CA INDEX NAME)


L7 ANSWER 77 OF 83 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 331745-88-1 CAPLUS
 CN Glycine, N-[(2,4-dinitrophenyl)sulfonyl]-N-[[2-[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]ethyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 331745-89-2 CAPLUS
 CN Glycine, N-[[2-[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]ethyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 331745-90-5 CAPLUS
 CN Carbamic acid, 2-[[2-(cyanoethyl)amino]-2-oxoethyl] [[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-, 4-methoxyphenyl ester (9CI) (CA INDEX NAME)


L7 ANSWER 77 OF 83 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 331746-06-6 CAPLUS
 CN Glycine, N-[[1-[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]ethyl]-, methyl ester (9CI) (CA INDEX NAME)




RN 331746-07-7 CAPLUS
 CN Glycine, N-[(4-methylphenoxy)carbonyl]-N-[[1-[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]ethyl]-, methyl ester (9CI) (CA INDEX NAME)




RN 331746-10-2 CAPLUS
 CN Glycine,
 N-[(4-methoxyphenoxy)carbonyl]-N-[[1S]-1-[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]ethyl]-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.


L7 ANSWER 77 OF 83 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 331746-12-4 CAPLUS
 CN Glycine, N-[[4-[[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]pentyl]-, methyl ester (9CI) (CA INDEX NAME)




RN 331746-13-5 CAPLUS
 CN Glycine, N-[[4-methoxyphenoxy]carbonyl]-N-[[4-[[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]-3-butenyl]-, methyl ester (9CI) (CA INDEX NAME)




RN 331746-14-6 CAPLUS
 CN Glycine, N-[[4-methoxyphenoxy]carbonyl]-N-[[4-[[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]butyl]-, methyl ester (9CI) (CA INDEX NAME)


L7 ANSWER 77 OF 83 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 331746-32-8 CAPLUS
 CN Glycine, N-[[4-methylphenoxy]carbonyl]-N-[[4-[[2-(5-methyl-2-phenyl-4-oxazolyl)methoxy]phenyl]methyl]-, methyl ester (9CI) (CA INDEX NAME)




RN 331746-43-1 CAPLUS
 CN Glycine, N-[[4-[[2-methyl-2-(5-methyl-2-phenyl-4-oxazolyl)propoxy]phenyl]methyl]-, methyl ester (9CI) (CA INDEX NAME)




RN 331746-44-2 CAPLUS
 CN Glycine, N-[[4-methoxyphenoxy]carbonyl]-N-[[4-[[2-methyl-2-(5-methyl-2-phenyl-4-oxazolyl)propoxy]phenyl]methyl]-, methyl ester (9CI) (CA INDEX NAME)


L7 ANSWER 77 OF 83 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 331746-21-5 CAPLUS
 CN Alanine, 2-methyl-N-[[4-[[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-, methyl ester (9CI) (CA INDEX NAME)




RN 331746-22-6 CAPLUS
 CN L-Alanine, N-[[4-[[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-, methyl ester (9CI) (CA INDEX NAME)




RN 331746-26-0 CAPLUS
 CN L-Alanine, N-[[4-methoxyphenoxy]carbonyl]-N-[[4-[[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]ethyl]-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.


L7 ANSWER 77 OF 83 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 331746-52-2 CAPLUS
 CN Glycine, N-[[4-methoxyphenoxy]carbonyl]-N-[[4-[[2-(4-methoxyphenyl)-5-methyl-4-oxazolyl]ethoxy]phenyl]methyl]-, methyl ester (9CI) (CA INDEX NAME)




RN 331746-67-9 CAPLUS
 CN Glycine, N-[[4-methoxyphenoxy]carbonyl]-N-[[4-[[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-, methyl ester (9CI) (CA INDEX NAME)



RN 331746-79-3 CAPLUS
 CN Glycine, N-[[4-methoxyphenoxy]carbonyl]-N-[[4-[[2-methyl-2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]-3-butenyl]-, methyl ester (9CI) (CA INDEX NAME)




RN 331746-94-2 CAPLUS
CN Glycine, N-([4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl)-N-[(phenylmethyl)amino]carbonyl-, ethyl ester (9CI) (CA INDEX NAME)



RN 439573-67-8 CAPLUS
CN Glycine, N-([4-methoxyphenoxy]carbonyl)-N-[(1S)-1-[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]hexyl]-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 24 THERE ARE 24 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE REFORMAT

L7 ANSWER 78 OF 83 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2002:315133 CAPLUS
DOCUMENT NUMBER: 136:336180
TITLE: Diabetes diagnosis by genotyping insulin receptor gene single-nucleotide polymorphisms
INVENTOR(S): Hosford, David; Purvis, Ian James
PATENT ASSIGNEE(S): Glaxo Group Limited, UK
SOURCE: PCT Int. Appl., 61 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002033121	A2	20020425	WO 2001-GB4660	20011019
WO 2002033121	A3	20031016		
W.	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
AU 2001095752	A5	20020429	AU 2001-95752	20011019
PRIORITY APPL. INFO.:			GB 2000-25678	A 20001019
			WO 2001-GB4660	W 20011019


OTHER SOURCE(S): MARPAT 136:336180

AB The invention provides a method of diagnosing diabetes or susceptibility to diabetes in an individual, comprising typing (i) the insulin receptor gene region or (ii) the insulin receptor protein of the individual. The invention also provides a diagnostic kit that comprises a polynucleotide, probe, primer, antibody (including an antibody fragment) or agent as defined herein. The invention also provides a nonhuman animal which has diabetes (typically type II diabetes) or is susceptible to diabetes and which is also transgenic for a polymorphism as mentioned above. The invention provides a method for treating a patient who has been diagnosed as having or being susceptible to diabetes by a method of the invention, comprising administering an effective amount of an anti-diabetes agent or an agent that prevents the development of diabetes to the patient. The inventors have shown that naturally occurring polymorphisms in the insulin receptor are functional. These functional polymorphisms are associated with migraine, a condition that is overrepresented in diabetics. The inventors isolated 48 single-nucleotide polymorphisms within the locus, of which we genotyped in a Caucasian population comprising 827 unrelated cases and 765 controls. Five single-nucleotide polymorphisms within the insulin receptor gene showed significant association with migraine. This association was independently replicated in a case-control population collected sep. IT 258345-41-4 258346-02-0

L7 ANSWER 78 OF 83 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)


RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses) (diabetes diagnosis by genotyping insulin receptor gene single-nucleotide polymorphisms)
RN 258345-41-4 CAPLUS
CN L-Tyrosine, N-[(1Z)-1-methyl-3-oxo-3-phenyl-1-propenyl]-O-[2-(5-methyl-2-phenyl-4-oxazolyl)ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 258346-02-0 CAPLUS
CN L-Tyrosine, O-[2-(5-methyl-2-phenyl-4-oxazolyl)ethyl]-N-[(1Z)-3-oxo-3-phenyl-1-(trifluoromethyl)-1-propenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



10788996

11/26/06

L7 ANSWER 79 OF 83 CAPLUS COPYRIGHT 2006 ACS ON STN
 ACCESSION NUMBER: 2001:581856 CAPLUS
 DOCUMENT NUMBER: 135:152795
 TITLE: Process for synthesis of oxazolethoxyphenylpropanoic acid derivative for use as NIDDM medicament
 INVENTOR(S): Davis, Roman; Kennedy, Andrew
 PATENT ASSIGNEE(S): Glaxo Group Limited, UK
 SOURCE: PCT Int. Appl., 26 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001057001	A1	20010809	WO 2001-EP1041	20010201
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, GR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, ME, MG, MW, MX, MY, NZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CP, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
PRIORITY APPLN. INFO.:			GB 2000-2667 A 20000204	

AB Process for synthesis of calcium salt of (2S)-2-[(1Z)-1-methyl-3-oxo-3-phenyl-1-propenyl]amino]-3-[4-(2-(5-methyl-2-phenyl-1,3-oxazol-4-yl)ethoxy)phenyl]propanoic acid and physiologically acceptable solvates thereof, useful as NIDDM medicament is disclosed.

IT 353239-32-4P
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); IMF (Industrial manufacture); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (synthesis of oxazolethoxyphenylpropanoic acid derivative for NIDDM medicament)
 RN 353239-32-4 CAPLUS
 CN L-Tyrosine, N-[(1Z)-1-methyl-3-oxo-3-phenyl-1-propenyl]-O-[2-(5-methyl-2-phenyl-4-oxazolyl)ethyl]-, calcium salt (2:1) (9CI) (CA INDEX NAME)

Absolute stereochemistry.
 Double bond geometry as shown.


L7 ANSWER 79 OF 83 CAPLUS COPYRIGHT 2006 ACS ON STN (Continued)



● 1/2 Ca


IT 258345-41-4P 353239-34-6P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (synthesis of oxazolethoxyphenylpropanoic acid derivative for NIDDM medicament)
 RN 258345-41-4 CAPLUS
 CN L-Tyrosine, N-[(1Z)-1-methyl-3-oxo-3-phenyl-1-propenyl]-O-[2-(5-methyl-2-phenyl-4-oxazolyl)ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
 Double bond geometry as shown.



RN 353239-34-6 CAPLUS
 CN L-Tyrosine, N-[(1Z)-1-methyl-3-oxo-3-phenyl-1-propenyl]-O-[2-(5-methyl-2-phenyl-4-oxazolyl)ethyl]-, phenylmethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.
 Double bond geometry as shown.




REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE
 FORMAT

L7 ANSWER 79 OF 83 CAPLUS COPYRIGHT 2006 ACS ON STN (Continued)

L7 ANSWER 80 OF 83 CAPLUS COPYRIGHT 2006 ACS ON STN
 ACCESSION NUMBER: 2001:282784 CAPLUS
 DOCUMENT NUMBER: 135:122706
 TITLE: Synthesis of 2-phenyloxazole derivatives containing amino acids as insulin sensitivity enhancers for treatment of type II Diabetes
 AUTHOR(S): Paul, Margaret M.; Winneroski, Leonard L.; York, Jeremy S.; Reinhard, Matt R.; Hoving, Richard C.; Gritton, William H.; Dominianni, Samuel J.
 CORPORATE SOURCE: Lilly Research Laboratories, A Division of Eli Lilly and Company Chemical Process Research and Development Division, Indianapolis, IN, 46285-4813, USA
 SOURCE: Heterocycles (2001), 55(4), 689-704
 CODEN: HTCYAM; ISSN: 0385-5414
 PUBLISHER: Japan Institute of Heterocyclic Chemistry
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 OTHER SOURCE(S): CASREACT 135:122706
 AB The preparation of N-(benzoxycarbonyl)-O-[(4-[2-(2-phenyl-4-oxazolyl)ethoxy]phenyl)methyl]-L-serine (I) and 7-[2-(2-phenyl-4-oxazolyl)ethoxy]-L-1,2,3,4-tetrahydro-N-(benzoxycarbonyl)isoquinoline-3-carboxylic acid (II), containing a 2-phenyloxazole moiety linked to an amino acid in place of the 2,4-thiazolidinedione pharmacophore, is described. The 2-phenyloxazole was incorporated into I and II in high yield by alkylation of 4-HOC6H4CHO or Me 1,2,3,4-tetrahydro-N-(benzoxycarbonyl)-7-hydroxyisoquinoline-3-carboxylate with 2-(2-phenyl-4-oxazolyl)ethyl 4-toluenesulfonate. Successful incorporation of serine into I required use of an N-trityl protecting group to minimize β -elimination and epimerization at the α -center.
 IT 201660-23-3P 201660-24-4P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (preparation of derivs. amino acid-containing phenyloxazoles)
 RN 201660-23-3 CAPLUS
 CN L-Serine, O-[(4-[2-(2-phenyl-4-oxazolyl)ethoxy]phenyl)methyl]-N-(triphenylmethyl)-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 201660-24-4 CAPLUS
 CN L-Serine, N-[(phenylmethoxy)carbonyl]-O-[(4-[2-(2-phenyl-4-oxazolyl)ethoxy]phenyl)methyl]-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.


10788996 11/26/06

L7 ANSWER 80 OF 83 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



IT 201659-96-3P
 RL: SPN (Synthetic preparation); PREP (Preparation)
 (preparation of derivs. amino acid-containing phenyloxazoles)
 RN 201659-96-3 CAPLUS
 CN L-Serine, N-[(phenylmethoxy)carbonyl]-O-[[4-[2-(2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.





REFERENCE COUNT: 13 THERE ARE 13 CITED REFERENCES AVAILABLE FOR THIS
 RECORD. ALL CITATIONS AVAILABLE IN THE RE
 FORMAT

L7 ANSWER 81 OF 83 CAPLUS COPYRIGHT 2006 ACS on STN
 ACCESSION NUMBER: 2001:167973 CAPLUS
 DOCUMENT NUMBER: 134:222710
 TITLE: Preparation of hypoglycemic sulfonyl pyrazolones and pyrazolines
 INVENTOR(S): Dominianni, Samuel James
 PATENT ASSIGNEE(S): Eli Lilly and Company, USA
 SOURCE: PCT Int. Appl., 55 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001016111	A2	20010308	WO 2000-US20778	20000816
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
RM:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			
EP 1212304	A2	20020612	EP 2000-959152	20000816
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL			
US 6617342	B1	20030909	US 2002-69029	20020416
PRIORITY APPL. INFO.:			US 1999-151166P	P 19990827
			WO 2000-US20778	W 20000816

OTHER SOURCE(S): MARPAT 134:222710
 GI


L7 ANSWER 81 OF 83 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



AB The title compds. [I; R1-R4 = alkyl, aryl, aralkyl, etc.; Z1 = H, O, S, N;

n = 0-2), useful for treating hyperglycemia associated with non-insulin dependent diabetes and for treating hyperlipidemia, were prepared and formulated. E.g., a 4-step synthesis of the pyrazolinone II which lowered blood glucose level in obese-diabetic mice (data given) was described.

IT 329191-83-5P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (preparation of hypoglycemic sulfonyl pyrazolones and pyrazolines)
 RN 329191-83-5 CAPLUS
 CN Acetic acid,
 [[4-[2-(2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]sulfonyl]-, methyl ester (9CI) (CA INDEX NAME)




L7 ANSWER 82 OF 83 CAPLUS COPYRIGHT 2006 ACS on STN
 ACCESSION NUMBER: 1999:595118 CAPLUS
 DOCUMENT NUMBER: 131:243262
 TITLE: Preparation of carboxylic acid derivatives as PPAR regulating agents
 INVENTOR(S): Tajima, Hisao; Nakayama, Yoshisuke; Fukushima, Daikichi
 PATENT ASSIGNEE(S): Ono Pharmaceutical Co., Ltd., Japan
 SOURCE: PCT Int. Appl., 255 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: Japanese
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9946232	A1	19990916	WO 1999-JP1134	19990309
W:	AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, GR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW			
RM:	GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			
AU 9932759	A1	19990927	AU 1999-32759	19990309
EP 1067109	A1	20010110	EP 1999-939188	19990309
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE, FI			
US 6506757	B1	20030114	US 2000-623913	20000911
US 2003153579	A1	20030814	US 2002-251805	20020923
US 7037914	B2	20060502		
US 2005250824	A1	20051110	US 2005-178639	20050712
PRIORITY APPL. INFO.:			JP 1998-58444	A 19980310
			JP 1998-87560	A 19980331
			WO 1999-JP1134	W 19990309
			US 2000-623913	A3 20000911
			US 2002-251805	A3 20020923


OTHER SOURCE(S): MARPAT 131:243262
 GI

Art Unit: 1626


with the following chemical structures:



(Compound 8b, p. 11, lines 25 – 35);



(Compound 10a, p. 11, lines 54 – 62);





and

(Compound 30, p. 18, lines 21 – 39).

Where the variables in formula (I) of the present invention are: (1) **Ring A** is cyclohexane; (2) **Ring B** is cyclohexane; (3) $R^1 - R^5$ are each hydrogen; (4) **X** is CH_2-O ; and (5) **Y** is CH_2-O ; then the compounds of the present invention in **Claims 1, 2, 3, 4, 5, 6 and 7** are directly anticipated by “Compound 8b” and “Compound 10a” from the prior art, as drawn above.

Where the variables in formula (I) of the present invention are: (1) **Ring A** is 1,3-dioxane; (2) **Ring B** is cyclohexane; (3) $R^1 - R^5$ are each hydrogen; (4) **X** is CH_2-O-CH_2 ; and (5) **Y** is CH_2-O-CH_2 ; then the compounds of the present invention in **Claims 1, 4 and 5** are directly

L7 ANSWER 82 OF 83 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




AB The title compds. I [A1 = alkylene, etc.; A2 = O, S; A3 = CH, N; n = 1-5; R1 = H, alkyl, etc.; R2 = H, halo, etc.; Cyc1 = phenylene, etc.; Cyc2 = heterocyclic ring, etc.; R3 = H, nitro, etc.; R4 = 2,4-thiazolidinedion-5-yl, etc.; provides are given] are prepared. Because of their effect of regulating PPAR (peroxisome proliferator-activated receptor), the compds. of the general formula I are useful as hypoglycemic agents, lipid-lowering agents, preventives and/or remedies for diseases associating metabolic errors (diabetes, obesity, syndrome X, hypercholesterolemia, hyperlipoproteinemia, etc.), hyperlipemia, arteriosclerosis, hypertension, circulatory diseases, overeating, ischemic heart diseases, etc., HDL cholesterol-elevating agents, LDL cholesterol and/or VLDL cholesterol-lowering agents and drugs for relieving risk factors of diabetes or syndrome X. Formulations containing a compound of this invention are given. Phenylloxazolylethoxyphenylmethylthioacetic derivative II


showed PPAR α agonist activity; the blood sugar in mice treated with II (at 38.9 mg/kg/day for 2 days) was 214 \pm 19 mg/dL, vs. 495 \pm 35 mg/dL in controls.

IT 244149-68-6P 244149-73-3P 244149-89-1P
244149-91-5P 244149-92-6P 244149-93-7P
244149-96-0P 244149-97-1P 244150-00-3P
244150-01-4P 244150-02-5P 244150-03-6P
244150-04-7P 244150-05-8P 244150-06-9P
244150-07-0P 244150-08-1P 244150-09-2P
244150-10-5P 244150-11-6P 244150-13-8P
244150-14-9P 244150-16-1P 244150-17-2P
244150-18-3P 244150-19-4P 244150-20-7P
244150-22-9P 244150-24-1P 244150-25-2P
244150-27-4P 244150-29-6P 244150-30-9P
244150-31-0P 244150-33-2P 244150-36-5P


L7 ANSWER 82 OF 83 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
oxazolyl]ethoxyphenyl]methyl]thio]-, methyl ester (9CI) (CA INDEX NAME)




RN 244149-91-5 CAPLUS
CN Acetic acid, [[[3-[2-(5-methyl-2-(4-(trifluoromethyl)phenyl)-4-oxazolyl]ethoxy]phenyl]methyl]thio]-, methyl ester (9CI) (CA INDEX NAME)



RN 244149-92-6 CAPLUS
CN Acetic acid, [[[3-[2-(2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]thio]-, methyl ester (9CI) (CA INDEX NAME)



RN 244149-93-7 CAPLUS
CN Acetic acid, [[[3-[2-(4-fluorophenyl)-5-methyl-4-oxazolyl]ethoxy]phenyl]methyl]thio]-, methyl ester (9CI) (CA INDEX NAME)



RN 244149-96-0 CAPLUS
CN Acetic acid, [[[3-[2-(2-(4-chlorophenyl)-5-methyl-4-oxazolyl]ethoxy]phenyl]methyl]thio]-, methyl ester (9CI) (CA INDEX NAME)


L7 ANSWER 82 OF 83 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)

244150-37-6P 244150-46-7P 244150-54-7P
244150-55-8P 244150-85-4P 244151-07-3P
244151-12-0P 244151-28-8P 244151-30-2P
244151-31-3P 244151-32-4P 244151-35-7P
244151-36-8P 244151-39-1P 244151-40-4P
244151-41-5P 244151-42-6P 244151-43-7P
244151-44-8P 244151-45-9P 244151-46-0P
244151-47-1P 244151-48-2P 244151-49-3P
244151-50-6P 244151-52-8P 244151-53-9P
244151-56-2P 244151-57-3P 244151-58-4P
244151-59-5P 244151-60-8P 244151-63-1P
244151-65-3P 244151-66-4P 244151-68-6P
244151-72-2P 244151-74-4P 244151-75-5P
244151-78-8P 244151-85-7P 244151-87-9P
244152-03-2P 244152-22-5P 244152-24-7P
244152-62-3P 244152-73-6P 244152-75-8P
244152-76-9P 244152-90-7P


RL: BAC (Biological activity or effector, except adverse); BSU

(Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses) (prepn. of carboxylic acid deriva. as PPAR regulating agents)

RN 244149-68-6 CAPLUS
CN Acetic acid, [[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]thio]-, methyl ester (9CI) (CA INDEX NAME)




RN 244149-73-3 CAPLUS
CN Acetic acid, [[[4-chloro-3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]thio]-, methyl ester (9CI) (CA INDEX NAME)




RN 244149-89-1 CAPLUS
CN Acetic acid, [[[3-[2-(5-methyl-2-(4-methylphenyl)-4-


L7 ANSWER 82 OF 83 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 244149-97-1 CAPLUS
CN Acetic acid, [[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)methoxy]phenyl]methyl]thio]-, methyl ester (9CI) (CA INDEX NAME)



RN 244150-00-3 CAPLUS
CN Acetic acid, [[[3-[2-(5-methyl-2-(2-methylphenyl)-4-oxazolyl]ethoxy]phenyl]methyl]thio]-, methyl ester (9CI) (CA INDEX NAME)




RN 244150-01-4 CAPLUS
CN Acetic acid, [[[3-[2-(5-methyl-2-(3-methylphenyl)-4-oxazolyl]ethoxy]phenyl]methyl]thio]-, methyl ester (9CI) (CA INDEX NAME)




RN 244150-02-5 CAPLUS
CN Acetic acid, [[[3-[2-(2-(4-methoxyphenyl)-5-methyl-4-oxazolyl]ethoxy]phenyl]methyl]thio]-, methyl ester (9CI) (CA INDEX NAME)


L7 ANSWER 82 OF 83 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 244150-03-6 CAPLUS
CN Acetic acid, [[[3-[2-(5-methyl-2-(4-nitrophenyl)-4-oxazolyl)ethoxy]phenyl]methyl]thio]-, methyl ester (9CI) (CA INDEX NAME)



RN 244150-04-7 CAPLUS
CN Acetic acid, [[[3-chloro-5-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]thio]-, methyl ester (9CI) (CA INDEX NAME)




RN 244150-05-8 CAPLUS
CN Acetic acid, [[[2-methyl-3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]thio]-, methyl ester (9CI) (CA INDEX NAME)




RN 244150-06-9 CAPLUS
CN Acetic acid, [[1-[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]ethyl]t


L7 ANSWER 82 OF 83 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
oxazolyl)ethoxy]phenyl]methyl]thio]-, methyl ester (9CI) (CA INDEX NAME)




RN 244150-11-6 CAPLUS
CN Acetic acid, [[[3-[2-[2-(4-ethylphenyl)-5-methyl-4-oxazolyl)ethoxy]phenyl]methyl]thio]-, methyl ester (9CI) (CA INDEX NAME)



RN 244150-13-8 CAPLUS
CN Acetic acid, [[[3-[2-(5-methyl-2-(4-propylphenyl)-4-oxazolyl)ethoxy]phenyl]methyl]thio]-, methyl ester (9CI) (CA INDEX NAME)




RN 244150-14-9 CAPLUS
CN Acetic acid, [[[3-[2-[5-methyl-2-(4-(1-methylethyl)phenyl)-4-oxazolyl)ethoxy]phenyl]methyl]thio]-, methyl ester (9CI) (CA INDEX NAME)




RN 244150-16-1 CAPLUS
CN Acetic acid, [[[3-[2-[2-(4-butylphenyl)-5-methyl-4-oxazolyl)ethoxy]phenyl]methyl]thio]-, methyl ester (9CI) (CA INDEX NAME)


L7 ANSWER 82 OF 83 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
hio]-, methyl ester (9CI) (CA INDEX NAME)




RN 244150-07-0 CAPLUS
CN Acetic acid, [[[3-[1-methyl-2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]thio]-, methyl ester (9CI) (CA INDEX NAME)



RN 244150-08-1 CAPLUS
CN Acetic acid, [[[3-[2-[2-phenyl-5-(trifluoromethyl)-4-oxazolyl)ethoxy]phenyl]methyl]thio]-, methyl ester (9CI) (CA INDEX NAME)




RN 244150-09-2 CAPLUS
CN Acetic acid, [[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)propoxy]phenyl]methyl]t




RN 244150-10-5 CAPLUS
CN Propanoic acid, 2-[[[3-[2-(5-methyl-2-phenyl-4-


L7 ANSWER 82 OF 83 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 244150-17-2 CAPLUS
CN Acetic acid, [[[3-[2-(5-ethyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]thi



RN 244150-18-3 CAPLUS
CN Acetic acid, [[[3-[2-(5-methyl-2-(2,3,5,6-tetrafluoro-4-methylphenyl)-4-oxazolyl)ethoxy]phenyl]methyl]thio]-, methyl ester (9CI) (CA INDEX NAME)




RN 244150-19-4 CAPLUS
CN Acetic acid, [[[3-[2-[5-methyl-2-(4-pentylphenyl)-4-oxazolyl)ethoxy]phenyl]methyl]thio]-, methyl ester (9CI) (CA INDEX NAME)




RN 244150-20-7 CAPLUS
CN Acetic acid, [[[3-[2-[2-(3-chloro-4-methylphenyl)-5-methyl-4-oxazolyl)ethoxy]phenyl]methyl]thio]-, methyl ester (9CI) (CA INDEX NAME)


L7 ANSWER 82 OF 83 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 244150-22-9 CAPLUS
CN Acetic acid, [[[(3-[2-[5-methyl-2-[4-(2-methylpropyl)phenyl]-4-oxazolyl]ethoxy]phenyl)methyl]thio]-, methyl ester (9CI) (CA INDEX NAME)



RN 244150-24-1 CAPLUS
CN Acetic acid, [[3-(2-[2-(4-(1,1-dimethylethyl)phenyl]-5-methyl-4-oxazolyl)ethoxy]phenyl)methyl]thio]-, methyl ester (9CI) (CA INDEX NAME)




RN 244150-25-2 CAPLUS
CN Acetic acid, [[[3-[2-[2-(4-cyclohexylphenyl)-5-methyl-4-oxazolyl]ethoxy]phenyl]methyl]thio]-, methyl ester (9CI) (CA INDEX NAME)




RN 244150-27-4 CAPLUS


L7 ANSWER 82 OF 83 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 244150-33-2 CAPLUS
CN Acetic acid, [[3-[2-[5-methyl-2-(4-(methylthio)phenyl)-4-oxazolyl]ethoxy]phenyl]methyl]thio]-, methyl ester (9CI) (CA INDEX NAME)



RN 244150-36-5 CAPLUS
CN Acetic acid, [[3-[2-[5-methyl-2-(4-methyl-3-nitrophenyl)-4-oxazolyl]ethoxy]phenyl]methyl]thio]-, methyl ester (9CI) (CA INDEX NAME)




RN 244150-37-6 CAPLUS
CN Acetic acid, [[3-[2-[2-[4-(dimethylamino)phenyl]-5-methyl-4-oxazolyl]ethoxy]phenyl]methyl]thio]-, methyl ester (9CI) (CA INDEX NAME)




RN 244150-46-7 CAPLUS
CN Acetic acid, [[[3-[2-[4-(4,5-dihydro-1,2,3-thiadiazol-4-yl)phenyl]-5-methyl-4-oxazolyl]ethoxy]phenyl]methyl]thio]-, methyl ester (9CI) (CA INDEX NAME)

L7 ANSWER 82 OF 83 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)


27 ANSWER 02 OF 05 CAPSUS COPYRIGHT 2000 ACS ON SIN (CONTINUED)
CN Acetic acid, [[3-[[5-methyl-2-[[4-(1-methylethyl)phenyl]-4-oxazolyl]methoxy]phenyl]methyl]thio]-, methyl ester (9CI) (CA INDEX NAME)



RN 244150-29-6 CAPLUS
CN Acetic acid, [[[(3-{2-[2-(3,4-dimethoxyphenyl)-5-methyl-4-oxazolyl]ethoxy}phenyl)methyl]thio]-, methyl ester (9CI) (CA INDEX NAME)




RN 244150-30-9 CAPLUS
CN Acetic acid, [{[3-[2-[5-methyl-2-[4-(trifluoromethoxy)phenyl]-4-oxazolyl]ethoxy]phenyl]methyl]thio]-, methyl ester (9CI) (CA INDEX NAME)




RN 244150-31-0 CAPLUS
CN Acetic acid, [[3-[2-[5-methyl-2-(3,4,5-trimethoxyphenyl)-4-oxazolyl]ethoxy]phenyl]methyl]thio]-, methyl ester (9CI) (CA INDEX NAME)


L7 ANSWER 82 OF 83 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 244150-54-7 CAPLUS
CN Acetic acid, [[3-[2-[5-methyl-2-[4-[(trifluoromethyl)thio]phenyl]-4-oxazolyl]ethoxy]phenyl]methyl]thio]-, methyl ester (9CI) (CA INDEX NAME)



RN 244150-55-8 CAPLUS
CN Acetic acid, [[[3-[2-[2-(4-cyanophenyl)-5-methyl-4-oxazolyl]ethoxy]phenyl]methyl]thio]-, methyl ester (9CI) (CA INDEX NAME)




RN 244150-85-4 CAPLUS
CN Acetic acid,
[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methoxy]-,
1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 244151-07-3 CAPLUS
CN Acetic acid,
[[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]th
io]- (9CI) (CA INDEX NAME)


L7 ANSWER 82 OF 83 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 244151-12-0 CAPLUS
CN Acetic acid, [[3-[2-(4-chloro-3-[(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl)methyl]thio]- (9CI) (CA INDEX NAME)



RN 244151-28-8 CAPLUS
CN Acetic acid, [[3-[2-(5-methyl-2-(4-methylphenyl)-4-oxazolyl)ethoxy]phenyl)methyl]thio]- (9CI) (CA INDEX NAME)




RN 244151-30-2 CAPLUS
CN Acetic acid, [[3-[2-(5-methyl-2-(4-(trifluoromethyl)phenyl)-4-oxazolyl)ethoxy]phenyl)methyl]thio]- (9CI) (CA INDEX NAME)




RN 244151-31-3 CAPLUS
CN Acetic acid, [[3-[2-(2-phenyl-4-oxazolyl)ethoxy]phenyl)methyl]thio]- (9CI) (CA INDEX NAME)


L7 ANSWER 82 OF 83 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 244151-40-4 CAPLUS
CN Acetic acid, [[3-[2-(5-methyl-2-(3-methylphenyl)-4-oxazolyl)ethoxy]phenyl)methyl]thio]- (9CI) (CA INDEX NAME)



RN 244151-41-5 CAPLUS
CN Acetic acid, [[3-[2-(5-methyl-2-(4-methoxyphenyl)-5-methyl-4-oxazolyl)ethoxy]phenyl)methyl]thio]- (9CI) (CA INDEX NAME)




RN 244151-42-6 CAPLUS
CN Acetic acid, [[3-[2-(5-methyl-2-(4-nitrophenyl)-4-oxazolyl)ethoxy]phenyl)methyl]thio]- (9CI) (CA INDEX NAME)




RN 244151-43-7 CAPLUS
CN Acetic acid, [[3-[2-(5-methyl-2-(4-nitrophenyl)-4-oxazolyl)ethoxy]phenyl)methyl]thio]- (9CI) (CA INDEX NAME)


L7 ANSWER 82 OF 83 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 244151-32-4 CAPLUS
CN Acetic acid, [[3-[2-(2-(4-fluorophenyl)-5-methyl-4-oxazolyl)ethoxy]phenyl)methyl]thio]- (9CI) (CA INDEX NAME)



RN 244151-35-7 CAPLUS
CN Acetic acid, [[3-[2-(2-(4-chlorophenyl)-5-methyl-4-oxazolyl)ethoxy]phenyl)methyl]thio]- (9CI) (CA INDEX NAME)




RN 244151-36-8 CAPLUS
CN Acetic acid, [[3-[2-(2-(4-chlorophenyl)-5-methyl-4-oxazolyl)ethoxy]phenyl)methyl]thio]- (9CI) (CA INDEX NAME)




RN 244151-39-1 CAPLUS
CN Acetic acid, [[3-[2-(2-(4-chlorophenyl)-5-methyl-4-oxazolyl)ethoxy]phenyl)methyl]thio]- (9CI) (CA INDEX NAME)


L7 ANSWER 82 OF 83 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 244151-44-8 CAPLUS
CN Acetic acid, [[3-[2-(2-(4-chlorophenyl)-5-methyl-4-oxazolyl)ethoxy]phenyl)methyl]thio]- (9CI) (CA INDEX NAME)



RN 244151-45-9 CAPLUS
CN Acetic acid, [[3-[2-(2-(4-chlorophenyl)-5-methyl-4-oxazolyl)ethoxy]phenyl)methyl]thio]- (9CI) (CA INDEX NAME)




RN 244151-46-0 CAPLUS
CN Acetic acid, [[3-[2-(2-(4-chlorophenyl)-5-methyl-4-oxazolyl)ethoxy]phenyl)methyl]thio]- (9CI) (CA INDEX NAME)




RN 244151-47-1 CAPLUS
CN Acetic acid, [[3-[2-(2-(4-chlorophenyl)-5-methyl-4-oxazolyl)ethoxy]phenyl)methyl]thio]- (9CI) (CA INDEX NAME)


L7 ANSWER 82 OF 83 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 244151-48-2 CAPLUS
CN Acetic acid, [[3-[2-(5-methyl-2-phenyl-4-oxazolyl)propoxy]phenyl]methyl]thio]- (9CI) (CA INDEX NAME)




RN 244151-49-3 CAPLUS
CN Propanoic acid, 2-[[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]thio]-, sodium salt (9CI) (CA INDEX NAME)



● Na


RN 244151-50-6 CAPLUS
CN Acetic acid, [[3-[2-(4-ethylphenyl)-5-methyl-4-oxazolyl]ethoxy]phenyl]methyl]thio]- (9CI) (CA INDEX NAME)




RN 244151-52-8 CAPLUS

L7 ANSWER 82 OF 83 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)


RN 244151-58-4 CAPLUS
CN Acetic acid, [[3-[2-[5-methyl-2-(2,3,5,6-tetrafluoro-4-methylphenyl)-4-oxazolyl]ethoxy]phenyl]methyl]thio]- (9CI) (CA INDEX NAME)




RN 244151-59-5 CAPLUS
CN Acetic acid, [[3-[2-[5-methyl-2-(4-pentylphenyl)-4-oxazolyl]ethoxy]phenyl]methyl]thio]- (9CI) (CA INDEX NAME)



RN 244151-60-8 CAPLUS
CN Acetic acid, [[3-[2-[2-(3-chloro-4-methylphenyl)-5-methyl-4-oxazolyl]ethoxy]phenyl]methyl]thio]- (9CI) (CA INDEX NAME)




RN 244151-63-1 CAPLUS
CN Acetic acid, [[3-[2-[5-methyl-2-[4-(2-methylpropyl)phenyl]-4-oxazolyl]ethoxy]phenyl]methyl]thio]- (9CI) (CA INDEX NAME)




RN 244151-65-3 CAPLUS
CN Acetic acid, [[3-[2-[2-[4-(1,1-dimethylethyl)phenyl]-5-methyl-4-oxazolyl]ethoxy]phenyl]methyl]thio]- (9CI) (CA INDEX NAME)

L7 ANSWER 82 OF 83 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)


CN Acetic acid, [[3-[2-[5-methyl-2-(4-propylphenyl)-4-oxazolyl]ethoxy]phenyl]methyl]thio]- (9CI) (CA INDEX NAME)




RN 244151-53-9 CAPLUS
CN Acetic acid, [[3-[2-[5-methyl-2-(4-(1-methylethyl)phenyl)-4-oxazolyl]ethoxy]phenyl]methyl]thio]- (9CI) (CA INDEX NAME)



RN 244151-56-2 CAPLUS
CN Acetic acid, [[3-[2-[2-(4-butylphenyl)-5-methyl-4-oxazolyl]ethoxy]phenyl]methyl]thio]- (9CI) (CA INDEX NAME)




RN 244151-57-3 CAPLUS
CN Acetic acid, [[3-[2-[5-ethyl-2-phenyl-4-oxazolyl]ethoxy]phenyl]methyl]thio]- (9CI) (CA INDEX NAME)




L7 ANSWER 82 OF 83 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)


CN Acetic acid, [[3-[2-[5-methyl-2-(4-cyclohexylphenyl)-4-oxazolyl]ethoxy]phenyl]methyl]thio]- (9CI) (CA INDEX NAME)




RN 244151-66-4 CAPLUS
CN Acetic acid, [[3-[2-[2-(4-cyclohexylphenyl)-5-methyl-4-oxazolyl]ethoxy]phenyl]methyl]thio]- (9CI) (CA INDEX NAME)



RN 244151-68-6 CAPLUS
CN Acetic acid, [[3-[2-[5-methyl-2-(4-(1-methylethyl)phenyl)-4-oxazolyl]ethoxy]phenyl]methyl]thio]- (9CI) (CA INDEX NAME)



RN 244151-72-2 CAPLUS
CN Acetic acid, [[3-[2-[2-(3,4-dimethoxyphenyl)-5-methyl-4-oxazolyl]ethoxy]phenyl]methyl]thio]- (9CI) (CA INDEX NAME)




RN 244151-74-4 CAPLUS
CN Acetic acid, [[3-[2-[5-methyl-2-[4-(trifluoromethoxy)phenyl]-4-oxazolyl]ethoxy]phenyl]methyl]thio]- (9CI) (CA INDEX NAME)


10788996

11/26/06


L7 ANSWER 82 OF 83 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 244151-75-5 CAPLUS
CN Acetic acid, [[3-[2-[5-methyl-2-(3,4,5-trimethoxyphenyl)-4-oxazolyl]ethoxy]phenyl]methyl]thio]- (9CI) (CA INDEX NAME)



RN 244151-78-8 CAPLUS
CN Acetic acid, [[3-[2-[5-methyl-2-(4-(methoxythio)phenyl)-4-oxazolyl]ethoxy]phenyl]methyl]thio]- (9CI) (CA INDEX NAME)




RN 244151-85-7 CAPLUS
CN Acetic acid, [[3-[2-[5-methyl-2-(4-methyl-3-nitrophenyl)-4-oxazolyl]ethoxy]phenyl]methyl]thio]- (9CI) (CA INDEX NAME)




RN 244151-87-9 CAPLUS
CN Acetic acid, [[3-[2-[2-[4-(dimethylamino)phenyl]-5-methyl-4-oxazolyl]ethoxy]phenyl]methyl]thio]- (9CI) (CA INDEX NAME)


L7 ANSWER 82 OF 83 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 244152-73-6 CAPLUS
CN Propanoic acid, 2-methyl-2-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]thio]-, ethyl ester (9CI) (CA INDEX NAME)



RN 244152-75-8 CAPLUS
CN Propanoic acid, 2-methyl-2-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]thio]-, sodium salt (9CI) (CA INDEX NAME)




RN 244152-76-9 CAPLUS
CN Propanoic acid, 2-methyl-2-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]thio]-, sodium salt (9CI) (CA INDEX NAME)




● Na

RN 244152-90-7 CAPLUS
CN Acetic acid, [[4-chloro-3-[2-[5-methyl-2-(4-methylphenyl)-4-oxazolyl]ethoxy]phenyl]methyl]thio]- (9CI) (CA INDEX NAME)


L7 ANSWER 82 OF 83 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 244152-03-2 CAPLUS
CN Acetic acid, [[3-[2-[5-methyl-2-(4-(1,3-thiadiazol-4-yl)phenyl)-4-oxazolyl]ethoxy]phenyl]methyl]thio]- (9CI) (CA INDEX NAME)



RN 244152-22-5 CAPLUS
CN Acetic acid, [[3-[2-[5-methyl-2-(4-((trifluoromethyl)thio)phenyl)-4-oxazolyl]ethoxy]phenyl]methyl]thio]- (9CI) (CA INDEX NAME)




RN 244152-24-7 CAPLUS
CN Acetic acid, [[3-[2-[2-(4-cyanophenyl)-5-methyl-4-oxazolyl]ethoxy]phenyl]methyl]thio]- (9CI) (CA INDEX NAME)



RN 244152-62-3 CAPLUS
CN Acetic acid, [[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methoxy]- (9CI) (CA INDEX NAME)

L7 ANSWER 82 OF 83 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



REFERENCE COUNT: 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE


FORMAT

L7 ANSWER 83 OF 83 CAPLUS COPYRIGHT 2006 ACS on STN
 ACCESSION NUMBER: 1998:55528 CAPLUS
 DOCUMENT NUMBER: 128:115229
 TITLE: Preparation of oxazolyethyltyrosine and oxazolyethoxyarylaerine derivatives as hypoglycemic and hypolipidemic compounds
 INVENTOR(S): Dominianni, Samuel J.; Faul, Margaret M.; Stucky, Russell D.; Winneroski, Leonard L., Jr.
 PATENT ASSIGNEE(S): Eli Lilly and Co., USA; Dominianni, Samuel J.; Faul, Margaret M.; Stucky, Russell D.; Winneroski, Leonard L., Jr.
 SOURCE: PCT Int. Appl., 88 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9800137	A1	19980108	WO 1997-US11576	19970630
W:	AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, GH, HU, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, BG, KZ, MD, RU, TJ, TM			
RW:	GH, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG			
CA 2259487	AA	19980108	CA 1997-2259487	19970630
AU 9737199	A1	19980121	AU 1997-37199	19970630
EP 925063	A1	19990630	EP 1997-934043	19970630
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, NL, SE, PT, IE, FI			
JP 2000515133	T2	20001114	JP 1998-504453	19970630
IL 121202	A1	20010826	IL 1997-121202	19970630
ZA 9705865	A	19990104	ZA 1997-5865	19970701
US 6194446	B1	20010227	US 1998-216471	19981218
US 6353027	B1	20020305	US 2000-518537	20000303
US 6541497	B1	20030401	US 2000-518607	20000303
PRIORITY APPLN. INFO.:			US 1996-21016P	P 19960701
			WO 1997-US11576	W 19970630
			US 1998-216471	A3 19981218

OTHER SOURCE(S): MARPAT 128:115229
 GI


L7 ANSWER 83 OF 83 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



AB This invention provides compds. I [Q = (CH₂)_p, CH₂OCH₂; R₀ = Q₁ (X = O, S), R₆- and R₇-substituted pyridyl, R₇C₆H₄, naphthyl, Q₂, Q₃; R₂ = C1-4 alkylaminocarbonyl, arylcarbonyl, aryloxy carbonyl, aryloxy-C1-4 alkylcarbonyl, arylaminocarbonyl, aryl-C1-4 acyl, aryl-C1-4 alkoxycarbonyl, aryl-C1-4 alkylaminocarbonyl, aryl-C1-4 alkylsulfonyl, amino protective group; R₃, R₄ = independently H, C1-4 alkyl, R₅ = CO₂H, CONH₂, CONH₂, 5-tetrazolyl; R₆ = H, C1-4 alkyl, aryl, aryl-C1-4 alkyl, R₇ = H, halo, C1-4 alkyl; R₉ = H, C1-4 alkyl, aryl; R₁₀, R₁₁ = independently H, C1-4 alkyl, aryl; W = (CH₂)_n; Y = O, S, S(O), SO₂, NH, CONH₂, NR₉SO₂, SO₂NR₉ attached at position 3 or 4; n = 1-4; p = 1-3] and their pharmaceutically acceptable salts, pharmaceutical formulations, and methods for treating hyperglycemia associated with non-insulin dependent diabetes and for treating hyperlipidemia. Thus, Mitsunobu coupling of 2-phenyl-4-(2-hydroxyethyl)oxazole (preparation given) with Z-L-Tyr-OH (Z = PhCH₂O₂C) gave 36.5% desired compound II (Q = CH₂). Similarly, O-alkylation of Ph₃C-L-Ser-OMe with 2-phenyl-4-[2-[4-(bromomethyl)phenoxy]ethyl]oxazole (preparation given) followed by protective group exchange and saponification gave serine derivative II (Q = CH₂OCH₂). Example hard gelatin capsule, tablet, suppository, suspension, i.v., and aerosol formulations are given. Prepared compds. I were tested for hypoglycemic and hypolipidemic activities in male obese-diabetic viable yellow (Avy) mice. IT 201659-96-3P 201660-13-1P
 R1: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses) (preparation of oxazolyethyltyrosine and oxazolyethoxyarylaerine derivs. as hypoglycemic and hypolipidemic compds.)
 RN 201659-96-3 CAPLUS


L7 ANSWER 83 OF 83 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
 CN L-Serine, N-[(phenylmethoxy)carbonyl]-O-[[4-[2-(2-phenyl-4-oxazoly)ethoxy]phenyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 201660-13-1 CAPLUS
 CN L-Serine, N-[(phenylmethoxy)carbonyl]-O-[[3-[2-(2-phenyl-4-oxazoly)ethoxy]phenyl]methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



IT 201660-23-3P 201660-24-4P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent) (preparation of oxazolyethyltyrosine and oxazolyethoxyarylaerine derivs. as hypoglycemic and hypolipidemic compds.)

RN 201660-23-3 CAPLUS
 CN L-Serine, O-[[4-[2-(2-phenyl-4-oxazoly)ethoxy]phenyl]methyl]-N-(triphenylmethyl)-, methyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 201660-24-4 CAPLUS
 CN L-Serine, N-[(phenylmethoxy)carbonyl]-O-[[4-[2-(2-phenyl-4-oxazoly)ethoxy]phenyl]methyl]-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L7 ANSWER 83 OF 83 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



REFERENCE COUNT: 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE
 FORMAT

10788996 11/26/06

=> logoff

ALL L# QUERIES AND ANSWER SETS ARE DELETED AT LOGOFF

LOGOFF? (Y)/N/HOLD:y

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

430.68

601.12

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)

SINCE FILE

TOTAL

ENTRY

SESSION

CA SUBSCRIBER PRICE

-62.25

-62.25

STN INTERNATIONAL LOGOFF AT 17:43:36 ON 26 NOV 2006